WO2008067527A1 - Inhibitors of protein tyrosine phosphatase for the treatment of muscle atrophy and related disorders - Google Patents

Inhibitors of protein tyrosine phosphatase for the treatment of muscle atrophy and related disorders Download PDF

Info

Publication number
WO2008067527A1
WO2008067527A1 PCT/US2007/086058 US2007086058W WO2008067527A1 WO 2008067527 A1 WO2008067527 A1 WO 2008067527A1 US 2007086058 W US2007086058 W US 2007086058W WO 2008067527 A1 WO2008067527 A1 WO 2008067527A1
Authority
WO
WIPO (PCT)
Prior art keywords
hydroxy
thiadiazolidin
aryl
heterocyclyl
cycloalkyl
Prior art date
Application number
PCT/US2007/086058
Other languages
French (fr)
Inventor
Angelika Christina Paul
Reza Halse
Alokesh Duttaroy
Laura Elizabeth Holton
Daniel Kemp
David J. Glass
David Weninger Barnes
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of WO2008067527A1 publication Critical patent/WO2008067527A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/433—Thidiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/06—Anabolic agents

Definitions

  • the invention relates to compounds that inhibit protein tyrosine phosphatase (PTP), particularly PTP-IB, and their use in the treatment of musculoskeletal disease.
  • PTP protein tyrosine phosphatase
  • Cellular signal transduction is a fundamental mechanism whereby external stimuli that regulate diverse cellular processes are relayed to the interior of cells.
  • One of the key biochemical mechanisms of signal transduction involves the reversible phosphorylation of proteins, which enables regulation of the activity of mature proteins by altering their structure and function.
  • the best characterized protein kinases in eukaryotes phosphorylate proteins on the alcohol moiety of serine, threonine and tyrosine residues. These kinases largely fall into two groups, those specific for phosphorylating serines and threonines, and those specific for phosphorylating tyrosines.
  • the phosphorylation state of a given substrate is also regulated by protein phosphatases, a class of proteins responsible for removal of the phosphate group added to a given substrate by a protein kinase.
  • the protein phosphatases can also be classified as being specific for either serine/threonine or tyrosine.
  • the known enzymes can be divided into two groups—receptor and non-receptor type proteins.
  • Most receptor-type protein tyrosine phosphatases (RPTPs) contain two conserved catalytic tyrosine phosphatase domains each of which encompasses a segment of 240 amino acid residues (Saito et al., Cell Growth and Diff. 2:59-65, 1991).
  • the RPTPs can be subclassified further based upon the amino acid sequence diversity of their extracellular domains (Saito, et al., supra; Krueger, et al., Proc. Natl. Acad. Sci. USA 89:7417-7421, 1992). Alignment of primary peptide sequences of both types of known PTPs shows some sequence consensus in catalytic domains and has made it possible to identify cDNAs encoding proteins with tyrosine phosphate activity via the polymerase chain reaction (PCR). Many kinases and phosphatases are involved in regulatory cascades wherein their substrates may include, but are not limited to, other kinases and phosphatases whose activities are regulated by their phosphorylation state. Ultimately the activity of some downstream effector is modulated by phosphorylation resulting from activation of such a pathway.
  • tyrosine kinases and/or tyrosine phosphatases plays a role in a variety of human disorders including cell proliferative disorders such as cancer, fibrotic disorders, disorders of the immune system and metabolic disorders such as diabetes.
  • the invention is based on the discovery that PTP inhibitors can be used to treat musculoskeletal diseases or conditions, particularly muscle atrophy, in a mammal such as a human individual or patient. Accordingly, the invention includes a method of treating a musculoskeletal disease by identifying an individual exhibiting the musculoskeletal disease or at risk for developing the musculoskeletal disease and administering to the individual a therapeutically effective amount of a PTP inhibitor sufficient to alleviate the musculoskeletal disease. The invention also includes the use of a PTP inhibitor in the manufacture of a medicament for the treatment or prevention of a musculoskeletal disease. In addition, the invention includes use of PTP inhibitors to increase muscle or bone mass in an individual, whether or not such an individual is at risk for or has a musculoskeletal disease.
  • the musculoskeletal disease can be muscle atrophy.
  • muscle atrophy There are many causes of muscle atrophy, including as a result of treatment with a glucocorticoid such as Cortisol, dexamethasone, betamethasone, prednisone, methylprednisolone, or prednisolone.
  • the muscle atrophy can also be a result of denervation due to nerve trauma or a result of degenerative, metabolic, or inflammatory neuropathy (e.g., Guillian-Barre syndrome, peripheral neuropathy, or exposure to environmental toxins or drugs).
  • the muscle atrophy can be a result of an adult motor neuron disease, infantile spinal muscular atrophy, juvenile spinal muscular atrophy, autoimmune motor neuropathy with multifocal conductor block, paralysis due to stroke or spinal cord injury, skeletal immobilization due to trauma, prolonged bed rest, voluntary inactivity, involuntary inactivity, metabolic stress or nutritional insufficiency, cancer, AIDS, fasting, rhabdomyolysis, a thyroid gland disorder, diabetes, benign congenital hypotonia, central core disease, nemalene myopathy, myotubular (centronuclear) myopathy, burn injury, chronic obstructive pulmonary disease, liver disease, sepsis, renal failure, congestive heart failure, or ageing.
  • the musculoskeletal disease can also be a muscular dystrophy syndrome, such as
  • the musculoskeletal disease can also be osteoporosis, a bone fracture, short stature, or dwarfism.
  • any suitable PTP inhibitor such as described in the next section, can be used to treat the above-mentioned musculoskeletal diseases. Since it is known that insulin-like growth factor- 1 (IGFl) has beneficial effects on the musculoskeletal system, IGFl or human Growth Hormone can be co-administered along with the PTP inhibitor in the methods of the invention.
  • IGFl insulin-like growth factor- 1
  • Figure 1 shows mean C2C12 myotube diameter from an experiment where two different PTPIb inhibitors were added to culture media +/- IGFl (mean +/- standard error of the mean).
  • Figure 2 shows percent muscle volume lost at two weeks.
  • Figure 3 shows results from an experiment where WT, HET, and KO mice had their right leg denervated by sciatic nerve resection.
  • the invention relates to the treatment of musculoskeletal diseases, in particular muscle atrophy, low bone density or mineral content, and short stature.
  • Any PTP inhibitor can be used in the methods of the invention, for example, the inhibitors described in US patents and patent application publications 7,115,624; 7,078,425; 7,022,730; 6,911,468; and 2005/0090502.
  • specific inhibitors of PTP particularly PTP-IB and T-cell PTP, can include the categories of compounds and specific compounds therein, as described below.
  • optionally substituted alkyl refers to unsubstituted or substituted straight or branched chain hydrocarbon groups having 1 to 20 carbon atoms, preferably 1 to 8 carbon atoms.
  • exemplary unsubstituted alkyl groups include methyl, ethyl, propyl, isopropyl, n-butyl, t-butyl, isobutyl, pentyl, hexyl, isohexyl, heptyl, 4,4-dimethylpentyl, octyl and the like.
  • Substituted alkyl groups include, but are not limited to, alkyl groups substituted by one or more of the following groups: halogen, hydroxy, cycloalkyl, cycloalkoxy, acyl, acyloxy, alkoxy, alkyloxyalkoxy, alkanoyloxy, amino, alkylamino, dialkylamino, acylamino, carbamoyl, thiol, alkylthio, alkylthiono, sulfonyl, sulfonamido, sulfamoyl, nitro, cyano, free or esterified carboxy, aryl, aryloxy, arylthio, alkenyl, alkynyl, aralkoxy, heteroaraloxy, heterocyclyl and heterocyclyloxy including indolyl, imidazolyl, furyl, thienyl, thiazolyl, pyrrolidyl, pyridy
  • halogen refers to fluorine, chlorine, bromine and iodine.
  • alkenyl refers to any of the above alkyl groups having at least 2 carbon atoms and containing a carbon to carbon double bond at the point of attachment.
  • alkynyl refers to any of the above alkyl groups having at least two carbon atoms and containing a carbon to carbon triple bond at the point of attachment. Groups having 2 to 8 carbon atoms are preferred.
  • alkylene refers to a straight-chain bridge of 1-6 carbon atoms connected by single bonds, e.g., -(CH2)x-, wherein x is 1-6, which may be interrupted with one or more heteroatoms selected from O, S, S(O), S(O)2 or NR", wherein R" may be hydrogen, alkyl, cycloalkyl, aryl, heterocyclyl, aralkyl, heteroaralkyl, acyl, carbamoyl, sulfonyl, alkoxycarbonyl, aryloxycarbonyl or aralkoxycarbonyl and the like; and the alkylene may further be substituted with one or more substituents selected from hydroxy, halogen, cyano, nitro, alkoxy, alkylthio, alkylthiono, sulfonyl, free or esterified carboxy, carbamoyl, sulfamoyl, optionally substituted amino, cyclo
  • cycloalkyl refers to optionally substituted monocyclic, bicyclic or tricyclic hydrocarbon groups of 3 to 12 carbon atoms, each of which may be substituted by one or more substituents such as alkyl, halo, oxo, hydroxy, alkoxy, alkanoyl, acylamino, carbamoyl, alkylamino, dialkylamino, thiol, alkylthio, nitro, cyano, carboxy, carboxyalkyl, alkoxycarbonyl, sulfonyl, sulfonamido, sulfamoyl, heterocyclyl and the like.
  • Exemplary monocyclic hydrocarbon groups include but are not limited to cyclopropyl, cyclobutyl, cyclopentyl, cyclopentenyl, cyclohexyl and cyclohexenyl and the like.
  • Exemplary bicyclic hydrocarbon groups include bornyl, indyl, hexahydroindyl, tetrahydronaphthyl, decahydronaphthyl, bicyclo[2.1.1]hexyl, bicyclo[2.2.1]heptyl, bicyclo[2.2.1]heptenyl, 6,6-dimethylbicyclo[3.1.1]heptyl, 2,6,6- trimethylbicyclo[3.1.1]heptyl, bicyclo[2.2.2]octyl and the like.
  • Exemplary tricyclic hydrocarbon groups include adamantyl and the like.
  • alkoxy refers to alkyl-O-.
  • alkanoyl refers to alkyl-C(O)-.
  • alkanoyloxy refers to alkyl-C(O)-O-.
  • alkylamino and “dialkylamino” refer to alkyl-NH- and (alkyl) 2 N-, respectively.
  • alkanoylamino refers to alkyl-C(O)-NH-.
  • alkylthio refers to alkyl-S-.
  • alkylaminothiocarbonyl refers to alkyl-NHC(S)-.
  • alkylsulfonyl refers to alkyl-S(O) 2 -.
  • alkoxycarbonyl refers to alkyl-O-C(O)-.
  • alkoxycarbonyloxy refers to alkyl-O-C(O)O-.
  • carboxycarbonyl refers to HO-C(O)C(O)-.
  • carbamoyl refers to H 2 NC(O)-, alkyl-NHC(O)-, (alkyl) 2 NC(O)-, aryl- NHC(O)-, alkyl(aryl)-NC(O)-, heteroaryl-NHC(O)-, alkyl(heteroaryl)-NC(O)-, aralkyl- NHC(O)-, alkyl(aralkyl)-NC(O)- and the like.
  • sulfamoyl refers to H 2 NS(O) 2 -, alkyl-NHS(O) 2 -, (alkyl) 2 NS(O) 2 -, aryl- NHS(O) 2 -, alkyl(aryl)-NS(O) 2 -, (aryl) 2 NS(O) 2 -, heteroaryl-NHS(O) 2 -, aralkyl-NHS(O) 2 -, heteroaralkyl-NHS(O) 2 - and the like.
  • sulfonamido refers to alkyl-S(O) 2 -NH-, aryl-S(O) 2 -NH-, aralkyl-S(O) 2 -NH-, heteroaryl-S(O) 2 -NH-, heteroaralkyl-S(O) 2 -NH-, alkyl-S(O) 2 -N(alkyl)-, aryl-S(O) 2 - N(alkyl)-, aralkyl-S(O) 2 -N(alkyl)-, heteroaryl-S(O) 2 -N(alkyl)-, heteroaralkyl-S(O) 2 - N(alkyl)- and the like.
  • sulfonyl refers to alkylsulfonyl, arylsulfonyl, heteroarylsulfonyl, aralkylsulfonyl, heteroaralkylsulfonyl and the like.
  • sulfonate or “sulfonyloxy” refers to alkyl-S(O) 2 -O-, aryl-S(O) 2 -O-, aralkyl- S(O) 2 -O-, heteroaryl-S(O) 2 -O-, heteroaralkyl-S(O) 2 -O- and the like.
  • optionally substituted amino refers to a primary or secondary amino group which may optionally be substituted by a substituent such as acyl, sulfonyl, alkoxycarbonyl, cycloalkoxycarbonyl, aryloxycarbonyl, heteroaryloxycarbonyl, aralkoxycarbonyl, heteroaralkoxycarbonyl, carboxycarbonyl, carbamoyl, alkylaminothiocarbonyl, arylaminothiocarbonyl and the like.
  • aryl refers to monocyclic or bicyclic aromatic hydrocarbon groups having 6 to 12 carbon atoms in the ring portion, such as phenyl, naphthyl, tetrahydronaphthyl, biphenyl and diphenyl groups, each of which may optionally be substituted by one to five substituents such as alkyl, trifluoromethyl, halo, hydroxy, alkoxy, acyl, alkanoyloxy, optionally substituted amino, thiol, alkylthio, nitro, cyano, carboxy, carboxyalkyl, alkoxycarbonyl, carbamoyl, alkylthiono, sulfonyl, sulfonamido, sulfonate, heterocyclyl and the like.
  • monocyclic aryl refers to optionally substituted phenyl as described under aryl.
  • aralkyl refers to an aryl group bonded directly through an alkyl group, such as benzyl.
  • aralkanoyl refers to aralkyl-C(O)-.
  • aralkylthio refers to aralkyl-S-.
  • aralkoxy refers to an aryl group bonded directly through an alkoxy group.
  • arylsulfonyl refers to aryl S(O) 2 .
  • arylthio refers to aryl-S-.
  • aroyl refers to aryl-C(O)-.
  • aroylamino refers to aryl-C(O)-NH-.
  • aryloxycarbonyl refers to aryl-O-C(O)-.
  • heterocyclyl refers to an optionally substituted, aromatic, or a partially or fully saturated nonaromatic cyclic group, for example, which is a 4- to 7- membered monocyclic, 7- to 12-membered bicyclic, or 10- to 15-membered tricyclic ring system, which has at least one heteroatom in at least one carbon atom containing ring.
  • Each ring of the heterocyclic group containing a heteroatom may have 1, 2 or 3 heteroatoms selected from nitrogen atoms, oxygen atoms and sulfur atoms, where the nitrogen and sulfur heteroatoms may also optionally be oxidized.
  • the heterocyclic group may be attached at a heteroatom or a carbon atom.
  • Exemplary monocyclic heterocyclic groups include pyrrolidinyl, pyrrolyl, pyrazolyl, oxetanyl, pyrazolinyl, imidazolyl, imidazolinyl, imidazolidinyl, oxazolyl, oxazolidinyl, isoxazolinyl, isoxazolyl, thiazolyl, thiadiazolyl, thiazolidinyl, isothiazolyl, isothiazolidinyl, furyl, tetrahydrofuryl, thienyl, oxadiazolyl, piperidinyl, piperazinyl, 2 oxopiperazinyl, 2 oxopiperidinyl, 2 oxopyrrolodinyl, 2 oxoazepinyl, azepinyl, 4 piperidonyl, pyridyl, pyrazinyl, pyrimidinyl,
  • bicyclic heterocyclic groups include indolyl, dihydroidolyl, benzothiazolyl, benzoxazinyl, benzoxazolyl, benzothienyl, benzothiazinyl, quinuclidinyl, quinolinyl, tetrahydroquinolinyl, decahydroquinolinyl, isoquinolinyl, tetrahydroisoquinolinyl, decahydroisoquinolinyl, benzimidazolyl, benzopyranyl, indolizinyl, benzofuryl, chromonyl, coumarinyl, benzopyranyl, benzodiazepinyl, cinnolinyl, quinoxalinyl, indazolyl, pyrrolopyridyl, furopyridinyl (such as furo[2,3 c]pyridinyl, furo[3,2 b]- pyridinyl]
  • Exemplary tricyclic heterocyclic groups include carbazolyl, dibenzoazepinyl, dithienoazepinyl, benzindolyl, phenanthrolinyl, acridinyl, phenanthridinyl, phenoxazinyl, phenothiazinyl, xanthenyl, carbolinyl and the like.
  • heterocyclyl includes substituted heterocyclic groups.
  • Substituted heterocyclic groups refer to heterocyclic groups that are substituted with 1, 2 or 3 substituents selected from the group consisting of the following: (a) optionally substituted alkyl; (b) hydroxy (or protected hydroxy);
  • alkoxycarbonyl such as unsubstituted lower alkoxycarbonyl
  • heterocyclooxy denotes a heterocyclic group bonded through an oxygen bridge.
  • heteroaryl refers to an aromatic heterocycle, for example monocyclic or bicyclic aryl, such as pyrrolyl, pyrazolyl, imidazolyl, oxazolyl, isoxazolyl, thiazolyl, isothiazolyl, furyl, thienyl, pyridyl, pyrazinyl, pyrimidinyl, pyridazinyl, indolyl, benzothiazolyl, benzoxazolyl, benzothienyl, quinolinyl, isoquinolinyl, benzimidazolyl, benzofuryl, and the like, optionally substituted by e.g. lower alkyl, lower alkoxy or halo.
  • heteroarylsulfonyl refers to heteroaryl S(O) 2 .
  • heteroaroyl refers to heteroaryl-C(O)-.
  • heteroaroylamino refers to heteroaryl-C(O)NH-.
  • heteroaryl refers to a heteroaryl group bonded through an alkyl group.
  • heteroaralkanoyl refers to heteroaralkyl-C(O)-.
  • heteroaralkanoylamino refers to heteroaralkyl-C(O)NH-.
  • acyl refers to alkanoyl, cycloalkanoyl, aroyl, heteroaroyl, aralkanoyl, heteroaralkanoyl and the like.
  • acyloxy refers to alkanoyloxy, cycloalkanoyloxy, aroyloxy, heteroaroyloxy, aralkanoyloxy, heteroaralkanoyloxy and the like.
  • acylamino refers to alkanoylamino, cycloalkanoylamino, aroylamino, heteroaroylamino, aralkanoylamino, heteroaralkanoylamino and the like.
  • esteerified carboxy refers to optionally substituted alkoxycarbonyl, cycloalkoxycarbonyl, aryloxycarbonyl, aralkoxycarbonyl, heterocyclooxycarbonyl and the like.
  • salts of any compound useful in the present invention refer to salts formed with bases, namely cationic salts such as alkali and alkaline earth metal salts, such as sodium, lithium, potassium, calcium, magnesium, as well as ammonium salts, such as ammonium, trimethylammonium, diethylammonium, and tris(hydroxymethyl)-methyl- i ammonium salts, and salts with amino acids.
  • bases namely cationic salts such as alkali and alkaline earth metal salts, such as sodium, lithium, potassium, calcium, magnesium, as well as ammonium salts, such as ammonium, trimethylammonium, diethylammonium, and tris(hydroxymethyl)-methyl- i ammonium salts, and salts with amino acids.
  • acid addition salts such as those formed with mineral acids, organic carboxylic acids and organic sulfonic acids e.g. hydrochloric acid, maleic acid and methanesulfonic acid, are possible provided a basic group, such as pyridyl, constitutes part of the structure.
  • protecting groups The purpose of introducing protecting groups is to protect the functional groups from undesired reactions with reaction components under the conditions used for carrying out a desired chemical transformation.
  • the need and choice of protecting groups for a particular reaction is known to those skilled in the art and depends on the nature of the functional group to be protected (hydroxyl group, amino group, etc.), the structure and stability of the molecule of which the substituent is a part and the reaction conditions.
  • Well known protecting groups that meet these conditions and their introduction and removal are described, for example, in McOmie, "Protective Groups in Organic Chemistry", Plenum Press, London, New York (1973); and Greene and Wuts, "Protective Groups in Organic Synthesis", John Wiley and Sons, Inc, New York (1999).
  • diluent preferably such as are inert to the reagents and are solvents thereof, of catalysts, condensing or said other agents respectively and/or inert atmospheres, at low temperatures, room temperature or elevated temperatures (preferably at or near the boiling point of the solvents used), and at atmospheric or super-atmospheric pressure.
  • the invention further includes any variant of the present processes, in which an intermediate product obtainable at any stage thereof is used as starting material and the remaining steps are carried out, or in which the starting materials are formed in situ under the reaction conditions, or in which the reaction components are used in the form of their salts or optically pure antipodes.
  • the compounds may be in the form of one of the possible isomers or mixtures thereof, for example, as substantially pure geometric (cis or trans) isomers, optical isomers (enantiomers, antipodes), racemates, or mixtures thereof.
  • the aforesaid possible isomers or mixtures thereof are within the purview of this invention.
  • Any resulting mixtures of isomers can be separated on the basis of the physico-chemical differences of the constituents, into the pure geometric or optical isomers, diastereoisomers, racemates, for example by chromatography and/or fractional crystallization.
  • Any resulting racemates of final products or intermediates can be resolved into the optical antipodes by known methods, e.g. by separation of the diastereoisomeric salts thereof, obtained with an optically active acid or base, and liberating the optically active acidic or basic compound.
  • the carboxylic acid intermediates can thus be resolved into their optical antipodes e.g.
  • Racemic products can also be resolved by chiral chromatography, e.g. high pressure liquid chromatography using a chiral adsorbent.
  • compounds useful in the invention are either obtained in the free form, as a salt thereof if salt forming groups are present or as prodrug derivatives thereof.
  • the NH-group of the l,l-dioxo-l,2,5-thiadiazolidin-3-one moiety may be converted into salts with pharmaceutically acceptable bases.
  • Salts may be formed using conventional methods, advantageously in the presence of an ethereal or alcoholic solvent, such as a lower alkanol. From the solutions of the latter, the salts may be precipitated with ethers, e.g. diethyl ether. Resulting salts may be converted into the free compounds by treatment with acids. These or other salts can also be used for purification of the compounds obtained.
  • Compounds useful in the invention having basic groups can be converted into acid addition salts, especially pharmaceutically acceptable salts. These are formed, for example, with inorganic acids, such as mineral acids, for example sulfuric acid, a phosphoric or hydrohalic acid, or with organic carboxylic acids, such as (Cj- 4 )alkanecarboxylic acids which, for example, are unsubstituted or substituted by halogen, for example acetic acid, such as saturated or unsaturated dicarboxylic acids, for example oxalic, succinic, maleic or fumaric acid, such as hydroxy-carboxylic acids, for example glycolic, lactic, malic, tartaric or citric acid, such as amino acids, for example aspartic or glutamic acid, or with organic sulfonic acids, such as (Ci- 4 )alkyl-sulfonic acids (for example methanesulfonic acid) or arylsulfonic acids which are unsubstituted or substituted (
  • Prodrug derivatives of any compound of the present invention are derivatives of said compounds which following administration release the parent compound in vivo via some chemical or physiological process, e.g., a prodrug on being brought to the physiological pH or through enzyme action is converted to the parent compound.
  • exemplary prodrug derivatives are, e.g., esters of free carboxylic acids and S-acyl and O-acyl derivatives of thiols, alcohols or phenols, wherein acyl has a meaning as defined herein.
  • ester derivatives convertible by solvolysis under physiological conditions to the parent carboxylic acid, e.g., lower alkyl esters, cycloalkyl esters, lower alkenyl esters, benzyl esters, mono- or di-substituted lower alkyl esters, such as the ⁇ -(amino, mono- or di-lower alkylamino, carboxy, lower alkoxycarbonyl)-lower alkyl esters, the ⁇ -(lower alkanoyloxy, lower alkoxycarbonyl or di-lower alkylaminocarbonyl)-lower alkyl esters, such as the pivaloyloxymethyl ester and the like conventionally used in the art.
  • lower alkyl esters e.g., lower alkyl esters, cycloalkyl esters, lower alkenyl esters, benzyl esters, mono- or di-substituted lower alkyl esters, such as the ⁇ -(
  • prodrug derivatives In view of the close relationship between the free compounds, the prodrug derivatives and the compounds in the form of their salts, whenever a compound is referred to in this context, a prodrug derivative and a corresponding salt is also intended, provided such is possible or appropriate under the circumstances.
  • the compounds, including their salts, can also be obtained in the form of their hydrates, or include other solvents used for their crystallization.
  • the pharmacologically active compounds useful in the invention may be employed in the manufacture of pharmaceutical compositions comprising an effective amount thereof in conjunction or admixture with excipients or carriers suitable for either enteral or parenteral application.
  • compositions may be sterilized and/or contain adjuvants, such as preserving, stabilizing, wetting or emulsifying agents, solution promoters, salts for regulating the osmotic pressure and/or buffers. In addition, they may also contain other therapeutically valuable substances.
  • adjuvants such as preserving, stabilizing, wetting or emulsifying agents, solution promoters, salts for regulating the osmotic pressure and/or buffers.
  • Said compositions are prepared according to conventional mixing, granulating or coating methods, respectively, and contain about 0.1-75%, preferably about 1-50%, of the active ingredient.
  • transdermal devices are in the form of a bandage comprising a backing member, a reservoir containing the compound optionally with carriers, optionally a rate controlling barrier to deliver the compound of the skin of the host at a controlled and predetermined rate over a prolonged period of time, and means to secure the device to the skin.
  • compositions useful in the invention may contain a therapeutically effective amount of a compound as defined above, either alone or in a combination with another therapeutic agent, e.g., each at an effective therapeutic dose as reported in the art.
  • a compound that can be administered along with the PTP inhibitor is human insulin-like growth factorl or IGFl, however formulated or stabilized, such as INCRELEXTM as developed by Tercica or as described in US 2006/0166328.
  • the structure of the therapeutic agents identified by code numbers, generic or trade names may be taken from the actual edition of the standard compendium "The Merck Index" or from databases, e.g., Patents International (e.g. IMS World Publications). The corresponding content thereof is hereby incorporated by reference.
  • treatment embraces all the different forms or modes of treatment as known to those of the pertinent art and in particular includes preventive, curative, delay of progression and palliative treatment.
  • the above-cited properties are demonstrable in vitro and in vivo tests, using advantageously mammals, e.g., mice, rats, dogs, monkeys or isolated organs, tissues and preparations thereof.
  • Said compounds can be applied in vitro in the form of solutions, e.g. preferably aqueous solutions, and in vivo either enterally, parenterally, advantageously intravenously, e.g. as a suspension or in aqueous solution.
  • the dosage in vitro may range between about 10 molar and 10 molar concentrations.
  • a therapeutically effective amount in vivo may range depending on the route of administration, between about 1 and 500 mg/kg, preferably between about 5 and 100 mg/kg.
  • the activity of a compound according to the invention may be assessed by the following methods or by following methods well described in the art (e.g. Peters G. et al. J. Biol. Chem, 2000, 275, 18201-09).
  • PTP-IB inhibitory activity in vitro may be determined as follows:
  • hPTP-lB Human PTP-IB activity in the presence of various agents is determined by measuring the amount of inorganic phosphate released from a phosphopeptide substrate using a 96-well microtiter plate format.
  • the assay (100 ⁇ L) is performed in an assay buffer comprised of 50 mM TRIS (pH 7.5), 50 mM NaCl, 3 mM DTT at ambient temperature.
  • the assay is typically performed in the presence of 0.4% dimethyl sulfoxide (DMSO). However, concentrations as high as 10% are used with certain poorly soluble compounds.
  • DMSO dimethyl sulfoxide
  • a typical reaction is initiated by the addition of 0.4 pmoles of hPTP-lB (amino acids 1-411) to wells containing assay buffer, 3 nmoles of the synthetic phosphopeptide substrate (GNGDp YMPMSPKS), and the test compound. After 10 min, 180 ⁇ L malachite green reagent (0.88 mM malachite green, 8.2 mM ammonium molybdate, aqueous 1 N HCl, and 0.01% Triton X-100) is added to terminate the reaction.
  • malachite green reagent (0.88 mM malachite green, 8.2 mM ammonium molybdate, aqueous 1 N HCl, and 0.01% Triton X-100
  • Inorganic phosphate a product of the enzyme reaction, is quantitiated after 15 min as the green color resulting from complexing with the Malichite reagent and is determined as an A 62 o using a Molecular Devices (Sunnyvale, CA) SpectraMAX Plus spectrophotometer. Test compounds are solubilized in 100 % DMSO (Sigma, D-8779) and diluted in DMSO. Activity is defined as the net change in absorbance resulting from the activity of the uninhibited hPTP-lB ⁇ n ] minus that of a tube with acid-inactivated hPTP- IB n-4 H].
  • the hPTP- IB [I-4 H] is cloned by PCR from a human hippocampal cDNA library (Clonetech) and inserted into a pET 19-b vector (Novagen) at the Ncol restriction site.
  • E. coli strain BL21 (DE3) is transformed with this clone and stored as a stock culture in 20% glycerol at -80° C.
  • a stock culture is inoculated into LB/Amp and grown at 37 0 C.
  • the assessment of human PTP-IB activity in the presence of various agents may be determined by measuring the hydrolysis products of known competing substrates. For example, cleavage of substrate para-nitrophenylphosphate (pNPP) results in the release of the yellow-colored para-nitrophenol (pNP) which can be monitored in real time using a spectrophotometer. Likewise, the hydrolysis of the fluorogenic substrate 6,8- difluoro-4-methylumbelliferyl phosphate ammonium salt (DiFMUP) results in the release of the fluorescent DiFMU which can be readily followed in a continuous mode with a fluorescence reader (Anal. Biochem. 273, 41, 1999; Anal. Biochem. 338, 32, 2005):
  • DiFMUP Assay Compounds are incubated with 1 nM recombinant human PTP-lB [ i -298] or PTP-IB [I-322] in buffer (50 mM Hepes, pH 7.0, 50 mM KCl, 1 mM EDTA, 3 mM DTT, 0.05% NP-40 (or 0.001% BSA) for 5 min at room temperature. The reaction is initiated by the addition of DiFMUP (6 ⁇ M final concentration) and run kinetically on fluorescence plate reader at 355 nm excitation and 460 nm emission wavelengths. Reaction rates over 15 min are used to calculate inhibition.
  • PTP-lB [ i -298] is expressed in E. coli BL21(DE3) containing plasmids constucted using pET19b vectors (Novagen).
  • the bacteria is grown in minimal media using an "On Demand" Fed-batch strategy. Typically, a 5.5 liter fermentation is initiated in Fed-batch mode and grown overnight unattended at 37 0 C. Optical densities varied between 20-24 OD 6O o and the cultrures are induced at 3O 0 C with IPTG to a final concentration of 0.5 mM.
  • the bacterial cells are harvested 8 hours later and yield 200-350 gm (wet weight). The cells are frozen as pellets and stored at -8O 0 C until use.
  • the pellet is collected at 35,000 x g, resuspended in 25 mL of lysis buffer using a Polytron and collected as before. The two supernatants are combined and centrifuged for 30 min at 100,000 x g. The soluble lysate could be stored at this stage at -80 0 C or used for further purification. Diafiltration using a 10 kD MWCO membrane is used to buffer exchange the protein and reduce the NaCl concentration prior to cation exchange chromatography. Diafiltration buffer contained 50 mM MES, 75 mM NaCl, 5 mM DTT, pH 6.5.
  • Soluble supernatant is then loaded onto a POROS 20 SP (1 x 10 cm) column equilibrated with cation exchange buffer (50 mM MES and 75 mM NaCl, pH 6.5) at a rate of 20 mL/min.
  • An analytical column (4.6 x 100 mm) is run in a similar fashion except the flow rate was reduced to 10 mL/min.
  • Protein is eluted from the column using a linear salt gradient (75-500 mM NaCl in 25 CV).
  • Fractions containing PTP-IBf 1-298] are identified and pooled according to SDS-PAGE analyses. Final purification is performed using Sephacryl S-100 HR (Pharmacia).
  • the column (2.6 x 35 cm) is equilibrated with 50 mM HEPES, 100 mM NaCl, 3 mM DTT, pH 7.5 and run at a flow rate of 2 mL/min.
  • the final protein is pooled and concentrated to ⁇ 5 mg/mL using an Ultrafree-15 concentrator (Millipore) with a MWCO 10,000.
  • the concentrated protein is stored at -80 0 C until use.
  • Ligand binding is detected by acquiring 1 H- 15 N HSQC spectra on 250 ⁇ L of 0.15 mM PTP-IB [I-298] in the presence and absence of added compound (1-2 mM). The binding is determined by the observation of 15 N- or ⁇ -amide chemical shift changes in two dimensional HSQC spectra upon the addition of a compound to 15 N-label protein. Because of the 15 N spectral editing, no signal from the ligand is observed, only protein signals. Thus, binding can be detected at high compound concentrations. Compounds which caused a pattern of chemical shift changes similar to the changes seen with known active site binders are considered positive.
  • Cells (-15 g) are thawed briefly at 37 0 C and resuspended in 50 mL of lysis buffer containing 50 mM Tris-HCl, 150 mM NaCl, 5 mM DTT, pH 8.0 containing one tablet of Complete (EDTA-free) protease cocktail (Boehringer Mannheim), 100 ⁇ M PMSF and 100 ⁇ g/mL DNase I.
  • the cells are lysed by sonication.
  • the pellet is collected at 35,000 x g, resuspended in 25 mL of lysis buffer using a Polytron and collected as before.
  • the two supernatants are combined and centrifuged for 30 min at 100,000 x g.
  • Diafiltration using a 10 kD MWCO membrane is used to buffer exchange the protein and reduce the NaCl concentration prior to cation exchange chromatography.
  • Diafiltration buffer contained 50 mM MES, 75 mM NaCl, 5 mM DTT, pH 6.5. Soluble supernatant is then loaded onto a POROS 20 SP (1 x 10 cm) column equilibrated with cation exchange buffer (50 mM MES and 75 mM NaCl, pH 6.5) at a rate of 20 mL/min. Protein is eluted from the column using a linear salt gradient (75-500 mM NaCl in 25 CV). Fractions containing PTP- lB's are identified and pooled according to SDS-PAGE analyses.
  • PTP-lBi -29 g is further purified by anion exchange chromatography using a POROS 20 HQ column (1 x 10 cm).
  • the pool from cation exchange chromatography is concentrated and buffer exchanged in 50 mM Tris-HCl, pH 7.5 containing 75 mM NaCl and 5 mM DTT.
  • Protein is loaded onto column at 20 mL/min and eluted using a linear NaCl gradient (75-500 mM in 25 CV).
  • Final purification is performed using Sephacryl S-100 HR (Pharmacia)(50 mM HEPES, 100 mM NaCl, 3 mM DTT, pH 7.5 ).
  • a PTP inhibitor is useful for the treatment of musculoskeletal disease, particularly muscle atrophy.
  • the following in vitro and animal model assays can be used.
  • C2C12 cells can be obtained from the American Type Tissue Culture Bank and propagated in standard growth media containing 10% horse serum. When cells reached 70% confluency the media is changed to differentiation media containing 2% horse serum. Three days after start of differentiation multinucleated myotubes should be present, with visible striations, indicating differentiation.
  • IGFl can be used as a positive control for activating the IGF-I receptor, or alternatively, combined with a PTPlB inhibitor to assess synergistic or additive effects. Consequently, PTPlB inhibitors and/or IGFl can be added to the media for various times.
  • Myotube Diameter Myotube diameter can be assessed 24 hours after addition of PTPlB inhibitor and/or IGFl to myotube media.
  • Cells are washed in saline and fixed in gluteraldehyde. Images can be obtained on an inverted microscope using the green fluorescent channel to visualize the auto- fluorescence induced by the gluteraldehyde fixation. Images are printed out at standard magnification and the sixty largest myotubes measured at their largest diameter (as previously published). The fifty largest myotubes in each group can be statistically compared using the Kruskal-Wallis One Way Analysis on Ranks. Differences are considered significant if p ⁇ 0.05 and designated by an asterisk in Figure 1.
  • pAKT assay Phosphorylation levels of AKT a protein that is phosphorylated when the IGFl protein binds to its receptor
  • pAKT ELISA kit Cell Signaling, Pathscan 7160
  • Cell Signaling, Pathscan 7170 Cell Signaling, Pathscan 7170
  • pIGFR assay Phosphorylation levels of the IGF receptor in cell cultures can be assessed by lysis of the cells, immunoprecipitation of the IGFR using anti-IGFR antibodies (Transduction Laboratories, Lexington, KY, USA), Western blot analysis using anti- phosphotyrosine antibodies (Upstate Biotechnology, USA). See, e.g., Shefi-Friedman et al., Am J Physiol Endocrinol Metab 281 :E16-E24, 2001.
  • PTPlB inhibitors and IGFl IGF 1R3 can be purchased from Sigma-Aldrich (12656) and added to culture media at a concentration of 10ng/ml. Multiple PTPlB inhibitors can be tested with or without IGFl .
  • a PTP inhibitor can act to increase skeletal muscle mass under an exercise context that already leads to muscle hypertrophy
  • the voluntary cage wheel eliminates physical and psychological insults that are common in forced exercised models, and are therefore more appropriate for evaluating candidate drugs that are used in relatively healthy individuals for whom increases in muscle mass is desirable.
  • mice can be randomly assigned to experimental (e.g., receiving PTP inhibitor) and control groups. Animals are individually housed in a cage containing an exercise wheel; sedentary control animals are housed in identical cages without a wheel.
  • the exercise wheels are described in Allen et al., J Appl Physiol 90:1900-1908, 2001. Briefly, the system consists of an 11.5 cm-diameter wheel with a 5.0 cm-wide running surface (model 6208, Petsmart, Phoenix, AZ) equipped with a digital magnetic counter (model BC 600, Sigma Sport,
  • Olney, IL Olney, IL that is activated by wheel rotation.
  • each wheel is engineered with a resistance mechanism allowing adjustment of the load. This is accomplished by attaching stainless steel fishing line to the cage top and wrapping the wire around an immovable pulley that is secured to the cage wheel at the axis of rotation so as to not contribute to the wheel load. The wire is again secured to the cage top with a spring and screw. This design permits fine adjustments of the wheel load, which is evenly distributed throughout the rotation of the wheel.
  • Daily exercise values for time and distance run are recorded for each exercised animal throughout the duration of the exercise period. All animals are given water and standard hard rodent chow ad libitum. Voluntary running (cage wheel exposure) can begin at an average age of about 12 weeks for all groups.
  • Exercised and sedentary control animals are euthanized by cervical dislocation under inhaled anesthesia immediately after the end of the specific exercise period. Body mass is measured, and specific muscles are rapidly excised, washed, and frozen for histological or biochemical assays at a future date.
  • mice Heterozygous PTPlB null mice can be purchased from Deltagen (San Carlos, CA, USA) and mated to produce offspring that are null, heterozygous, or wild-type litter mates. Mice are housed under ACUC protocol 06 MG 0144 and maintained with food and water ad libitum in a 12 hour light cycle. Mice can be genotyped by PCR on tail biopsies.
  • the right sciatic nerve is resected during deep anesthesia under ACUC protocol 06 MG 0189. Briefly, anesthesia is induced using isofluorane inhalation, the right leg shaved and sterilized. An incision is then made through the skin of the lateral right leg and the sciatic nerve visualized. The nerve is cut and a 0.3 to 0.5 section removed to prevent reattachment. The incision was closed with wound clips and the mice returned to their cages for recovery from anesthesia. The contralateral leg is unperturbed and serves as internal control. Mice are euthanized 14 days after denervation surgery and muscles and other tissues isolated for further processing.
  • Muscle and Tissue Weight The following tissues can be dissected from PTPlB knock out knock out (KO), heterozygous (HET), and wild-type (WT) mice 14 days after denervation of the right hind limb: left and right tibialis anterior muscles, left and right extensor digitorum longus muscles, left and right soleus muscles, left and right gastrocnemius muscles, heart, liver, spleen, epididimal white adipose tissue, brown adipose tissue, and blood for serum isolation. Each tissue is freed from connective tissue and weighed, before being snap frozen for further analysis to be completed.
  • KO PTPlB knock out knock out
  • HET heterozygous mice
  • WT wild-type mice 14 days after denervation of the right hind limb: left and right tibialis anterior muscles, left and right extensor digitorum longus muscles, left and right soleus muscles, left and right gastrocnemius muscles, heart, liver,
  • C2C12 myotubes with PTPlB inhibitors can result in an increase in myotube size, when the diameter of the fifty largest myotubes is measured.
  • IGFl alone is added to C2C12 myotubes media at a concentration of 10ng/ml, myotubes can be significantly hypertrophied.
  • a PTP inhibitor can result in an increase in myotube diameter that is significantly bigger than the diameter of untreated myotubes. There might not be a statistical significance between cells treated with either IGFl or an inhibitor individually, but when myotubes are treated with both IGFl and an inhibitor simultaneously, this could result in a significant increase in myotube diameter when compared to the singly-treated cells.
  • IGFl and a PTP inhibitor act at least additively potentially synergistically to produce larger myotubes and therefore indicate that IGFl and a PTP inhibitor can be co-administered to a mammal to increase muscle mass or to treat muscle atrophy.
  • assay results can indicate that a PTP inhibitor is active alone, in which case use of the inhibitor in monotherapy to increase muscle mass or to treat muscle atrophy is indicated.
  • Figure 1 shows mean C2C12 myotube diameter from an experiment where two different PTPIb inhibitors were added to culture media +/- IGFl (mean +/- standard error of the mean). The results show a significant increase in myotube diameter by IGFl and compounds 2 alone.
  • PTPlB null mice can be used to test whether absence of PTPlB can prevent or ameliorate skeletal muscle atrophy.
  • muscle weight of denervated muscles is compared to contralateral muscles from the control leg (wet muscle weight is normalized to individual body weight).
  • WT mice lose about 40% of gastrocnemius muscle mass, compared with a 30% loss in heterozygous mice and 20% in homozygous null mice.
  • Half of the denervation-induced muscle atrophy is prevented in KO gastrocnemius muscle compared to WT gastrocnemius muscle
  • Figure 3 shows results from an experiment where WT, HET, and KO mice had their right leg denervated by sciatic nerve resection.
  • the ratios shown are mean fiber areas from the denervated limb divided by fiber area from the contralateral control limb (mean +/- standard error of the mean) and can show significantly less denervation-induced atrophy in HET and KO mice when compared to WT mice.
  • Phosphorylation of AKT is a downstream event of IGFlR phosphorylation.
  • Levels of AKT phosphorylation can be used as a read-out of activation of the IGFl pathway in C2C12 myotubes treated with a PTP inhibitor +/- IGFl for one hour.
  • a PTP inhibitor alone can increase phosphorylation levels of AKT by for example at least 50% (e.g., 65%).
  • IGF 1 treatment is known to cause AKT phosphorylation, but treatment of IGFl and a PTP inhibitor can further increases AKT phosphorylation by at least 25% (e.g., 35%) above that induced by IGF 1 alone. Treatment with an PTP inhibitor can therefore increase activation of the IGFl pathway, possibly resulting in a significant increase in myotube diameter in the manner described above.
  • results from experiments such as described above can indicate that PTP inhibitors, particularly PTPlB inhibitors, increase levels of pAKT, which in turn result in a physiological increase in myotube diameter.
  • Observations can include: • A PTP inhibitor causes a significant increase in C2C12 myotube diameter by itself and acts at least additively with IGFl in media to further increase myotube size.
  • a PTP inhibitor causes a significant increase in C2C12 myotubes when compared to untreated myotubes.
  • a PTP inhibitor exhibits in vitro or in vivo activity for increasing muscle mass, e.g., by way of modulating the IGFl signaling pathway at the level of AKT phosphorylation, such PTP inhibitors would then also be useful for other diseases known to be amenable to IGFl or human Growth Hormone treatment, such as dwarfism, low bone density or mineral content, osteoporosis or short stature.
  • Ri is hydrogen, -C(O)R 6 , -C(O)NR 7 R 8 or -C(O)OR 9 in which R 6 and R 7 are, independently from each other, hydrogen, cycloalkyl, aryl, heterocyclyl, aralkyl, heteroaralkyl or alkyl optionally substituted with one to four substituents selected from the group consisting of halogen, cycloalkyl, cycloalkoxy, alkoxy, alkyloxyalkoxy, amino, alkylamino, dialkylamino, aryl, aryloxy and heterocyclyl;
  • R 8 and R 9 are, independently from each other, cycloalkyl, aryl, heterocyclyl, aralkyl, heteroaralkyl or alkyl optionally substituted with one to four substituents selected from the group consisting of halogen, cycloalkyl, cycloalkoxy, alkoxy, alkyloxyalkoxy, amino, alkylamino, dialkylamino, aryl, aryloxy and heterocyclyl;
  • R 2 , R 3 , R 4 and R 5 are, independently from each other, hydrogen, hydroxy, halogen, cyano, nitro, alkoxy, alkylthio, alkylthiono, sulfonyl, free or esterified carboxy, carbamoyl, sulfamoyl, optionally substituted amino, cycloalkyl, aryl, heterocyclyl, alkenyl, alkynyl or (Ci -8 )alkyl optionally substituted with one to four substituents selected from the group consisting of halogen, hydroxy, cycloalkyl, cycloalkoxy, acyl, acyloxy, alkoxy, alkyloxyalkoxy, amino, alkylamino, dialkylamino, acylamino, carbamoyl, thiol, alkylthio, alkylthiono, sulfonyl, sulfonamido, sulfamo
  • R 2 and R 3 combined are alkylene which together with the ring atoms to which they are attached form a 3- to 7-membered fused ring; or
  • R 2 and R 3 combined are alkylene which together with the carbon atom to which they are attached form a 3- to 7-membered spirocyclic ring; or a pharmaceutically acceptable salt thereof.
  • Ri is hydrogen, -C(O)R 6 , -C(O)NR 7 R 8 or -C(O)OR 9 in which
  • R 6 and R 7 are, independently from each other, hydrogen, cycloalkyl, aryl, heterocyclyl, aralkyl, heteroaralkyl or alkyl optionally substituted with one to four substituents selected from the group consisting of halogen, cycloalkyl, cycloalkoxy, alkoxy, alkyloxyalkoxy, amino, alkylamino, dialkylamino, aryl, aryloxy and heterocyclyl;
  • R 8 and R 9 are, independently from each other, cycloalkyl, aryl, heterocyclyl, aralkyl, heteroaralkyl or alkyl optionally substituted with one to four substituents selected from the group consisting of halogen, cycloalkyl, cycloalkoxy, alkoxy, alkyloxyalkoxy, amino, alkylamino, dialkylamino, aryl, aryloxy and heterocyclyl;
  • R 2 , R 3 , R 4 and R 5 are, independently from each other, hydrogen, hydroxy, halogen, cyano, nitro, alkoxy, alkylthio, alkylthiono, sulfonyl, free or esterified carboxy, carbamoyl, sulfamoyl, optionally substituted amino, cycloalkyl, aryl, heterocyclyl, alkenyl, alkynyl or (Ci -8 )alkyl optionally substituted with one to four substituents selected from the group consisting of halogen, hydroxy, cycloalkyl, cycloalkoxy, acyl, acyloxy, alkoxy, alkyloxyalkoxy, amino, alkylamino, dialkylamino, acylamino, carbamoyl, thiol, alkylthio, alkylthiono, sulfonyl, sulfonamido, sulfamo
  • R 2 and R 3 combined are alkylene which together with the ring atoms to which they are attached form a 5- to 7-membered fused ring; or or a pharmaceutically acceptable salt thereof.
  • Ri is hydrogen, -C(O)R 6 , -C(O)NR 7 R 8 or -C(O)OR 9 in which
  • R 6 and R 7 are, independently from each other, hydrogen, cycloalkyl, aryl, heterocyclyl, aralkyl, heteroaralkyl or alkyl optionally substituted with one to four substituents selected from the group consisting of halogen, cycloalkyl, cycloalkoxy, alkoxy, alkyloxyalkoxy, amino, alkylamino, dialkylamino, aryl, aryloxy and heterocyclyl;
  • R 8 and R 9 are, independently from each other, cycloalkyl, aryl, heterocyclyl, aralkyl, heteroaralkyl or alkyl optionally substituted with one to four substituents selected from the group consisting of halogen, cycloalkyl, cycloalkoxy, alkoxy, alkyloxyalkoxy, amino, alkylamino, dialkylamino, aryl, aryloxy and heterocyclyl;
  • R 2 and R 3 are, independently from each other, hydrogen, hydroxy, halogen, cyano, nitro, alkoxy, alkylthio, alkylthiono, sulfonyl, free or esterified carboxy, carbamoyl, sulfamoyl, optionally substituted amino, cycloalkyl, aryl, heterocyclyl, alkenyl, alkynyl or (Ci.
  • alkyl optionally substituted with one to four substituents selected from the group consisting of halogen, hydroxy, cycloalkyl, cycloalkoxy, acyl, acyloxy, alkoxy, alkyloxyalkoxy, amino, alkylamino, dialkylamino, acylamino, carbamoyl, thiol, alkylthio, alkylthiono, sulfonyl, sulfonamido, sulfamoyl, nitro, cyano, free or esterified carboxy, aryl, aryloxy, arylthio, alkenyl, alkynyl, aralkoxy, heteroaralkoxy, heterocyclyl and heterocyclyloxy; or a pharmaceutically acceptable salt thereof.
  • substituents selected from the group consisting of halogen, hydroxy, cycloalkyl, cycloalkoxy, acyl, acyloxy, alkoxy, alky
  • R 2 is -Y-(CH 2 ) n -CRioRii-(CH 2 ) m -X in which
  • Y is oxygen or S(O) q in which q is zero or an integer of 1 or 2;
  • Y is absent; n is an integer from 1 to 6;
  • Rio and Rn are, independently from each other, hydrogen or lower alkyl; or Rio and Rn combined are alkylene which together with the carbon atom to which they are attached form a 3- to 7-membered ring; m is zero or an integer of 1 or 2; X is hydroxy, alkoxy, cycloalkyl, cycloalkoxy, acyl, acyloxy, carbamoyl, cyano, trifluoromethyl, free or esterified carboxy, monocyclic aryl or heterocyclyl; or a pharmaceutically acceptable salt thereof. Further preferred are compounds of formula (IB) wherein
  • R 3 is hydrogen; or a pharmaceutically acceptable salt thereof.
  • n is an integer of 2 or 3;
  • Rio and Rn are, independently from each other, hydrogen or lower alkyl; m is zero or 1; X is hydroxy, carbamoyl, cyano, trifluoromethyl, free or esterified carboxy, monocyclic aryl or heterocyclyl; or a pharmaceutically acceptable salt thereof.
  • Rio and Rn are lower alkyl; m is zero or 1;
  • X is hydroxy, cyano or free or esterified carboxy; or a pharmaceutically acceptable salt thereof.
  • R 10 and R 11 are methyl; or a pharmaceutically acceptable salt thereof.
  • R 1 is hydrogen or -C(O)R 6 in which R 6 is monocyclic aryl; or a pharmaceutically acceptable salt thereof.
  • R 1 is hydrogen or -C(O)R 6 , -C(O)NR 7 R 8 or -C(O)OR 9 in which
  • R 6 and R 7 are, independently from each other, hydrogen, cycloalkyl, aryl, heterocyclyl, aralkyl, heteroaralkyl or alkyl optionally substituted with one to four substituents selected from the group consisting of halogen, cycloalkyl, cycloalkoxy, alkoxy, alkyloxyalkoxy, amino, alkylamino, dialkylamino, aryl, aryloxy and heterocyclyl;
  • Rg and Rg are, independently from each other, cycloalkyl, aryl, heterocyclyl, aralkyl, heteroaralkyl or alkyl optionally substituted with one to four substituents selected from the group consisting of halogen, cycloalkyl, cycloalkoxy, alkoxy, alkyloxyalkoxy, amino, alkylamino, dialkylamino, aryl, aryloxy and heterocyclyl;
  • R 2 , R 3 , R 4 and R 5 are, independently from each other, hydrogen, hydroxy, halogen, cyano, nitro, alkoxy, alkylthio, alkylthiono, sulfonyl, free or esterified carboxy, carbamoyl, sulfamoyl, optionally substituted amino, cycloalkyl, aryl, heterocyclyl, alkenyl, alkynyl or (C 1-8 )alkyl optionally substituted with one to four substituents selected from the group consisting of halogen, hydroxy, cycloalkyl, cycloalkoxy, acyl, acyloxy, alkoxy, alkyloxyalkoxy, amino, alkylamino, dialkylamino, acylamino, carbamoyl, thiol, alkylthio, alkylthiono, sulfonyl, sulfonamido, sulfamoy
  • R 2 and R3 combined are alkylene which together with the carbon atom to which they are attached form a 3- to 7-membered spirocyclic ring; p is zero or 1; or a pharmaceutically acceptable salt thereof.
  • R 2 and R3 are, independently from each other, hydrogen, halogen or (Ci- 4 )alkyl optionally substituted by at least one halogen; or a pharmaceutically acceptable salt thereof.
  • Preferred are also compounds of formula (IC) wherein p is 1; or a pharmaceutically acceptable salt thereof.
  • Ri is hydrogen or -C(O)R 6 , -C(O)NR 7 R 8 or -C(O)OR 9 in which R 6 and R 7 are, independently from each other, hydrogen, cycloalkyl, aryl, heterocyclyl, aralkyl, heteroaralkyl or alkyl optionally substituted with one to four substituents selected from the group consisting of halogen, cycloalkyl, cycloalkoxy, alkoxy, alkyloxyalkoxy, amino, alkylamino, dialkylamino, aryl, aryloxy and heterocyclyl;
  • Rs and R 9 are, independently from each other, cycloalkyl, aryl, heterocyclyl, aralkyl, heteroaralkyl or alkyl optionally substituted with one to four substituents selected from the group consisting of halogen, cycloalkyl, cycloalkoxy, alkoxy, alkyloxyalkoxy, amino, alkylamin
  • R 2 , R 3 , R 4 and R 5 are, independently from each other, hydrogen, hydroxy, halogen, cyano, nitro, alkoxy, alkylthio, alkylthiono, sulfonyl, free or esterified carboxy, carbamoyl, sulfamoyl, optionally substituted amino, cycloalkyl, aryl, heterocyclyl, alkenyl, alkynyl or (Ci ⁇ alkyl optionally substituted with one to four substituents selected from the group consisting of halogen, hydroxy, cycloalkyl, cycloalkoxy, acyl, acyloxy, alkoxy, alkyloxyalkoxy, amino, alkylamino, dialkylamino, acylamino, carbamoyl, thiol, alkylthio, alkylthiono, sulfonyl, sulfonamido, sulfamoyl,
  • R 2 and R 3 are, independently from each other, hydrogen, halogen or (C ⁇ alkyl optionally substituted by at least one halogen; or a pharmaceutically acceptable salt thereof.
  • R 2 and R 3 are, independently from each other, hydrogen, halogen or (C ⁇ alkyl optionally substituted by at least one halogen; or a pharmaceutically acceptable salt thereof.
  • Ri is hydrogen or -C(O)R 6 in which R 6 is monocyclic aryl; or a pharmaceutically acceptable salt thereof.
  • Ri is hydrogen or -C(O)R 6 in which R 6 is monocyclic aryl; or a pharmaceutically acceptable salt thereof.
  • Y is oxygen or S(O) q in which q is zero or an integer of 1 or 2;
  • Y is absent; n is an integer from 1 to 6;
  • Rio and Rn are, independently from each other, hydrogen or lower alkyl; or Rio and Rn combined are alkylene which together with the carbon atom to which they are attached form a 3- to 7-membered ring; m is zero or an integer of 1 or 2; X is hydroxy, alkoxy, cycloalkyl, cycloalkoxy, acyl, acyloxy, carbamoyl, cyano, trifluoromethyl, free or esterified carboxy, monocyclic aryl or heterocyclyl; or a pharmaceutically acceptable salt thereof.
  • R 3 is hydrogen; or a pharmaceutically acceptable salt thereof.
  • n is an integer of 2 or 3;
  • Rio and Rn are, independently from each other, hydrogen or lower alkyl; m is zero or 1 ;
  • X is hydroxy, carbamoyl, cyano, trifluoromethyl, free or esterified carboxy, monocyclic aryl or heterocyclyl; or a pharmaceutically acceptable salt thereof.
  • Y is absent; or a pharmaceutically acceptable salt thereof.
  • Rio and Rn are lower alkyl; m is zero or 1 ;
  • X is hydroxy, cyano or free or esterified carboxy; or a pharmaceutically acceptable salt thereof.
  • Rio and Rn are methyl; or a pharmaceutically acceptable salt thereof.
  • Ri is hydrogen or -C(O)R 6 in which R 6 is monocyclic aryl; or a pharmaceutically acceptable salt thereof.
  • Particular embodiments are: 5-(3,6-Dihydroxynaphthalen-2-yl)-l,l-dioxo-l,2,5-thiadiazolidin-3-one;
  • Acetic acid 4-[6-hydroxy-7-(l,l,4-trioxo-l,2,5-thiadiazolidin-2-yl)-naphthalen-2-yl]-2- methyl butyl ester; 5-[3-Hydroxy-7-(5,5,5-trifluoro-4-hydroxypentyl)-naphthalen-2-yl]- 1,1 -dioxo- 1,2,5- thiadiazolidin-3-one;
  • Benzoic acid 6-(3-cyano-3-methylpro ⁇ yl)-3-(l,l,4-trioxo-l,2,5-thiadiazolidin-2-yl)- naphthalen-2-yl ester; 2,2-Dimethylpropionic acid 6-(3-cyano-3-methylpropyl)-3-(l,l,4-trioxo-l,2,5- thiadiazolidin-2-yl)-naphthalen-2-yl ester;
  • 2-Ethylbutyric acid 6-(3-cyano-3-methylpropyl)-3-(l,l,4-trioxo-l,2,5-thiadiazolidin-2- yl)-naphthalen-2-yl ester;
  • Hexanoic acid 6-(3-cyano-3-methylpropyl)-3-(l,l,4-trioxo-l,2,5-thiadiazolidin-2-yl)- naphthalen-2-yl ester;
  • Pentanoic acid 6-(3-cyano-3-methylpropyl)-3-(l,l,4-trioxo-l,2,5-thiadiazolidin-2-yl)- naphthalen-2-yl ester;
  • Ri is hydrogen, -C(O)R 2 , -C(O)NR 3 R 4 or -C(O)OR 5 in which R 2 and R 3 are, independently from each other, hydrogen, cycloalkyl, aryl, heterocyclyl, aralkyl, heteroaralkyl or alkyl optionally substituted with one to four substituents selected from the group consisting of halogen, cycloalkyl, cycloalkoxy, alkoxy, alkyloxyalkoxy, amino, alkylamino, dialkylamino, aryl, aryloxy and heterocyclyl; R 4 and R 5 are, independently from each other, cycloalkyl, aryl, heterocyclyl, aralkyl, heteroaralkyl or alkyl optionally substituted with one to four substituents selected from the group consisting of halogen, cycloalkyl, cycloalkoxy, alkoxy, alkyloxyalkoxy, amino, alkylamino
  • U, W and V are, independently from each other, hydrogen, hydroxy, halogen, cyano, nitro, alkoxy, alkylthio, alkylthiono, sulfonyl, free or esterified carboxy, carbamoyl, sulfamoyl, optionally substituted amino, cycloalkyl, aryl, aryloxy, arylthio, heterocyclyl, heterocycloyloxy, alkenyl, alkynyl or optionally substituted with one to four substituents selected from the group consisting of halogen, hydroxy, cycloalkyl, cycloalkoxy, acyl, acyloxy, alkoxy, alkyloxyalkoxy, amino, alkylamino, dialkylamino, acylamino, carbamoyl, thiol, alkylthio, alkylthiono, sulfonyl, sulfonamido, sulfamo
  • W and V combined together with the carbon atoms to which they are attached form an optionally substituted aromatic, or partially or fully saturated nonaromatic 5- to 8- membered carbocyclic or heterocyclic ring; or a pharmaceutically acceptable salt thereof.
  • V is hydrogen; or a pharmaceutically acceptable salt thereof.
  • Ri is hydrogen, -C(O)R 2 , -C(O)NR 3 R 4 or -C(O)OR 5 in which
  • R 2a and R 3a combined are alkylene which together with the carbon atom to which they are attached form a 3- to 7-membered spirocyclic ring; or a pharmaceutically acceptable salt thereof.
  • Ri is hydrogen, -C(O)R 2 , -C(O)NR 3 R 4 or -C(O)OR 5 in which
  • R 2 and R 3 are, independently from each other, hydrogen, cycloalkyl, aryl, heterocyclyl, aralkyl, heteroaralkyl or alkyl optionally substituted with one to four substituents selected from the group consisting of halogen, cycloalkyl, cycloalkoxy, alkoxy, alkyloxyalkoxy, amino, alkylamino, dialkylamino, aryl, aryloxy and heterocyclyl;
  • R 4 and R 5 are, independently from each other, cycloalkyl, aryl, heterocyclyl, aralkyl, heteroaralkyl or alkyl optionally substituted with one to four substituents selected from the group consisting of halogen, cycloalkyl, cycloalkoxy, alkoxy, alkyloxyalkoxy, amino, alkylamino, dialkylamino, aryl, aryloxy and heterocyclyl;
  • R2a, R3 a> IW and Rsa are, independently from each other, hydrogen, hydroxy, halogen, cyano, nitro, alkoxy, alkylthio, alkylthiono, sulfonyl, free or esterified carboxy, carbamoyl, sulfamoyl, optionally substituted amino, cycloalkyl, aryl, heterocyclyl, alkenyl, alkynyl or (Ci.g)alkyl optionally substituted with one to four substituents selected from the group consisting of halogen, hydroxy, cycloalkyl, cycloalkoxy, acyl, acyloxy, alkoxy, alkyloxyalkoxy, amino, alkylamino, dialkylamino, acylamino, carbamoyl, thiol, alkylthio, alkylthiono, sulfonyl, sulfonamido, sulfamo
  • R 1 is hydrogen, -C(O)R 2 , -C(O)NR 3 R 4 or -C(O)OR 5 in which
  • R 2 and R 3 are, independently from each other, hydrogen, cycloalkyl, aryl, heterocyclyl, aralkyl, heteroaralkyl or alkyl optionally substituted with one to four substituents selected from the group consisting of halogen, cycloalkyl, cycloalkoxy, alkoxy, alkyloxyalkoxy, amino, alkylamino, dialkylamino, aryl, aryloxy and heterocyclyl;
  • R 4 and R 5 are, independently from each other, cycloalkyl, aryl, heterocyclyl, aralkyl, heteroaralkyl or alkyl optionally substituted with one to four substituents selected from the group consisting of halogen, cycloalkyl, cycloalkoxy, alkoxy, alkyloxyalkoxy, amino, alkylamino, dialkylamino, aryl, aryloxy and heterocyclyl;
  • R 2a and R 3a are, independently from each other, hydrogen, hydroxy, halogen, cyano, nitro, alkoxy, alkylthio, alkylthiono, sulfonyl, free or esterified carboxy, carbamoyl, sulfamoyl, optionally substituted amino, cycloalkyl, aryl, heterocyclyl, alkenyl, alkynyl or (C 1- g)alkyl optionally substituted with one to four substituents selected from the group consisting of halogen, hydroxy, cycloalkyl, cycloalkoxy, acyl, acyloxy, alkoxy, alkyloxyalkoxy, amino, alkylamino, dialkylamino, acylamino, carbamoyl, thiol, alkylthio, alkylthiono, sulfonyl, sulfonamido, sulfamoyl, nitro,
  • R ⁇ a and R 7a are, independently from each other, hydrogen or lower alkyl; or R ⁇ a and R 7a combined are alkylene which together with the carbon atom to which they are attached form a 3- to 7-membered ring; m is zero or an integer of 1 or 2;
  • X a is hydroxy, alkoxy, cycloalkyl, cycloalkoxy, acyl, acyloxy, carbamoyl, cyano, trifluoromethyl, free or esterified carboxy, monocyclic aryl or heterocyclyl; or a pharmaceutically acceptable salt thereof.
  • R 3a is hydrogen; or a pharmaceutically acceptable salt thereof.
  • n is an integer of 2 or 3; and R 7a are, independently from each other, hydrogen or lower alkyl; m is zero or 1;
  • X a is hydroxy, carbamoyl, cyano, trifluoromethyl, free or esterified carboxy, monocyclic aryl or heterocyclyl; or a pharmaceutically acceptable salt thereof.
  • Y a is absent; or a pharmaceutically acceptable salt thereof.
  • R ⁇ a and R 7a are lower alkyl; m is zero or 1;
  • X a is hydroxy, cyano or free or esterified carboxy; or a pharmaceutically acceptable salt thereof.
  • R ⁇ a and R 7a are methyl; or a pharmaceutically acceptable salt thereof.
  • Ri is hydrogen or -C(O)R 2 in which R 2 is monocyclic aryl; or a pharmaceutically acceptable salt thereof.
  • R 1 is hydrogen, -C(O)R 2 , -C(O)NR 3 R 4 or -C(O)OR 5 in which
  • R 2 and R 3 are, independently from each other, hydrogen, cycloalkyl, aryl, heterocyclyl, aralkyl, heteroaralkyl or alkyl optionally substituted with one to four substituents selected from the group consisting of halogen, cycloalkyl, cycloalkoxy, alkoxy, alkyloxyalkoxy, amino, alkylamino, dialkylamino, aryl, aryloxy and heterocyclyl;
  • R 4 and R 5 are, independently from each other, cycloalkyl, aryl, heterocyclyl, aralkyl, heteroaralkyl or alkyl optionally substituted with one to four substituents selected from the group consisting of halogen, cycloalkyl, cycloalkoxy, alkoxy, alkyloxyalkoxy, amino, alkylamino, dialkylamino, aryl, aryloxy and heterocyclyl;
  • R2a, R3a, R4a and R 52 are, independently from each other, hydrogen, hydroxy, halogen, cyano, nitro, alkoxy, alkylthio, alkylthiono, sulfonyl, free or esterified carboxy, carbamoyl, sulfamoyl, optionally substituted amino, cycloalkyl, aryl, heterocyclyl, alkenyl, alkynyl or (Ci.s)alkyl optionally substituted with one to four substituents selected from the group consisting of halogen, hydroxy, cycloalkyl, cycloalkoxy, acyl, acyloxy, alkoxy, alkyloxyalkoxy, amino, alkylamino, dialkylamino, acylamino, carbamoyl, thiol, alkylthio, alkylthiono, sulfonyl, sulfonamido, sulfamo
  • R 2a and R 32 combined are alkylene which together with the carbon atom to which they are attached form a 3- to 7-membered spirocyclic ring; p is zero or 1 ; or a pharmaceutically acceptable salt thereof.
  • R 2a and R 3a are, independently from each other, hydrogen, halogen or (Ci ⁇ alkyl optionally substituted by at least one halogen; or a pharmaceutically acceptable salt thereof.
  • Ri is hydrogen, -C(O)R 2 , -C(O)NR 3 R 4 or -C(O)OR 5 in which
  • R 2 and R 3 are, independently from each other, hydrogen, cycloalkyl, aryl, heterocyclyl, aralkyl, heteroaralkyl or alkyl optionally substituted with one to four substituents selected from the group consisting of halogen, cycloalkyl, cycloalkoxy, alkoxy, alkyloxyalkoxy, amino, alkylamino, dialkylamino, aryl, aryloxy and heterocyclyl;
  • R 4 and R 5 are, independently from each other, cycloalkyl, aryl, heterocyclyl, aralkyl, heteroaralkyl or alkyl optionally substituted with one to four substituents selected from the group consisting of halogen, cycloalkyl, cycloalkoxy, alkoxy, alkyloxyalkoxy, amino, alkylamino, dialkylamino, aryl, aryloxy and heterocyclyl;
  • R2a, R3a, R4a and R 5a are, independently from each other, hydrogen, hydroxy, halogen, cyano, nitro, alkoxy, alkylthio, alkylthiono, sulfonyl, free or esterified carboxy, carbamoyl, sulfamoyl, optionally substituted amino, cycloalkyl, aryl, heterocyclyl, alkenyl, alkynyl or (Ci ⁇ alkyl optionally substituted with one to four substituents selected from the group consisting of halogen, hydroxy, cycloalkyl, cycloalkoxy, acyl, acyloxy, alkoxy, alkyloxyalkoxy, amino, alkylamino, dialkylamino, acylamino, carbamoyl, thiol, alkylthio, alkylthiono, sulfonyl, sulfonamido, sulfamoy
  • R 2a and R 3a combined are alkylene which together with the carbon atom to which they are attached form a 3- to 7-membered spirocyclic ring; or a pharmaceutically acceptable salt thereof.
  • R 2a and R 3a combined are alkylene which together with the carbon atom to which they are attached form a 3- to 5-membered spirocyclic ring; or a pharmaceutically acceptable salt thereof.
  • Ri is hydrogen or -C(O)R 2 in which R 2 is monocyclic aryl; or a pharmaceutically acceptable salt thereof.
  • Preferred are also compounds of formula (Ia 4 ), designated as the D group, wherein R 2a is -Y a -(CH 2 ) n -CR 6a R 7a -(CH 2 ) m -X a in which
  • R ⁇ a and R 7a are, independently from each other, hydrogen or lower alkyl; or R 63 and R 7a combined are alkylene which together with the carbon atom to which they are attached form a 3- to 7-membered ring; m is zero or an integer of 1 or 2; X 2 is hydroxy, alkoxy, cycloalkyl, cycloalkoxy, acyl, acyloxy, carbamoyl, cyano, trifluoromethyl, free or esterified carboxy, monocyclic aryl or heterocyclyl; or a pharmaceutically acceptable salt thereof.
  • R 3a is hydrogen; or a pharmaceutically acceptable salt thereof.
  • n is an integer of 2 or 3;
  • R 63 and R 7a are, independently from each other, hydrogen or lower alkyl; m is zero or 1 ;
  • X a is hydroxy, carbamoyl, cyano, trifluoromethyl, free or esterified carboxy, monocyclic aryl or heterocyclyl; or a pharmaceutically acceptable salt thereof.
  • Y 3 is absent; or a pharmaceutically acceptable salt thereof.
  • R ⁇ a and R 7a are lower alkyl; m is zero or 1 ;
  • Xa is hydroxy, cyano or free or esterified carboxy; or a pharmaceutically acceptable salt thereof.
  • R ⁇ a and R 7a are methyl; or a pharmaceutically acceptable salt thereof.
  • Ri is hydrogen or -C(O)R 2 in which R 2 is monocyclic aryl; or a pharmaceutically acceptable salt thereof.
  • U and V are hydrogen; W is aryloxy, arylthio or methyl substituted with monocyclic aryl; or a pharmaceutically acceptable salt thereof.
  • Ri is hydrogen, -C(O)R 2 , -C(O)NR 3 R 4 or -C(O)OR 5 in which
  • R 2 and R 3 are, independently from each other, hydrogen, cycloalkyl, aryl, heterocyclyl, aralkyl, heteroaralkyl or alkyl optionally substituted with one to four substituents selected from the group consisting of halogen, cycloalkyl, cycloalkoxy, alkoxy, alkyloxyalkoxy r amino, alkylamino, dialkylamino, aryl, aryloxy and heterocyclyl;
  • R 4 and R 5 are, independently from each other, cycloalkyl, aryl, heterocyclyl, aralkyl, heteroaralkyl or alkyl optionally substituted with one to four substituents selected from the group consisting of halogen, cycloalkyl, cycloalkoxy, alkoxy, alkyloxyalkoxy, amino, alkylamino, dialkylamino, aryl, aryloxy and heterocyclyl;
  • R 2b , R 3b and R ⁇ are, independently from each other, hydrogen, hydroxy, halogen, cyano, nitro, alkoxy, alkylthio, alkylthiono, sulfonyl, free or esterified carboxy, carbamoyl, sulfamoyl, optionally substituted amino, cycloalkyl, aryl, heterocyclyl, alkenyl, alkynyl or (Ci- 8 )alkyl optionally substituted with one to four
  • R 2b and R 3b combined are alkylene which together with the ring atoms to which they are attached form a 5- to 7-membered fused ring provided R 2 and R 3 are attached to carbon atoms adjacent to each other; or
  • R 2b and R 3b combined together with the carbon atom to which they are attached form a fused 5- to 6-membered aromatic or heteroaromatic ring provided R 2 and R 3 are attached to carbon atoms adjacent to each other;
  • X b is hydrogen, fluoro, cyano, or free or esterified carboxy; or Xb is -NRSbC(O)R 61 ,, -NR 5b C(O)OR 7b , -NR 5b S(O) 2 R 8b , -(CH 2 ) r S(O) 2 R 9b , -OS(O) 2 R 1 Ob or
  • Rs b is hydrogen, lower alkyl, acyl, alkoxycarbonyl or sulfonyl
  • R 6 ⁇ R 7b , R ⁇ b , R 9b and Rio b are, independently from each other, cycloalkyl, aryl, heterocyclyl, aralkyl, heteroaralkyl or (Ci -8 )alkyl optionally substituted with one to four substituents selected from the group consisting of halogen, hydroxy, cycloalkyl, cycloalkoxy, acyl, acyloxy, alkoxy, alkyloxyalkoxy, amino, alkylamino, dialkylamino, acylamino, carbamoyl, thiol, alkylthio, alkylthiono, sulfonyl, sulfonamido, sulfamoyl, nitro, cyano, free or esterified carboxy, aryl, aryloxy, arylthio, alkenyl, alkynyl, aralkoxy, heteroaralkoxy, heterocyclyl
  • R t3b and Ri 4b are, independently from each other, hydrogen, alkyl, cycloalkyl, aralkyl, aryl or heterocyclyl; or
  • Ri 3b and Ri 4b combined are alkylene which together with the nitrogen atom to which they are attached form a 4- to 7-membered ring;
  • R ⁇ b and Ri 2b are, independently from each other, hydrogen, alkyl, cycloalkyl, aralkyl, aryl or heterocyclyl; or
  • R ⁇ b and Ri 2b combined are alkylene which together with the nitrogen atom to which they are attached form a 4- to 7-membered ring; r and s are, independently from each other, zero or an integer of 1; or C-X b is replaced by nitrogen;
  • Y b is O, S or CH 2 ; or a pharmaceutically acceptable salt thereof.
  • Yb is CH 2 ; or a pharmaceutically acceptable salt thereof. Further preferred are the compounds of formula (Ib) having the formula
  • R is hydrogen, -C(O)R 2 , -C(O)NR 3 R 4 or -C(O)OR 5 in which R 2 and R 3 are, independently from each other, hydrogen, cycloalkyl, aryl, heterocyclyl, aralkyl, heteroaralkyl or alkyl optionally substituted with one to four substituents selected from the group consisting of halogen, cycloalkyl, cycloalkoxy, alkoxy, alkyloxyalkoxy, amino, alkylamino, dialkylamino, aryl, aryloxy and heterocyclyl; R 4 and R 5 are, independently from each other, cycloalkyl, aryl, heterocyclyl, aralkyl, heteroaralkyl or alkyl optionally substituted with one to four substituents selected from the group consisting of halogen, cycloalkyl, cycloalkoxy, alkoxy, alkyloxyalkoxy, amino, alkylamino
  • R2t > , R 3 b and R ⁇ are, independently from each other, hydrogen, hydroxy, halogen, cyano, nitro, alkoxy, alkylthio, alkylthiono, sulfonyl, free or esterified carboxy, carbamoyl, sulfamoyl, optionally substituted amino, cycloalkyl, aryl, heterocyclyl, alkenyl, alkynyl or (Ci.g)alkyl optionally substituted with one to four substituents selected from the group consisting of halogen, hydroxy, cycloalkyl, cycloalkoxy, acyl, acyloxy, alkoxy, alkyloxyalkoxy, amino, alkylamino, dialkylamino, acylamino, carbamoyl, thiol, alkylthio, alkylthiono, sulfonyl, sulfonamido, sulfamoy
  • R 2b and R 3b combined together with the carbon atom to which they are attached form a fused 5- to 6-membered aromatic or heteroaromatic ring;
  • X b is cyano;
  • X b is -NR5bC(O)R6b, -NR 5b C(O)OR 7b , -NR 5b S(O) 2 R 8 b, -(CH 2 ) r S(O) 2 R 9b or -OS(O) 2 R 10b in which
  • R 5b is hydrogen or lower alkyl
  • R ⁇ b, R7b > Rsb > RB and Rjob are, independently from each other, cycloalkyl, aryl, heterocyclyl, aralkyl, heteroaralkyl or (Ci_ 8 )alkyl optionally substituted with one to four substituents selected from the group consisting of halogen, hydroxy, cycloalkyl, cycloalkoxy, acyl, acyloxy, alkoxy, alkyloxyalkoxy, amino, alkylamino, dialkylamino, acylamino, carbamoyl, thiol, alkylthio, alkylthiono, sulfonyl, sulfonamido, sulfamoyl, nitro, cyano, free or esterified carboxy, aryl, aryloxy, arylthio, alkenyl, alkynyl, aralkoxy, heteroaralkoxy, heterocyclyl and heterocyclyloxy
  • R ⁇ b, R ⁇ b and R% are, independently from each other, -NR ⁇ bRub in which
  • Ri3 b and Ri4 b are, independently from each other, hydrogen, alkyl, cycloalkyl, aralkyl, aryl or heterocyclyl; or
  • Ri 3b and R ⁇ b combined are alkylene which together with the nitrogen atom to which they are attached form a 4- to 7-membered ring; r is zero; or
  • C-X b is replaced by nitrogen; or a pharmaceutically acceptable salt thereof.
  • Xb is -NR 5b S(O) 2 R 8b or -OS(O) 2 R ]0 b in which
  • Rs b is hydrogen or lower alkyl
  • R 8b and Rio b are, independently from each other, cycloalkyl, aryl, heterocyclyl, aralkyl, heteroaralkyl or (Cj. 8 )alkyl optionally substituted with one to four substituents selected from the group consisting of halogen, hydroxy, cycloalkyl, cycloalkoxy, acyl, acyloxy, alkoxy, alkyloxyalkoxy, amino, alkylamino, dialkylamino, acylamino, carbamoyl, thiol, alkylthio, alkylthiono, sulfonyl, sulfonamido, sulfamoyl, nitro, cyano, free or esterified carboxy, aryl, aryloxy, arylthio, alkenyl, alkynyl, aralkoxy, heteroaralkoxy, heterocyclyl and heterocyclyloxy; or a pharmaceutically acceptable salt thereof
  • R 5b is hydrogen; or a pharmaceutically acceptable salt thereof.
  • Rgb and Riob are, independently from each other, monocyclic aryl or or a pharmaceutically acceptable salt thereof.
  • Ri is hydrogen or -C(O)R 2 in which R 2 is monocyclic aryl; or a pharmaceutically acceptable salt thereof.
  • R2 b> R3b and R4b are, independently from each other, hydrogen, halogen, hydroxy, monocyclic aryl, C( 1-4 )alkoxy or optionally substituted with at least one halogen; or a pharmaceutically acceptable salt thereof.
  • R 8b and Rio b are, independently from each other, monocyclic aryl or C(i_ 4 )alkyl; or a pharmaceutically acceptable salt thereof.
  • Ri is hydrogen or -C(O)R 2 in which R 2 is monocyclic aryl; or a pharmaceutically acceptable salt thereof.
  • Ri is hydrogen, -C(O)R 2 , -C(O)NR 3 R 4 or -C(O)OR 5 in which R 2 and R 3 are, independently from each other, hydrogen, cycloalkyl, aryl, heterocyclyl, aralkyl, heteroaralkyl or alkyl optionally substituted with one to four substituents selected from the group consisting of halogen, cycloalkyl, cycloalkoxy, alkoxy, alkyloxyalkoxy, amino, alkylamino, dialkylamino, aryl, aryloxy and heterocyclyl;
  • R 4 and R 5 are, independently from each other, cycloalkyl, aryl, heterocyclyl, aralkyl, heteroaralkyl or alkyl optionally substituted with one to four substituents selected from the group consisting of halogen, cycloalkyl, cycloalkoxy, alkoxy, alkyloxyalkoxy, amino, alkylamino, dialkylamino, aryl, aryloxy and heterocyclyl;
  • U is alkoxy, alkylthio, alkylthiono, sulfonyl, cycloalkyl, aryl, aryloxy, heterocyclyl, alkenyl, alkynyl or (Ci -8 )alkyl optionally substituted with one to four substituents selected from the group consisting of halogen, hydroxy, cycloalkyl, cycloalkoxy, acyl, acyloxy, alkoxy, alkyloxyalkoxy, optionally substituted amino, carbamoyl, thiol, alkylthio, alkylthiono, sulfonyl, sulfamoyl, nitro, cyano, free or esterified carboxy, aryl, aryloxy, arylthio, alkenyl, alkynyl, aralkoxy, heteroaralkoxy, heterocyclyl and heterocyclyloxy;
  • W and V are, independently from each other, hydrogen, halogen, (Ci -3 )alkyl or (Ci -3 )alkoxy; or a pharmaceutically acceptable salt thereof.
  • Y c is oxygen or S(O) V in which v is zero or an integer of 1 or 2; or Y c is C ⁇ C; or
  • Y c is absent; p and t are, independently from each other, zero or an integer from 1 to 8; R 2c and R 3c are, independently from each other, hydrogen or lower alkyl; or R 2c and R 3c combined are alkylene which together with the carbon atom to which they are attached form a 3- to 7-membered ring;
  • X 0 is hydroxy, alkoxy, cycloalkyl, cycloalkoxy, acyl, acyloxy, carbamoyl, optionally substituted amino, cyano, trifluoromethyl, free or esterified carboxy, heterocyclyl, monocyclic aryl or monocyclic aryloxy; or a pharmaceutically acceptable salt thereof.
  • R 2c and R 3c are hydrogen; or a pharmaceutically acceptable salt thereof.
  • R 2c and R 3c are, independently from each other, hydrogen or lower alkyl
  • X 0 is hydroxy, carbamoyl, cyano, trifluoromethyl, free or esterified carboxy, heterocyclyl, monocyclic aryl or monocyclic aryloxy; or a pharmaceutically acceptable salt thereof.
  • Y c is C ⁇ C; or Y c is absent; or a pharmaceutically acceptable salt thereof.
  • X 0 is hydroxy, cyano or free or esterified carboxy; or a pharmaceutically acceptable salt thereof.
  • R 2c and R 3c are methyl; or a pharmaceutically acceptable salt thereof.
  • Ri is hydrogen or -C(O)R 2 in which R 2 is monocyclic aryl; or a pharmaceutically acceptable salt thereof.
  • Y c is absent; p is an integer of 4 or 5; t is zero;
  • R 2c and R ⁇ c are hydrogen
  • X 0 is monocyclic aryloxy; or a pharmaceutically acceptable salt thereof.
  • Ri is hydrogen or -C(O)R 2 in which R 2 is monocyclic aryl; or a pharmaceutically acceptable salt thereof.
  • R 2c and R 3c are hydrogen; X 0 is hydroxy, cyano or free or esterified carboxy; or a pharmaceutically acceptable salt thereof.
  • X 0 is hydroxy, cyano or free or esterified carboxy; or a pharmaceutically acceptable salt thereof.
  • Preferred are the compounds in the K group wherein Ri is hydrogen or -C(O)R 2 in which R 2 is monocyclic aryl; or a pharmaceutically acceptable salt thereof.
  • Ri is hydrogen, -C(O)R 2 , -C(O)NR 3 R 4 or -C(O)OR 5 in which
  • R 2 and R 3 are, independently from each other, hydrogen, cycloalkyl, aryl, heterocyclyl, aralkyl, heteroaralkyl or alkyl optionally substituted with one to four substituents selected from the group consisting of halogen, cycloalkyl, cycloalkoxy, alkoxy, alkyloxyalkoxy, amino, alkylamino, dialkylamino, aryl, aryloxy and heterocyclyl;
  • R 4 and R 5 are, independently from each other, cycloalkyl, aryl, heterocyclyl, aralkyl, heteroaralkyl or alkyl optionally substituted with one to four substituents selected from the group consisting of halogen, cycloalkyl, cycloalkoxy, alkoxy, alkyloxyalkoxy, amino, alkylamino, dialkylamino, aryl, aryloxy and heterocyclyl;
  • R 4C , R 5C and R 60 are, independently from each other, hydrogen, hydroxy, halogen, cyano, nitro, alkoxy, alkylthio, alkylthiono, sulfonyl, free or esterified carboxy, carbamoyl, sulfamoyl, optionally substituted amino, cycloalkyl, aryl, heterocyclyl, alkenyl, alkynyl or (Ci.
  • alkyl optionally substituted with one to four substituents selected from the group consisting of halogen, hydroxy, cycloalkyl, cycloalkoxy, acyl, acyloxy, alkoxy, alkyloxyalkoxy, optionally substituted amino, carbamoyl, thiol, alkylthio, alkylthiono, sulfonyl, sulfamoyl, nitro, cyano, free or esterified carboxy, aryl, aryloxy, arylthio, alkenyl, alkynyl, aralkoxy, heteroaralkoxy, heterocyclyl and heterocyclyloxy; or C-R 4C , C-R 5C and C-R 60 are, independently from each other, replaced by nitrogen; or a pharmaceutically acceptable salt thereof.
  • Ri is hydrogen or -C(O)R 2 in which R 2 is monocyclic aryl; or a pharmaceutically acceptable salt thereof.
  • Ri is hydrogen, -C(O)R 2 , -C(O)NR 3 R 4 or -C(O)OR 5 in which R 2 and R 3 are, independently from each other, hydrogen, cycloalkyl, aryl, heterocyclyl, aralkyl, heteroaralkyl or alkyl optionally substituted with one to four substituents selected from the group consisting of halogen, cycloalkyl, cycloalkoxy, alkoxy, alkyloxyalkoxy, amino, alkylamino, dialkylamino, aryl, aryloxy and heterocyclyl; R 4 and R 5 are, independently from each other, cycloalkyl, aryl, heterocyclyl, aralkyl, heteroaralkyl or alkyl optionally substituted with one to four substituents selected from the group consisting of halogen, cycloalkyl, cycloalkoxy, alkoxy, alkyloxyalkoxy, amino, alkylamin
  • R 7c is hydrogen, sulfonyl, cycloalkyl, aryl, heterocyclyl or (Ci -8 )alkyl optionally substituted with one to four substituents selected from the group consisting of halogen, hydroxy, cycloalkyl, cycloalkoxy, acyl, acyloxy, alkoxy, alkyloxyalkoxy, optionally substituted amino, carbamoyl, thiol, alkylthio, alkylthiono, sulfonyl, sulfamoyl, nitro, cyano, free or esterified carboxy, aryl, aryloxy, arylthio, alkenyl, alkynyl, aralkoxy, heteroaralkoxy, heterocyclyl and heterocyclyloxy; R 8C and R 9C are, independently from each other, hydrogen or lower alkyl; or
  • C-R 8c and C-R 9C are, independently from each other, replaced by nitrogen; or a pharmaceutically acceptable salt thereof.
  • C-R 8C is replaced by nitrogen; R9c is hydrogen; or a pharmaceutically acceptable salt thereof.
  • Ri is hydrogen, -C(O)R 2 , -C(O)NR 3 R 4 or -C(O)OR 5 in which
  • R 2 and R 3 are, independently from each other, hydrogen, cycloalkyl, aryl, heterocyclyl, aralkyl, heteroaralkyl or alkyl optionally substituted with one to four substituents selected from the group consisting of halogen, cycloalkyl, cycloalkoxy, alkoxy, alkyloxyalkoxy, amino, alkylamino, dialkylamino, aryl, aryloxy and heterocyclyl;
  • R 4 and Rs are, independently from each other, cycloalkyl, aryl, heterocyclyl, aralkyl, heteroaralkyl or alkyl optionally substituted with one to four substituents selected from the group consisting of halogen, cycloalkyl, cycloalkoxy, alkoxy, alkyloxyalkoxy, amino, alkylamino, dialkylamino, aryl, aryloxy and heterocyclyl;
  • R 7c is hydrogen, sulfonyl, cycloalkyl, aryl, heterocyclyl or (Ci.g)alkyl optionally substituted with one to four substituents selected from the group consisting of halogen, hydroxy, cycloalkyl, cycloalkoxy, acyl, acyloxy, alkoxy, alkyloxyalkoxy, optionally substituted amino, carbamoyl, thiol, alkylthio, alkylthiono, sulfonyl, sulfamoyl, nitro, cyano, free or esterified carboxy, aryl, aryloxy, arylthio, alkenyl, alkynyl, aralkoxy, heteroaralkoxy, heterocyclyl and heterocyclyloxy; or a pharmaceutically acceptable salt thereof.
  • R 7c is -(CH 2 ) p -CRio c Rii c -(CH 2 ),-Z c in which p and t are, independently from each other, zero or an integer from 1 to 6;
  • RiOc and Rn c are, independently from each other, hydrogen or lower alkyl; or
  • Ri Oc and Rj i c combined are alkylene which together with the carbon atom to which they are attached form a 3- to 7-membered ring;
  • Z c is hydroxy, alkoxy, cycloalkyl, cycloalkoxy, acyl, acyloxy, carbamoyl, optionally substituted amino, cyano, trifluoromethyl, free or esterified carboxy, heterocyclyl, monocyclic aryl or monocyclic aryloxy; or a pharmaceutically acceptable salt thereof.
  • Ri Oc and Ri lc are, independently from each other, hydrogen or lower alkyl; Z c is hydroxy, carbamoyl, cyano, trifluoromethyl, free or esterified carboxy, heterocyclyl, monocyclic aryl or monocyclic aryloxy; or a pharmaceutically acceptable salt thereof.
  • Ri Oc and Ri lc are hydrogen; Z c is hydroxy, cyano or free or esterified carboxy; or a pharmaceutically acceptable salt thereof.
  • Ri is hydrogen or -C(O)R 2 in which R 2 is monocyclic aryl; or a pharmaceutically acceptable salt thereof.
  • Benzoic acid 4-fluoro-3-(l,l,4-trioxo-l,2,5-thiadiazolidin-2-yl)-naphthalen-2-yl ester;
  • Benzoic acid 4-fluoro-6-(5-hydroxy-4,4-dimethylpentyl)-3-(l,l,4-trioxo- 1,2,5- thiadiazolidin-2-yl)-naphthalen-2-yl ester; Benzoic acid 3-fluoro-5-(2-methanesulfonyloxy-5-rnethylbenzyl)-2-( 1,1, 4-trioxo- 1,2,5- thiadiazolidin-2-yl)-phenyl ester;
  • Benzoic acid 4-(6-cyano-6,6-dimethylhexyl)-3-fluoro-2-( 1,1, 4-trioxo- 1,2,5- thiadiazolidin-2-yl)-phenyl ester; Benzoic acid 3-fluoro-5-(2-methanesulfonylamino-5-methylbenzyl)-2-( 1 , 1 ,4-trioxo-
  • Y is oxygen or S(O) q in which q is zero or an integer of 1 or 2; or Y is C ⁇ Q or
  • Y is absent; n and m are, independently from each other, zero or an integer from 1 to 8;
  • R 8 and R 9 are, independently from each other, hydrogen or lower alkyl
  • R 8 and R 9 combined are alkylene which together with the carbon atom to which they are attached form a 3- to 7-membered ring;
  • X is hydroxy, alkoxy, cycloalkyl, cycloalkoxy, acyl, acyloxy, carbamoyl, optionally substituted amino, cyano, trifluoromethyl, free or esterified carboxy, heterocyclyl, monocyclic aryl or monocyclic aryloxy; or a pharmaceutically acceptable salt thereof.
  • R 2 and R 3 are hydrogen; or a pharmaceutically acceptable salt thereof.
  • n is zero or an integer from 1 to 3;
  • m is zero or 1 ;
  • R 8 and R 9 are, independently from each other, hydrogen or lower alkyl
  • X is hydroxy, carbamoyl, cyano, trifluoromethyl, free or esterified carboxy, heterocyclyl, monocyclic aryl or monocyclic aryloxy; or a pharmaceutically acceptable salt thereof.
  • B group the compounds in the A group, designated as the B group, wherein
  • Y is C ⁇ C; or Y is absent; or a pharmaceutically acceptable salt thereof.
  • Y is absent; n is an integer of 5 or 6; m is zero or 1 ;
  • X is hydroxy, cyano or free or esterified carboxy; or a pharmaceutically acceptable salt thereof.
  • Rg and R 9 are methyl; or a pharmaceutically acceptable salt thereof.
  • Ri is hydrogen or -C(O)R 4 in which R 4 is monocyclic aryl; or a pharmaceutically acceptable salt thereof.
  • R 8 and R 9 are hydrogen
  • X is monocyclic aryloxy; or a pharmaceutically acceptable salt thereof.
  • Preferred are the compounds in the C group wherein
  • Ri is hydrogen or -C(O)R 4 in which R 4 is monocyclic aryl; or a pharmaceutically acceptable salt thereof.
  • Rg and R 9 are hydrogen; X is hydroxy, cyano or free or esterified carboxy; or a pharmaceutically acceptable salt thereof.
  • R 2 and R 3 are hydrogen; or a pharmaceutically acceptable salt thereof.
  • Ri is hydrogen, -C(O)R 4 , -C(O)NR 5 R 6 or -C(O)OR 7 in which
  • R 4 and R 5 are, independently from each other, hydrogen, cycloalkyl, aryl, heterocyclyl, aralkyl, heteroaralkyl or alkyl optionally substituted with one to four substituents selected from the group consisting of halogen, cycloalkyl, cycloalkoxy, alkoxy, alkyloxyalkoxy, amino, alkylamino, dialkylamino, aryl, aryloxy and heterocyclyl;
  • R 6 and R 7 are, independently from each other, cycloalkyl, aryl, heterocyclyl, aralkyl, heteroaralkyl or alkyl optionally substituted with one to four substituents selected from the group consisting of halogen, cycloalkyl, cycloalkoxy, alkoxy, alkyloxyalkoxy, amino, alkylamino, dialkylamino, aryl, aryloxy and heterocyclyl;
  • Rio, Rn and Ri 2 are, independently from each other, hydrogen, hydroxy, halogen, cyano, nitro, alkoxy, alkylthio, alkylthiono, sulfonyl, free or esterified carboxy, carbamoyl, sulfamoyl, optionally substituted amino, cycloalkyl, aryl, heterocyclyl, alkenyl, alkynyl or (Ci -8 )alkyl optionally substituted with one to four substituents selected from the group consisting of halogen, hydroxy, cycloalkyl, cycloalkoxy, acyl, acyloxy, alkoxy, alkyloxyalkoxy, optionally substituted amino, carbamoyl, thiol, alkylthio, alkylthiono, sulfonyl, sulfamoyl, nitro, cyano, free or esterified carboxy, aryl, aryloxy, ary
  • R is hydrogen or -C(O)R 4 in which R 4 is monocyclic aryl; or a pharmaceutically acceptable salt thereof.
  • R is hydrogen, -C(O)R 4 , -C(O)NR 5 R 6 or -C(O)OR 7 in which
  • R 4 and R 5 are, independently from each other, hydrogen, cycloalkyl, aryl, heterocyclyl, aralkyl, heteroaralkyl or alkyl optionally substituted with one to four substituents selected from the group consisting of halogen, cycloalkyl, cycloalkoxy, alkoxy, alkyloxyalkoxy, amino, alkylamino, dialkylamino, aryl, aryloxy and heterocyclyl;
  • R 6 and R 7 are, independently from each other, cycloalkyl, aryl, heterocyclyl, aralkyl, heteroaralkyl or alkyl optionally substituted with one to four substituents selected from the group consisting of halogen, cycloalkyl, cycloalkoxy, alkoxy, alkyloxyalkoxy, amino, alkylamino, dialkylamino, aryl, aryloxy and heterocyclyl;
  • Ri 3 is hydrogen, sulfon
  • Ri 5 is hydrogen; or a pharmaceutically acceptable salt thereof.
  • Ri is hydrogen, -C(O)R 4 , -C(O)NR 5 R 6 or -C(O)OR 7 in which R 4 and R 5 are, independently from each other, hydrogen, cycloalkyl, aryl, heterocyclyl, aralkyl, heteroaralkyl or alkyl optionally substituted with one to four substituents selected from the group consisting of halogen, cycloalkyl, cycloalkoxy, alkoxy, alkyloxyalkoxy, amino, alkylamino, dialkylamino, aryl, aryloxy and heterocyclyl;
  • R 6 and R 7 are, independently from each other, cycloalkyl, aryl, heterocyclyl, aralkyl, heteroaralkyl or alkyl optionally substituted with one to four substituents selected from the group consisting of halogen, cycloalkyl, cycloalkoxy, alkoxy, alkyloxyalkoxy, amino, alkylamino, dialkylamino, aryl, aryloxy and heterocyclyl;
  • R B is hydrogen, sulfonyl, cycloalkyl, aryl, heterocyclyl or (Ci -8 )alkyl optionally substituted with one to four substituents selected from the group consisting of halogen, hydroxy, cycloalkyl, cycloalkoxy, acyl, acyloxy, alkoxy, alkyloxyalkoxy, optionally substituted amino, carbamoyl, thiol, alkylthio, alkylthiono, sulfonyl, sulfamoyl, nitro, cyano, free or esterified carboxy, aryl, aryloxy, arylthio, alkenyl, alkynyl, aralkoxy, heteroaralkoxy, heterocyclyl and heterocyclyloxy; or a pharmaceutically acceptable salt thereof.
  • R 13 is -(CH 2 ) n -CR 16 R 17 -(CH 2 ) m -Z in which n and m are, independently from each other, zero or an integer from 1 to 6; Ri 6 and R] 7 are, independently from each other, hydrogen or lower alkyl; or
  • Ri 6 and R ]7 combined are alkylene which together with the carbon atom to which they are attached form a 3- to 7-membered ring;
  • Z is hydroxy, alkoxy, cycloalkyl, cycloalkoxy, acyl, acyloxy, carbamoyl, optionally substituted amino, cyano, trifluoromethyl, free or esterified carboxy, heterocyclyl, monocyclic aryl or monocyclic aryloxy; or a pharmaceutically acceptable salt thereof.
  • Ri 6 and R] 7 are, independently from each other, hydrogen or lower alkyl
  • Z is hydroxy, carbamoyl, cyano, trifluoromethyl, free or esterified carboxy, heterocyclyl, monocyclic aryl or monocyclic aryloxy; or a pharmaceutically acceptable salt thereof.
  • Ri 6 and Ri 7 are hydrogen;
  • Z is hydroxy, cyano or free or esterified carboxy; or a pharmaceutically acceptable salt thereof.
  • Ri is hydrogen or -C(O)R 4 in which R 4 is monocyclic aryl; or a pharmaceutically acceptable salt thereof.
  • Benzoic acid 4-(6-cyano-6,6-dimethylhexyl)-2-( 1 , 1 ,4-trioxo- 1 ,2,5-thiadiazolidin-2-yl)- phenylester; or a pharmaceutically acceptable salt thereof.
  • R 1 is hydrogen, -C(O)R 5 , -C(O)NR 6 R 7 or -C(O)OR 8 in which
  • R 5 and R 6 are, independently from each other, hydrogen, cycloalkyl, aryl, heterocyclyl, aralkyl, heteroaralkyl or alkyl optionally substituted with one to four substituents selected from the group consisting of halogen, cycloalkyl, cycloalkoxy, alkoxy, alkyloxyalkoxy, amino, alkylamino, dialkylamino, aryl, aryloxy and heterocyclyl;
  • R 7 and R 8 are, independently from each other, cycloalkyl, aryl, heterocyclyl, aralkyl, heteroaralkyl or alkyl optionally substituted with one to four substituents selected from the group consisting of halogen, cycloalkyl, cycloalkoxy, alkoxy, alkyloxyalkoxy, amino, alkylamino, dialkylamino, aryl, aryloxy and heterocyclyl;
  • R 2 , R 3 and R 4 are, independently from each other, hydrogen, hydroxy, halogen, cyano, nitro, alkoxy, alkylthio, alkylthiono, sulfonyl, free or esterified carboxy, carbamoyl, sulfamoyl, optionally substituted amino, cycloalkyl, aryl, heterocyclyl, alkenyl, alkynyl or (Ci_ 8 )alkyl optionally substituted with one to four substituent
  • R 2 and R 3 combined together with the carbon atom to which they are attached form a fused 5- to 6-membered aromatic or heteroaromatic ring provided R 2 and R 3 are attached to carbon atoms adjacent to each other;
  • X is hydrogen, fluoro, cyano, or free or esterified carboxy;
  • X is -NR 9 C(O)R 10 , -NR 9 C(O)OR n , -NR 9 S(O) 2 R 12 , -(CH 2 ) m S(O) 2 R 13 , -OS(O) 2 R 14 or -O n C(O)NR 15 R 16 in which
  • R 9 is hydrogen, lower alkyl, acyl, alkoxycarbonyl or sulfonyl;
  • R 10 , R 11 , R 12 , R ⁇ and R 14 are, independently from each other, cycloalkyl, aryl, heterocyclyl, aralkyl, heteroaralkyl or (C 1-8 )alkyl optionally substituted with one to four substituents selected from the group consisting of halogen, hydroxy, cycloalkyl, cycloalkoxy, acyl, acyloxy, alkoxy, alkyloxyalkoxy, amino, alkylamino, dialkylamino, acylamino, carbamoyl, thiol, alkylthio, alkylthiono, sulfonyl, sulfonamido, sulfamoyl, nitro, cyano, free or esterified carboxy, aryl, aryloxy, arylthio, alken
  • Ri 7 and Rig are, independently from each other, hydrogen, alkyl, cycloalkyl, aralkyl, aryl or heterocyclyl; or
  • Ri 7 and Rig combined are alkylene which together with the nitrogen atom to which they are attached form a 4- to 7-membered ring; Ri 5 and Ri 6 are, independently from each other, hydrogen, alkyl, cycloalkyl, aralkyl, aryl or heterocyclyl; or
  • R1 5 and R) 6 combined are alkylene which together with the nitrogen atom to which they are attached form a 4- to 7-membered ring; m and n are, independently from each other, zero or an integer of 1 ; or C-X is replaced by nitrogen;
  • Y is CH 2 , O or S; or a pharmaceutically acceptable salt thereof.
  • Ri is hydrogen, -C(O)R 5 , -C(O)NR 6 R 7 or -C(O)OR 8 in which R. 5 and R 6 are, independently from each other, hydrogen, cycloalkyl, aryl, heterocyclyl, aralkyl, heteroaralkyl or alkyl optionally substituted with one to four substituents selected from the group consisting of halogen, cycloalkyl, cycloalkoxy, alkoxy, alkyloxyalkoxy, amino, alkylamino, dialkylamino, aryl, aryloxy and heterocyclyl; R 7 and R$ are, independently from each other, cycloalkyl, aryl, heterocyclyl, aralkyl, heteroaralkyl or alkyl optionally substituted with one to four substituents selected from the group consisting of halogen, cycloalkyl, cycloalkoxy, alkoxy, alkyloxyalkoxy, amino, alkylamin
  • R 2 and R 3 combined are alkylene which together with the ring atoms to which they are attached form a 5- to 7-membered fused ring; or R 2 and R 3 combined together with the carbon atom to which they are attached form a fused 5- to 6-membered aromatic or heteroaromatic ring;
  • X is cyano;
  • X is -NR 9 C(O)Ri 0 , -NR 9 C(O)ORn, -NR 9 S(O) 2 Rj 2 , -(CH 2 ) m S(O) 2 Ri 3 or -OS(O) 2 Ri 4 in which R 9 is hydrogen or lower alkyl;
  • Rio, Rn, Ri 2 , Rn and R J4 are, independently from each other, cycloalkyl, aryl, heterocyclyl, aralkyl, heteroaralkyl or (Ci_ 8 )alkyl optionally substituted with one to four substituents selected from the group consisting of halogen, hydroxy, cycloalkyl, cycloalkoxy, acyl, acyloxy, alkoxy, alkyloxyalkoxy, amino, alkylamino, dialkylamino, acylamino, carbamoyl, thiol, alkylthio, alkylthiono, sulfonyl, sulfonamido, sulfamoyl, nitro, cyano, free or esterified carboxy, aryl, aryloxy, arylthio, alkenyl, alkynyl, aralkoxy, heteroaralkoxy, heterocyclyl and heterocyclyloxy;
  • Ri 7 and Ri 8 combined are alkylene which together with the nitrogen atom to which they are attached form a 4- to 7-membered ring; m is zero; or
  • C-X is replaced by nitrogen; or a pharmaceutically acceptable salt thereof.
  • X is cyano
  • X is -NR 9 S(O) 2 Ri 2 or -OS(O) 2 Ri 4 in which R 9 is hydrogen or lower alkyl;
  • Ri 2 and Ri 4 are, independently from each other, cycloalkyl, aryl, heterocyclyl, aralkyl, heteroaralkyl or (Ci. 8 )alkyl optionally substituted with one to four substituents selected from the group consisting of halogen, hydroxy, cycloalkyl, cycloalkoxy, acyl, acyloxy, alkoxy, alkyloxyalkoxy, amino, alkylamino, dialkylamino, acylamino, carbamoyl, thiol, alkylthio, alkylthiono, sulfonyl, sulfonamido, sulfamoyl, nitro, cyano, free or esterified carboxy, aryl, aryloxy, arylthio, alkenyl, alkynyl, aralkoxy, heteroaralkoxy, heterocyclyl and heterocyclyloxy; or a pharmaceutically acceptable salt thereof.
  • Ri 2 and R ⁇ are, independently from each other, monocyclic aryl or C ⁇ j alkyl; or a pharmaceutically acceptable salt thereof.
  • Ri is hydrogen or -C(O)R 5 in which R 5 is monocyclic aryl; or a pharmaceutically acceptable salt thereof.
  • R 2 , R 3 and R 4 are, independently from each other, hydrogen, halogen, hydroxy, monocyclic aryl, optionally substituted with at least one halogen; or a pharmaceutically acceptable salt thereof.
  • R 9 is hydrogen; or a pharmaceutically acceptable salt thereof.
  • Ri 2 and Ri 4 are, independently from each other, monocyclic aryl or C (I-4 ⁇ IlCyI; or a pharmaceutically acceptable salt thereof.
  • Ri is hydrogen or -C(O)R 5 in which R 5 is monocyclic aryl; or a pharmaceutically acceptable salt thereof.
  • Ethanesulfonic acid ⁇ 2-[3-hydroxy-4-( 1 , 1 ,4-trioxo- 1 ,2,5-thiadiazolidin-2-yl)-benzyl]- phenyl ⁇ -amide;
  • Propane- 1 -sulfonic acid ⁇ 2-[3-hydroxy-4-(l,l,4-trioxo-l,2,5-thiadiazolidin-2-yl)-benzyl]- phenyl ⁇ -amide;
  • Butane- 1 -sulfonic acid ⁇ 2-[3-hydroxy-4-(l,l,4-trioxo-l,2,5-thiadiazolidin-2-yl)-benzyl]- phenyl ⁇ -amide;
  • Methanesulfonic acid 2-[3-hydroxy-4-(l,l,4-trioxo-l,2,5-thiadiazolidin-2-yl)-benzyl]-4- methoxyphenyl ester;
  • Methanesulfonic acid 4-chloro-2-[3-hydroxy-4-(l,l,4-trioxo-l,2,5-thiadiazolidin-2-yl)- benzyl]-6-methylphenyl ester;
  • Propane-2-sulfonic acid ⁇ 4-fluoro-2-[3-hydroxy-4-(l,l,4-trioxo-l,2,5-thiadiazolidin-2- yl)-benzyl]-phenyl ⁇ -amide;
  • Propane- 1 -sulfonic acid ⁇ 2-[3-hydroxy-4-(l,l,4-trioxo-l,2,5-thiadiazolidin-2-yl)-benzyl]-
  • Methanesulfonic acid 4-tert-butyl-2-[3-hydroxy-4-( 1,1, 4-trioxo-l, 2,5-thiadiazolidin-2- yl)-benzyl]-phenyl ester;
  • Ethanesulfonic acid ⁇ 2-[3-hydroxy-4-( 1,1, 4-trioxo-l, 2,5-thiadiazolidin-2-yl)-benzyl]-4- methoxypheny 1 ⁇ -amide;
  • Propane- 1 -sulfonic acid ⁇ 2-[3-hydroxy-4-( 1,1, 4-trioxo-l, 2,5-thiadiazolidin-2 -yl)-benzyl]-
  • Methanesulfonic acid 5-chloro-2-[3-hydroxy-4-(l,l,4-trioxo-l,2,5-thiadiazolidin-2-yl)- benzyl]-phenyl ester; Methanesulfonic acid 2-[3-hydroxy-4-(l,l,4-trioxo-l,2,5-thiadiazolidin-2-yl)-benzyl]-5- methoxyphenyl ester;
  • Benzoic acid 5-[2-(benzoylmethanesulfonylamino)-benzyl]-2-(l,l,4-trioxo-l,2,5- thiadiazolidin-2-yl)-phenyl ester;
  • 2-Amino-3-methylbutyric acid 5-(2-methanesulfonyloxy-benzyl)-2-(l,l,4-trioxo-l,2,5- thiadiazolidin-2-yl)-phenyl ester;
  • Q is: i) -X, or ii) -Y-(CH 2 ) n -(CR 8 R 9 ) p -(CH 2 ) m -Z-X in which
  • Y is cyclopropyl
  • Y is absent; n and m are, independently from each other, zero or an integer from 1 to 8; R 8 and R 9 are, independently from each other, hydrogen, hydroxyl, alkoxy, alkanoyl, alkanoylamino, alkoxycarbonyl, aralkyl, heteroaryl, heterocyclyl, carbamoyl, aryl, or alkyl; or
  • R 8 and R 9 combined are alkylene which together with the carbon atom to which they are attached form a 3- to 7-membered ring; p is zero or an integer selected from 1 or 2 Z is absent; Z is -C(O)-O-; or Z is -C(O)-; or Z is -C(O)-NR ⁇ -alkylene- or -C(O)-NR ⁇ -alkylene-O-, wherein Ra is H or lower alkyl; or
  • Z is -CO-NR ⁇ -(CH 2 ) n .-(CR 8 R 9 )p-(CH 2 ) m . - or -C(O)-NR ⁇ -(CH 2 ) n -(CR 8 .R 9 )p- (CH 2 ) m - -O-, wherein p' is zero or an integer of 1, n' and m' are, independently from each other, zero or an integer from 1 to 8, R 8 - and R 9 - are, independently from each other, hydrogen or lower alkyl, Ra is H or lower alkyl; or
  • Z is -NR ⁇ '-C(O)-, or -NR ⁇ '-C(O)-O-, wherein Ra' is H or lower alkyl, or Ra' and R 9 combined are alkylene which together with the carbon atom to which they are attached form a 3- to 7-membered ring; or Z is -C(O)-NH-NH-C(O)-O-; or Z is -S(O) 2 -, or -S(O)-; or
  • Z is -NRp-S(O) 2 - , wherein R ⁇ is H, lower alkyl, or R ⁇ and R 9 combined are alkylene which together with the carbon atom to which they are attached form a 3- to 7-membered ring; or Z is -NH-S(O) 2 -NH-C(O)-O-; or Z is -NRy-C(O)-NRy'-; wherein Ry' is H, alkyl, aryl, heterocyclyl or lower alkoxy and R ⁇ is H, lower alkyl, or R ⁇ and R 9 combined are alkylene which together with the carbon atom to which they are attached form a 3- to 7-membered ring; or R ⁇ ' and X combined are alkylene which together with the carbon atom to which they are attached form a 3- to 7-membered ring or Z is -NRx-C(O)-NH-S(O) 2 -, wherein R ⁇ is H or lower alkyl,
  • X is hydrogen, hydroxy, NH 2 , halogen, alkoxy, alkylthio, alkyl, -S(O)-OH, alkyl, cycloalkyl, cycloalkoxy, acyl, acyloxy, carbamoyl, optionally substituted amino, cyano, trifluoromethyl, free or esterified carboxy, heterocyclyl, heterocyclooxy, heteroaryl, heteroaralkyl, aryl, aralkyl, aralkoxy, aryloxy, aralkylthio, arylthio;
  • Ri is hydrogen, -C(O)R 4 , -C(O)NR 5 R 6 or -C(O)OR 7 in which R 4 and R 5 are, independently from each other, hydrogen, cycloalkyl, aryl, heterocyclyl, aralkyl, heteroaralkyl or alkyl optionally substituted with one to four substituents selected from the group consisting of hal
  • R 2 and R 3 are, independently from each other, hydrogen, halogen, (Q ⁇ alkyl or (Ci -3 )alkoxy; or a pharmaceutically acceptable salt thereof, and wherein n + m + p is > 1 or is 0, when X is aryl, and Y and Z are absent, n + m + p is not 0 when X is -O-aryl, and Y and Z are absent, or n + m + p is not 0 when X is -S-aryl, and Y and Z are absent, or n + m + p is not 0 when X is ⁇ CH 2 -aryl, and Y and Z are absent, or n + m + p is not 0 when X is aryl, Z is absent and Y is -O- or Y is -S-, or wherein Q cannot be -CH 2 -aryl, -S-aryl or -O-aryl.
  • the orientation of the Ztreatment is with the X group on the right side of the listed function -Z->X e.g. Z is -NR ⁇ '-C(O)- means Z is -NR ⁇ '-C(O)-X.
  • Y is cyclopropyl
  • Y is absent; n and m are, independently from each other, zero or an integer from 1 to 8; R 8 and R 9 are, independently from each other, hydrogen, hydroxyl, alkoxy, alkanoyl, alkanoylamino, alkoxycarbonyl, aralkyl, heteroaryl, heterocyclyl, carbamoyl, aryl, or alkyl; or R 8 and R 9 combined are alkylene which together with the carbon atom to which they are attached form a 3- to 7-membered ring; p is zero or an integer selected from 1 or 2
  • Z is absent; Z is -C(O)-O-; or
  • Z is -C(O)-
  • Z is -C(O)-NR ⁇ -alkylene- or -C(O)-NR ⁇ -alkylene-O-, wherein R ⁇ is H or lower alkyl; or
  • Z is -CO-NR ⁇ -(CH 2 ) n > -(CR 8 > R 9 > V-(CH 2 ) m > -, Or -C(O)-NRa-(CH 2 V-(CRrR 9 Op - (CH 2 ) m ' -O-, wherein p' is zero or an integer of 1, n' and m' are, independently from each other, zero or an integer from 1 to 8, R 8 ' and R 9 ' are, independently from each other, hydrogen or lower alkyl, Ra is H or lower alkyl; or
  • Z is -NR ⁇ '-C(O)-, or -NRa' -C(O)-O-, wherein Ra' is H or lower alkyl, or Ra' and R 9 combined are alkylene which together with the carbon atom to which they are attached form a 3- to 7-membered ring; or
  • Z is -C(O)-NH-NH-C(O)-O-;
  • Z is -S(O) 2 -, or -S(O)-;
  • Z is -NR ⁇ -S(O) 2 - , wherein R ⁇ is H, lower alkyl, or R ⁇ and R 9 combined are alkylene which together with the carbon atom to which they are attached form a 3- to 7-membered ring; or
  • Z is -NH-S(O) 2 -NH-C(O)-O-;
  • Z is -NR ⁇ -C(O)-NR ⁇ '-; wherein R ⁇ ' is H, alkyl, aryl, heterocyclyl, or lower alkoxy and
  • R ⁇ is H, lower alkyl, or Ryand R 9 combined are alkylene which together with the carbon atom to which they are attached form a 3- to 7-membered ring; or R ⁇ ) and X combined are alkylene which together with the carbon atom to which they are attached form a 3- to
  • Z is -NRT-C(O)-NH-S(O) 2 -, wherein R ⁇ is H or lower alkyl
  • X is hydrogen, hydroxy, NH 2 , halogen, alkoxy, alkylthio, alkyl, -S(O)-OH, alkyl, cycloalkyl, cycloalkoxy, acyl, acyloxy, carbamoyl, optionally substituted amino, cyano, trifluoromethyl, free or esterified carboxy, heterocyclyl, heterocyclooxy, heteroaryl, heteroaralkyl, aryl, aralkyl, aralkoxy, aryloxy, aralkylthio, arylthio; Ri is hydrogen, -C(O)R 4 , -C(O)NR 5 R 6 or -C(O)OR 7 in which
  • R 4 and R 5 are, independently from each other, hydrogen, cycloalkyl, aryl, heterocyclyl, aralkyl, heteroaralkyl or alkyl optionally substituted with one to four substituents selected from the group consisting of halogen, cycloalkyl, cycloalkoxy, alkoxy, alkyloxyalkoxy, amino, alkylamino, dialkylamino, aryl, aryloxy and heterocyclyl;
  • R 6 and R 7 are, independently from each other, cycloalkyl, aryl, heterocyclyl, aralkyl, heteroaralkyl or alkyl optionally substituted with one to four substituents selected from the group consisting of halogen, cycloalkyl, cycloalkoxy, alkoxy, alkyloxyalkoxy, amino, alkylamino, dialkylamino, aryl, aryloxy and heterocyclyl;
  • R 2 and R 3 are, independently from each other, hydrogen, halogen, (Ci -3 )alkyl or (Ci.
  • n + m + p is > 1 or is 0, when X is aryl, and Y and Z are absent, n + m + p is not 0 when X is -O-aryl, and Y and Z are absent, or n + m + p is not 0 when X is -S-aryl, and Y and Z are absent, or n + m + p is not 0 when X is -CH 2 -aryl, and Y and Z are absent, or n + m + p is not 0 when X is aryl, Z is absent and Y is -O- or Y is -S-, or wherein Q cannot be -CH 2 -aryl, -S-aryl or -O-aryl.
  • the orientation of the Ztreatment is with the X group on the right side of the listed function -Z ⁇ X e.g. Z is -NR ⁇ '-C(O)- means Z is -NR ⁇ '-C(0)-X.
  • Y is cyclopropyl
  • X is, hydrogen, hydroxy, NH 2 , halogen, alkoxy, alkylthio, alkyl, -S(O)-OH, alkyl, cycloalkyl, cyano, trifluoromethyl, free or esterified carboxy, heterocyclyl, heteroaryl, heteroaralkyl, aryl, aralkyl, aryloxy;
  • Ri is hydrogen; or a pharmaceutically acceptable salt thereof.
  • m + n + p is between 0 and 7 or preferably between 0 and 5, or a pharmaceutically acceptable salt thereof.
  • Y is oxygen or S(O) q in which q is zero or an integer of 1 or 2;
  • Y is cyclopropyl
  • Y is absent; n and m are, independently from each other, zero or an integer from 1 to 8;
  • R 8 and R 9 are, independently from each other, hydrogen, hydroxyl, alkoxy, alkanoyl, alkanoylamino, alkoxycarbonyl, aralkyl, heteroaryl, heterocyclyl, carbamoyl, aryl, or alkyl; p is zero or an integer selected from 1 or 2 Z is absent;
  • Z is -CO-O-
  • Z is -CO-
  • X is hydrogen, hydroxy, NH 2 , halogen, alkoxy, alkylthio, -SO-OH, alkyl, cycloalkyl, cycloalkoxy, acyl, acyloxy, carbamoyl, optionally substituted amino, cyano, trifluoromethyl, free or esterified carboxy, heterocyclyl, heterocyclooxy, heteroaryl, heteroaralkyl, aryl, aralkyl, aralkoxy, aryloxy, aralkylthio, arylthio; or a pharmaceutically acceptable salt thereof.
  • Y is oxygen; or Y is cyclopropyl; or
  • Y is absent; or a pharmaceutically acceptable salt thereof.
  • R 8 and R 9 are, independently from each other, hydrogen, alkoxy, alkanoyl, alkoxycarbonyl, aralkyl, aryl, or alkyl; or a pharmaceutically acceptable salt thereof.
  • R 2 and R 3 are hydrogen; or a pharmaceutically acceptable salt thereof.
  • Preferred are the compounds in the A group wherein
  • Ri is hydrogen; or a pharmaceutically acceptable salt thereof.
  • n + p is between 0 and 4, or a pharmaceutically acceptable salt thereof.
  • n + p is between 1 and 3
  • n is 1, or a pharmaceutically acceptable salt thereof.
  • Y is oxygen or S(O) q in which q is zero or an integer of 1 or 2;
  • Y is absent; n and m are, independently from each other, zero or an integer from 1 to 8;
  • Rg and R 9 are, independently from each other, hydrogen, hydroxyl, alkoxy, alkanoyl, alkanoylamino, alkoxycarbonyl, aralkyl, heteroaryl, heterocyclyl, carbamoyl, aryl, or alkyl; or
  • Rg and R 9 combined are alkylene which together with the carbon atom to which they are attached form a 3- to 7-membered ring; p is zero or an integer selected from 1 or 2
  • Z is absent;
  • X is hydrogen, hydroxy, NH 2 , halogen, alkoxy, alkylthio, -SO-OH, alkyl, cycloalkyl, cycloalkoxy, acyl, acyloxy, carbamoyl, optionally substituted amino, cyano, trifluoromethyl, free or esterified carboxy, heterocyclyl, heterocyclooxy, heteroaryl, heteroaralkyl, aryl, aralkyl, aralkoxy, aryloxy, aralkylthio, arylthio; or a pharmaceutically acceptable salt thereof.
  • Rg and R 9 are, independently from each other, hydrogen, alkoxy, alkanoyl, alkoxycarbonyl, aralkyl, or alkyl; or a pharmaceutically acceptable salt thereof.
  • X is hydrogen, NH 2 , hydroxy, alkylthio, -SO-OH, alkyl, cycloalkyl, cyano, trifluoromethyl, free or esterified carboxy, heterocyclyl, heteroaryl, aryl; or a pharmaceutically acceptable salt thereof.
  • R 2 and R 3 are hydrogen; or a pharmaceutically acceptable salt thereof.
  • n + p is between 0 and 6 or preferably 0 and 4, or a pharmaceutically acceptable salt thereof.
  • n is between 0 and 6 or preferably 0 and 4, and p is 0, or a pharmaceutically acceptable salt thereof.
  • Other preferred compounds are the compounds in the B group, wherein X is selected from phenyl or heteroaryl, preferably unsusbtituted or substituted by at least one substituent e.g. one or two, which is preferably a substituent selected from carboxy, carbamoyl, and lower alkyl, or a pharmaceutically acceptable salt thereof.
  • n is 1 , 2 or 3, preferably 1 or 2
  • m + m + p is preferably 2 or 3
  • p is 1 or 0, and
  • X is cycloalkyl, heterocyclyl, heteroaryl, or aryl, preferably unsusbtituted or substituted by at least one substituent e.g. one or two, which is preferably a substituent selected from sulfonamido, carboxy, carbamoyl, and lower alkyl, or a pharmaceutically acceptable salt thereof.
  • n + n 1, 2 or 3, preferably 1 or 2
  • m + n + p 2, 3 or 4, preferably 2 or 3
  • p is 1 or 0, and
  • X is aryl, preferably unsusbtituted or substituted by at least one substituent e.g. one or two, which is preferably a substituent selected from sulfonamido, carboxy, carbamoyl, and lower alkyl, or a pharmaceutically acceptable salt thereof.
  • X is "amide" type heterocyclyl, cycloalkyl substituted by at least one substituent e.g. one or two, which is preferably sulfonamide, or aryl substituted by at least one substituent e.g. one or two, which is preferably sulfonamido or a pharmaceutically acceptable salt thereof.
  • Y is absent; n and m are, independently from each other, zero or an integer from 1 to 8;
  • R 8 and R 9 are, independently from each other, hydrogen, hydroxyl, alkoxy, alkanoyl, alkanoylamino, alkoxycarbonyl, aralkyl, heteroaryl, heterocyclyl, carbamoyl, aryl, or alkyl; or
  • R 8 and R 9 combined are alkylene which together with the carbon atom to which they are attached form a 3- to 7-membered ring; p is zero or an integer selected from 1 or 2 Z is -CO-NR ⁇ -alkylene- or -CO-NR ⁇ -alkylene-O-, wherein Rq is H or lower alkyl; or
  • Z is -CO-NR ⁇ -(CH 2 ) n '-(CR 8 'R 9 ') p '-(CH 2 ) m ' - or
  • Z is -NR ⁇ '-CO-, or -NR ⁇ '-CO-O- wherein Ra' is, H or lower alkyl, or Ra' and R 9 combined are alkylene which together with the carbon atom to which they are attached form a 3- to 7-membered ring; or
  • Z is -CO-NH-NH-CO-O-; or X is hydrogen, hydroxy, NH 2 , halogen, alkoxy, alkylthio, -SO-OH, alkyl, cycloalkyl, cycloalkoxy, acyl, acyloxy, carbamoyl, optionally substituted amino, cyano, trifluoromethyl, free or esterif ⁇ ed carboxy, heterocyclyl, heterocyclooxy, heteroaryl, heteroaralkyl, aryl, aralkyl, aralkoxy, aryloxy, aralkylthio, arylthio; or a pharmaceutically acceptable salt thereof.
  • R 8 and R 9 are, independently from each other, hydrogen, alkanoylamino, aralkyl, aryl, or alkyl; or a pharmaceutically acceptable salt thereof.
  • R 2 and R 3 are hydrogen; or a pharmaceutically acceptable salt thereof.
  • Ri is hydrogen; or a pharmaceutically acceptable salt thereof.
  • m + n + p is between 0 and 6 or preferably between 0 and 4, or a pharmaceutically acceptable salt thereof.
  • n + n + p is between 1 and 3 (i.e. 1, 2 or 3)
  • m + n is between 1 and 3 (i.e. 1, 2 or 3) and p is 0
  • m + n + p is between 1 and 3 (i.e. 1, 2 or 3) and p is 1 m is 0, n is between 1 and 2 (i.e. 1, or 2) and p is 1 or a pharmaceutically acceptable salt thereof.
  • n' and m' are independently from each other, zero or an integer from 1 to 6, and p' is zero or an integer of 1, or a pharmaceutically acceptable salt thereof.
  • p' + n' + m' is comprised between zero and 5, or between 3 and 5 i.e. 3, 4 or 5, or a pharmaceutically acceptable salt thereof.
  • n' and m' are independently from each other, zero or an integer from 1 to 6, preferably from 1 to 4, or a pharmaceutically acceptable salt thereof.
  • n' + m' is between 0 and 5, or between 3 and 5, preferably 4, and p' is 0, or a pharmaceutically acceptable salt thereof.
  • X is phenyl, preferably unsusbtituted or substituted preferably by at least one, e.g. one or two, of the substituents selected preferably from alkoxycarbonyl, carboxy, alkoxy, cyano, lower alkyl, (lower alkyl)-NHC(O)-, (lower alkyl) 2 -NC(O> and hydroxy.
  • X is halogen, cyano, trifluoromethyl, heterocyclyl, heteroaryl, aryl, or a pharmaceutically acceptable salt thereof.
  • R 2 and R 3 are hydrogen; or a pharmaceutically acceptable salt thereof.
  • X is aryl substituted by an "amide" type heterocyclyl, or a pharmaceutically acceptable salt thereof.
  • Y is absent; n and m are, independently from each other, zero or an integer from 1 to 8; Rg and R 9 are, independently from each other, hydrogen, hydroxyl, alkoxy, alkanoyl, alkanoylamino, alkoxycarbonyl, aralkyl, heteroaryl, heterocyclyl, carbamoyl, aryl, or alkyl; or
  • R 8 and R9 combined are alkylene which together with the carbon atom to which they are attached form a 3- to 7-membered ring; p is zero or an integer selected from 1 or 2
  • Z is -SO 2 -, or -SO-;
  • Z is -NR ⁇ -SO 2 - , wherein R ⁇ is H, lower alkyl, or R ⁇ and R 9 combined are alkylene which together with the carbon atom to which they are attached form a 3- to 7-membered ring preferably 5-, 6- or 7- membered ring; or Z is -NH-SO 2 -NH-CO-O-; or
  • X is hydrogen, hydroxy, NH 2 , halogen, alkoxy, alkylthio, -SO-OH, alkyl, cycloalkyl, cycloalkoxy, acyl, acyloxy, carbamoyl, optionally substituted amino, cyano, trifluoromethyl, free or esterified carboxy, heterocyclyl, heterocyclooxy, heteroaryl, heteroaralkyl, aryl, aralkyl, aralkoxy, aryloxy, aralkylthio, arylthio; or a pharmaceutically acceptable salt thereof.
  • Y is absent; or a pharmaceutically acceptable salt thereof.
  • R 8 and R 9 are, independently from each other, hydrogen, aralkyl, heteroaryl, heterocyclyl, heterocyclyl, carbamoyl; or
  • Rg and R9 combined are alkylene which together with the carbon atom to which they are attached form a 3- to 7-membered ring; or a pharmaceutically acceptable salt thereof.
  • X is hydrogen, alkyl, cycloalkyl, heteroaryl, aryl, aralkyl; or a pharmaceutically acceptable salt thereof.
  • R 2 and R 3 are hydrogen; or a pharmaceutically acceptable salt thereof.
  • m + n + p is between 0 and 7 or preferably between 0 and 5, or a pharmaceutically acceptable salt thereof.
  • n + n is 1 or 2
  • m is 0 or 1
  • p is 1, or n is 1 or 2
  • m is 0 or 1
  • p is 1 when R 8 is hydrogen and R 9 is selected from aralkyl, heteroaryl, heterocyclyl, heterocyclyl, or carbamoyl; or a pharmaceutically acceptable salt thereof.
  • X is selected from phenyl, biphenyl, benzyl, lower alkyl, methyl substituted by on or two pheny, ethyl substituted by on or two pheny, or methyl substituted by cycloalkyl
  • Y is oxygen or S(O) q in which q is zero or an integer of 1 or 2;
  • Y is absent; n and m are, independently from each other, zero or an integer from 1 to 8;
  • R 8 and R 9 are, independently from each other, hydrogen, hydroxyl, alkoxy, alkanoyl, alkanoylamino, alkoxycarbonyl, aralkyl, heteroaryl, heterocyclyl, carbamoyl, aryl, or alkyl; or
  • R 8 and R 9 combined are alkylene which together with the carbon atom to which they are attached form a 3- to 7-membered ring; p is zero or an integer selected from 1 or 2
  • Z is -NR ⁇ -CO-NR ⁇ 1 -; wherein Ry 1 is H, alkyl, aryl, heterocyclyl, or lower alkoxy and R ⁇ is H, lower alkyl, or R ⁇ and R 9 combined are alkylene which together with the carbon atom to which they are attached form a 3- to 7-membered ring; or R ⁇ ' and X combined are alkylene which together with the carbon atom to which they are attached form a 3- to
  • Z is -NRT-CO-NH-SO 2 -, wherein R ⁇ is H or lower alkyl
  • X is hydrogen, hydroxy, NH 2 , halogen, alkoxy, alkylthio, -SO-OH, alkyl, cycloalkyl, cycloalkoxy, acyl, acyloxy, carbamoyl, optionally substituted amino, cyano, trifluoromethyl, free or esterif ⁇ ed carboxy, heterocyclyl, heterocyclooxy, heteroaryl, heteroaralkyl, aryl, aralkyl, aralkoxy, aryloxy, aralkylthio, arylthio; or a pharmaceutically acceptable salt thereof.
  • R 8 and R 9 are, independently from each other, hydrogen; or a pharmaceutically acceptable salt thereof.
  • X is hydrogen, alkyl, cycloalkyl, heterocyclyl, aryl, aralkyl; or a pharmaceutically acceptable salt thereof.
  • R 2 and R 3 are hydrogen; or a pharmaceutically acceptable salt thereof.
  • R ⁇ ' is H or lower alkyl, or a pharmaceutically acceptable salt thereof.
  • Ri is hydrogen; or a pharmaceutically acceptable salt thereof.
  • m + n + p is between 0 and 7 or preferably between 0 and 5 or between 2 and 3, or a pharmaceutically acceptable salt thereof.
  • X is lower alkyl, phenyl, benzyl, or cyclohexyl, or a pharmaceutically acceptable salt thereof.
  • alkyl preferably refers to a lower alkyl
  • aryl is preferably a phenyl
  • at least one of R 8 or R 9 is hydrogen

Abstract

The invention relates to the use of protein tyrosine phosphatase inhibitors for the treatment of musculoskeletal diseases, particularly for the treatment of muscle atrophy.

Description

INHIBITORS OF PROTEIN TYROSINE PHOSPHATASE FOR THE TREATMENT OF MUSCLE ATROPHY AND RELATED DISORDERS
Field of the Invention The invention relates to compounds that inhibit protein tyrosine phosphatase (PTP), particularly PTP-IB, and their use in the treatment of musculoskeletal disease.
Background of the Invention
Cellular signal transduction is a fundamental mechanism whereby external stimuli that regulate diverse cellular processes are relayed to the interior of cells. One of the key biochemical mechanisms of signal transduction involves the reversible phosphorylation of proteins, which enables regulation of the activity of mature proteins by altering their structure and function. The best characterized protein kinases in eukaryotes phosphorylate proteins on the alcohol moiety of serine, threonine and tyrosine residues. These kinases largely fall into two groups, those specific for phosphorylating serines and threonines, and those specific for phosphorylating tyrosines.
The phosphorylation state of a given substrate is also regulated by protein phosphatases, a class of proteins responsible for removal of the phosphate group added to a given substrate by a protein kinase. The protein phosphatases can also be classified as being specific for either serine/threonine or tyrosine. The known enzymes can be divided into two groups—receptor and non-receptor type proteins. Most receptor-type protein tyrosine phosphatases (RPTPs) contain two conserved catalytic tyrosine phosphatase domains each of which encompasses a segment of 240 amino acid residues (Saito et al., Cell Growth and Diff. 2:59-65, 1991). The RPTPs can be subclassified further based upon the amino acid sequence diversity of their extracellular domains (Saito, et al., supra; Krueger, et al., Proc. Natl. Acad. Sci. USA 89:7417-7421, 1992). Alignment of primary peptide sequences of both types of known PTPs shows some sequence consensus in catalytic domains and has made it possible to identify cDNAs encoding proteins with tyrosine phosphate activity via the polymerase chain reaction (PCR). Many kinases and phosphatases are involved in regulatory cascades wherein their substrates may include, but are not limited to, other kinases and phosphatases whose activities are regulated by their phosphorylation state. Ultimately the activity of some downstream effector is modulated by phosphorylation resulting from activation of such a pathway.
It is well established that the abnormal or inappropriate activity of tyrosine kinases and/or tyrosine phosphatases plays a role in a variety of human disorders including cell proliferative disorders such as cancer, fibrotic disorders, disorders of the immune system and metabolic disorders such as diabetes.
Summary of the Invention
The invention is based on the discovery that PTP inhibitors can be used to treat musculoskeletal diseases or conditions, particularly muscle atrophy, in a mammal such as a human individual or patient. Accordingly, the invention includes a method of treating a musculoskeletal disease by identifying an individual exhibiting the musculoskeletal disease or at risk for developing the musculoskeletal disease and administering to the individual a therapeutically effective amount of a PTP inhibitor sufficient to alleviate the musculoskeletal disease. The invention also includes the use of a PTP inhibitor in the manufacture of a medicament for the treatment or prevention of a musculoskeletal disease. In addition, the invention includes use of PTP inhibitors to increase muscle or bone mass in an individual, whether or not such an individual is at risk for or has a musculoskeletal disease.
In particular, the musculoskeletal disease can be muscle atrophy. There are many causes of muscle atrophy, including as a result of treatment with a glucocorticoid such as Cortisol, dexamethasone, betamethasone, prednisone, methylprednisolone, or prednisolone. The muscle atrophy can also be a result of denervation due to nerve trauma or a result of degenerative, metabolic, or inflammatory neuropathy (e.g., Guillian-Barre syndrome, peripheral neuropathy, or exposure to environmental toxins or drugs). In addition, the muscle atrophy can be a result of an adult motor neuron disease, infantile spinal muscular atrophy, juvenile spinal muscular atrophy, autoimmune motor neuropathy with multifocal conductor block, paralysis due to stroke or spinal cord injury, skeletal immobilization due to trauma, prolonged bed rest, voluntary inactivity, involuntary inactivity, metabolic stress or nutritional insufficiency, cancer, AIDS, fasting, rhabdomyolysis, a thyroid gland disorder, diabetes, benign congenital hypotonia, central core disease, nemalene myopathy, myotubular (centronuclear) myopathy, burn injury, chronic obstructive pulmonary disease, liver disease, sepsis, renal failure, congestive heart failure, or ageing.
The musculoskeletal disease can also be a muscular dystrophy syndrome, such as
Duchenne, Becker, myotonic, fascioscapulohumeral, Emery-Deifuss, oculopharyngeal, scapulohumeral, limb girdle, a congenital muscular dystrophy, or hereditary distal myopathy. The musculoskeletal disease can also be osteoporosis, a bone fracture, short stature, or dwarfism.
Any suitable PTP inhibitor, such as described in the next section, can be used to treat the above-mentioned musculoskeletal diseases. Since it is known that insulin-like growth factor- 1 (IGFl) has beneficial effects on the musculoskeletal system, IGFl or human Growth Hormone can be co-administered along with the PTP inhibitor in the methods of the invention.
All cited references or documents are hereby incorporated by reference.
Breif Description of the Drawings Figure 1 shows mean C2C12 myotube diameter from an experiment where two different PTPIb inhibitors were added to culture media +/- IGFl (mean +/- standard error of the mean).
Figure 2 shows percent muscle volume lost at two weeks. Figure 3 shows results from an experiment where WT, HET, and KO mice had their right leg denervated by sciatic nerve resection.
Detailed Description of the Invention The invention relates to the treatment of musculoskeletal diseases, in particular muscle atrophy, low bone density or mineral content, and short stature. Any PTP inhibitor can be used in the methods of the invention, for example, the inhibitors described in US patents and patent application publications 7,115,624; 7,078,425; 7,022,730; 6,911,468; and 2005/0090502. In addition, specific inhibitors of PTP, particularly PTP-IB and T-cell PTP, can include the categories of compounds and specific compounds therein, as described below.
Definitions for Chemical Structures
Listed below are definitions of various terms used to describe the compounds of the instant invention. These definitions apply to the terms as they are used throughout the specification unless they are otherwise limited in specific instances either individually or as part of a larger group. In general, whenever an alkyl group is referred to as a part of the structure, an optionally substituted alkyl is also intended.
Accordingly, the term "optionally substituted alkyl" refers to unsubstituted or substituted straight or branched chain hydrocarbon groups having 1 to 20 carbon atoms, preferably 1 to 8 carbon atoms. Exemplary unsubstituted alkyl groups include methyl, ethyl, propyl, isopropyl, n-butyl, t-butyl, isobutyl, pentyl, hexyl, isohexyl, heptyl, 4,4-dimethylpentyl, octyl and the like. Substituted alkyl groups include, but are not limited to, alkyl groups substituted by one or more of the following groups: halogen, hydroxy, cycloalkyl, cycloalkoxy, acyl, acyloxy, alkoxy, alkyloxyalkoxy, alkanoyloxy, amino, alkylamino, dialkylamino, acylamino, carbamoyl, thiol, alkylthio, alkylthiono, sulfonyl, sulfonamido, sulfamoyl, nitro, cyano, free or esterified carboxy, aryl, aryloxy, arylthio, alkenyl, alkynyl, aralkoxy, heteroaraloxy, heterocyclyl and heterocyclyloxy including indolyl, imidazolyl, furyl, thienyl, thiazolyl, pyrrolidyl, pyridyl, pyrimidyl, piperidyl, morpholinyl and the like. The term "lower alkyl" refers to any of the above alkyl groups as described above having
1 to 7, preferably 1 to 4 carbon atoms.
The term "halogen" or "halo" refers to fluorine, chlorine, bromine and iodine.
The term "alkenyl" refers to any of the above alkyl groups having at least 2 carbon atoms and containing a carbon to carbon double bond at the point of attachment. Groups having
2 to 8 carbon atoms are preferred.
The term "alkynyl" refers to any of the above alkyl groups having at least two carbon atoms and containing a carbon to carbon triple bond at the point of attachment. Groups having 2 to 8 carbon atoms are preferred.
The term "alkylene" refers to a straight-chain bridge of 1-6 carbon atoms connected by single bonds, e.g., -(CH2)x-, wherein x is 1-6, which may be interrupted with one or more heteroatoms selected from O, S, S(O), S(O)2 or NR", wherein R" may be hydrogen, alkyl, cycloalkyl, aryl, heterocyclyl, aralkyl, heteroaralkyl, acyl, carbamoyl, sulfonyl, alkoxycarbonyl, aryloxycarbonyl or aralkoxycarbonyl and the like; and the alkylene may further be substituted with one or more substituents selected from hydroxy, halogen, cyano, nitro, alkoxy, alkylthio, alkylthiono, sulfonyl, free or esterified carboxy, carbamoyl, sulfamoyl, optionally substituted amino, cycloalkyl, aryl, heterocyclyl, alkenyl, alkynyl or (Cl-8)alkyl optionally substituted with one to four substituents selected from the group consisting of halogen, hydroxy, cycloalkyl, cycloalkoxy, acyl, acyloxy, alkoxy, alkyloxyalkoxy, amino, alkylamino, dialkylamino, acylamino, carbamoyl, thiol, alkylthio, alkylthiono, sulfonyl, sulfonamido, sulfamoyl, nitro, cyano, free or esterified carboxy, aryl, aryloxy, arylthio, alkenyl, alkynyl, aralkoxy, heteroaralkoxy, heterocyclyl, heterocyclyloxy and the like.
The term "cycloalkyl" refers to optionally substituted monocyclic, bicyclic or tricyclic hydrocarbon groups of 3 to 12 carbon atoms, each of which may be substituted by one or more substituents such as alkyl, halo, oxo, hydroxy, alkoxy, alkanoyl, acylamino, carbamoyl, alkylamino, dialkylamino, thiol, alkylthio, nitro, cyano, carboxy, carboxyalkyl, alkoxycarbonyl, sulfonyl, sulfonamido, sulfamoyl, heterocyclyl and the like.
Exemplary monocyclic hydrocarbon groups include but are not limited to cyclopropyl, cyclobutyl, cyclopentyl, cyclopentenyl, cyclohexyl and cyclohexenyl and the like. Exemplary bicyclic hydrocarbon groups include bornyl, indyl, hexahydroindyl, tetrahydronaphthyl, decahydronaphthyl, bicyclo[2.1.1]hexyl, bicyclo[2.2.1]heptyl, bicyclo[2.2.1]heptenyl, 6,6-dimethylbicyclo[3.1.1]heptyl, 2,6,6- trimethylbicyclo[3.1.1]heptyl, bicyclo[2.2.2]octyl and the like. Exemplary tricyclic hydrocarbon groups include adamantyl and the like.
The term "alkoxy" refers to alkyl-O-.
The term "alkanoyl" refers to alkyl-C(O)-.
The term "alkanoyloxy" refers to alkyl-C(O)-O-.
The terms "alkylamino" and "dialkylamino" refer to alkyl-NH- and (alkyl)2N-, respectively.
The term "alkanoylamino" refers to alkyl-C(O)-NH-.
The term "alkylthio" refers to alkyl-S-.
The term "alkylaminothiocarbonyl" refers to alkyl-NHC(S)-.
The term "trialkylsilyl" refers to (alkyl)3Si-.
The term "trialkylsilyloxy" refers to (alkyl)3Si0-. The term "alkylthiono" refers to alkyl-S(O)-.
The term "alkylsulfonyl" refers to alkyl-S(O)2-.
The term "alkoxycarbonyl" refers to alkyl-O-C(O)-.
The term "alkoxycarbonyloxy" refers to alkyl-O-C(O)O-.
The term "carboxycarbonyl" refers to HO-C(O)C(O)-.
The term "carbamoyl" refers to H2NC(O)-, alkyl-NHC(O)-, (alkyl)2NC(O)-, aryl- NHC(O)-, alkyl(aryl)-NC(O)-, heteroaryl-NHC(O)-, alkyl(heteroaryl)-NC(O)-, aralkyl- NHC(O)-, alkyl(aralkyl)-NC(O)- and the like.
The term "sulfamoyl" refers to H2NS(O)2-, alkyl-NHS(O)2-, (alkyl)2NS(O)2-, aryl- NHS(O)2-, alkyl(aryl)-NS(O)2-, (aryl)2NS(O)2-, heteroaryl-NHS(O)2-, aralkyl-NHS(O)2-, heteroaralkyl-NHS(O)2- and the like.
The term "sulfonamido" refers to alkyl-S(O)2-NH-, aryl-S(O)2-NH-, aralkyl-S(O)2-NH-, heteroaryl-S(O)2-NH-, heteroaralkyl-S(O)2-NH-, alkyl-S(O)2-N(alkyl)-, aryl-S(O)2- N(alkyl)-, aralkyl-S(O)2-N(alkyl)-, heteroaryl-S(O)2-N(alkyl)-, heteroaralkyl-S(O)2- N(alkyl)- and the like.
The term "sulfonyl" refers to alkylsulfonyl, arylsulfonyl, heteroarylsulfonyl, aralkylsulfonyl, heteroaralkylsulfonyl and the like.
The term "sulfonate" or "sulfonyloxy" refers to alkyl-S(O)2-O-, aryl-S(O)2-O-, aralkyl- S(O)2-O-, heteroaryl-S(O)2-O-, heteroaralkyl-S(O)2-O- and the like. The term "optionally substituted amino" refers to a primary or secondary amino group which may optionally be substituted by a substituent such as acyl, sulfonyl, alkoxycarbonyl, cycloalkoxycarbonyl, aryloxycarbonyl, heteroaryloxycarbonyl, aralkoxycarbonyl, heteroaralkoxycarbonyl, carboxycarbonyl, carbamoyl, alkylaminothiocarbonyl, arylaminothiocarbonyl and the like.
The term "aryl" refers to monocyclic or bicyclic aromatic hydrocarbon groups having 6 to 12 carbon atoms in the ring portion, such as phenyl, naphthyl, tetrahydronaphthyl, biphenyl and diphenyl groups, each of which may optionally be substituted by one to five substituents such as alkyl, trifluoromethyl, halo, hydroxy, alkoxy, acyl, alkanoyloxy, optionally substituted amino, thiol, alkylthio, nitro, cyano, carboxy, carboxyalkyl, alkoxycarbonyl, carbamoyl, alkylthiono, sulfonyl, sulfonamido, sulfonate, heterocyclyl and the like.
The term "monocyclic aryl" refers to optionally substituted phenyl as described under aryl.
The term "aralkyl" refers to an aryl group bonded directly through an alkyl group, such as benzyl.
The term "aralkanoyl" refers to aralkyl-C(O)-.
The term "aralkylthio" refers to aralkyl-S-.
The term "aralkoxy" refers to an aryl group bonded directly through an alkoxy group. The term "arylsulfonyl" refers to aryl S(O)2.
The term "arylthio" refers to aryl-S-.
The term "aroyl" refers to aryl-C(O)-. The term "aroylamino" refers to aryl-C(O)-NH-.
The term "aryloxycarbonyl" refers to aryl-O-C(O)-.
The term "heterocyclyl" or "heterocyclo" refers to an optionally substituted, aromatic, or a partially or fully saturated nonaromatic cyclic group, for example, which is a 4- to 7- membered monocyclic, 7- to 12-membered bicyclic, or 10- to 15-membered tricyclic ring system, which has at least one heteroatom in at least one carbon atom containing ring. Each ring of the heterocyclic group containing a heteroatom may have 1, 2 or 3 heteroatoms selected from nitrogen atoms, oxygen atoms and sulfur atoms, where the nitrogen and sulfur heteroatoms may also optionally be oxidized. The heterocyclic group may be attached at a heteroatom or a carbon atom.
Exemplary monocyclic heterocyclic groups include pyrrolidinyl, pyrrolyl, pyrazolyl, oxetanyl, pyrazolinyl, imidazolyl, imidazolinyl, imidazolidinyl, oxazolyl, oxazolidinyl, isoxazolinyl, isoxazolyl, thiazolyl, thiadiazolyl, thiazolidinyl, isothiazolyl, isothiazolidinyl, furyl, tetrahydrofuryl, thienyl, oxadiazolyl, piperidinyl, piperazinyl, 2 oxopiperazinyl, 2 oxopiperidinyl, 2 oxopyrrolodinyl, 2 oxoazepinyl, azepinyl, 4 piperidonyl, pyridyl, pyrazinyl, pyrimidinyl, pyridazinyl, tetrahydropyranyl, morpholinyl, thiamorpholinyl, thiamorpholinyl sulfoxide, thiamorpholinyl sulfone, 1,3 dioxolane and tetrahydro 1,1 dioxothienyl, l,l,4-trioxo-l,2,5-thiadiazolidin-2-yl and the like.
Exemplary bicyclic heterocyclic groups include indolyl, dihydroidolyl, benzothiazolyl, benzoxazinyl, benzoxazolyl, benzothienyl, benzothiazinyl, quinuclidinyl, quinolinyl, tetrahydroquinolinyl, decahydroquinolinyl, isoquinolinyl, tetrahydroisoquinolinyl, decahydroisoquinolinyl, benzimidazolyl, benzopyranyl, indolizinyl, benzofuryl, chromonyl, coumarinyl, benzopyranyl, benzodiazepinyl, cinnolinyl, quinoxalinyl, indazolyl, pyrrolopyridyl, furopyridinyl (such as furo[2,3 c]pyridinyl, furo[3,2 b]- pyridinyl] or furo[2,3 b]pyridinyl), dihydroisoindolyl, l,3-dioxo-l,3-dihydroisoindol-2- yl, dihydroquinazolinyl (such as 3,4 dihydro-4 oxo-quinazolinyl), phthalazinyl and the like. Exemplary tricyclic heterocyclic groups include carbazolyl, dibenzoazepinyl, dithienoazepinyl, benzindolyl, phenanthrolinyl, acridinyl, phenanthridinyl, phenoxazinyl, phenothiazinyl, xanthenyl, carbolinyl and the like.
The term "heterocyclyl" includes substituted heterocyclic groups. Substituted heterocyclic groups refer to heterocyclic groups that are substituted with 1, 2 or 3 substituents selected from the group consisting of the following: (a) optionally substituted alkyl; (b) hydroxy (or protected hydroxy);
(c) halo;
(d) oxo (i.e. =0);
(e) optionally substituted amino, alkylamino or dialkylamino;
(f) alkoxy; (g) cycloalkyl;
(h) carboxy;
(i) heterocyclooxy;
(j) alkoxycarbonyl, such as unsubstituted lower alkoxycarbonyl;
(k) mercapto; (1) nitro;
(m) cyano;
(n) sulfamoyl or sulfonamido;
(o) alkylcarbonyloxy;
(p) arylcarbonyloxy; (q) arylthio;
(r) aryloxy;
(s) alkylthio;
(t) formyl;
(u) carbamoyl; (v) aralkyl; and (w) aryl substituted with alkyl, cycloalkyl, alkoxy, hydroxy, amino, acylamino, alkylamino, dialkylamino or halo.
The term "heterocyclooxy" denotes a heterocyclic group bonded through an oxygen bridge.
The term "heteroaryl" refers to an aromatic heterocycle, for example monocyclic or bicyclic aryl, such as pyrrolyl, pyrazolyl, imidazolyl, oxazolyl, isoxazolyl, thiazolyl, isothiazolyl, furyl, thienyl, pyridyl, pyrazinyl, pyrimidinyl, pyridazinyl, indolyl, benzothiazolyl, benzoxazolyl, benzothienyl, quinolinyl, isoquinolinyl, benzimidazolyl, benzofuryl, and the like, optionally substituted by e.g. lower alkyl, lower alkoxy or halo.
The term "heteroarylsulfonyl" refers to heteroaryl S(O)2 .
The term "heteroaroyl" refers to heteroaryl-C(O)-.
The term "heteroaroylamino" refers to heteroaryl-C(O)NH-.
The term "heteroaralkyl" refers to a heteroaryl group bonded through an alkyl group.
The term "heteroaralkanoyl" refers to heteroaralkyl-C(O)-.
The term "heteroaralkanoylamino" refers to heteroaralkyl-C(O)NH-.
The term "acyl" refers to alkanoyl, cycloalkanoyl, aroyl, heteroaroyl, aralkanoyl, heteroaralkanoyl and the like.
The term "acyloxy" refers to alkanoyloxy, cycloalkanoyloxy, aroyloxy, heteroaroyloxy, aralkanoyloxy, heteroaralkanoyloxy and the like.
The term "acylamino" refers to alkanoylamino, cycloalkanoylamino, aroylamino, heteroaroylamino, aralkanoylamino, heteroaralkanoylamino and the like. The term "esterified carboxy" refers to optionally substituted alkoxycarbonyl, cycloalkoxycarbonyl, aryloxycarbonyl, aralkoxycarbonyl, heterocyclooxycarbonyl and the like.
Pharmaceutically acceptable salts of any compound useful in the present invention refer to salts formed with bases, namely cationic salts such as alkali and alkaline earth metal salts, such as sodium, lithium, potassium, calcium, magnesium, as well as ammonium salts, such as ammonium, trimethylammonium, diethylammonium, and tris(hydroxymethyl)-methyl-iammonium salts, and salts with amino acids.
Similarly acid addition salts, such as those formed with mineral acids, organic carboxylic acids and organic sulfonic acids e.g. hydrochloric acid, maleic acid and methanesulfonic acid, are possible provided a basic group, such as pyridyl, constitutes part of the structure.
In starting compounds and intermediates which are converted to the compounds useful in the invention in a manner described herein, functional groups present, such as amino, thiol, carboxyl, and hydroxy groups, are optionally protected by conventional protecting groups that are common in preparative organic chemistry. Protected amino, thiol,' carboxyl, and hydroxyl groups are those that can be converted under mild conditions into free amino thiol, carboxyl and hydroxyl groups without the molecular framework being destroyed or other undesired side reactions taking place.
The purpose of introducing protecting groups is to protect the functional groups from undesired reactions with reaction components under the conditions used for carrying out a desired chemical transformation. The need and choice of protecting groups for a particular reaction is known to those skilled in the art and depends on the nature of the functional group to be protected (hydroxyl group, amino group, etc.), the structure and stability of the molecule of which the substituent is a part and the reaction conditions. Well known protecting groups that meet these conditions and their introduction and removal are described, for example, in McOmie, "Protective Groups in Organic Chemistry", Plenum Press, London, New York (1973); and Greene and Wuts, "Protective Groups in Organic Synthesis", John Wiley and Sons, Inc, New York (1999).
The above mentioned reactions are carried out according to standard methods, in the presence or absence of diluent, preferably such as are inert to the reagents and are solvents thereof, of catalysts, condensing or said other agents respectively and/or inert atmospheres, at low temperatures, room temperature or elevated temperatures (preferably at or near the boiling point of the solvents used), and at atmospheric or super-atmospheric pressure.
The invention further includes any variant of the present processes, in which an intermediate product obtainable at any stage thereof is used as starting material and the remaining steps are carried out, or in which the starting materials are formed in situ under the reaction conditions, or in which the reaction components are used in the form of their salts or optically pure antipodes.
Compounds useful in the invention and intermediates can also be converted into each other according to methods generally known per se.
Depending on the choice of starting materials and methods, the compounds may be in the form of one of the possible isomers or mixtures thereof, for example, as substantially pure geometric (cis or trans) isomers, optical isomers (enantiomers, antipodes), racemates, or mixtures thereof. The aforesaid possible isomers or mixtures thereof are within the purview of this invention.
Any resulting mixtures of isomers can be separated on the basis of the physico-chemical differences of the constituents, into the pure geometric or optical isomers, diastereoisomers, racemates, for example by chromatography and/or fractional crystallization. Any resulting racemates of final products or intermediates can be resolved into the optical antipodes by known methods, e.g. by separation of the diastereoisomeric salts thereof, obtained with an optically active acid or base, and liberating the optically active acidic or basic compound. The carboxylic acid intermediates can thus be resolved into their optical antipodes e.g. by fractional crystallization of D- or L-(alpha-methylbenzylamine, cinchonidine, cinchonine, quinine, quinidine, ephedrine, dehydroabietylamine, brucine or strychnine)-salts. Racemic products can also be resolved by chiral chromatography, e.g. high pressure liquid chromatography using a chiral adsorbent.
Finally, compounds useful in the invention are either obtained in the free form, as a salt thereof if salt forming groups are present or as prodrug derivatives thereof. In particular, the NH-group of the l,l-dioxo-l,2,5-thiadiazolidin-3-one moiety, may be converted into salts with pharmaceutically acceptable bases. Salts may be formed using conventional methods, advantageously in the presence of an ethereal or alcoholic solvent, such as a lower alkanol. From the solutions of the latter, the salts may be precipitated with ethers, e.g. diethyl ether. Resulting salts may be converted into the free compounds by treatment with acids. These or other salts can also be used for purification of the compounds obtained.
Compounds useful in the invention having basic groups can be converted into acid addition salts, especially pharmaceutically acceptable salts. These are formed, for example, with inorganic acids, such as mineral acids, for example sulfuric acid, a phosphoric or hydrohalic acid, or with organic carboxylic acids, such as (Cj- 4)alkanecarboxylic acids which, for example, are unsubstituted or substituted by halogen, for example acetic acid, such as saturated or unsaturated dicarboxylic acids, for example oxalic, succinic, maleic or fumaric acid, such as hydroxy-carboxylic acids, for example glycolic, lactic, malic, tartaric or citric acid, such as amino acids, for example aspartic or glutamic acid, or with organic sulfonic acids, such as (Ci-4)alkyl-sulfonic acids (for example methanesulfonic acid) or arylsulfonic acids which are unsubstituted or substituted (for example by halogen). Preferred are salts formed with hydrochloric acid, methanesulfonic acid and maleic acid. Prodrug derivatives of any compound of the present invention are derivatives of said compounds which following administration release the parent compound in vivo via some chemical or physiological process, e.g., a prodrug on being brought to the physiological pH or through enzyme action is converted to the parent compound. Exemplary prodrug derivatives are, e.g., esters of free carboxylic acids and S-acyl and O-acyl derivatives of thiols, alcohols or phenols, wherein acyl has a meaning as defined herein. Preferred are pharmaceutically acceptable ester derivatives convertible by solvolysis under physiological conditions to the parent carboxylic acid, e.g., lower alkyl esters, cycloalkyl esters, lower alkenyl esters, benzyl esters, mono- or di-substituted lower alkyl esters, such as the ω-(amino, mono- or di-lower alkylamino, carboxy, lower alkoxycarbonyl)-lower alkyl esters, the α-(lower alkanoyloxy, lower alkoxycarbonyl or di-lower alkylaminocarbonyl)-lower alkyl esters, such as the pivaloyloxymethyl ester and the like conventionally used in the art.
In view of the close relationship between the free compounds, the prodrug derivatives and the compounds in the form of their salts, whenever a compound is referred to in this context, a prodrug derivative and a corresponding salt is also intended, provided such is possible or appropriate under the circumstances.
The compounds, including their salts, can also be obtained in the form of their hydrates, or include other solvents used for their crystallization.
Thus, the pharmacologically active compounds useful in the invention may be employed in the manufacture of pharmaceutical compositions comprising an effective amount thereof in conjunction or admixture with excipients or carriers suitable for either enteral or parenteral application. Preferred are tablets and gelatin capsules comprising the active ingredient together with: a) diluents, e.g., lactose, dextrose, sucrose, mannitol, sorbitol, cellulose and/or glycine; b) lubricants, e.g., silica, talcum, stearic acid, its magnesium or calcium salt and/or polyethyleneglycol; for tablets also c) binders, e.g., magnesium aluminum silicate, starch paste, gelatin, tragacanth, methylcellulose, sodium carboxymethylcellulose and or polyvinylpyrrolidone; if desired d) disintegrants, e.g., starches, agar, alginic acid or its sodium salt, or effervescent mixtures; and/or e) absorbants, colorants, flavors and sweeteners. Injectable compositions are preferably aqueous isotonic solutions or suspensions, and suppositories are advantageously prepared from fatty emulsions or suspensions.
Said compositions may be sterilized and/or contain adjuvants, such as preserving, stabilizing, wetting or emulsifying agents, solution promoters, salts for regulating the osmotic pressure and/or buffers. In addition, they may also contain other therapeutically valuable substances. Said compositions are prepared according to conventional mixing, granulating or coating methods, respectively, and contain about 0.1-75%, preferably about 1-50%, of the active ingredient.
Suitable formulations for transdermal application include a therapeutically effective amount of a compound of the invention with carrier. Advantageous carriers include absorbable pharmacologically acceptable solvents to assist passage through the skin of the host. Characteristically, transdermal devices are in the form of a bandage comprising a backing member, a reservoir containing the compound optionally with carriers, optionally a rate controlling barrier to deliver the compound of the skin of the host at a controlled and predetermined rate over a prolonged period of time, and means to secure the device to the skin.
The pharmaceutical compositions useful in the invention may contain a therapeutically effective amount of a compound as defined above, either alone or in a combination with another therapeutic agent, e.g., each at an effective therapeutic dose as reported in the art. One such compound that can be administered along with the PTP inhibitor is human insulin-like growth factorl or IGFl, however formulated or stabilized, such as INCRELEX™ as developed by Tercica or as described in US 2006/0166328. The structure of the therapeutic agents identified by code numbers, generic or trade names may be taken from the actual edition of the standard compendium "The Merck Index" or from databases, e.g., Patents International (e.g. IMS World Publications). The corresponding content thereof is hereby incorporated by reference.
As used throughout the specification and in the claims, the term "treatment" embraces all the different forms or modes of treatment as known to those of the pertinent art and in particular includes preventive, curative, delay of progression and palliative treatment.
The above-cited properties are demonstrable in vitro and in vivo tests, using advantageously mammals, e.g., mice, rats, dogs, monkeys or isolated organs, tissues and preparations thereof. Said compounds can be applied in vitro in the form of solutions, e.g. preferably aqueous solutions, and in vivo either enterally, parenterally, advantageously intravenously, e.g. as a suspension or in aqueous solution. The dosage in vitro may range between about 10 molar and 10 molar concentrations. A therapeutically effective amount in vivo may range depending on the route of administration, between about 1 and 500 mg/kg, preferably between about 5 and 100 mg/kg.
The activity of a compound according to the invention may be assessed by the following methods or by following methods well described in the art (e.g. Peters G. et al. J. Biol. Chem, 2000, 275, 18201-09).
For example, the PTP-IB inhibitory activity in vitro may be determined as follows:
Assessment of human PTP-IB (hPTP-lB) activity in the presence of various agents is determined by measuring the amount of inorganic phosphate released from a phosphopeptide substrate using a 96-well microtiter plate format. The assay (100 μL) is performed in an assay buffer comprised of 50 mM TRIS (pH 7.5), 50 mM NaCl, 3 mM DTT at ambient temperature. The assay is typically performed in the presence of 0.4% dimethyl sulfoxide (DMSO). However, concentrations as high as 10% are used with certain poorly soluble compounds. A typical reaction is initiated by the addition of 0.4 pmoles of hPTP-lB (amino acids 1-411) to wells containing assay buffer, 3 nmoles of the synthetic phosphopeptide substrate (GNGDp YMPMSPKS), and the test compound. After 10 min, 180 μL malachite green reagent (0.88 mM malachite green, 8.2 mM ammonium molybdate, aqueous 1 N HCl, and 0.01% Triton X-100) is added to terminate the reaction. Inorganic phosphate, a product of the enzyme reaction, is quantitiated after 15 min as the green color resulting from complexing with the Malichite reagent and is determined as an A62o using a Molecular Devices (Sunnyvale, CA) SpectraMAX Plus spectrophotometer. Test compounds are solubilized in 100 % DMSO (Sigma, D-8779) and diluted in DMSO. Activity is defined as the net change in absorbance resulting from the activity of the uninhibited hPTP-lBμ^n] minus that of a tube with acid-inactivated hPTP- IBn-4 H].
The hPTP- IB[I-4 H] is cloned by PCR from a human hippocampal cDNA library (Clonetech) and inserted into a pET 19-b vector (Novagen) at the Ncol restriction site. E. coli strain BL21 (DE3) is transformed with this clone and stored as a stock culture in 20% glycerol at -80° C. For enzyme production, a stock culture is inoculated into LB/Amp and grown at 370C. Expression of PTP-IB is initiated by induction with ImM IPTG after the culture had reached an OD6O0 = 0.6. After 4h, the bacterial pellet is collected by centrifugation. Cells are resuspended in 7OmL lysis buffer (5OmM Tris, 100 mM NaCl, 5mM DTT, 0.1% Triton X-100, pH7.6), incubated on ice for 30 min then sonicated (4 X lOsec bursts at full power). The lysate is centrifuged at 100,000 x g for 60 min and the supernatant is buffer exchanged and purified on a cation exchange POROS 20SP column followed by an anion exchange Source 30Q (Pharmacia) column, using linear NaCl gradient elutions. Enzyme is pooled, adjusted to lmg/mL and frozen at - 8O0C.
Alternatively, the assessment of human PTP-IB activity in the presence of various agents may be determined by measuring the hydrolysis products of known competing substrates. For example, cleavage of substrate para-nitrophenylphosphate (pNPP) results in the release of the yellow-colored para-nitrophenol (pNP) which can be monitored in real time using a spectrophotometer. Likewise, the hydrolysis of the fluorogenic substrate 6,8- difluoro-4-methylumbelliferyl phosphate ammonium salt (DiFMUP) results in the release of the fluorescent DiFMU which can be readily followed in a continuous mode with a fluorescence reader (Anal. Biochem. 273, 41, 1999; Anal. Biochem. 338, 32, 2005):
pNPP Assay
Compounds are incubated with 1 nM recombinant human PTP-IB[I^8] or PTP-IB[I-322J in buffer (50 raM Hepes, pH 7.0, 50 mM KCl, 1 mM EDTA, 3 mM DTT, 0.05% NP-40 for 5 min at room temperature. The reaction is initiated by the addition of pNPP (2 mM final concentration) and run for 120 min at room temperature. Reactions are quenched with 5 N NaOH. Absorbance at 405 nm is measured using any standard 384 well plate reader.
DiFMUP Assay Compounds are incubated with 1 nM recombinant human PTP-lB[i-298] or PTP-IB[I-322] in buffer (50 mM Hepes, pH 7.0, 50 mM KCl, 1 mM EDTA, 3 mM DTT, 0.05% NP-40 (or 0.001% BSA) for 5 min at room temperature. The reaction is initiated by the addition of DiFMUP (6 μM final concentration) and run kinetically on fluorescence plate reader at 355 nm excitation and 460 nm emission wavelengths. Reaction rates over 15 min are used to calculate inhibition.
PTP-lB[i-298] is expressed in E. coli BL21(DE3) containing plasmids constucted using pET19b vectors (Novagen). The bacteria is grown in minimal media using an "On Demand" Fed-batch strategy. Typically, a 5.5 liter fermentation is initiated in Fed-batch mode and grown overnight unattended at 370C. Optical densities varied between 20-24 OD6Oo and the cultrures are induced at 3O0C with IPTG to a final concentration of 0.5 mM. The bacterial cells are harvested 8 hours later and yield 200-350 gm (wet weight). The cells are frozen as pellets and stored at -8O0C until use. All steps are performed at 40C unless noted. Cells (-15 g) are thawed briefly at 370C and resuspended in 50 mL of lysis buffer containing 50 mM Tris-HCl, 150 mM NaCl, 5 mM DTT, pH 8.0 containing one tablet of Complete (EDTA-free) protease cocktail (Boehringer Mannheim), 100 μM PMSF and 100 μg/mL DNase I. The cells are lysed by sonication (4 x 10 second burst, full power) using a Virsonic 60 (Virtus). The pellet is collected at 35,000 x g, resuspended in 25 mL of lysis buffer using a Polytron and collected as before. The two supernatants are combined and centrifuged for 30 min at 100,000 x g. The soluble lysate could be stored at this stage at -80 0C or used for further purification. Diafiltration using a 10 kD MWCO membrane is used to buffer exchange the protein and reduce the NaCl concentration prior to cation exchange chromatography. Diafiltration buffer contained 50 mM MES, 75 mM NaCl, 5 mM DTT, pH 6.5. Soluble supernatant is then loaded onto a POROS 20 SP (1 x 10 cm) column equilibrated with cation exchange buffer (50 mM MES and 75 mM NaCl, pH 6.5) at a rate of 20 mL/min. An analytical column (4.6 x 100 mm) is run in a similar fashion except the flow rate was reduced to 10 mL/min. Protein is eluted from the column using a linear salt gradient (75-500 mM NaCl in 25 CV). Fractions containing PTP-IBf1-298] are identified and pooled according to SDS-PAGE analyses. Final purification is performed using Sephacryl S-100 HR (Pharmacia). The column (2.6 x 35 cm) is equilibrated with 50 mM HEPES, 100 mM NaCl, 3 mM DTT, pH 7.5 and run at a flow rate of 2 mL/min. The final protein is pooled and concentrated to ~5 mg/mL using an Ultrafree-15 concentrator (Millipore) with a MWCO 10,000. The concentrated protein is stored at -80 0C until use.
Competitive binding to the active site of the enzyme can be determined as follows:
Ligand binding is detected by acquiring 1H-15N HSQC spectra on 250 μL of 0.15 mM PTP-IB[I-298] in the presence and absence of added compound (1-2 mM). The binding is determined by the observation of 15N- or Η-amide chemical shift changes in two dimensional HSQC spectra upon the addition of a compound to 15N-label protein. Because of the 15N spectral editing, no signal from the ligand is observed, only protein signals. Thus, binding can be detected at high compound concentrations. Compounds which caused a pattern of chemical shift changes similar to the changes seen with known active site binders are considered positive.
All proteins are expressed in E. coli BL21 (DE3) containing plasmids constructed using pET19b vectors (Novagen). Uniformly 15N-labeled PTP-IBi-298 is produced by growth of bacteria on minimal media containing 15N-labeled ammonium chloride. All purification steps are performed at 40C. Cells (-15 g) are thawed briefly at 370C and resuspended in 50 mL of lysis buffer containing 50 mM Tris-HCl, 150 mM NaCl, 5 mM DTT, pH 8.0 containing one tablet of Complete (EDTA-free) protease cocktail (Boehringer Mannheim), 100 μM PMSF and 100 μg/mL DNase I. The cells are lysed by sonication. The pellet is collected at 35,000 x g, resuspended in 25 mL of lysis buffer using a Polytron and collected as before. The two supernatants are combined and centrifuged for 30 min at 100,000 x g. Diafiltration using a 10 kD MWCO membrane is used to buffer exchange the protein and reduce the NaCl concentration prior to cation exchange chromatography. Diafiltration buffer contained 50 mM MES, 75 mM NaCl, 5 mM DTT, pH 6.5. Soluble supernatant is then loaded onto a POROS 20 SP (1 x 10 cm) column equilibrated with cation exchange buffer (50 mM MES and 75 mM NaCl, pH 6.5) at a rate of 20 mL/min. Protein is eluted from the column using a linear salt gradient (75-500 mM NaCl in 25 CV). Fractions containing PTP- lB's are identified and pooled according to SDS-PAGE analyses. PTP-lBi-29g is further purified by anion exchange chromatography using a POROS 20 HQ column (1 x 10 cm). The pool from cation exchange chromatography is concentrated and buffer exchanged in 50 mM Tris-HCl, pH 7.5 containing 75 mM NaCl and 5 mM DTT. Protein is loaded onto column at 20 mL/min and eluted using a linear NaCl gradient (75-500 mM in 25 CV). Final purification is performed using Sephacryl S-100 HR (Pharmacia)(50 mM HEPES, 100 mM NaCl, 3 mM DTT, pH 7.5 ). The NMR samples are composed of uniformly 15N- labeled PTP-IBi-298 (0.15 mM) and inhibitor (1-2 mM) in a 10%D2O/90%H2O Bis-Tris- di9 buffer (50 mM, pH = 6.5) solution containing NaCl (50 mM), DL-I, 4-Dithiothreitol- dio (5mM) and Sodium azide (0.02%).
The 1H-15N HSQC NMR spectra are recorded at 2O0C, on Bruker DRX500 or DMX600 NMR spectrometers. In all NMR experiments, pulsed field gradients are applied to afford the suppression of solvent signal. Quadrature detection in the indirectly detected dimensions is accomplished by using the States-TPPI method. The data are processed using Bruker software and analyzed using NMRCompass software (MSI) on Silicon Graphics computers. Analytical Methods for Measuring Inhibitor Activity in Muscle Disease Models
To determine if a PTP inhibitor is useful for the treatment of musculoskeletal disease, particularly muscle atrophy, the following in vitro and animal model assays can be used.
Tissue Culture
C2C12 cells can be obtained from the American Type Tissue Culture Bank and propagated in standard growth media containing 10% horse serum. When cells reached 70% confluency the media is changed to differentiation media containing 2% horse serum. Three days after start of differentiation multinucleated myotubes should be present, with visible striations, indicating differentiation. IGFl can be used as a positive control for activating the IGF-I receptor, or alternatively, combined with a PTPlB inhibitor to assess synergistic or additive effects. Consequently, PTPlB inhibitors and/or IGFl can be added to the media for various times.
Myotube Diameter Myotube diameter can be assessed 24 hours after addition of PTPlB inhibitor and/or IGFl to myotube media. Cells are washed in saline and fixed in gluteraldehyde. Images can be obtained on an inverted microscope using the green fluorescent channel to visualize the auto- fluorescence induced by the gluteraldehyde fixation. Images are printed out at standard magnification and the sixty largest myotubes measured at their largest diameter (as previously published). The fifty largest myotubes in each group can be statistically compared using the Kruskal-Wallis One Way Analysis on Ranks. Differences are considered significant if p<0.05 and designated by an asterisk in Figure 1.
pAKT assay Phosphorylation levels of AKT, a protein that is phosphorylated when the IGFl protein binds to its receptor, can be assessed using a commercially available pAKT ELISA kit (Cell Signaling, Pathscan 7160) and the corresponding total AKT ELISA kit (Cell Signaling, Pathscan 7170), following manufacturer instructions. pIGFR assay Phosphorylation levels of the IGF receptor in cell cultures can be assessed by lysis of the cells, immunoprecipitation of the IGFR using anti-IGFR antibodies (Transduction Laboratories, Lexington, KY, USA), Western blot analysis using anti- phosphotyrosine antibodies (Upstate Biotechnology, USA). See, e.g., Shefi-Friedman et al., Am J Physiol Endocrinol Metab 281 :E16-E24, 2001.
PTPlB inhibitors and IGFl IGF 1R3 can be purchased from Sigma-Aldrich (12656) and added to culture media at a concentration of 10ng/ml. Multiple PTPlB inhibitors can be tested with or without IGFl .
In Vivo Testing in Mouse Exercise Models of Hypertrophy
To determine whether a PTP inhibitor can act to increase skeletal muscle mass under an exercise context that already leads to muscle hypertrophy, one can subject treated and untreated animals to exercise and determine whether animals receiving the PTP inhibitor have developed larger muscles than untreated animals.
One model known in the art is based on the use of a voluntary running wheel with user- variable loads (see, e.g., Konhilas et al., Am J Physiol Heart Circ Physiol 289:H455- H465, 2005). The voluntary cage wheel eliminates physical and psychological insults that are common in forced exercised models, and are therefore more appropriate for evaluating candidate drugs that are used in relatively healthy individuals for whom increases in muscle mass is desirable.
Any suitable mouse strain can be used. For example, male C57B1/6J mice can be randomly assigned to experimental (e.g., receiving PTP inhibitor) and control groups. Animals are individually housed in a cage containing an exercise wheel; sedentary control animals are housed in identical cages without a wheel. The exercise wheels are described in Allen et al., J Appl Physiol 90:1900-1908, 2001. Briefly, the system consists of an 11.5 cm-diameter wheel with a 5.0 cm-wide running surface (model 6208, Petsmart, Phoenix, AZ) equipped with a digital magnetic counter (model BC 600, Sigma Sport,
Olney, IL) that is activated by wheel rotation. In addition, each wheel is engineered with a resistance mechanism allowing adjustment of the load. This is accomplished by attaching stainless steel fishing line to the cage top and wrapping the wire around an immovable pulley that is secured to the cage wheel at the axis of rotation so as to not contribute to the wheel load. The wire is again secured to the cage top with a spring and screw. This design permits fine adjustments of the wheel load, which is evenly distributed throughout the rotation of the wheel. Daily exercise values for time and distance run are recorded for each exercised animal throughout the duration of the exercise period. All animals are given water and standard hard rodent chow ad libitum. Voluntary running (cage wheel exposure) can begin at an average age of about 12 weeks for all groups. Each group continues running under varying resistance, depending on experimental group, for 50 days until the animals are about 19 weeks of age. The load on the wheel is determined by hanging known weights on the wheel until the wheel was slightly displaced. All exercise groups begin with no load on the cage wheel for the first week. However, the "no-load" condition is actually 2 g, which is determined as the load necessary to maintain wheel inertia and frictional load. Considering a wheel acclimatization period of 1 week, wheel loads can be changed at one-week intervals, except for higher loads, which can be changed after 2 weeks. The range of loads can be anywhere from 2 g to up to 12 g. Exercised and sedentary control animals are euthanized by cervical dislocation under inhaled anesthesia immediately after the end of the specific exercise period. Body mass is measured, and specific muscles are rapidly excised, washed, and frozen for histological or biochemical assays at a future date.
Alternative exercise hypertrophy models are also available to the skilled artisan. See, e.g., the treadmill exercise model described in Lerman et al., J Appl Physiol 92:2245- 2255, 2002.
In Vivo testing on PTPlB null mutant Mice
In this in vivo model, lack of PTPIb can be tested for the ability to maintain muscle mass under conditions that generally reduce muscle mass. Mice Heterozygous PTPlB null mice can be purchased from Deltagen (San Carlos, CA, USA) and mated to produce offspring that are null, heterozygous, or wild-type litter mates. Mice are housed under ACUC protocol 06 MG 0144 and maintained with food and water ad libitum in a 12 hour light cycle. Mice can be genotyped by PCR on tail biopsies.
Denervation The right sciatic nerve is resected during deep anesthesia under ACUC protocol 06 MG 0189. Briefly, anesthesia is induced using isofluorane inhalation, the right leg shaved and sterilized. An incision is then made through the skin of the lateral right leg and the sciatic nerve visualized. The nerve is cut and a 0.3 to 0.5 section removed to prevent reattachment. The incision was closed with wound clips and the mice returned to their cages for recovery from anesthesia. The contralateral leg is unperturbed and serves as internal control. Mice are euthanized 14 days after denervation surgery and muscles and other tissues isolated for further processing.
Muscle and Tissue Weight The following tissues can be dissected from PTPlB knock out knock out (KO), heterozygous (HET), and wild-type (WT) mice 14 days after denervation of the right hind limb: left and right tibialis anterior muscles, left and right extensor digitorum longus muscles, left and right soleus muscles, left and right gastrocnemius muscles, heart, liver, spleen, epididimal white adipose tissue, brown adipose tissue, and blood for serum isolation. Each tissue is freed from connective tissue and weighed, before being snap frozen for further analysis to be completed.
Experimental Set-Up and Analyis The effect of PTPlB inhibition on muscle disease can be measured, as described above, in an in vitro model system of skeletal muscle atrophy, using the C2C12 cell line, and in an in vivo model of skeletal muscle atrophy, using PTPlB wild type, heterozygous, and homozygous null mice in combination with denervation-induced skeletal muscle atrophy.
Treatment of C2C12 myotubes with PTPlB inhibitors can result in an increase in myotube size, when the diameter of the fifty largest myotubes is measured. When IGFl alone is added to C2C12 myotubes media at a concentration of 10ng/ml, myotubes can be significantly hypertrophied. A PTP inhibitor can result in an increase in myotube diameter that is significantly bigger than the diameter of untreated myotubes. There might not be a statistical significance between cells treated with either IGFl or an inhibitor individually, but when myotubes are treated with both IGFl and an inhibitor simultaneously, this could result in a significant increase in myotube diameter when compared to the singly-treated cells. Such a result would indicate that IGFl and a PTP inhibitor act at least additively potentially synergistically to produce larger myotubes and therefore indicate that IGFl and a PTP inhibitor can be co-administered to a mammal to increase muscle mass or to treat muscle atrophy. Alternatively, assay results can indicate that a PTP inhibitor is active alone, in which case use of the inhibitor in monotherapy to increase muscle mass or to treat muscle atrophy is indicated.
Figure 1 shows mean C2C12 myotube diameter from an experiment where two different PTPIb inhibitors were added to culture media +/- IGFl (mean +/- standard error of the mean). The results show a significant increase in myotube diameter by IGFl and compounds 2 alone. When IGFl is added in combination with PTPIb inhibitors 1 (l-[3- Hydroxy-4-(l,l,4-trioxo-[l,2,5]thiadiazolidin-2-yl)-benzyl]-l,2,4,5-tetrahydro- benzo[c]azepin-3-one) or compound 2 (2-(4-{2-Acetylamino-3-[3-hydroxy-4-(l,l,4- trioxo-[l,2,5]thiadiazolidin-2-yl)-phenyl]-propionylamino}-butoxy)-6-hydroxy-benzoic acid methyl ester), a synergistic effect can be seen. In Figure 1 "*" refers to a statistically significant difference to untreatedAIGFl control, and "#" refers to a statistically significant difference to untreated/+IGFl control.
In addition, PTPlB null mice can be used to test whether absence of PTPlB can prevent or ameliorate skeletal muscle atrophy. Fourteen days after denervation of the right hind limb, muscle weight of denervated muscles is compared to contralateral muscles from the control leg (wet muscle weight is normalized to individual body weight). Using this animal model of skeletal muscle atrophy, there is significant sparing of muscles in heterozygous and knock-out mice. WT mice lose about 40% of gastrocnemius muscle mass, compared with a 30% loss in heterozygous mice and 20% in homozygous null mice. Half of the denervation-induced muscle atrophy is prevented in KO gastrocnemius muscle compared to WT gastrocnemius muscle
In addition to measurements of muscle mass in these animal models, it is possible to determine the effect of any agent tested in the models by harvesting muscle tissues as described above and viewing cross-sections of the muscle fibers via histology. One can then observe any increase in muscle fiber diameter when an agent such as a PTP inhibitor is administered to the animal.
Figure 3 shows results from an experiment where WT, HET, and KO mice had their right leg denervated by sciatic nerve resection. The ratios shown are mean fiber areas from the denervated limb divided by fiber area from the contralateral control limb (mean +/- standard error of the mean) and can show significantly less denervation-induced atrophy in HET and KO mice when compared to WT mice.
Phosphorylation of AKT is a downstream event of IGFlR phosphorylation. Levels of AKT phosphorylation can be used as a read-out of activation of the IGFl pathway in C2C12 myotubes treated with a PTP inhibitor +/- IGFl for one hour. A PTP inhibitor alone can increase phosphorylation levels of AKT by for example at least 50% (e.g., 65%). IGF 1 treatment is known to cause AKT phosphorylation, but treatment of IGFl and a PTP inhibitor can further increases AKT phosphorylation by at least 25% (e.g., 35%) above that induced by IGF 1 alone. Treatment with an PTP inhibitor can therefore increase activation of the IGFl pathway, possibly resulting in a significant increase in myotube diameter in the manner described above.
Results from experiments such as described above can indicate that PTP inhibitors, particularly PTPlB inhibitors, increase levels of pAKT, which in turn result in a physiological increase in myotube diameter. Observations can include: • A PTP inhibitor causes a significant increase in C2C12 myotube diameter by itself and acts at least additively with IGFl in media to further increase myotube size.
• A PTP inhibitor causes a significant increase in C2C12 myotubes when compared to untreated myotubes.
Furthermore, in vivo atrophy study using PTPlB KO, HET, and WT mice with denervation-induced muscle atrophy can show that inhibition of PTPlB prevents skeletal muscle atrophy.
Provided that a PTP inhibitor exhibits in vitro or in vivo activity for increasing muscle mass, e.g., by way of modulating the IGFl signaling pathway at the level of AKT phosphorylation, such PTP inhibitors would then also be useful for other diseases known to be amenable to IGFl or human Growth Hormone treatment, such as dwarfism, low bone density or mineral content, osteoporosis or short stature.
Specific Examples of PTP Inhibitors
The methods of the invention can be practiced with l,l-dioxo-l,2,5-thiadiazolidin-3-one derivatives as described in the categories below.
Category 1 PTP Inhibitors
The methods of the present invention can be practiced with the compounds of the formula
Figure imgf000029_0001
wherein Q combined together with the carbon atoms to which it is attached form an aromatic, or a partially or fully saturated nonaromatic 5- to 8-membered carbocyclic or heterocyclic ring;
Ri is hydrogen, -C(O)R6, -C(O)NR7R8 or -C(O)OR9 in which R6 and R7 are, independently from each other, hydrogen, cycloalkyl, aryl, heterocyclyl, aralkyl, heteroaralkyl or alkyl optionally substituted with one to four substituents selected from the group consisting of halogen, cycloalkyl, cycloalkoxy, alkoxy, alkyloxyalkoxy, amino, alkylamino, dialkylamino, aryl, aryloxy and heterocyclyl;
R8 and R9 are, independently from each other, cycloalkyl, aryl, heterocyclyl, aralkyl, heteroaralkyl or alkyl optionally substituted with one to four substituents selected from the group consisting of halogen, cycloalkyl, cycloalkoxy, alkoxy, alkyloxyalkoxy, amino, alkylamino, dialkylamino, aryl, aryloxy and heterocyclyl;
R2, R3, R4 and R5 are, independently from each other, hydrogen, hydroxy, halogen, cyano, nitro, alkoxy, alkylthio, alkylthiono, sulfonyl, free or esterified carboxy, carbamoyl, sulfamoyl, optionally substituted amino, cycloalkyl, aryl, heterocyclyl, alkenyl, alkynyl or (Ci-8)alkyl optionally substituted with one to four substituents selected from the group consisting of halogen, hydroxy, cycloalkyl, cycloalkoxy, acyl, acyloxy, alkoxy, alkyloxyalkoxy, amino, alkylamino, dialkylamino, acylamino, carbamoyl, thiol, alkylthio, alkylthiono, sulfonyl, sulfonamido, sulfamoyl, nitro, cyano, free or esterified carboxy, aryl, aryloxy, arylthio, alkenyl, alkynyl, aralkoxy, heteroaralkoxy, heterocyclyl and heterocyclyloxy; or
R2 and R3 combined are alkylene which together with the ring atoms to which they are attached form a 3- to 7-membered fused ring; or
R2 and R3 combined are alkylene which together with the carbon atom to which they are attached form a 3- to 7-membered spirocyclic ring; or a pharmaceutically acceptable salt thereof.
Preferred are compounds in the A group having the formula
Figure imgf000031_0001
wherein
Ri is hydrogen, -C(O)R6, -C(O)NR7R8 or -C(O)OR9 in which
R6 and R7 are, independently from each other, hydrogen, cycloalkyl, aryl, heterocyclyl, aralkyl, heteroaralkyl or alkyl optionally substituted with one to four substituents selected from the group consisting of halogen, cycloalkyl, cycloalkoxy, alkoxy, alkyloxyalkoxy, amino, alkylamino, dialkylamino, aryl, aryloxy and heterocyclyl; R8 and R9 are, independently from each other, cycloalkyl, aryl, heterocyclyl, aralkyl, heteroaralkyl or alkyl optionally substituted with one to four substituents selected from the group consisting of halogen, cycloalkyl, cycloalkoxy, alkoxy, alkyloxyalkoxy, amino, alkylamino, dialkylamino, aryl, aryloxy and heterocyclyl;
R2, R3, R4 and R5 are, independently from each other, hydrogen, hydroxy, halogen, cyano, nitro, alkoxy, alkylthio, alkylthiono, sulfonyl, free or esterified carboxy, carbamoyl, sulfamoyl, optionally substituted amino, cycloalkyl, aryl, heterocyclyl, alkenyl, alkynyl or (Ci-8)alkyl optionally substituted with one to four substituents selected from the group consisting of halogen, hydroxy, cycloalkyl, cycloalkoxy, acyl, acyloxy, alkoxy, alkyloxyalkoxy, amino, alkylamino, dialkylamino, acylamino, carbamoyl, thiol, alkylthio, alkylthiono, sulfonyl, sulfonamido, sulfamoyl, nitro, cyano, free or esterified carboxy, aryl, aryloxy, arylthio, alkenyl, alkynyl, aralkoxy, heteroaralkoxy, heterocyclyl and heterocyclyloxy; or
R2 and R3 combined are alkylene which together with the ring atoms to which they are attached form a 5- to 7-membered fused ring; or or a pharmaceutically acceptable salt thereof.
Preferred are compounds of formula (IA) wherein R4 and R5 are hydrogen; or a pharmaceutically acceptable salt thereof.
Further preferred are compounds of formula (IA) having the formula
Figure imgf000032_0001
wherein
Ri is hydrogen, -C(O)R6, -C(O)NR7R8 or -C(O)OR9 in which
R6 and R7 are, independently from each other, hydrogen, cycloalkyl, aryl, heterocyclyl, aralkyl, heteroaralkyl or alkyl optionally substituted with one to four substituents selected from the group consisting of halogen, cycloalkyl, cycloalkoxy, alkoxy, alkyloxyalkoxy, amino, alkylamino, dialkylamino, aryl, aryloxy and heterocyclyl;
R8 and R9 are, independently from each other, cycloalkyl, aryl, heterocyclyl, aralkyl, heteroaralkyl or alkyl optionally substituted with one to four substituents selected from the group consisting of halogen, cycloalkyl, cycloalkoxy, alkoxy, alkyloxyalkoxy, amino, alkylamino, dialkylamino, aryl, aryloxy and heterocyclyl; R2 and R3 are, independently from each other, hydrogen, hydroxy, halogen, cyano, nitro, alkoxy, alkylthio, alkylthiono, sulfonyl, free or esterified carboxy, carbamoyl, sulfamoyl, optionally substituted amino, cycloalkyl, aryl, heterocyclyl, alkenyl, alkynyl or (Ci. 8)alkyl optionally substituted with one to four substituents selected from the group consisting of halogen, hydroxy, cycloalkyl, cycloalkoxy, acyl, acyloxy, alkoxy, alkyloxyalkoxy, amino, alkylamino, dialkylamino, acylamino, carbamoyl, thiol, alkylthio, alkylthiono, sulfonyl, sulfonamido, sulfamoyl, nitro, cyano, free or esterified carboxy, aryl, aryloxy, arylthio, alkenyl, alkynyl, aralkoxy, heteroaralkoxy, heterocyclyl and heterocyclyloxy; or a pharmaceutically acceptable salt thereof.
Preferred are compounds of formula (IB) wherein R2 is -Y-(CH2)n-CRioRii-(CH2)m-X in which
Y is oxygen or S(O)q in which q is zero or an integer of 1 or 2; or
Y is trans CH=CH; or
Y is absent; n is an integer from 1 to 6;
Rio and Rn are, independently from each other, hydrogen or lower alkyl; or Rio and Rn combined are alkylene which together with the carbon atom to which they are attached form a 3- to 7-membered ring; m is zero or an integer of 1 or 2; X is hydroxy, alkoxy, cycloalkyl, cycloalkoxy, acyl, acyloxy, carbamoyl, cyano, trifluoromethyl, free or esterified carboxy, monocyclic aryl or heterocyclyl; or a pharmaceutically acceptable salt thereof. Further preferred are compounds of formula (IB) wherein
R3 is hydrogen; or a pharmaceutically acceptable salt thereof.
Further preferred are also compounds of formula (IB) wherein n is an integer of 2 or 3;
Rio and Rn are, independently from each other, hydrogen or lower alkyl; m is zero or 1; X is hydroxy, carbamoyl, cyano, trifluoromethyl, free or esterified carboxy, monocyclic aryl or heterocyclyl; or a pharmaceutically acceptable salt thereof.
More preferred are compounds of formula (IB) wherein Y is absent; or a pharmaceutically acceptable salt thereof. Even more preferred are compounds of formula (IB) wherein n is 3;
Rio and Rn are lower alkyl; m is zero or 1;
X is hydroxy, cyano or free or esterified carboxy; or a pharmaceutically acceptable salt thereof.
Most preferred are compounds of formula (IB) wherein
R10 and R11 are methyl; or a pharmaceutically acceptable salt thereof.
Especially preferred are compounds of formula (IB) wherein
R1 is hydrogen or -C(O)R6 in which R6 is monocyclic aryl; or a pharmaceutically acceptable salt thereof.
Preferred are also compounds in the A group having the formula
Figure imgf000034_0001
wherein
R1 is hydrogen or -C(O)R6, -C(O)NR7R8 or -C(O)OR9 in which
R6 and R7 are, independently from each other, hydrogen, cycloalkyl, aryl, heterocyclyl, aralkyl, heteroaralkyl or alkyl optionally substituted with one to four substituents selected from the group consisting of halogen, cycloalkyl, cycloalkoxy, alkoxy, alkyloxyalkoxy, amino, alkylamino, dialkylamino, aryl, aryloxy and heterocyclyl;
Rg and Rg are, independently from each other, cycloalkyl, aryl, heterocyclyl, aralkyl, heteroaralkyl or alkyl optionally substituted with one to four substituents selected from the group consisting of halogen, cycloalkyl, cycloalkoxy, alkoxy, alkyloxyalkoxy, amino, alkylamino, dialkylamino, aryl, aryloxy and heterocyclyl;
R2, R3, R4 and R5 are, independently from each other, hydrogen, hydroxy, halogen, cyano, nitro, alkoxy, alkylthio, alkylthiono, sulfonyl, free or esterified carboxy, carbamoyl, sulfamoyl, optionally substituted amino, cycloalkyl, aryl, heterocyclyl, alkenyl, alkynyl or (C1-8)alkyl optionally substituted with one to four substituents selected from the group consisting of halogen, hydroxy, cycloalkyl, cycloalkoxy, acyl, acyloxy, alkoxy, alkyloxyalkoxy, amino, alkylamino, dialkylamino, acylamino, carbamoyl, thiol, alkylthio, alkylthiono, sulfonyl, sulfonamido, sulfamoyl, nitro, cyano, free or esterified carboxy, aryl, aryloxy, arylthio, alkenyl, alkynyl, aralkoxy, heteroaralkoxy, heterocyclyl and heterocyclyloxy; or R2 and R3 combined are alkylene which together with the ring atoms to which they are attached form a 3- to 7-membered fused ring; or
R2 and R3 combined are alkylene which together with the carbon atom to which they are attached form a 3- to 7-membered spirocyclic ring; p is zero or 1; or a pharmaceutically acceptable salt thereof.
Preferred are compounds of formula (IC) wherein R4 and R5 are hydrogen; or a pharmaceutically acceptable salt thereof.
Preferred are also compounds of formula (IC) wherein
R2 and R3 are, independently from each other, hydrogen, halogen or (Ci-4)alkyl optionally substituted by at least one halogen; or a pharmaceutically acceptable salt thereof. Preferred are also compounds of formula (IC) wherein p is 1; or a pharmaceutically acceptable salt thereof.
Further preferred are compounds of formula (IC) having the formula
Figure imgf000035_0001
wherein
Ri is hydrogen or -C(O)R6, -C(O)NR7R8 or -C(O)OR9 in which R6 and R7 are, independently from each other, hydrogen, cycloalkyl, aryl, heterocyclyl, aralkyl, heteroaralkyl or alkyl optionally substituted with one to four substituents selected from the group consisting of halogen, cycloalkyl, cycloalkoxy, alkoxy, alkyloxyalkoxy, amino, alkylamino, dialkylamino, aryl, aryloxy and heterocyclyl; Rs and R9 are, independently from each other, cycloalkyl, aryl, heterocyclyl, aralkyl, heteroaralkyl or alkyl optionally substituted with one to four substituents selected from the group consisting of halogen, cycloalkyl, cycloalkoxy, alkoxy, alkyloxyalkoxy, amino, alkylamino, dialkylamino, aryl, aryloxy and heterocyclyl;
R2, R3, R4 and R5 are, independently from each other, hydrogen, hydroxy, halogen, cyano, nitro, alkoxy, alkylthio, alkylthiono, sulfonyl, free or esterified carboxy, carbamoyl, sulfamoyl, optionally substituted amino, cycloalkyl, aryl, heterocyclyl, alkenyl, alkynyl or (Ci^alkyl optionally substituted with one to four substituents selected from the group consisting of halogen, hydroxy, cycloalkyl, cycloalkoxy, acyl, acyloxy, alkoxy, alkyloxyalkoxy, amino, alkylamino, dialkylamino, acylamino, carbamoyl, thiol, alkylthio, alkylthiono, sulfonyl, sulfonamido, sulfamoyl, nitro, cyano, free or esterified carboxy, aryl, aryloxy, arylthio, alkenyl, alkynyl, aralkoxy, heteroaralkoxy, heterocyclyl and heterocyclyloxy; or R2 and R3 combined are alkylene which together with the carbon atom to which they are attached form a 3- to 7-membered spirocyclic ring; or a pharmaceutically acceptable salt thereof.
Preferred are compounds of formula (ID) wherein R4 and R5 are hydrogen; or a pharmaceutically acceptable salt thereof.
Preferred are also compounds of formula (ID), designated as the B group, wherein R2 and R3 are, independently from each other, hydrogen, halogen or (C^alkyl optionally substituted by at least one halogen; or a pharmaceutically acceptable salt thereof. Preferred are compounds in the B group wherein
Ri is hydrogen or -C(O)R6 in which R6 is monocyclic aryl; or a pharmaceutically acceptable salt thereof.
Preferred are also compounds of formula (ID), designated as the C group, wherein R2 and R3 combined are alkylene which together with the carbon atom to which they are attached form a 3- to 5-membered spirocyclic ring; or a pharmaceutically acceptable salt thereof.
Preferred are compounds in the C group, wherein
Ri is hydrogen or -C(O)R6 in which R6 is monocyclic aryl; or a pharmaceutically acceptable salt thereof.
Preferred are also compounds of formula (ID), designated as the D group, wherein R2 is -Y-(CH2)n-CRioRi r(CH2)m-X in which
Y is oxygen or S(O)q in which q is zero or an integer of 1 or 2; or
Y is trans CH=CH; or
Y is absent; n is an integer from 1 to 6;
Rio and Rn are, independently from each other, hydrogen or lower alkyl; or Rio and Rn combined are alkylene which together with the carbon atom to which they are attached form a 3- to 7-membered ring; m is zero or an integer of 1 or 2; X is hydroxy, alkoxy, cycloalkyl, cycloalkoxy, acyl, acyloxy, carbamoyl, cyano, trifluoromethyl, free or esterified carboxy, monocyclic aryl or heterocyclyl; or a pharmaceutically acceptable salt thereof.
Preferred are compounds in the D group wherein R3 is hydrogen; or a pharmaceutically acceptable salt thereof. Further preferred are compounds in the D group wherein n is an integer of 2 or 3;
Rio and Rn are, independently from each other, hydrogen or lower alkyl; m is zero or 1 ;
X is hydroxy, carbamoyl, cyano, trifluoromethyl, free or esterified carboxy, monocyclic aryl or heterocyclyl; or a pharmaceutically acceptable salt thereof.
More preferred are compounds in the D group wherein
Y is absent; or a pharmaceutically acceptable salt thereof.
Even more preferred are compounds in the D group wherein n is 3;
Rio and Rn are lower alkyl; m is zero or 1 ;
X is hydroxy, cyano or free or esterified carboxy; or a pharmaceutically acceptable salt thereof.
Most preferred are compounds in the D group wherein
Rio and Rn are methyl; or a pharmaceutically acceptable salt thereof.
Especially preferred are compounds in the D group wherein
Ri is hydrogen or -C(O)R6 in which R6 is monocyclic aryl; or a pharmaceutically acceptable salt thereof.
Particular embodiments are: 5-(3,6-Dihydroxynaphthalen-2-yl)-l,l-dioxo-l,2,5-thiadiazolidin-3-one;
5-(3,7-Dihydroxynaphthalen-2-yl)- 1 , 1 -dioxo- 1 ,2,5-thiadiazolidin-3-one potassium salt; 5-(7-Bromo-3-hydroxynaphthalen-2-yl)-l,l-dioxo-l,2,5-thiadiazolidin-3-one;
5-(7-Ethyl-3-hydroxynaphthalen-2-yl)-l,l-dioxo-l,2,5-thiadiazolidin-3-one;
5-{3-Hydroxy-7-[2-(4-methoxyphenyl)-ethyl]-naphthalen-2-yl}-l,l-dioxo-l,2,5- thiadiazolidin-3-one; 5-{3-Hydroxy-7-[2-(4-trifluoromethylphenyl)-ethyl]-naphthalen-2-yl}-l, 1-dioxo- 1,2,5- thiadiazolidin-3-one;
5-{3-Hydroxy-7-[2-(3-methoxyphenyl)-ethyl]-naphthalen-2-yl}-l,l-dioxo-l,2,5- thiadiazolidin-3-one;
5-[3-Hydroxy-7-(4-methylpentyl)-naphthalen-2-yl]- 1 , 1 -dioxo- 1 ,2,5-thiadiazolidin-3-one; {3-[6-Hydroxy-7-(l,l,4-trioxo-l,2,5-thiadiazolidin-2-yl)naphthalen-2-yl]-phenyl}-acetic acid;
5-(3-Hydroxy-7-phenylnaphthalen-2-yl)- 1,1 -dioxo- l,2,5-thiadiazolidin-3-one;
3-[6-Hydroxy-7-(l,l,4-trioxo-l,2,5-thiadiazolidin-2-yl)-naphthalen-2-yl]-benzoic acid;
5-[3-Hydroxy-7-(3-trifluoromethoxyphenyl)-naphthalen-2-yl]- 1,1 -dioxo- 1,2,5- thiadiazolidin-3-one;
{3-[6-Hydroxy-7-(l,l,4-trioxo-l,2,5-thiadiazolidin-2-yl)-naphthalen-2-yl]- pheny 1 } acetonitri Ie;
5-[3-Hydroxy-7-(3-hydroxyrnethylphenyl)-naphthalen-2-yl]-l,l-dioxo-l,2,5- thiadiazolidin-3-one; 3-{3-[6-Hydroxy-7-(l,l,4-trioxo-thiadiazolidin-2-yl)-naphthalen-2yl]-phenyl}-propionic acid;
6-Hydroxy-7-(l,l,4-trioxo-l,2,5-thiadiazolidin-2-yl)-naphthalene-2-carbonitrile;
3-[6-Hydroxy-7-(l , 1 ,4-trioxo- 1 ,2,5-thiadiazolidin-2-yl)-naphthalen-2-yl]-benzonitrile;
5-[7-(3,3-Dimethylbutyl)-3-hydroxynaphthalen-2-yl]- 1,1 -dioxo- 1, 2,5 -thiadiazolidin-3- one;
5-[3-Hydroxy-7-(3-trifluoromethylphenyl)-naphthalen-2-yl]- 1,1 -dioxo- 1,2,5- thiadiazolidin-3-one;
3-[6-Hydroxy-7-(l,l,4-trioxo-l,2,5-thiadiazolidin-2-yl)-naphthalen-2-yl]-benzoic acid ethyl ester; 5-[3-Hydroxy-7-(3-methanesulfonylphenyl)-naphthalen-2-yl]-l,l-dioxo-l,2,5- thiadiazolidin-3-one; 3-{3-[6-Hydroxy-7-(l,l,4-trioxo-l,2,5-thiadiazolidin-2-yl)-naphthalen-2-yl]-phenyl}- propionitrile;
5-[3-Hydroxy-7-(3-methoxymethylphenyl)-naphthalen-2-yl]- 1,1 -dioxo- 1,2,5- thiadiazolidin-3-one; 5-(7-Furan-3-yl-3-hydroxynaphthalen-2 -yl)- 1,1 -dioxo- l,2,5-thiadiazolidin-3-one; iV-{3-[6-Hydroxy-7-(l,l,4-trioxo-l,2,5-thiadiazolidin-2-yl)-naphthalen-2-yl]-phenyl}- methanesulfonamide;
5-[7-(2-Fluorophenyl)-3-hydroxynaphthalen-2-yl]- 1,1 -dioxo- l,2,5-thiadiazolidin-3-one;
5-(3-Hydroxy-7-o-tolylnaphthalen-2-yl)- 1,1 -dioxo- l,2,5-thiadiazolidin-3-one; 5-(3-Hydroxy-7-pentylnaphthalen-2-yl)- 1,1 -dioxo- l,2,5-thiadiazolidin-3-one;
5-(3-Hydroxy-7-propylnaphthalen-2-yl)- 1,1 -dioxo- l,2,5-thiadiazolidin-3-one;
5-[3-Hydroxy-7-(tetrahydrofiiran-3-yl)-naphthalen-2-yl]- 1,1 -dioxo- 1, 2,5-thiadiazolidin-
3 -one;
{3-[6-Hydroxy-7-(l,l,4-trioxo-l,2,5-thiadiazolidin-2-yl)-naphthalen-2-yl]-phenyl}-acetic acid ethyl ester;
3-{3-[6-Hydroxy-7-(l,l,4-trioxo-l,2,5-thiadiazolidin-2-yl)-naphthalen-2-yl]-phenyl}- propionic acid ethyl ester;
5-[6-Hydroxy-7-(l,l,4-trioxo-l,2,5-thiadiazolidin-2-yl)-naphthalen-2-yl]-pentanoic acid ethyl ester; 4-[6-Hydroxy-7-(l,l,4-trioxo-l,2,5-thiadiazolidin-2-yl)-naphthalen-2-yl]-2,2-dimethyl- butyric acid;
5-[3-Hydroxy-7-((S)-4-hydroxypentyl)-naphthalen-2-yl]-l,l-dioxo-l,2,5-thiadiazolidin-
3 -one;
4-[6-Hydroxy-7-(l,l,4-trioxo-l,2,5-thiadiazolidin-2-yl)-naphthalen-2-yl]-2- methylbutyronitrile;
5-[6-Hydroxy-7-(l,l,4-trioxo-l,2,5-thiadiazolidin-2-yl)-naphthalen-2-yl]-2- methylpentanoic acid ethyl ester;
5 - [3 -Hydroxy-7-(3 -methy lbuty l)-naphthalen-2-y 1] - 1 , 1 -dioxo- 1 ,2,5 -thiadiazolidin-3 -one;
5-[6-Hydroxy-7-(l,l,4-trioxo-l,2,5-thiadiazolidin-2-yl)-naphthalen-2-yl]-2,2- dimethylpentanenitrile;
5-[6-Hydroxy-7-(l,l,4-trioxo-l,2,5-thiadiazolidin-2-yl)-naphthalen-2-yl]-pentanoic acid; 5-[3-Hydroxy-7-(5-hydroxypentyl)-naphthalen-2-yl]-l,l-dioxo-l,2,5-thiadiazolidin-3- one;
2-Hydroxy-6-{2-[6-hydroxy-7-(l,l,4-trioxo-l,2,5-thiadiazolidin-2-yl)-naphthalen-2- yloxy]-ethoxy}-N,N-dimethylbenzamide; 2-Hydroxy-6-{4-[6-hydroxy-7-(l,l,4-trioxo-l,2,5-thiadiazolidin-2-yl)-naphthalen-2-yl]- butoxy}-N,N-dimethylbenzamide;
5 - {3 -Hydroxy-7-[3 -(2-hydroxyethoxy)-propy l]-naphthalen-2-y 1 } - 1 , 1 -dioxo- 1,2,5- thiadiazolidin-3-one;
5- {3 -Hydroxy-7-[2-(2-methoxyphenyl)-ethyl]-naphthalen-2-yl } - 1 , 1 -dioxo- 1,2,5- thiadiazolidin-3-one;
5-[3-Hydroxy-7-(5-oxohexyl)-naphthalen-2-yl]- 1,1 -dioxo- l,2,5-thiadiazolidin-3-one;
5-{7-[3-(3,5-Dimethylpyrazol-l-yl)-propyl]-3-hydroxy-naphthalen-2-yl}-l,l-dioxo- l,2,5-thiadiazolidin-3-one;
5 - { 3 -Hydroxy-7-[3 -(2-oxocyclohexyl)-propyl]-naphthalen-2-y 1 } - 1 , 1 -dioxo- 1,2,5- thiadiazolidin-3-one;
5-{3-Hydroxy-7-[4-hydroxy-4-(tetrahydrofuran-2-yl)-butyl]-naphthalen-2-yl}-l,l-dioxo- l,2,5-thiadiazolidin-3-one;
5 - { 3 -Hydroxy-7-[ 1 -(2-oxopyrrol idin- 1 -y l)-ethy l]naphthalen-2-yl } - 1 , 1 -dioxo- 1,2,5- thiadiazolidin-3-one; 5 -[3-Hydroxy-7-(3-phenylpropyl)-naphthalen-2-y I]- 1 , 1 -dioxo- 1 ,2,5 -thiadiazolidin-3-one;
5-[3-Hydroxy-7-(3-pentafluorophenylpropyl)-naphthalen-2-yl]- 1,1 -dioxo- 1,2,5- thiadiazolidin-3-one;
2-{3-[6-Hydroxy-7-(l,l,4-trioxo-l,2,5-thiadiazolidin-2-yl)-naphthalen-2-yl]- propyl}benzonitrile; 5 -[3-Hydroxy-7-((i?)-4-hydroxypentyl)-naphthalen-2-yl]- 1 , 1 -dioxo- 1 ,2,5 -thiadiazolidin- 3-one;
5-[3-Hydroxy-7-(4-hydroxypentyl)-naphthalen-2-yl]-l,l-dioxo-l,2,5-thiadiazolidin-3- one;
5-[3-Hydroxy-7-(4-hydroxy-3-methylbutyl)-naphthalen-2-yl]-l,l-dioxo- 1,2,5- thiadiazolidin-3-one; 5-[7-(4-Ethyl-4-hydroxyhexyl)-3-hydroxynaphthalen-2-yl]- 1,1 -dioxo- 1,2,5- thiadiazolidin-3-one;
5-[3-Hydroxy-7-(4-hydroxyheptyl)-naphthalen-2-yl]- 1,1 -dioxo- 1,2, 5-thiadiazolidin-3- one; S-jS-Hydroxy-T-P-Cl-hydroxycyclohexyO-propyπ-naphthalen^-yl}-!, 1-1,2,5- thiadiazolidin-3-one;
5-[6-Hydroxy-7-(l,l,4-trioxo-l,2,5-thiadiazolidin-2-yl)-naphthalen-2-yl]-2,2- dimethylpentanoic acid;
5-{3-Hydroxy-7-[2-((15',2i?)-2-hydroxycyclopentyl)-ethyl]-naphthalen-2-yl}-l,l-dioxo- l,2,5-thiadiazolidin-3-one;
5-[6-Hydroxy-7-( 1 , 1 ,4-trioxo- 1 ,2,5-thiadiazolidin-2-yl)-naphthalen-2-yl]-pentanenitrile;
5-{3-Hydroxy-7-[3-(2-hydroxycyclohexyl)-propyl]-naphthalen-2-yl}-l,l-dioxo-l,2,5- thiadiazolidin-3-one;
5-[6-Hydroxy-7-(l,l,4-trioxo-l,2,5-thiadiazolidin-2-yl)-naphthalen-2-yl]-2,2- dimethylpentanoic acid methyl ester;
5-[3-Hydroxy-7-(5,5,5-trifluoro-4-hydroxy-4-methylpentyl)-naphthalen-2-yl]-l,l-dioxo- l,2,5-thiadiazolidin-3-one;
Acetic acid 4-[6-hydroxy-7-(l,l,4-trioxo-l,2,5-thiadiazolidin-2-yl)-naphthalen-2-yl]-2- methyl butyl ester; 5-[3-Hydroxy-7-(5,5,5-trifluoro-4-hydroxypentyl)-naphthalen-2-yl]- 1,1 -dioxo- 1,2,5- thiadiazolidin-3-one;
5-[3-Hydroxy-7-(4-hydroxy-4-methylpentyl)-naphthalen-2-yl]- 1,1 -dioxo- 1,2,5- thiadiazolidin-3-one;
5-(7-Cyclopentyl-3-hydroxynaphthalen-2-yl)-l,l-dioxo-l,2,5-thiadiazolidin-3-one; 5-(7-Cyclohexyl-3-hydroxynaphthalen-2-yl)-l,l-dioxo-l,2,5-thiadiazolidin-3-one;
5-[3-Hydroxy-7-(3-methylsulfanylphenyl)-naphthalen-2-yl]- 1,1 -dioxo- 1,2,5- thiadiazolidin-3-one;
5-[3-Hydroxy-7-((£)-4-hydroxy-4-methylpent-l-enyl)-naphthalen-2-yl]-l,l-dioxo-l,2,5- thiadiazolidin-3-one; 5-[6-Hydroxy-7-(l,l,4-trioxo-l,2,5-thiadiazolidin-2-yl)-naphthalen-2-yl]-thiophene-2- carbonitrile; {3-[6-Hydroxy-7-(l,l,4-trioxo-l,2,5-thiadiazolidin-2-yl)-naphthalen-2-yl]-benzyl}- carbamic acid methyl ester;
(£)-5-[6-Hydroxy-7-(l , 1 ,4-trioxo- 1 ,2,5-thiadiazolidin-2-yl)-naphthalen-2-yl]-pent-4- enenitrile; (£)-5-[6-Hydroxy-7-(l,l,4-trioxo-l,2,5-thiadiazolidin-2-yl)-naphthalen-2-yl]-
2methylpent-4-enoic acid ethyl ester;
(£)-5-[6-Hydroxy-7-(l,l,4-trioxo-l,2,5-thiadiazolidin-2-yl)naphthalen-2-yl]-2- methylpent-4-enoic acid;
(£)-5-[6-Hydroxy-7-(l,l,4-trioxo-l,2,5-thiadiazolidin-2-yl)-naphthalen-2-yl]-pent-4- enoic acid;
5-[6-Hydroxy-7-(l,l,4-trioxo-l,2,5-thiadiazolidin-2-yl)-naphthalen-2-yl]-pentanoic acid isopropyl ester;
5-[6-Hydroxy-7-(l,l,4-trioxo-l,2,5-thiadiazolidin-2-yl)-naphthalen-2-yl]-2- methylpentanoic acid methyl ester; 5-[6-Hydroxy-7-(l,l,4-trioxo-l,2,5-thiadiazolidin-2-yl)-naphthalen-2-yl]-2- methylpentanoic acid;
5-[7-(4,5-Dihydroxy-4,5-dimethylhex-l-enyl)-3-hydroxynaphthalen-2-yl]-l,l-dioxo-
1 ,2,5-thiadiazolidin-3-one;
5-[7-(4,5-Dihydroxy-4,5-dimethylhexyl)-3-hydroxynaphthalen-2-yl]-l,l-dioxo-l,2,5- thiadiazolidin-3-one;
5-[7-(4,4-Dimethylpentyl)-3-hydroxynaphthalen-2-yl]-l,l-dioxo-l,2,5-thiadiazolidin-3- one;
Benzoic acid 6-(3-cyano-3-methylproρyl)-3-(l,l,4-trioxo-l,2,5-thiadiazolidin-2-yl)- naphthalen-2-yl ester; 2,2-Dimethylpropionic acid 6-(3-cyano-3-methylpropyl)-3-(l,l,4-trioxo-l,2,5- thiadiazolidin-2-yl)-naphthalen-2-yl ester;
Propionic acid 6-(3-cyano-3-methylpropyl)-3-(l,l,4-trioxo-l,2,5-thiadiazolidin-2-yl)- naphthalen-2-yl ester;
2-Ethylbutyric acid 6-(3-cyano-3-methylpropyl)-3-(l,l,4-trioxo-l,2,5-thiadiazolidin-2- yl)-naphthalen-2-yl ester; Hexanoic acid 6-(3-cyano-3-methylpropyl)-3-(l,l,4-trioxo-l,2,5-thiadiazolidin-2-yl)- naphthalen-2-yl ester;
2-Acetoxy-benzoic acid 6-(3-cyano-3-methylpropyl)-3-(l,l,4-trioxo-l,2,5-thiadiazolidin-
2-yl)-naphthalen-2-yl ester; Pentanoic acid 6-(3-cyano-3-methylpropyl)-3-(l,l,4-trioxo-l,2,5-thiadiazolidin-2-yl)- naphthalen-2-yl ester;
Acetic acid 6-(3-cyano-3-methylpropyl)-3-(l,l,4-trioxo-l,2,5-thiadiazolidin-2-yl)- naphthalen-2-yl ester;
3-Methylbenzoic acid 6-(3-cyano-3-methylpropyl)-3-(l,l,4-trioxo-l,2,5-thiadiazolidin-2- yl)-naphthalen-2-yl ester;
2-Methylbenzoic acid 6-(3-cyano-3-methylpropyl)-3-(l,l,4-trioxo-l,2,5-thiadiazolidin-2- yl)-naphthalen-2-yl ester;
4-Butylbenzoic acid 6-(3-cyano-3-methylpropyl)-3-(l,l,4-trioxo-l,2,5-thiadiazolidin-2- yl)-naphthalen-2-yl ester; Cyclohexanecarboxylic acid 6-(3-cyano-3-methylpropyl)-3-(l,l,4-trioxo-l,2,5- thiadiazolidin-2-yl)-naphthalen-2-yl ester;
4-rerr-Butylbenzoic acid 6-(3-cyano-3-methylpropyl)-3-(l,l,4-trioxo-l, 2,5- thiadiazolidin-2-yl)-naphthalen-2-yl ester;
2,2-Dimethylpropionic acid 6-(3-cyanophenyl)-3-(l, l,4-trioxo-l,2,5-thiadiazolidin-2-yl)- naphthalen-2-yl ester;
Benzoic acid 6-(4-ethoxycarbonylbutyl)-3-(l,l,4-trioxo-l,2,5-thiadiazolidin-2-yl)- naphthalen-2-yl ester;
Benzoic acid 6-(3-methylbutyl)-3-(l,l,4-trioxo-l,2,5-thiadiazolidin-2-yl)-naphthalen-2-yl ester; Benzoic acid 6-((£)-4-hydroxy-4-methylpent-l-enyl)-3-(l,l,4-trioxo-l,2,5-thiadiazolidin-
2-yl)-naphthalen-2-yl ester;
Benzoic acid 6-methyl-3-(l,l,4-trioxo-l,2,5-thiadiazolidin-2-yl)-naphthalen-2-yl ester;
Benzoic acid 6-(5-hydroxy-4,4-dimethylpentyl)-3-(l,l,4-trioxo-l,2,5-thiadiazolidin-2- yl)-naphthalen-2-yl ester; 5-[3-Hydroxy-7-(5-hydroxy-4,4-dimethylpentyl)-naphthalen-2-yl]-l,l-dioxo- 1,2,5- thiadiazolidin-3-one; 5-(3-Hyrdoxy-5 ,6,7, 8-tetrahydronapthalen-2-yl)- 1,1 -dioxo- l,2,5-thiadiazolidin-3-one;
5-(3,6-Dihydroxy-5 ,6,7, 8-tetrahydronaphthalen-2-yl)- 1,1 -dioxo- l,2,5-thiadiazolidin-3- one;
5-(3-Hydroxy-6-methoxy-5,6,7,8-tetrahydronaphthalen-2-yl)-l,l-dioxo- 1,2,5- thiadiazolidin-3-one;
5-(6-Ethoxy-3-hydroxy-5,6,7,8-tetrahydronaphthalen-2-yl)- 1,1 -dioxo- 1,2,5- thiadiazolidin-3-one;
5-(3-Hydroxy-7-methyl-5,6,7,8-tetrahydronaphthalen-2-yl)- 1 , 1 -dioxo- 1 ,2,5- thiadiazolidin-3-one; 5-(3-Hydroxy-7,7-dimethyl-5,6,7,8-tetrahydronaphthalen-2-yl)- 1 , 1 -dioxo- 1 ,2,5- thiadiazolidin-3-one;
5-(3-Hydroxy-7-trifluoromethyl-5,6,7,8-tetrahydronaphthalen-2-yl)- 1,1 -dioxo- 1,2,5- thiadiazolidin-3-one;
5-(3-Hydroxy-7-isopropyl-5 ,6,7, 8-tetrahydronaphthalen-2-yl)- 1,1 -dioxo- 1,2,5- thiadiazolidin-3-one;
5-(7-Ethyl-3-hydroxy-5,6,7,8-tetrahydronaphthalen-2-yl)- 1,1 -dioxo- 1,2,5-thiadiazolidin-
3-one;
5-(7,7-Diethyl-3-hydroxy-5,6,7,8-tetrahydronaphthalen-2-yl)- 1,1 -dioxo- 1,2,5- thiadiazolidin-3-one; 5-(3-Hydroxy-7,7-dipropyl-5,6,7,8-tetrahydronaphthalen-2-yl)- 1,1 -dioxo- 1,2,5- thiadiazolidin-3-one;
5-(6'-Hydroxy-3',4'-dihydro- 1 Η-spiro[cyclopentane- 1 ,2'-naphthalen]-7'-yl) 1 ,2,5- thiadiazolidin-3-one 1,1 -dioxide;
5-((.S)-7-Ethyl-3-hydroxy-5,6,7,8-tetrahydronaphthalen-2-yl)- 1,1 -dioxo- 1,2,5- thiadiazolidin-3-one;
5-[6-Hydroxy-7-(l,l,4-trioxo-l,2,5-thiadiazolidin-2-yl)-l,2,3,4-tetrahydronaphthalen-2- yl]-2,2-dimethylpentanoic acid methyl ester;
5-[6-Hydroxy-7-( 1 , 1 ,4-trioxo- 1 ,2,5-thiadiazolidin-2-yl)- 1 ,2,3,4-tetrahydronaphthalen-2- yl]-2,2-dimethylpentanoic acid; 5-(6-Hydroxy-2-methyl-2,3-dihydrobenzo[b]thiophen-5-yl)-l,l-dioxo-l,2,5- thiadiazolidin-3-one; 5-(6-Hydroxyindan-5-yl)- 1 , 1 -dioxo- 1 ,2,5-thiadiazolidin-3-one;
5-(6-Hydroxy-2,2-dimethylindan-5-yl)-l,l-dioxo-l,2,5-thiadiazolidin-3-one;
5-(6-Hydroxy-2-methylindan-5-yl)- 1,1 -dioxo- l,2,5-thiadiazolidin-3-one;
Benzoic acid 6,6-dimethyl-3-(l,l,4-trioxo-l,2,5-thiadiazolidin-2-yl)-5 ,6,7,8- tetrahydronaphthalen-2-yl ester;
Benzoic acid (S)-6-ethyl-3-(l,l,4-trioxo-l,2,5-thiadiazolidin-2-yl)-5,6,7,8- tetrahydronaphthalen-2-yl ester;
Benzoic acid 6-ethyl-3-(l,l,4-trioxo-l,2,5-thiadiazolidin-2-yl)-5,6,7,8- tetrahydronaphthalen-2-yl ester; Benzoic acid 6,6-diethyl-3-(l,l,4-trioxo-l,2,5-thiadiazolidin-2-yl)-5,6,7,8- tetrahydronaphthalen-2-yl ester;
Benzoic acid 2,2-dimethyl-6-(l,l,4-trioxo-l,2,5-thiadiazolidin-2-yl)-indan-5-yl ester;
5-(3-Allyloxy-6-hydroxybenzo[</]isoxazol-5-yl)- 1,1 -dioxo- l,2,5-thiadiazolidin-3-one;
S-Hydroxy-ό-ClJ^-trioxo-l^^-thiadiazolidin^-y^-lH-indole^-carboxylic acid ethyl ester potassium salt;
5-Ηydroxy-6-( 1 , 1 ,4-trioxo- 1 ,2,5-thiadiazolidin-2-yl)- 1 H-indole-2-carboxylic acid 3- methyl-butyl ester;
5-Ηydroxy-6-( 1 , 1 ,4-trioxo- 1 ,2,5-thiadiazolidin-2-yl)- 1 H-indole-2-carboxylic acid isobutyl ester; 5-Ηydroxy-6-(l,l,4-trioxo-l,2,5-thiadiazolidin-2-yl)-lH-indole-2-carboxylic acid; and
5-(7-Ηydroxy-3-methoxy-2-oxo-2H-chromen-6-yl)-l,l-dioxo-l,2,5-thiadiazolidin-3-one;
5-(3-Ηydroxy-7-methoxynaphthalen-2-yl)-l,l-dioxo-[l,2,5]thiadiazolidin-3-one;
5-(3-Hydroxy-7-methoxynaphthalen-2-yl)-l,l-dioxo-[l,2,5]thiadiazolidin-3-one potassium salt; 5-(3-Hydroxy-7-propoxynaphthalen-2-yl)-l,l-dioxo-[l,2,5]thiadiazolidin-3-one;
5-(3-Hydroxy-7-propoxynaphthalen-2-yl)-l,l-dioxo-[l,2,5]thiadiazolidin-3-one potassium salt;
5-(3-Hydroxynaphthalen-2-yl)-l,l-dioxo-[l,2,5]thiadiazolidin-3-one;
5-(3-Hydroxynaphthalen-2-yl)-l,l-dioxo-[l,2,5]thiadiazolidin-3-one potassium salt; 5-(3-Hydroxy-7-methyl-naphthalen-2-yl)- 1,1 -dioxo- l,2,5-thiadiazolidin-3-one; and 5-(3-Hydroxy-7-methyl-naphthalen-2-yl)-l,l-dioxo-l,2,5-thiadiazolidin-3-one potassium salt or a pharmaceutically acceptable salt thereof.
Category 2 PTP Inhibitors
The methods of the invention can be practiced with the compounds of the formula
Figure imgf000047_0001
wherein
Ri is hydrogen, -C(O)R2, -C(O)NR3R4 or -C(O)OR5 in which R2 and R3 are, independently from each other, hydrogen, cycloalkyl, aryl, heterocyclyl, aralkyl, heteroaralkyl or alkyl optionally substituted with one to four substituents selected from the group consisting of halogen, cycloalkyl, cycloalkoxy, alkoxy, alkyloxyalkoxy, amino, alkylamino, dialkylamino, aryl, aryloxy and heterocyclyl; R4 and R5 are, independently from each other, cycloalkyl, aryl, heterocyclyl, aralkyl, heteroaralkyl or alkyl optionally substituted with one to four substituents selected from the group consisting of halogen, cycloalkyl, cycloalkoxy, alkoxy, alkyloxyalkoxy, amino, alkylamino, dialkylamino, aryl, aryloxy and heterocyclyl;
U, W and V are, independently from each other, hydrogen, hydroxy, halogen, cyano, nitro, alkoxy, alkylthio, alkylthiono, sulfonyl, free or esterified carboxy, carbamoyl, sulfamoyl, optionally substituted amino, cycloalkyl, aryl, aryloxy, arylthio, heterocyclyl, heterocycloyloxy, alkenyl, alkynyl or
Figure imgf000047_0002
optionally substituted with one to four substituents selected from the group consisting of halogen, hydroxy, cycloalkyl, cycloalkoxy, acyl, acyloxy, alkoxy, alkyloxyalkoxy, amino, alkylamino, dialkylamino, acylamino, carbamoyl, thiol, alkylthio, alkylthiono, sulfonyl, sulfonamido, sulfamoyl, nitro, cyano, free or esterified carboxy, aryl, aryloxy, arylthio, alkenyl, alkynyl, aralkoxy, heteroaralkoxy, heterocyclyl and heterocyclyloxy; or U and W combined together with the carbon atoms to which they are attached form an optionally substituted aromatic, or a partially or fully saturated nonaromatic 5- to 8- membered carbocyclic or heterocyclic ring; or
W and V combined together with the carbon atoms to which they are attached form an optionally substituted aromatic, or partially or fully saturated nonaromatic 5- to 8- membered carbocyclic or heterocyclic ring; or a pharmaceutically acceptable salt thereof.
Preferred are the compounds of formula (I) wherein U and W combined together with the carbon atoms to which they are attached form an optionally substituted aromatic, or a partially or fully saturated nonaromatic 5- to 8- membered carbocyclic or heterocyclic ring;
V is hydrogen; or a pharmaceutically acceptable salt thereof.
Further preferred are the compounds of formula (I) having the formula
Figure imgf000048_0001
wherein
Qa combined together with the carbon atoms to which it is attached form an aromatic, or a partially or fully saturated nonaromatic 5- to 8-membered carbocyclic or heterocyclic ring;
Ri is hydrogen, -C(O)R2, -C(O)NR3R4 or -C(O)OR5 in which
R2 and R3 are, independently from each other, hydrogen, cycloalkyl, aryl, heterocyclyl, aralkyl, heteroaralkyl or alkyl optionally substituted with one to four substituents selected from the group consisting of halogen, cycloalkyl, cycloalkoxy, alkoxy, alkyloxyalkoxy, amino, alkylamino, dialkylamino, aryl, aryloxy and heterocyclyl; R4 and R5 are, independently from each other, cycloalkyl, aryl, heterocyclyl, aralkyl, heteroaralkyl or alkyl optionally substituted with one to four substituents selected from the group consisting of halogen, cycloalkyl, cycloalkoxy, alkoxy, alkyloxyalkoxy, amino, alkylamino, dialkylamino, aryl, aryloxy and heterocyclyl; R2a, R3a, R4a and R5a are, independently from each other, hydrogen, hydroxy, halogen, cyano, nitro, alkoxy, alkylthio, alkylthiono, sulfonyl, free or esterified carboxy, carbamoyl, sulfamoyl, optionally substituted amino, cycloalkyl, aryl, heterocyclyl, alkenyl, alkynyl or
Figure imgf000049_0001
optionally substituted with one to four substituents selected from the group consisting of halogen, hydroxy, cycloalkyl, cycloalkoxy, acyl, acyloxy, alkoxy, alkyloxyalkoxy, amino, alkylamino, dialkylamino, acylamino, carbamoyl, thiol, alkylthio, alkylthiono, sulfonyl, sulfonamido, sulfamoyl, nitro, cyano, free or esterified carboxy, aryl, aryloxy, arylthio, alkenyl, alkynyl, aralkoxy, heteroaralkoxy, heterocyclyl and heterocyclyloxy; or R2a and R3a combined are alkylene which together with the ring atoms to which they are attached form a 3- to 7-membered fused ring; or
R2a and R3a combined are alkylene which together with the carbon atom to which they are attached form a 3- to 7-membered spirocyclic ring; or a pharmaceutically acceptable salt thereof.
Preferred are compounds of formula (Ia), designated as the A group, wherein
Qa combined together with the carbon atoms to which it is attached form an aromatic, or a partially or fully saturated 5- to 6-membered carbocyclic ring; or a pharmaceutically acceptable salt thereof.
Preferred are compounds in the A group having the formula
Figure imgf000049_0002
wherein
Ri is hydrogen, -C(O)R2, -C(O)NR3R4 or -C(O)OR5 in which
R2 and R3 are, independently from each other, hydrogen, cycloalkyl, aryl, heterocyclyl, aralkyl, heteroaralkyl or alkyl optionally substituted with one to four substituents selected from the group consisting of halogen, cycloalkyl, cycloalkoxy, alkoxy, alkyloxyalkoxy, amino, alkylamino, dialkylamino, aryl, aryloxy and heterocyclyl; R4 and R5 are, independently from each other, cycloalkyl, aryl, heterocyclyl, aralkyl, heteroaralkyl or alkyl optionally substituted with one to four substituents selected from the group consisting of halogen, cycloalkyl, cycloalkoxy, alkoxy, alkyloxyalkoxy, amino, alkylamino, dialkylamino, aryl, aryloxy and heterocyclyl;
R2a, R3a> IW and Rsa are, independently from each other, hydrogen, hydroxy, halogen, cyano, nitro, alkoxy, alkylthio, alkylthiono, sulfonyl, free or esterified carboxy, carbamoyl, sulfamoyl, optionally substituted amino, cycloalkyl, aryl, heterocyclyl, alkenyl, alkynyl or (Ci.g)alkyl optionally substituted with one to four substituents selected from the group consisting of halogen, hydroxy, cycloalkyl, cycloalkoxy, acyl, acyloxy, alkoxy, alkyloxyalkoxy, amino, alkylamino, dialkylamino, acylamino, carbamoyl, thiol, alkylthio, alkylthiono, sulfonyl, sulfonamido, sulfamoyl, nitro, cyano, free or esterified carboxy, aryl, aryloxy, arylthio, alkenyl, alkynyl, aralkoxy, heteroaralkoxy, heterocyclyl and heterocyclyloxy; or R2a and R3a combined are alkylene which together with the ring atoms to which they are attached form a 5- to 7-membered fused ring; or or a pharmaceutically acceptable salt thereof. Preferred are compounds of formula (Ia1) wherein R43 and R5a are hydrogen; or a pharmaceutically acceptable salt thereof.
Further preferred are compounds of formula (Ia1) having the formula
Figure imgf000051_0001
wherein
R1 is hydrogen, -C(O)R2, -C(O)NR3R4 or -C(O)OR5 in which
R2 and R3 are, independently from each other, hydrogen, cycloalkyl, aryl, heterocyclyl, aralkyl, heteroaralkyl or alkyl optionally substituted with one to four substituents selected from the group consisting of halogen, cycloalkyl, cycloalkoxy, alkoxy, alkyloxyalkoxy, amino, alkylamino, dialkylamino, aryl, aryloxy and heterocyclyl; R4 and R5 are, independently from each other, cycloalkyl, aryl, heterocyclyl, aralkyl, heteroaralkyl or alkyl optionally substituted with one to four substituents selected from the group consisting of halogen, cycloalkyl, cycloalkoxy, alkoxy, alkyloxyalkoxy, amino, alkylamino, dialkylamino, aryl, aryloxy and heterocyclyl;
R2a and R3a are, independently from each other, hydrogen, hydroxy, halogen, cyano, nitro, alkoxy, alkylthio, alkylthiono, sulfonyl, free or esterified carboxy, carbamoyl, sulfamoyl, optionally substituted amino, cycloalkyl, aryl, heterocyclyl, alkenyl, alkynyl or (C1-g)alkyl optionally substituted with one to four substituents selected from the group consisting of halogen, hydroxy, cycloalkyl, cycloalkoxy, acyl, acyloxy, alkoxy, alkyloxyalkoxy, amino, alkylamino, dialkylamino, acylamino, carbamoyl, thiol, alkylthio, alkylthiono, sulfonyl, sulfonamido, sulfamoyl, nitro, cyano, free or esterified carboxy, aryl, aryloxy, arylthio, alkenyl, alkynyl, aralkoxy, heteroaralkoxy, heterocyclyl and heterocyclyloxy; or a pharmaceutically acceptable salt thereof.
Preferred are compounds of formula (Ia2) wherein R23 is -Ya-(CH2)n-CR6aR7a-(CH2)m-Xa in which Ya is oxygen or S(O)q in which q is zero or an integer of 1 or 2; or
Ya is trans CH=CH; or Ya is absent; n is an integer from 1 to 6;
R^a and R7a are, independently from each other, hydrogen or lower alkyl; or R^a and R7a combined are alkylene which together with the carbon atom to which they are attached form a 3- to 7-membered ring; m is zero or an integer of 1 or 2;
Xa is hydroxy, alkoxy, cycloalkyl, cycloalkoxy, acyl, acyloxy, carbamoyl, cyano, trifluoromethyl, free or esterified carboxy, monocyclic aryl or heterocyclyl; or a pharmaceutically acceptable salt thereof.
Further preferred are compounds of formula (Ia2) wherein
R3a is hydrogen; or a pharmaceutically acceptable salt thereof.
Further preferred are also compounds of formula (Ia2) wherein n is an integer of 2 or 3; and R7a are, independently from each other, hydrogen or lower alkyl; m is zero or 1;
Xa is hydroxy, carbamoyl, cyano, trifluoromethyl, free or esterified carboxy, monocyclic aryl or heterocyclyl; or a pharmaceutically acceptable salt thereof.
More preferred are compounds of formula (Ia2) wherein
Ya is absent; or a pharmaceutically acceptable salt thereof.
Even more preferred are compounds of formula (Ia2) wherein n is 3;
R^a and R7a are lower alkyl; m is zero or 1;
Xa is hydroxy, cyano or free or esterified carboxy; or a pharmaceutically acceptable salt thereof.
Most preferred are compounds of formula (Ia2) wherein
Rόa and R7a are methyl; or a pharmaceutically acceptable salt thereof.
Especially preferred are compounds of formula (Ia2) wherein
Ri is hydrogen or -C(O)R2 in which R2 is monocyclic aryl; or a pharmaceutically acceptable salt thereof.
Preferred are also compounds in the A group having the formula
Figure imgf000053_0001
wherein
R1 is hydrogen, -C(O)R2, -C(O)NR3R4 or -C(O)OR5 in which
R2 and R3 are, independently from each other, hydrogen, cycloalkyl, aryl, heterocyclyl, aralkyl, heteroaralkyl or alkyl optionally substituted with one to four substituents selected from the group consisting of halogen, cycloalkyl, cycloalkoxy, alkoxy, alkyloxyalkoxy, amino, alkylamino, dialkylamino, aryl, aryloxy and heterocyclyl;
R4 and R5 are, independently from each other, cycloalkyl, aryl, heterocyclyl, aralkyl, heteroaralkyl or alkyl optionally substituted with one to four substituents selected from the group consisting of halogen, cycloalkyl, cycloalkoxy, alkoxy, alkyloxyalkoxy, amino, alkylamino, dialkylamino, aryl, aryloxy and heterocyclyl;
R2a, R3a, R4a and R52 are, independently from each other, hydrogen, hydroxy, halogen, cyano, nitro, alkoxy, alkylthio, alkylthiono, sulfonyl, free or esterified carboxy, carbamoyl, sulfamoyl, optionally substituted amino, cycloalkyl, aryl, heterocyclyl, alkenyl, alkynyl or (Ci.s)alkyl optionally substituted with one to four substituents selected from the group consisting of halogen, hydroxy, cycloalkyl, cycloalkoxy, acyl, acyloxy, alkoxy, alkyloxyalkoxy, amino, alkylamino, dialkylamino, acylamino, carbamoyl, thiol, alkylthio, alkylthiono, sulfonyl, sulfonamido, sulfamoyl, nitro, cyano, free or esterified carboxy, aryl, aryloxy, arylthio, alkenyl, alkynyl, aralkoxy, heteroaralkoxy, heterocyclyl and heterocyclyloxy; or R2a and R3a combined are alkylene which together with the ring atoms to which they are attached form a 3- to 7-membered fused ring; or
R2a and R32 combined are alkylene which together with the carbon atom to which they are attached form a 3- to 7-membered spirocyclic ring; p is zero or 1 ; or a pharmaceutically acceptable salt thereof.
Preferred are compounds of formula (Ia3) wherein R42 and Rs2 are hydrogen; or a pharmaceutically acceptable salt thereof.
Preferred are also compounds of formula (Ia3) wherein
R2a and R3a are, independently from each other, hydrogen, halogen or (Ci^alkyl optionally substituted by at least one halogen; or a pharmaceutically acceptable salt thereof.
Preferred are also compounds of formula (Ia3) wherein p is 1; or a pharmaceutically acceptable salt thereof.
Further preferred are compounds of formula (Ia3) having the formula
Figure imgf000055_0001
wherein
Ri is hydrogen, -C(O)R2, -C(O)NR3R4 or -C(O)OR5 in which
R2 and R3 are, independently from each other, hydrogen, cycloalkyl, aryl, heterocyclyl, aralkyl, heteroaralkyl or alkyl optionally substituted with one to four substituents selected from the group consisting of halogen, cycloalkyl, cycloalkoxy, alkoxy, alkyloxyalkoxy, amino, alkylamino, dialkylamino, aryl, aryloxy and heterocyclyl; R4 and R5 are, independently from each other, cycloalkyl, aryl, heterocyclyl, aralkyl, heteroaralkyl or alkyl optionally substituted with one to four substituents selected from the group consisting of halogen, cycloalkyl, cycloalkoxy, alkoxy, alkyloxyalkoxy, amino, alkylamino, dialkylamino, aryl, aryloxy and heterocyclyl;
R2a, R3a, R4a and R5a are, independently from each other, hydrogen, hydroxy, halogen, cyano, nitro, alkoxy, alkylthio, alkylthiono, sulfonyl, free or esterified carboxy, carbamoyl, sulfamoyl, optionally substituted amino, cycloalkyl, aryl, heterocyclyl, alkenyl, alkynyl or (Ci^alkyl optionally substituted with one to four substituents selected from the group consisting of halogen, hydroxy, cycloalkyl, cycloalkoxy, acyl, acyloxy, alkoxy, alkyloxyalkoxy, amino, alkylamino, dialkylamino, acylamino, carbamoyl, thiol, alkylthio, alkylthiono, sulfonyl, sulfonamido, sulfamoyl, nitro, cyano, free or esterified carboxy, aryl, aryloxy, arylthio, alkenyl, alkynyl, aralkoxy, heteroaralkoxy, heterocyclyl and heterocyclyloxy; or
R2a and R3a combined are alkylene which together with the carbon atom to which they are attached form a 3- to 7-membered spirocyclic ring; or a pharmaceutically acceptable salt thereof.
Preferred are compounds of formula (Ia4) wherein Rta and R5a are hydrogen; or a pharmaceutically acceptable salt thereof.
Preferred are also compounds of formula (Ia4), designated as the B group, wherein R2a and R32 are, independently from each other, hydrogen, halogen or (Ci_4)alkyl optionally substituted by at least one halogen; or a pharmaceutically acceptable salt thereof.
Preferred are compounds in the B group wherein Ri is hydrogen or -C(O)R2 in which R2 is monocyclic aryl; or a pharmaceutically acceptable salt thereof.
Preferred are also compounds of formula (Ia4), designated as the C group, wherein
R2a and R3a combined are alkylene which together with the carbon atom to which they are attached form a 3- to 5-membered spirocyclic ring; or a pharmaceutically acceptable salt thereof.
Preferred are compounds in the C group, wherein
Ri is hydrogen or -C(O)R2 in which R2 is monocyclic aryl; or a pharmaceutically acceptable salt thereof. Preferred are also compounds of formula (Ia4), designated as the D group, wherein R2a is -Ya-(CH2)n-CR6aR7a-(CH2)m-Xa in which
Ya is oxygen or S(O)q in which q is zero or an integer of 1 or 2; or Ya is trans CH=CH; or Ya is absent; n is an integer from 1 to 6;
Rδa and R7a are, independently from each other, hydrogen or lower alkyl; or R63 and R7a combined are alkylene which together with the carbon atom to which they are attached form a 3- to 7-membered ring; m is zero or an integer of 1 or 2; X2 is hydroxy, alkoxy, cycloalkyl, cycloalkoxy, acyl, acyloxy, carbamoyl, cyano, trifluoromethyl, free or esterified carboxy, monocyclic aryl or heterocyclyl; or a pharmaceutically acceptable salt thereof.
Preferred are compounds in the D group wherein
R3a is hydrogen; or a pharmaceutically acceptable salt thereof.
Further preferred are compounds in the D group wherein n is an integer of 2 or 3;
R63 and R7a are, independently from each other, hydrogen or lower alkyl; m is zero or 1 ;
Xa is hydroxy, carbamoyl, cyano, trifluoromethyl, free or esterified carboxy, monocyclic aryl or heterocyclyl; or a pharmaceutically acceptable salt thereof.
More preferred are compounds in the D group wherein
Y3 is absent; or a pharmaceutically acceptable salt thereof.
Even more preferred are compounds in the D group wherein n is 3;
Rόa and R7a are lower alkyl; m is zero or 1 ;
Xa is hydroxy, cyano or free or esterified carboxy; or a pharmaceutically acceptable salt thereof.
Most preferred are compounds in the D group wherein
Rόa and R7a are methyl; or a pharmaceutically acceptable salt thereof.
Especially preferred are compounds in the D group wherein
Ri is hydrogen or -C(O)R2 in which R2 is monocyclic aryl; or a pharmaceutically acceptable salt thereof.
Preferred are also the compounds of formula (I), wherein
U and V are hydrogen; W is aryloxy, arylthio or methyl substituted with monocyclic aryl; or a pharmaceutically acceptable salt thereof.
Further preferred are also the compounds of formula (I) having the formula
Figure imgf000058_0001
wherein
Ri is hydrogen, -C(O)R2, -C(O)NR3R4 or -C(O)OR5 in which
R2 and R3 are, independently from each other, hydrogen, cycloalkyl, aryl, heterocyclyl, aralkyl, heteroaralkyl or alkyl optionally substituted with one to four substituents selected from the group consisting of halogen, cycloalkyl, cycloalkoxy, alkoxy, alkyloxyalkoxy r amino, alkylamino, dialkylamino, aryl, aryloxy and heterocyclyl;
R4 and R5 are, independently from each other, cycloalkyl, aryl, heterocyclyl, aralkyl, heteroaralkyl or alkyl optionally substituted with one to four substituents selected from the group consisting of halogen, cycloalkyl, cycloalkoxy, alkoxy, alkyloxyalkoxy, amino, alkylamino, dialkylamino, aryl, aryloxy and heterocyclyl; R2b, R3b and R^ are, independently from each other, hydrogen, hydroxy, halogen, cyano, nitro, alkoxy, alkylthio, alkylthiono, sulfonyl, free or esterified carboxy, carbamoyl, sulfamoyl, optionally substituted amino, cycloalkyl, aryl, heterocyclyl, alkenyl, alkynyl or (Ci-8)alkyl optionally substituted with one to four substituents selected from the group consisting of halogen, hydroxy, cycloalkyl, cycloalkoxy, acyl, acyloxy, alkoxy, alkyloxyalkoxy, amino, alkylamino, dialkylamino, acylamino, carbamoyl, thiol, alkylthio, alkylthiono, sulfonyl, sulfonamido, sulfamoyl, nitro, cyano, free or esterified carboxy, aryl, aryloxy, arylthio, alkenyl, alkynyl, aralkoxy, heteroaralkoxy, heterocyclyl and heterocyclyloxy; or
R2b and R3b combined are alkylene which together with the ring atoms to which they are attached form a 5- to 7-membered fused ring provided R2 and R3 are attached to carbon atoms adjacent to each other; or
R2b and R3b combined together with the carbon atom to which they are attached form a fused 5- to 6-membered aromatic or heteroaromatic ring provided R2 and R3 are attached to carbon atoms adjacent to each other;
Xb is hydrogen, fluoro, cyano, or free or esterified carboxy; or Xb is -NRSbC(O)R61,, -NR5bC(O)OR7b, -NR5bS(O)2R8b, -(CH2)rS(O)2R9b, -OS(O)2R1Ob or
-O8C(O)NRi ibRi2b in which
Rsb is hydrogen, lower alkyl, acyl, alkoxycarbonyl or sulfonyl;
R6^ R7b, Rβb, R9b and Riob are, independently from each other, cycloalkyl, aryl, heterocyclyl, aralkyl, heteroaralkyl or (Ci-8)alkyl optionally substituted with one to four substituents selected from the group consisting of halogen, hydroxy, cycloalkyl, cycloalkoxy, acyl, acyloxy, alkoxy, alkyloxyalkoxy, amino, alkylamino, dialkylamino, acylamino, carbamoyl, thiol, alkylthio, alkylthiono, sulfonyl, sulfonamido, sulfamoyl, nitro, cyano, free or esterified carboxy, aryl, aryloxy, arylthio, alkenyl, alkynyl, aralkoxy, heteroaralkoxy, heterocyclyl and heterocyclyloxy; or
Figure imgf000059_0001
are, independently from each other, -NR]3bRi4b in which
Rt3b and Ri4b are, independently from each other, hydrogen, alkyl, cycloalkyl, aralkyl, aryl or heterocyclyl; or
Ri3b and Ri4b combined are alkylene which together with the nitrogen atom to which they are attached form a 4- to 7-membered ring; Rπb and Ri2b are, independently from each other, hydrogen, alkyl, cycloalkyl, aralkyl, aryl or heterocyclyl; or
Rπb and Ri2b combined are alkylene which together with the nitrogen atom to which they are attached form a 4- to 7-membered ring; r and s are, independently from each other, zero or an integer of 1; or C-Xb is replaced by nitrogen;
Yb is O, S or CH2; or a pharmaceutically acceptable salt thereof.
Preferred are the compounds of formula (Ib) wherein
Yb is CH2; or a pharmaceutically acceptable salt thereof. Further preferred are the compounds of formula (Ib) having the formula
Figure imgf000060_0001
wherein
R, is hydrogen, -C(O)R2, -C(O)NR3R4 or -C(O)OR5 in which R2 and R3 are, independently from each other, hydrogen, cycloalkyl, aryl, heterocyclyl, aralkyl, heteroaralkyl or alkyl optionally substituted with one to four substituents selected from the group consisting of halogen, cycloalkyl, cycloalkoxy, alkoxy, alkyloxyalkoxy, amino, alkylamino, dialkylamino, aryl, aryloxy and heterocyclyl; R4 and R5 are, independently from each other, cycloalkyl, aryl, heterocyclyl, aralkyl, heteroaralkyl or alkyl optionally substituted with one to four substituents selected from the group consisting of halogen, cycloalkyl, cycloalkoxy, alkoxy, alkyloxyalkoxy, amino, alkylamino, dialkylamino, aryl, aryloxy and heterocyclyl;
R2t>, R3b and R^ are, independently from each other, hydrogen, hydroxy, halogen, cyano, nitro, alkoxy, alkylthio, alkylthiono, sulfonyl, free or esterified carboxy, carbamoyl, sulfamoyl, optionally substituted amino, cycloalkyl, aryl, heterocyclyl, alkenyl, alkynyl or (Ci.g)alkyl optionally substituted with one to four substituents selected from the group consisting of halogen, hydroxy, cycloalkyl, cycloalkoxy, acyl, acyloxy, alkoxy, alkyloxyalkoxy, amino, alkylamino, dialkylamino, acylamino, carbamoyl, thiol, alkylthio, alkylthiono, sulfonyl, sulfonamido, sulfamoyl, nitro, cyano, free or esterified carboxy, aryl, aryloxy, arylthio, alkenyl, alkynyl, aralkoxy, heteroaralkoxy, heterocyclyl and heterocyclyloxy; or R2b and R3b combined are alkylene which together with the ring atoms to which they are attached form a 5- to 7-membered fused ring; or
R2b and R3b combined together with the carbon atom to which they are attached form a fused 5- to 6-membered aromatic or heteroaromatic ring; Xb is cyano; or
Xb is -NR5bC(O)R6b, -NR5bC(O)OR7b, -NR5bS(O)2R8b, -(CH2)rS(O)2R9b or -OS(O)2R10b in which
R5b is hydrogen or lower alkyl;
R^b, R7b> Rsb> RB and Rjob are, independently from each other, cycloalkyl, aryl, heterocyclyl, aralkyl, heteroaralkyl or (Ci_8)alkyl optionally substituted with one to four substituents selected from the group consisting of halogen, hydroxy, cycloalkyl, cycloalkoxy, acyl, acyloxy, alkoxy, alkyloxyalkoxy, amino, alkylamino, dialkylamino, acylamino, carbamoyl, thiol, alkylthio, alkylthiono, sulfonyl, sulfonamido, sulfamoyl, nitro, cyano, free or esterified carboxy, aryl, aryloxy, arylthio, alkenyl, alkynyl, aralkoxy, heteroaralkoxy, heterocyclyl and heterocyclyloxy; or
Rόb, Rβb and R% are, independently from each other, -NRπbRub in which
Ri3b and Ri4b are, independently from each other, hydrogen, alkyl, cycloalkyl, aralkyl, aryl or heterocyclyl; or
Ri 3b and R^b combined are alkylene which together with the nitrogen atom to which they are attached form a 4- to 7-membered ring; r is zero; or
C-Xb is replaced by nitrogen; or a pharmaceutically acceptable salt thereof.
Preferred are the compounds of formula (Ibj) wherein Xb is cyano; or
Xb is -NR5bS(O)2R8b or -OS(O)2R]0b in which
Rsb is hydrogen or lower alkyl;
R8b and Riob are, independently from each other, cycloalkyl, aryl, heterocyclyl, aralkyl, heteroaralkyl or (Cj.8)alkyl optionally substituted with one to four substituents selected from the group consisting of halogen, hydroxy, cycloalkyl, cycloalkoxy, acyl, acyloxy, alkoxy, alkyloxyalkoxy, amino, alkylamino, dialkylamino, acylamino, carbamoyl, thiol, alkylthio, alkylthiono, sulfonyl, sulfonamido, sulfamoyl, nitro, cyano, free or esterified carboxy, aryl, aryloxy, arylthio, alkenyl, alkynyl, aralkoxy, heteroaralkoxy, heterocyclyl and heterocyclyloxy; or a pharmaceutically acceptable salt thereof.
Especially preferred are the compounds of formula (Ib]), designated as the E group, wherein
R5b is hydrogen; or a pharmaceutically acceptable salt thereof.
Preferred are the compounds in the E group wherein
Rgb and Riob are, independently from each other, monocyclic aryl or
Figure imgf000062_0001
or a pharmaceutically acceptable salt thereof.
Further preferred are the compounds in the E group wherein Ri is hydrogen or -C(O)R2 in which R2 is monocyclic aryl; or a pharmaceutically acceptable salt thereof.
Especially preferred are also the compounds of formula (Ibi), designated as the F group, wherein
R2b> R3b and R4b are, independently from each other, hydrogen, halogen, hydroxy, monocyclic aryl, C(1-4)alkoxy or
Figure imgf000062_0002
optionally substituted with at least one halogen; or a pharmaceutically acceptable salt thereof.
Preferred are the compounds in the F group wherein Rsb is hydrogen; or a pharmaceutically acceptable salt thereof.
Further preferred are the compounds in the F group wherein R8b and Riob are, independently from each other, monocyclic aryl or C(i_4)alkyl; or a pharmaceutically acceptable salt thereof.
More preferred are the compounds in the F group wherein Ri is hydrogen or -C(O)R2 in which R2 is monocyclic aryl; or a pharmaceutically acceptable salt thereof.
Preferred are also the compound of formula (I), designated as the G group, wherein
Ri is hydrogen, -C(O)R2, -C(O)NR3R4 or -C(O)OR5 in which R2 and R3 are, independently from each other, hydrogen, cycloalkyl, aryl, heterocyclyl, aralkyl, heteroaralkyl or alkyl optionally substituted with one to four substituents selected from the group consisting of halogen, cycloalkyl, cycloalkoxy, alkoxy, alkyloxyalkoxy, amino, alkylamino, dialkylamino, aryl, aryloxy and heterocyclyl;
R4 and R5 are, independently from each other, cycloalkyl, aryl, heterocyclyl, aralkyl, heteroaralkyl or alkyl optionally substituted with one to four substituents selected from the group consisting of halogen, cycloalkyl, cycloalkoxy, alkoxy, alkyloxyalkoxy, amino, alkylamino, dialkylamino, aryl, aryloxy and heterocyclyl;
U is alkoxy, alkylthio, alkylthiono, sulfonyl, cycloalkyl, aryl, aryloxy, heterocyclyl, alkenyl, alkynyl or (Ci-8)alkyl optionally substituted with one to four substituents selected from the group consisting of halogen, hydroxy, cycloalkyl, cycloalkoxy, acyl, acyloxy, alkoxy, alkyloxyalkoxy, optionally substituted amino, carbamoyl, thiol, alkylthio, alkylthiono, sulfonyl, sulfamoyl, nitro, cyano, free or esterified carboxy, aryl, aryloxy, arylthio, alkenyl, alkynyl, aralkoxy, heteroaralkoxy, heterocyclyl and heterocyclyloxy;
W and V are, independently from each other, hydrogen, halogen, (Ci-3)alkyl or (Ci-3)alkoxy; or a pharmaceutically acceptable salt thereof.
Preferred are the compounds in the G group, designated as the H group, wherein
U is -Yc-(CH2)p-CR2cR3c-(CH2)t-Xc in which
Yc is oxygen or S(O)V in which v is zero or an integer of 1 or 2; or Yc is C≡ C; or
Yc is absent; p and t are, independently from each other, zero or an integer from 1 to 8; R2c and R3c are, independently from each other, hydrogen or lower alkyl; or R2c and R3c combined are alkylene which together with the carbon atom to which they are attached form a 3- to 7-membered ring; X0 is hydroxy, alkoxy, cycloalkyl, cycloalkoxy, acyl, acyloxy, carbamoyl, optionally substituted amino, cyano, trifluoromethyl, free or esterified carboxy, heterocyclyl, monocyclic aryl or monocyclic aryloxy; or a pharmaceutically acceptable salt thereof.
Preferred are the compounds in the H group wherein R2c and R3c are hydrogen; or a pharmaceutically acceptable salt thereof.
Further preferred are the compounds in the H group wherein p is zero or an integer from 1 to 3; t is zero or 1;
R2c and R3c are, independently from each other, hydrogen or lower alkyl;
X0 is hydroxy, carbamoyl, cyano, trifluoromethyl, free or esterified carboxy, heterocyclyl, monocyclic aryl or monocyclic aryloxy; or a pharmaceutically acceptable salt thereof.
Especially preferred are the compounds in the H group, designated as the I group, wherein Yc is C≡ C; or Yc is absent; or a pharmaceutically acceptable salt thereof.
Preferred are the compounds in the I group wherein Yc is absent; p is an integer of 5 or 6; t is zero or 1 ; R2c and R3c are lower alkyl;
X0 is hydroxy, cyano or free or esterified carboxy; or a pharmaceutically acceptable salt thereof.
Further preferred are the compounds in the I group wherein R2c and R3c are methyl; or a pharmaceutically acceptable salt thereof.
Especially preferred are the compounds in the I group wherein Ri is hydrogen or -C(O)R2 in which R2 is monocyclic aryl; or a pharmaceutically acceptable salt thereof.
Preferred are also the compounds in the I group, designated as the J group, wherein
Yc is absent; p is an integer of 4 or 5; t is zero;
R2c and R^c are hydrogen;
X0 is monocyclic aryloxy; or a pharmaceutically acceptable salt thereof.
Preferred are the compounds in the J group wherein
Ri is hydrogen or -C(O)R2 in which R2 is monocyclic aryl; or a pharmaceutically acceptable salt thereof.
Preferred are also the compounds in the J group, designated as the K group, wherein
p is an integer of 2 or 3; t is zero;
R2c and R3c are hydrogen; X0 is hydroxy, cyano or free or esterified carboxy; or a pharmaceutically acceptable salt thereof. Preferred are the compounds in the K group wherein Ri is hydrogen or -C(O)R2 in which R2 is monocyclic aryl; or a pharmaceutically acceptable salt thereof.
Preferred are also the compounds in the G group, designated as the L group, wherein Qc is monocyclic aryl or 5- to 6-membered heterocyclic ring; or a pharmaceutically acceptable salt thereof.
Preferred are the compounds in the L group, designated as the M group, wherein R2c and R3c are hydrogen; or a pharmaceutically acceptable salt thereof.
Preferred are the compounds in the M group having the formula
Figure imgf000066_0001
wherein
Ri is hydrogen, -C(O)R2, -C(O)NR3R4 or -C(O)OR5 in which
R2 and R3 are, independently from each other, hydrogen, cycloalkyl, aryl, heterocyclyl, aralkyl, heteroaralkyl or alkyl optionally substituted with one to four substituents selected from the group consisting of halogen, cycloalkyl, cycloalkoxy, alkoxy, alkyloxyalkoxy, amino, alkylamino, dialkylamino, aryl, aryloxy and heterocyclyl; R4 and R5 are, independently from each other, cycloalkyl, aryl, heterocyclyl, aralkyl, heteroaralkyl or alkyl optionally substituted with one to four substituents selected from the group consisting of halogen, cycloalkyl, cycloalkoxy, alkoxy, alkyloxyalkoxy, amino, alkylamino, dialkylamino, aryl, aryloxy and heterocyclyl;
R4C, R5C and R60 are, independently from each other, hydrogen, hydroxy, halogen, cyano, nitro, alkoxy, alkylthio, alkylthiono, sulfonyl, free or esterified carboxy, carbamoyl, sulfamoyl, optionally substituted amino, cycloalkyl, aryl, heterocyclyl, alkenyl, alkynyl or (Ci.8)alkyl optionally substituted with one to four substituents selected from the group consisting of halogen, hydroxy, cycloalkyl, cycloalkoxy, acyl, acyloxy, alkoxy, alkyloxyalkoxy, optionally substituted amino, carbamoyl, thiol, alkylthio, alkylthiono, sulfonyl, sulfamoyl, nitro, cyano, free or esterified carboxy, aryl, aryloxy, arylthio, alkenyl, alkynyl, aralkoxy, heteroaralkoxy, heterocyclyl and heterocyclyloxy; or C-R4C, C-R5C and C-R60 are, independently from each other, replaced by nitrogen; or a pharmaceutically acceptable salt thereof.
Preferred are the compounds of formula (Ic) wherein R4C and R5c are hydrogen; or a pharmaceutically acceptable salt thereof.
Preferred are also the compounds of formula (Ic) wherein Ri is hydrogen or -C(O)R2 in which R2 is monocyclic aryl; or a pharmaceutically acceptable salt thereof.
Preferred are also the compounds in the M group having the formula
Figure imgf000067_0001
wherein Ri is hydrogen, -C(O)R2, -C(O)NR3R4 or -C(O)OR5 in which R2 and R3 are, independently from each other, hydrogen, cycloalkyl, aryl, heterocyclyl, aralkyl, heteroaralkyl or alkyl optionally substituted with one to four substituents selected from the group consisting of halogen, cycloalkyl, cycloalkoxy, alkoxy, alkyloxyalkoxy, amino, alkylamino, dialkylamino, aryl, aryloxy and heterocyclyl; R4 and R5 are, independently from each other, cycloalkyl, aryl, heterocyclyl, aralkyl, heteroaralkyl or alkyl optionally substituted with one to four substituents selected from the group consisting of halogen, cycloalkyl, cycloalkoxy, alkoxy, alkyloxyalkoxy, amino, alkylamino, dialkylamino, aryl, aryloxy and heterocyclyl;
R7c is hydrogen, sulfonyl, cycloalkyl, aryl, heterocyclyl or (Ci-8)alkyl optionally substituted with one to four substituents selected from the group consisting of halogen, hydroxy, cycloalkyl, cycloalkoxy, acyl, acyloxy, alkoxy, alkyloxyalkoxy, optionally substituted amino, carbamoyl, thiol, alkylthio, alkylthiono, sulfonyl, sulfamoyl, nitro, cyano, free or esterified carboxy, aryl, aryloxy, arylthio, alkenyl, alkynyl, aralkoxy, heteroaralkoxy, heterocyclyl and heterocyclyloxy; R8C and R9C are, independently from each other, hydrogen or lower alkyl; or
C-R8c and C-R9C are, independently from each other, replaced by nitrogen; or a pharmaceutically acceptable salt thereof.
Preferred are the compounds of formula (Ici) wherein
C-R8C is replaced by nitrogen; R9c is hydrogen; or a pharmaceutically acceptable salt thereof.
Further preferred are the compounds of formula (Ici) having the formula
Figure imgf000068_0001
wherein
Ri is hydrogen, -C(O)R2, -C(O)NR3R4 or -C(O)OR5 in which
R2 and R3 are, independently from each other, hydrogen, cycloalkyl, aryl, heterocyclyl, aralkyl, heteroaralkyl or alkyl optionally substituted with one to four substituents selected from the group consisting of halogen, cycloalkyl, cycloalkoxy, alkoxy, alkyloxyalkoxy, amino, alkylamino, dialkylamino, aryl, aryloxy and heterocyclyl; R4 and Rs are, independently from each other, cycloalkyl, aryl, heterocyclyl, aralkyl, heteroaralkyl or alkyl optionally substituted with one to four substituents selected from the group consisting of halogen, cycloalkyl, cycloalkoxy, alkoxy, alkyloxyalkoxy, amino, alkylamino, dialkylamino, aryl, aryloxy and heterocyclyl;
R7c is hydrogen, sulfonyl, cycloalkyl, aryl, heterocyclyl or (Ci.g)alkyl optionally substituted with one to four substituents selected from the group consisting of halogen, hydroxy, cycloalkyl, cycloalkoxy, acyl, acyloxy, alkoxy, alkyloxyalkoxy, optionally substituted amino, carbamoyl, thiol, alkylthio, alkylthiono, sulfonyl, sulfamoyl, nitro, cyano, free or esterified carboxy, aryl, aryloxy, arylthio, alkenyl, alkynyl, aralkoxy, heteroaralkoxy, heterocyclyl and heterocyclyloxy; or a pharmaceutically acceptable salt thereof.
Preferred are the compounds of formula (Ic2) wherein R7c is -(CH2)p-CRiocRiic-(CH2),-Zc in which p and t are, independently from each other, zero or an integer from 1 to 6;
RiOc and Rnc are, independently from each other, hydrogen or lower alkyl; or
RiOc and Rj ic combined are alkylene which together with the carbon atom to which they are attached form a 3- to 7-membered ring; Zc is hydroxy, alkoxy, cycloalkyl, cycloalkoxy, acyl, acyloxy, carbamoyl, optionally substituted amino, cyano, trifluoromethyl, free or esterified carboxy, heterocyclyl, monocyclic aryl or monocyclic aryloxy; or a pharmaceutically acceptable salt thereof.
Further preferred are the compounds of formula (Ic2) wherein p is an integer from 1 to 3; t is zero or 1;
RiOc and Ri lc are, independently from each other, hydrogen or lower alkyl; Zc is hydroxy, carbamoyl, cyano, trifluoromethyl, free or esterified carboxy, heterocyclyl, monocyclic aryl or monocyclic aryloxy; or a pharmaceutically acceptable salt thereof.
More preferred are the compounds of formula (Ic2) wherein RiOc and Ri lc are hydrogen; Zc is hydroxy, cyano or free or esterified carboxy; or a pharmaceutically acceptable salt thereof.
Most preferred are the compounds of formula (Ic2) wherein
Ri is hydrogen or -C(O)R2 in which R2 is monocyclic aryl; or a pharmaceutically acceptable salt thereof.
Particular embodiments of the compounds are:
Methanesulfonic acid 2-[3-fluoro-5-hydroxy-4-(l,l,4-trioxo-l,2,5-thiadiazolidin-2-yl)- benzyl]-4-methylphenyl ester;
Methanesulfonic acid 2-[3-fluoro-5-hydroxy-4-( 1,1, 4-trioxo-l, 2,5-thiadiazolidin-2-yl)- benzyl]-5-methylphenyl ester;
Methanesulfonic acid 2-[3-fluoro-5-hydroxy-4-( 1 , 1 ,4-trioxo- 1 ,2,5-thiadiazolidin-2-yl)- benzyl]-6-methylphenyl ester;
Methanesulfonic acid 2-[3-fluoro-5-hydroxy-4-( 1,1, 4-trioxo-l, 2,5-thiadiazolidin-2-yl)- benzyl]-phenyl ester; N-{2-[3-Fluoro-5-hydroxy-4-(l,l,4-trioxo-l,2,5-thiadiazolidin-2-yl)-benzyl]-5- methylphenyl}-methanesulfonamide;
N-{2-[3-Fluoro-5-hydroxy-4-( 1 , 1 ,4-trioxo- 1 ,2,5-thiadiazolidin-2-yl)-benzyl]-4- methylphenyl}-methanesulfonamide; iV-{2-[3-Fluoro-5-hydroxy-4-(l,l, 4-trioxo-l, 2,5-thiadiazolidin-2-yl)-benzyl]-phenyl}- methanesulfonamide;
5-(4-Benzyl-2-fluoro-6-hydroxy-phenyl)-l,l-dioxo-l,2,5-thiadiazolidin-3-one; 5-(2-Fluoro-6-hydroxy-4-methylphenyl)-l,l-dioxo-l,2,5-thiadiazolidin-3-one;
Benzoic acid 5-benzyl-3-fluoro-2-(l,l,4-trioxo-l,2,5-thiadiazolidin-2-yl)-phenyl ester;
Benzoic acid 3-fluoro-5-methyl-2-(l,l,4-trioxo-l,2,5-thiadiazolidin-2-yl)-phenyl ester;
5-(4-Cyclobutylmethyl-2-fluoro-6-hydroxyphenyl)-l,l-dioxo-l,2,5-thiadiazolidin-3-one potassium salt;
5 -(4-Cyclohexylmethyl-2-fluoro-6-hydroxyphenyl)- 1 , 1 -dioxo- 1 ,2,5-thiadiazolidin-3-one;
7-[2-Fluoro-4-hydroxy-3-(l,l,4-trioxo-l,2,5-thiadiazolidin-2-yl)-phenyl]-2,2- dimethylheptanenitrile;
5-(2,4-Difluoro-6-hydroxyphenyl)- 1,1 -dioxo- l,2,5-thiadiazolidin-3-one; 5-( 1 -Fluoro-3-hydroxy-7-methylnaphthalen-2-yl)- 1 , 1 -dioxo- 1 ,2,5 -thiadiazolidin-3-one;
5-( 1 -Fluoro-3-hydroxynaphthalen-2-yl)- 1 , 1 -dioxo- 1 ,2,5-thiadiazol idin-3-one;
5-(7-Ethyl-l-fluoro-3-hydroxy-5,6,7,8-tetrahydronaphthalen-2-yl)- 1,1 -dioxo- 1,2,5- thiadiazolidin-3-one;
5-[l-Fluoro-3-hydroxy-7-(5-hydroxy-4,4-dimethylpentyl)-naphthalen-2-yl]-l,l-dioxo- l,2,5-thiadiazolidin-3-one;
5-[8-Fluoro-6-hydroxy-7-(l,l,4-trioxo-l,2,5-thiadiazolidin-2-yl)-naphthalen-2-yl]-2,2- dimethyl-pentanoic acid;
Benzoic acid 4-fluoro-6-methyl-3-( 1 , 1 ,4-trioxo- 1 ,2,5-thiadiazolidin-2-yl)-naphthalen-2-yl ester; Benzoic acid 6-ethyl-4-fluoro-3-(l,l,4-trioxo-l,2,5-thiadiazolidin-2-yl)-5,6,7,8- tetrahydronaphthalen-2-yl ester;
Benzoic acid 4-fluoro-3-(l,l,4-trioxo-l,2,5-thiadiazolidin-2-yl)-naphthalen-2-yl ester;
Benzoic acid 4-fluoro-6-(5-hydroxy-4,4-dimethylpentyl)-3-(l,l,4-trioxo- 1,2,5- thiadiazolidin-2-yl)-naphthalen-2-yl ester; Benzoic acid 3-fluoro-5-(2-methanesulfonyloxy-5-rnethylbenzyl)-2-( 1,1, 4-trioxo- 1,2,5- thiadiazolidin-2-yl)-phenyl ester;
Benzoic acid 3-fluoro-5-(2-methanesulfonyloxy-4-methylbenzyl)-2-(l, 1, 4-trioxo- 1,2,5- thiadiazolidin-2-yl)-phenyl ester;
Benzoic acid 4-(6-cyano-6,6-dimethylhexyl)-3-fluoro-2-( 1,1, 4-trioxo- 1,2,5- thiadiazolidin-2-yl)-phenyl ester; Benzoic acid 3-fluoro-5-(2-methanesulfonylamino-5-methylbenzyl)-2-( 1 , 1 ,4-trioxo-
1 ,2,5-thiadiazolidin-2-yl)-phenyl ester;
Benzoic acid 3-fluoro-5-(2-methanesulfonylarnino-4-methylbenzyl)-2-( 1 , 1 ,4-trioxo-
1 ,2,5-thiadiazolidin-2-yl)-phenyl ester; and
Benzoic acid 3-fluoro-5-(2-methanesulfonyloxy-3-methylbenzyl)-2-( 1 ,1, 4-trioxo- 1 ,2,5- thiadiazolidin-2-yl)-phenyl ester; or a pharmaceutically acceptable salt thereof.
Category 3 PTP Inhibitors
The methods of the present invention can be practiced with the compounds of the formula
Figure imgf000072_0001
wherein
Q is alkoxy, alkylthio, alkylthiono, sulfonyl, cycloalkyl, aryl, heterocyclyl, alkenyl, alkynyl or (Ci^alkyl optionally substituted with one to four substituents selected from the group consisting of halogen, hydroxy, cycloalkyl, cycloalkoxy, acyl, acyloxy, alkoxy, alkyloxyalkoxy, optionally substituted amino, carbamoyl, thiol, alkylthio, alkylthiono, sulfonyl, sulfamoyl, nitro, cyano, free or esterified carboxy, aryl, aryloxy, arylthio, alkenyl, alkynyl, aralkoxy, heteroaralkoxy, heterocyclyl and heterocyclyloxy; Ri is hydrogen, -C(O)R4, -C(O)NR5R6 or -C(O)OR7 in which
R4 and R5 are, independently from each other, hydrogen, cycloalkyl, aryl, heterocyclyl, aralkyl, heteroaralkyl or alkyl optionally substituted with one to four substituents selected from the group consisting of halogen, cycloalkyl, cycloalkoxy, alkoxy, alkyloxyalkoxy, amino, alkylamino, dialkylamino, aryl, aryloxy and heterocyclyl; R6 and R7 are, independently from each other, cycloalkyl, aryl, heterocyclyl, aralkyl, heteroaralkyl or alkyl optionally substituted with one to four substituents selected from the group consisting of halogen, cycloalkyl, cycloalkoxy, alkoxy, alkyloxyalkoxy, amino, alkylamino, dialkylamino, aryl, aryloxy and heterocyclyl; R2 and R3 are, independently from each other, hydrogen, halogen, (Ci-3)alkyl or (Ci-3)alkoxy; or a pharmaceutically acceptable salt thereof.
Preferred are the compounds of formula (I), designated as the A group, wherein Q is -Y-(CH2)n-CR8R9-(CH2)m-X in which
Y is oxygen or S(O)q in which q is zero or an integer of 1 or 2; or Y is C≡Q or
Y is absent; n and m are, independently from each other, zero or an integer from 1 to 8;
R8 and R9 are, independently from each other, hydrogen or lower alkyl; or
R8 and R9 combined are alkylene which together with the carbon atom to which they are attached form a 3- to 7-membered ring;
X is hydroxy, alkoxy, cycloalkyl, cycloalkoxy, acyl, acyloxy, carbamoyl, optionally substituted amino, cyano, trifluoromethyl, free or esterified carboxy, heterocyclyl, monocyclic aryl or monocyclic aryloxy; or a pharmaceutically acceptable salt thereof.
Preferred are the compounds in the A group wherein
R2 and R3 are hydrogen; or a pharmaceutically acceptable salt thereof.
Further preferred are the compounds in the A group wherein n is zero or an integer from 1 to 3; m is zero or 1 ;
R8 and R9 are, independently from each other, hydrogen or lower alkyl;
X is hydroxy, carbamoyl, cyano, trifluoromethyl, free or esterified carboxy, heterocyclyl, monocyclic aryl or monocyclic aryloxy; or a pharmaceutically acceptable salt thereof. Especially preferred are the compounds in the A group, designated as the B group, wherein
Y is C≡C; or Y is absent; or a pharmaceutically acceptable salt thereof.
Preferred are the compounds in the B group wherein
Y is absent; n is an integer of 5 or 6; m is zero or 1 ;
Rs and R9 are lower alkyl;
X is hydroxy, cyano or free or esterified carboxy; or a pharmaceutically acceptable salt thereof.
Further preferred are the compounds in the B group wherein
Rg and R9 are methyl; or a pharmaceutically acceptable salt thereof.
Especially preferred are the compounds in the B group wherein Ri is hydrogen or -C(O)R4 in which R4 is monocyclic aryl; or a pharmaceutically acceptable salt thereof.
Preferred are also the compounds in the B group, designated as the C group, wherein Y is absent; n is an integer of 4 or 5; m is zero;
R8 and R9 are hydrogen;
X is monocyclic aryloxy; or a pharmaceutically acceptable salt thereof. Preferred are the compounds in the C group wherein
Ri is hydrogen or -C(O)R4 in which R4 is monocyclic aryl; or a pharmaceutically acceptable salt thereof.
Preferred are also the compounds in the B group, designated as the D group, wherein Y is C≡C; n is an integer of 2 or 3; m is zero;
Rg and R9 are hydrogen; X is hydroxy, cyano or free or esterified carboxy; or a pharmaceutically acceptable salt thereof.
Preferred are the compounds in the D group wherein Ri is hydrogen or -C(O)R4 in which R4 is monocyclic aryl; or a pharmaceutically acceptable salt thereof.
Preferred are the compounds of formula (I), designated as the E group, wherein Q is monocyclic aryl or 5- to 6-membered heterocyclic ring; or a pharmaceutically acceptable salt thereof.
Preferred are the compounds in the E group, designated as the G group, wherein
R2 and R3 are hydrogen; or a pharmaceutically acceptable salt thereof.
Preferred are the compounds in the G group having the formula
Figure imgf000076_0001
wherein
Ri is hydrogen, -C(O)R4, -C(O)NR5R6 or -C(O)OR7 in which
R4 and R5 are, independently from each other, hydrogen, cycloalkyl, aryl, heterocyclyl, aralkyl, heteroaralkyl or alkyl optionally substituted with one to four substituents selected from the group consisting of halogen, cycloalkyl, cycloalkoxy, alkoxy, alkyloxyalkoxy, amino, alkylamino, dialkylamino, aryl, aryloxy and heterocyclyl; R6 and R7 are, independently from each other, cycloalkyl, aryl, heterocyclyl, aralkyl, heteroaralkyl or alkyl optionally substituted with one to four substituents selected from the group consisting of halogen, cycloalkyl, cycloalkoxy, alkoxy, alkyloxyalkoxy, amino, alkylamino, dialkylamino, aryl, aryloxy and heterocyclyl;
Rio, Rn and Ri2 are, independently from each other, hydrogen, hydroxy, halogen, cyano, nitro, alkoxy, alkylthio, alkylthiono, sulfonyl, free or esterified carboxy, carbamoyl, sulfamoyl, optionally substituted amino, cycloalkyl, aryl, heterocyclyl, alkenyl, alkynyl or (Ci-8)alkyl optionally substituted with one to four substituents selected from the group consisting of halogen, hydroxy, cycloalkyl, cycloalkoxy, acyl, acyloxy, alkoxy, alkyloxyalkoxy, optionally substituted amino, carbamoyl, thiol, alkylthio, alkylthiono, sulfonyl, sulfamoyl, nitro, cyano, free or esterified carboxy, aryl, aryloxy, arylthio, alkenyl, alkynyl, aralkoxy, heteroaralkoxy, heterocyclyl and heterocyclyloxy; or C-Rio, C-Rn and C-Ri2 are, independently from each other, replaced by nitrogen; or a pharmaceutically acceptable salt thereof.
Preferred are the compounds of formula (IA) wherein Rio and Rn are hydrogen; or a pharmaceutically acceptable salt thereof.
Preferred are also the compounds of formula (IA) wherein R) is hydrogen or -C(O)R4 in which R4 is monocyclic aryl; or a pharmaceutically acceptable salt thereof.
Preferred are also the compounds in the G group having the formula
Figure imgf000077_0001
wherein R, is hydrogen, -C(O)R4, -C(O)NR5R6 or -C(O)OR7 in which
R4 and R5 are, independently from each other, hydrogen, cycloalkyl, aryl, heterocyclyl, aralkyl, heteroaralkyl or alkyl optionally substituted with one to four substituents selected from the group consisting of halogen, cycloalkyl, cycloalkoxy, alkoxy, alkyloxyalkoxy, amino, alkylamino, dialkylamino, aryl, aryloxy and heterocyclyl; R6 and R7 are, independently from each other, cycloalkyl, aryl, heterocyclyl, aralkyl, heteroaralkyl or alkyl optionally substituted with one to four substituents selected from the group consisting of halogen, cycloalkyl, cycloalkoxy, alkoxy, alkyloxyalkoxy, amino, alkylamino, dialkylamino, aryl, aryloxy and heterocyclyl; Ri3 is hydrogen, sulfonyl, cycloalkyl, aryl, heterocyclyl or (Ci.g)alkyl optionally substituted with one to four substituents selected from the group consisting of halogen, hydroxy, cycloalkyl, cycloalkoxy, acyl, acyloxy, alkoxy, alkyloxyalkoxy, optionally substituted amino, carbamoyl, thiol, alkylthio, alkylthiono, sulfonyl, sulfamoyl, nitro, cyano, free or esterified carboxy, aryl, aryloxy, arylthio, alkenyl, alkynyl, aralkoxy, heteroaralkoxy, heterocyclyl and heterocyclyloxy; RH and R15 are, independently from each other, hydrogen or lower alkyl; or C-Ri4 and C-R15 are, independently from each other, replaced by nitrogen; or a pharmaceutically acceptable salt thereof.
Preferred are the compounds of formula (IB) wherein
C-Ri4 is replaced by nitrogen;
Ri 5 is hydrogen; or a pharmaceutically acceptable salt thereof.
Further preferred are the compounds of formula (IB) having the formula
Figure imgf000078_0001
wherein
Ri is hydrogen, -C(O)R4, -C(O)NR5R6 or -C(O)OR7 in which R4 and R5 are, independently from each other, hydrogen, cycloalkyl, aryl, heterocyclyl, aralkyl, heteroaralkyl or alkyl optionally substituted with one to four substituents selected from the group consisting of halogen, cycloalkyl, cycloalkoxy, alkoxy, alkyloxyalkoxy, amino, alkylamino, dialkylamino, aryl, aryloxy and heterocyclyl;
R6 and R7 are, independently from each other, cycloalkyl, aryl, heterocyclyl, aralkyl, heteroaralkyl or alkyl optionally substituted with one to four substituents selected from the group consisting of halogen, cycloalkyl, cycloalkoxy, alkoxy, alkyloxyalkoxy, amino, alkylamino, dialkylamino, aryl, aryloxy and heterocyclyl;
RB is hydrogen, sulfonyl, cycloalkyl, aryl, heterocyclyl or (Ci-8)alkyl optionally substituted with one to four substituents selected from the group consisting of halogen, hydroxy, cycloalkyl, cycloalkoxy, acyl, acyloxy, alkoxy, alkyloxyalkoxy, optionally substituted amino, carbamoyl, thiol, alkylthio, alkylthiono, sulfonyl, sulfamoyl, nitro, cyano, free or esterified carboxy, aryl, aryloxy, arylthio, alkenyl, alkynyl, aralkoxy, heteroaralkoxy, heterocyclyl and heterocyclyloxy; or a pharmaceutically acceptable salt thereof. Preferred are the compounds of formula (IC) wherein R13 is -(CH2)n-CR16R17-(CH2)m-Z in which n and m are, independently from each other, zero or an integer from 1 to 6; Ri6 and R]7 are, independently from each other, hydrogen or lower alkyl; or
Ri6 and R]7 combined are alkylene which together with the carbon atom to which they are attached form a 3- to 7-membered ring;
Z is hydroxy, alkoxy, cycloalkyl, cycloalkoxy, acyl, acyloxy, carbamoyl, optionally substituted amino, cyano, trifluoromethyl, free or esterified carboxy, heterocyclyl, monocyclic aryl or monocyclic aryloxy; or a pharmaceutically acceptable salt thereof.
Further preferred are the compounds of formula (IC) wherein n is an integer from 1 to 3; m is zero or 1 ;
Ri6 and R]7 are, independently from each other, hydrogen or lower alkyl;
Z is hydroxy, carbamoyl, cyano, trifluoromethyl, free or esterified carboxy, heterocyclyl, monocyclic aryl or monocyclic aryloxy; or a pharmaceutically acceptable salt thereof.
More preferred are the compounds of formula (IC) wherein
Ri6 and Ri7 are hydrogen;
Z is hydroxy, cyano or free or esterified carboxy; or a pharmaceutically acceptable salt thereof.
Most preferred are the compounds of formula (IC) wherein
Ri is hydrogen or -C(O)R4 in which R4 is monocyclic aryl; or a pharmaceutically acceptable salt thereof.
Particular embodiments of the compounds are:
5-[2-Hydroxy-5-(lH-pyrrol-2-yl)-phenyl]-l,l-dioxo-l,2,5-thiadiazolidin-3-one; 5-(4-Hydroxybiphenyl-3-yl)-l,l-dioxo-l,2,5-thiadiazolidin-3-one;
5-[2-Hydroxy-5-(2H-pyrazol-3-yl)-phenyl]-l,l-dioxo-l,2,5-thiadiazolidin-3-one;
5-[2-Ηydroxy-5-(l -methyl- lH-pyrazol-4-yl)-phenyl]-l,l-dioxo-l,2,5-thiadiazolidin-3- one; 5-(5-Furan-3-yl-2-hydroxyphenyl)- 1 , 1 -dioxo- 1 ,2,5-thiadiazolidin-3-one;
5-[2-Ηydroxy-5-(lH-pyrazol-4-yl)-phenyl]-l,l-dioxo-l,2,5-thiadiazolidin-3-one;
5-(4'-Acetyl-4-hydroxybiphenyl-3-y I)- 1 , 1 -dioxo- 1 ,2,5-thiadiazolidin-3-one;
5-(4'-Benzoyl-4-hydroxybiphenyl-3-yl)-l,l-dioxo-l,2,5-thiadiazolidin-3-one;
5-[2-Ηydroxy-5-(lH-pyrrol-3-yl)-phenyl]- 1,1 -dioxo- 1 ,2,5-thiadiazolidin-3-one; Methanesulfonic acid 4'-hydroxy-3'-(l,l,4-trioxo-l,2,5-thiadiazolidin-2-yl)-biphenyl-3-yl ester;
5-(3'-Amino-4-hydroxybiphenyl-3-yl)-l,l -dioxo- l,2,5-thiadiazolidin-3-one;
5-(4-Ηydroxy-2'-methylbiphenyl-3-yl)-l,l-dioxo-l,2,5-thiadiazolidin-3-one;
5-[2-Hydroxy-5-(lH-indol-2-yl)-phenyl]-l,l-dioxo-l,2,5-thiadiazolidin-3-one; [4'-Ηydroxy-3'-(l,l,4-trioxo-l,2,5-thiadiazolidin-2-yl)-biphenyl-3-yl]-acetonitrile;
4'-Hydroxy-3'-(l,l,4-trioxo-l,2,5-thiadiazolidin-2-yl)-biphenyl-3-carboxylic acid (2- cyanoethyl)-amide;
3-[4'-Hydroxy-3'-(l,l,4-trioxo-l,2,5-thiadiazolidin-2-yl)-biphenyl-3-yl]-propionic acid methyl ester; 4'-Hydroxy-3'-(l,l,4-trioxo-l,2,5-thiadiazolidin-2-yl)-biphenyl-3-carboxylic acid (2- carbamoylethyl)-amide;
5-[3'-(2-Aminoethyl)-4-hydroxybiphenyl-3-yl]-l,l-dioxo-l,2,5-thiadiazolidin-3-one;
5-(3'-Aminomethyl-4-hydroxybiphenyl-3-yl)- 1 , 1 -dioxo- 1 ,2,5-thiadiazolidin-3-one;
5-(2-Hydroxy-5-pyridin-3-yl-pheny I)- 1 , 1 -dioxo- 1 ,2,5-thiadiazolidin-3-one; 5-(4-Hydroxy-2'-methoxy-biphenyl-3-yl)- 1 , 1 -dioxo- 1 ,2,5-thiadiazolidin-3-one;
5-(2-Hydroxy-5-pyridin-4-y 1-pheny I)- 1 , 1 -dioxo- 1 ,2,5-thiadiazolidin-3-one;
^'-Hydroxy-S'^lJ^-trioxo-l^^-thiadiazolidin^-yO-biphenyM-y^-acetic acid;
5-(4'-Chloro-4-hydroxybiphenyl-3-yl)- 1,1 -dioxo- l,2,5-thiadiazolidin-3-one;
5-(3'-Chloro-4-hydroxybiphenyl-3-yl)-l,l-dioxo-l,2,5-thiadiazolidin-3-one; 5-[2-Hydroxy-5-(6-methoxypyridin-3-yl)-phenyl]-l,l-dioxo-l,2,5-thiadiazolidin-3-one;
5-[5-(6-Fluoropyridin-3-yl)-2-hydroxyphenyl]-l,l-dioxo-l,2,5-thiadiazolidin-3-one; S-^'-Hydroxy-S'-ClJ^-trioxo-l^^-thiadiazolidin^-yO-biphenyl-S-ylJ-propionic acid ethyl ester;
5-(4-Hydroxy-3'-methylbiphenyl-3-yl)-l,l-dioxo-l,2,5-thiadiazolidin-3-one;
5-(3'-Fluoro-4-hydroxybiphenyl-3-yl)-l,l-dioxo-l,2,5-thiadiazolidin-3-one; 5-(4'-Fluoro-4-hydroxybiphenyl-3-yl-l,l-dioxo-l,2,5-thiadiazolidin-3-one;
5-(4-Hydroxy-4'-methylbiphenyl-3-yl)-l,l-dioxo-l,2,5-thiadiazolidin-3-one;
3-[4'-Hydroxy-3'-(l,l,4-trioxo-l,2,5-thiadiazolidin-2-yl)-biphenyl-3-yl]-propionitrile;
4'-Hydroxy-3'-(l,l,4-trioxo-l,2,5-thiadiazolidin-2-yl)-biphenyl-3-carbonitrile;
5-(4-Hydroxy-3',5'-dimethylbiphenyl-3-yl)-l,l-dioxo-l,2,5-thiadiazolidin-3-one; 5-(4-Hydroxy-3'-methoxybiphenyl-3-yl)-l,l-dioxo-l,2,5-thiadiazolidin-3-one;
N-(2-Hydroxyethyl)-2-[4'-hydroxy-3'-(l,l,4-trioxo-l,2,5-thiadiazolidin-2-yl)-biphenyl-4- yl]-acetamide;
2,2,2-Trifluoro-N-[4'-hydroxy-3'-(l,l,4-trioxo-l,2,5-thiadiazolidin-2-yl)-biphenyl-3-yl]- acetamide; l-Ethyl-3-[4'-hydroxy-3'-(l,l,4-trioxo-l,2,5-thiadiazolidin-2-yl)-biphenyl-3-yl]-urea; l-Ethyl-3-[4'-hydroxy-3'-(l,l,4-trioxo-l,2,5-thiadiazolidin-2-yl)-biphenyl-3-ylmethyl]- urea;
^'-Hydroxy-S'-^lJ^-trioxo-l^jS-thiadiazolidin^-yO-biphenyl-S-ylmethylJ-carbamic acid methyl ester; N-[4'-Hydroxy-3'-(l,l,4-trioxo-l,2,5-thiadiazolidin-2-yl)-biphenyl-3-ylmethyl]- acetamide;
[4'-Hydroxy-3'-(l,l,4-trioxo-l,2,5-thiadiazolidin-2-yl)-biphenyl-3-ylmethyl]-carbamic acid benzyl ester; l-Ethyl-3-[4'-hydroxy-3'-(l,l,4-trioxo-l,2,5-thiadiazolidin-2-yl)-biphenyl-4-yl]-urea; S-^'-Hydroxy-S'-ClJ^-trioxo-l^^-thiadiazolidin^-yO-biphenyl-S-ylJ-propionic acid;
5-{4-[4-Hydroxy-3-(l,l,4-trioxo-l,2,5-thiadiazolidin-2-yl)-phenyl]-pyrazol-l-yl}- pentanoic acid;
5-[2-Hydroxy-5-(l-propyl-lH-pyrazol-4-yl)-phenyl]-l,l-dioxo-l,2,5-thiadiazolidin-3- one; 5-[2-Hydroxy-5-(l-isobutyl-lH-pyrazol-4-yl)-phenyl]-l,l-dioxo-l,2,5-thiadiazolidin-3- one; 5-{4-[4-Hydroxy-3-(l,l,4-trioxo-l,2,5-thiadiazolidin-2-yl)-phenyl]-lH-pyrazol-l-yl}- pentanoic acid ethyl ester;
5-{2-Ηydroxy-5-[l-(4,4,4-trifluorobutyl)-lH-pyrazol-4-yl]-phenyl}-l, l-dioxo-l,2,5- thiadiazolidin-3-one; 5-{2-Ηydroxy-5-[l-(3-methylbutyl)-lH-pyrazol-4-yl]-phenyl}-l,l-dioxo-l,2,5- thiadiazolidin-3-one;
5-{4-[4-Ηydroxy-3-(l,l,4-trioxo-l,2,5-thiadiazolidin-2-yl)-phenyl]-lH-pyrazol-l-yl}- pentanenitrile;
4-{4-[4-Ηydroxy-3-(l,l,4-trioxo-l,2,5-thiadiazolidin-2-yl)-phenyl]-lH-pyrazol-l-yl}- butyronitrile;
5-(2-Ηydroxy-5-phenoxyphenyl)- 1 , 1 -dioxo- 1 ,2,5-thiadiazolidin-3-one;
5-(2-Hydroxy-5-methoxyphenyl)- 1 , 1 -dioxo- 1 ,2,5-thiadiazolidin-3-one;
5-(5-Benzyl-2-hydroxyphenyl)- 1 , 1 -dioxo- 1 ,2,5-thiadiazolidin-3-one;
5-(2-Hydroxy-5-methylphenyl)-l , 1 -dioxo-1 ,2,5-thiadiazolidin-3-one; 5-(5-Hexyl-2-hydroxyphenyl)- 1,1 -dioxo- l,2,5-thiadiazolidin-3-one;
5-(5-Butyl-2-hydroxyphenyl)- 1,1 -dioxo-1, 2, 5-thiadiazolidin-3-one;
5-[2-Hydroxy-5-(tetrahydrofuran-3-yl)-phenyl]- 1,1 -dioxo- l,2,5-thiadiazolidin-3-one;
5-[5-(4-Fluorophenylethynyl)-2-hydroxyphenyl]- 1 , 1 -dioxo- 1 ,2;5-thiadiazolidin-3-one;
6-[4-Hydroxy-3-(l,l,4-trioxo-l,2,5-thiadiazolidin-2-yl)-phenyl]-hex-5-ynenitrile; 6-[4-Hydroxy-3-(l,l,4-trioxo-l,2,5-thiadiazolidin-2-yl)-phenyl]-hex-5-ynoic acid;
5-[5-(3,3-Dimethyl-but-l-ynyl)-2-hydroxyphenyl]- 1,1 -dioxo- l,2,5-thiadiazolidin-3-one;
5-[2-Hydroxy-5-(5-methylhexyl)-phenyl]- 1,1 -dioxo-1, 2, 5-thiadiazolidin-3-one;
6-[4-Hydroxy-3-(l,l,4-trioxo-l,2,5-thiadiazolidin-2-yl)-phenyl]-hexanoic acid;
5-[5-(Benzylaminomethyl)-2-hydroxyphenyl]- 1 , 1 -dioxo- 1 ,2,5-thiadiazolidin-3-one; 5-(5-Butylaminomethyl-2-hydroxyphenyl)- 1 , 1 -dioxo-1 ,2, 5-thiadiazolidin-3-one;
5-{2-Hydroxy-5-[(2-methoxybenzylamino)-methyl]-phenyl}-l,l -dioxo- 1,2,5- thiadiazolidin-3-one;
5-{5-[(2-Ethoxybenzylamino)-methyl]-2-hydroxyphenyl}- 1,1 -dioxo-1, 2, 5-thiadiazolidin-
3-one; 5-{2-Hydroxy-5-[(2-isopropoxybenzylamino)-methyl]-phenyl}- 1,1 -dioxo- 1,2,5- thiadiazolidin-3-one; 5-(2-Hydroxy-5- { [2-( 1 -methyl-2-phenylethoxy)-benzylamino]-methyl }-phenyl)- 1,1- dioxo-l,2,5-thiadiazolidin-3-one;
5-[2-Hydroxy-5-(3-methylbutoxy)-phenyl]- 1 , 1 -dioxo- 1 ,2,5-thiadiazolidin-3 -one;
5-[2-Hydroxy-5-(4-methylpentyloxy)-phenyl]-l,l-dioxo-l,2,5-thiadiazolidin-3-one; 5-(2-Hydroxy-5-propoxyphenyl)- 1 , 1 -dioxo- 1 ,2,5-thiadiazolidin-3-one;
2-Hydroxy-6-{4-[4-hydroxy-3-(l,l,4-trioxo-l,2,5-thiadiazolidin-2-yl)-phenyl]-butoxy}-
N,N-dimethylbenzamide;
2-Hydroxy-6-{5-[4-hydroxy-3-(l,l,4-trioxo-l,2,5-thiadiazolidin-2-yl)-phenyl]- pentyloxy}-N,N-dimethylbenzamide; 2-Hydroxy-6-{6-[4-hydroxy-3-(l,l,4-trioxo-l,2,5-thiadiazolidin-2-yl)-phenyl]- hexyloxy}-N,N-dimethylbenzamide;
2-Fluoro-6-{6-[4-hydroxy-3-(l,l,4-trioxo-l,2,5-thiadiazolidin-2-yl)-phenyl]-hexyloxy}-
N,N-dimethylbenzamide;
2-Hydroxy-6-{7-[4-hydroxy-3-(l,l,4-trioxo-l,2,5-thiadiazolidin-2-yl)-phenyl]- heptyloxy}-N,N-dimethylbenzamide;
5-(4-Hydroxy-4'-hydroxymethylbiphenyl-3-yl)-l,l-dioxo-l,2,5-thiadiazolidin-3-one;
5-(2-Hydroxy-4,5-dimethylphenyl)-l,l -dioxo- l,2,5-thiadiazolidin-3-one;
5 -[4-Hydroxy-3 -( 1 , 1 ,4-trioxo- 1 ,2,5 -thiadiazolidin-2-yl)-pheny 1] -2,2-dimethy lpentanoic acid; δ-^-Hydroxy-S-ClJ^-trioxo-l^^-thiadiazolidin^-yO-phenylJ^^-dimethyloctanoic acid ethyl ester;
8-[4-Hydroxy-3-(l,l,4-trioxo-l,2,5-thiadiazolidin-2-yl)-phenyl]-2,2-dimethyloctanoic acid;
7-[4-Hydroxy-3-(l,l,4-trioxo-l,2,5-thiadiazolidin-2-yl)-phenyl]-2,2-dimethylheptanoic acid;
6-[4-Hydroxy-3-(l,l,4-trioxo-l,2,5-thiadiazolidin-2-yl)-phenyl]-2,2-dimethylhexanoic acid;
7-[4-Hydroxy-3-(l,l,4-trioxo-l,2,5-thiadiazolidin-2-yl)-phenyl]-2,2-dimethylheptanoic acid ethyl ester; 8-[4-Hydroxy-3-(l,l,4-trioxo-l,2,5-thiadiazolidin-2-yl)-phenyl]-2,2- dimethyloctanenitrile; 5-[2 -Hydro xy-5-(6-hydroxy-6-methylheptyl)-phenyl]- 1 , 1 -dioxo- 1 ,2,5-thiadiazolidin-3- one;
5-[2-Hydroxy-5-(7-hydroxy-6,6-dimethylheptyl)-phenyl]- 1 , 1 -dioxo- 1 ,2,5-thiadiazolidin-
3-one; 5-[2-Hydroxy-5-(5-hydroxy-5-methylhexyl)-phenyl]-l,l-dioxo-l ,2,5-thiadiazolidin-3- one;
5-[2-hydroxy-5-(8-hydroxy-7,7-dimethyloctyl)-phenyl]- 1 , 1 -dioxo- 1 ,2,5-thiadiazolidin-3- one;
7-[4-Hydroxy-3-( 1 , 1 ,4-trioxo- 1 ,2,5-thiadiazolidin-2-yl)-phenyl]-2,2- dimethylheptanenitrile;
5-[2-Hydroxy-5-(5-hydroxy-5-methylhex- 1 -ynyl)-phenyl]- 1 , 1 -dioxo- 1 ,2,5-thiadiazolidin-
3-one;
5-[2-Hydroxy-5-(2-pyridin-3-yl-ethyl)-phenyl]-l,l-dioxo-l,2,5- thiadiazolidin-3-one;
5-(2-Hydroxy-4-methyl-5-pentylphenyl)-l,l-dioxo-l,2,5-thiadiazolidin-3-one; 5-(2-Hydroxy-4-methyl-5-propylphenyl)-l , 1 -dioxo-1 ,2,5-thiadiazolidin-3-one;
5-(5-Heptyl-2-hydroxy-4-methylphenyl)- 1 , 1 -dioxo- 1 ,2,5-thiadiazolidin-3-one;
5-[5-(2-Cyclohexylethyl)-2-hydroxy-4-methylphenyl]- 1 , 1 -dioxo- 1 ,2,5-thiadiazolidin-3- one;
Benzoic acid 4-(7-hydroxy-6,6-dimethylheptyl)-2-(l , 1 ,4-trioxo- 1 ,2, 5-thiadiazolidin-2- yl)-phenyl ester; and
Benzoic acid 4-(6-cyano-6,6-dimethylhexyl)-2-( 1 , 1 ,4-trioxo- 1 ,2,5-thiadiazolidin-2-yl)- phenylester; or a pharmaceutically acceptable salt thereof.
Category 4 PTP Inhibitors
The methods of the invention can be practiced with the compounds of the formula
Figure imgf000084_0001
wherein R1 is hydrogen, -C(O)R5, -C(O)NR6R7 or -C(O)OR8 in which
R5 and R6 are, independently from each other, hydrogen, cycloalkyl, aryl, heterocyclyl, aralkyl, heteroaralkyl or alkyl optionally substituted with one to four substituents selected from the group consisting of halogen, cycloalkyl, cycloalkoxy, alkoxy, alkyloxyalkoxy, amino, alkylamino, dialkylamino, aryl, aryloxy and heterocyclyl;
R7 and R8 are, independently from each other, cycloalkyl, aryl, heterocyclyl, aralkyl, heteroaralkyl or alkyl optionally substituted with one to four substituents selected from the group consisting of halogen, cycloalkyl, cycloalkoxy, alkoxy, alkyloxyalkoxy, amino, alkylamino, dialkylamino, aryl, aryloxy and heterocyclyl; R2, R3 and R4 are, independently from each other, hydrogen, hydroxy, halogen, cyano, nitro, alkoxy, alkylthio, alkylthiono, sulfonyl, free or esterified carboxy, carbamoyl, sulfamoyl, optionally substituted amino, cycloalkyl, aryl, heterocyclyl, alkenyl, alkynyl or (Ci_8)alkyl optionally substituted with one to four substituents selected from the group consisting of halogen, hydroxy, cycloalkyl, cycloalkoxy, acyl, acyloxy, alkoxy, alkyloxyalkoxy, amino, alkylamino, dialkylamino, acylamino, carbamoyl, thiol, alkylthio, alkylthiono, sulfonyl, sulfonamido, sulfamoyl, nitro, cyano, free or esterified carboxy, aryl, aryloxy, arylthio, alkenyl, alkynyl, aralkoxy, heteroaralkoxy, heterocyclyl and heterocyclyloxy; or R2 and R3 combined are alkylene which together with the ring atoms to which they are attached form a 5- to 7-membered fused ring provided R2 and R3 are attached to carbon atoms adjacent to each other; or
R2 and R3 combined together with the carbon atom to which they are attached form a fused 5- to 6-membered aromatic or heteroaromatic ring provided R2 and R3 are attached to carbon atoms adjacent to each other; X is hydrogen, fluoro, cyano, or free or esterified carboxy; or
X is -NR9C(O)R10, -NR9C(O)ORn, -NR9S(O)2R12, -(CH2)mS(O)2R13, -OS(O)2R14 or -OnC(O)NR15R16 in which
R9 is hydrogen, lower alkyl, acyl, alkoxycarbonyl or sulfonyl; R10, R11, R12, R^ and R14 are, independently from each other, cycloalkyl, aryl, heterocyclyl, aralkyl, heteroaralkyl or (C1-8)alkyl optionally substituted with one to four substituents selected from the group consisting of halogen, hydroxy, cycloalkyl, cycloalkoxy, acyl, acyloxy, alkoxy, alkyloxyalkoxy, amino, alkylamino, dialkylamino, acylamino, carbamoyl, thiol, alkylthio, alkylthiono, sulfonyl, sulfonamido, sulfamoyl, nitro, cyano, free or esterified carboxy, aryl, aryloxy, arylthio, alkenyl, alkynyl, aralkoxy, heteroaralkoxy, heterocyclyl and heterocyclyloxy; or Rio, Ri2 and R13 are, independently from each other, -NR^Rig in which
Ri7 and Rig are, independently from each other, hydrogen, alkyl, cycloalkyl, aralkyl, aryl or heterocyclyl; or
Ri7 and Rig combined are alkylene which together with the nitrogen atom to which they are attached form a 4- to 7-membered ring; Ri5 and Ri6 are, independently from each other, hydrogen, alkyl, cycloalkyl, aralkyl, aryl or heterocyclyl; or
R15 and R)6 combined are alkylene which together with the nitrogen atom to which they are attached form a 4- to 7-membered ring; m and n are, independently from each other, zero or an integer of 1 ; or C-X is replaced by nitrogen;
Y is CH2, O or S; or a pharmaceutically acceptable salt thereof.
Preferred are the compounds of formula (I) wherein Y is CH2; or a pharmaceutically acceptable salt thereof.
Further preferred are the compounds of formula (I) having the formula
Figure imgf000086_0001
wherein
Ri is hydrogen, -C(O)R5, -C(O)NR6R7 or -C(O)OR8 in which R.5 and R6 are, independently from each other, hydrogen, cycloalkyl, aryl, heterocyclyl, aralkyl, heteroaralkyl or alkyl optionally substituted with one to four substituents selected from the group consisting of halogen, cycloalkyl, cycloalkoxy, alkoxy, alkyloxyalkoxy, amino, alkylamino, dialkylamino, aryl, aryloxy and heterocyclyl; R7 and R$ are, independently from each other, cycloalkyl, aryl, heterocyclyl, aralkyl, heteroaralkyl or alkyl optionally substituted with one to four substituents selected from the group consisting of halogen, cycloalkyl, cycloalkoxy, alkoxy, alkyloxyalkoxy, amino, alkylamino, dialkylamino, aryl, aryloxy and heterocyclyl; R2, R3 and R4 are, independently from each other, hydrogen, hydroxy, halogen, cyano, nitro, alkoxy, alkylthio, alkylthiono, sulfonyl, free or esterified carboxy, carbamoyl, sulfamoyl, optionally substituted amino, cycloalkyl, aryl, heterocyclyl, alkenyl, alkynyl or (Ci_8)alkyl optionally substituted with one to four substituents selected from the group consisting of halogen, hydroxy, cycloalkyl, cycloalkoxy, acyl, acyloxy, alkoxy, alkyloxyalkoxy, amino, alkylamino, dialkylamino, acylamino,. carbamoyl, thiol, alkylthio, alkylthiono, sulfonyl, sulfonamido, sulfamoyl, nitro, cyano, free or esterified carboxy, aryl, aryloxy, arylthio, alkenyl, alkynyl, aralkoxy, heteroaralkoxy, heterocyclyl and heterocyclyloxy; or
R2 and R3 combined are alkylene which together with the ring atoms to which they are attached form a 5- to 7-membered fused ring; or R2 and R3 combined together with the carbon atom to which they are attached form a fused 5- to 6-membered aromatic or heteroaromatic ring; X is cyano; or
X is -NR9C(O)Ri0, -NR9C(O)ORn, -NR9S(O)2Rj2, -(CH2)mS(O)2Ri3 or -OS(O)2Ri4 in which R9 is hydrogen or lower alkyl;
Rio, Rn, Ri2, Rn and RJ4 are, independently from each other, cycloalkyl, aryl, heterocyclyl, aralkyl, heteroaralkyl or (Ci_8)alkyl optionally substituted with one to four substituents selected from the group consisting of halogen, hydroxy, cycloalkyl, cycloalkoxy, acyl, acyloxy, alkoxy, alkyloxyalkoxy, amino, alkylamino, dialkylamino, acylamino, carbamoyl, thiol, alkylthio, alkylthiono, sulfonyl, sulfonamido, sulfamoyl, nitro, cyano, free or esterified carboxy, aryl, aryloxy, arylthio, alkenyl, alkynyl, aralkoxy, heteroaralkoxy, heterocyclyl and heterocyclyloxy; or Rio, Ri2 and Rn are, independently from each other, -NRi7Ri8 in which Ri7 and Ri8 are, independently from each other, hydrogen, alkyl, cycloalkyl, aralkyl, aryl or heterocyclyl; or
Ri7 and Ri8 combined are alkylene which together with the nitrogen atom to which they are attached form a 4- to 7-membered ring; m is zero; or
C-X is replaced by nitrogen; or a pharmaceutically acceptable salt thereof.
Preferred are the compounds of formula (IA) wherein
X is cyano; or
X is -NR9S(O)2Ri2 or -OS(O)2Ri4 in which R9 is hydrogen or lower alkyl;
Ri2 and Ri4 are, independently from each other, cycloalkyl, aryl, heterocyclyl, aralkyl, heteroaralkyl or (Ci.8)alkyl optionally substituted with one to four substituents selected from the group consisting of halogen, hydroxy, cycloalkyl, cycloalkoxy, acyl, acyloxy, alkoxy, alkyloxyalkoxy, amino, alkylamino, dialkylamino, acylamino, carbamoyl, thiol, alkylthio, alkylthiono, sulfonyl, sulfonamido, sulfamoyl, nitro, cyano, free or esterified carboxy, aryl, aryloxy, arylthio, alkenyl, alkynyl, aralkoxy, heteroaralkoxy, heterocyclyl and heterocyclyloxy; or a pharmaceutically acceptable salt thereof.
Especially preferred are the compounds of formula (IA), designated as the A group, wherein R9 is hydrogen; or a pharmaceutically acceptable salt thereof.
Preferred are the compounds in the A group wherein
Ri2 and Rμ are, independently from each other, monocyclic aryl or C^jalkyl; or a pharmaceutically acceptable salt thereof.
Further preferred are the compounds in the A group wherein Ri is hydrogen or -C(O)R5 in which R5 is monocyclic aryl; or a pharmaceutically acceptable salt thereof.
Especially preferred are also the compounds of formula (IA), designated as the B group, wherein
R2, R3 and R4 are, independently from each other, hydrogen, halogen, hydroxy, monocyclic aryl,
Figure imgf000089_0001
optionally substituted with at least one halogen; or a pharmaceutically acceptable salt thereof.
Preferred are the compounds in the B group wherein
R9 is hydrogen; or a pharmaceutically acceptable salt thereof.
Further preferred are the compounds in the B group wherein Ri2 and Ri4 are, independently from each other, monocyclic aryl or C(I-4^IlCyI; or a pharmaceutically acceptable salt thereof.
More preferred are the compounds in the B group wherein Ri is hydrogen or -C(O)R5 in which R5 is monocyclic aryl; or a pharmaceutically acceptable salt thereof.
Particular embodiments of the compounds are:
5-(4-Benzyl-2-hydroxyphenyl)-l,l-dioxo-l,2,5-thiadiazolidin-3-one;
5-[2-Hydroxy-4-(3-hydroxybenzyl)-phenyl]-l,l-dioxo-l,2,5-thiadiazolidin-3-one;
5-[2-Hydroxy-4-(3-methoxybenzyl)-phenyl]-l,l-dioxo-l,2,5-thiadiazolidin-3-one;
5-[4-(2-Fluoro-3-trifluoromethylbenzyl)-2-hydroxyphenyl]-l, 1-dioxo- 1,2,5- thiadiazolidin-3-one;
2-[3-Hydroxy-4-(l,l,4-trioxo-l,2,5-thiadiazolidin-2-yl)-benzyl]-benzonitrile; 5-[4-(2-Fluorobenzyl)-2-hydroxyphenyl]-l,l-dioxo-l,2,5-thiadiazolidin-3-one;
5-(2-Hydroxy-4-naphthalen-2-ylmethylphenyl)- 1 , 1 -dioxo- 1 ,2,5-thiadiazolidin-3-one;
5-[2-Hydroxy-4-(3-trifluoromethylbenzylphenyl]- 1 , 1 -dioxo- 1 ,2,5-thiadiazolidin-3-one;
5-[2-Hydroxy-4-(2-methylbenzyl)phenyl]- 1,1 -dioxo- l,2,5-thiadiazolidin-3-one; 5-[4-(4-Fluorobenzyl)-2 -hydro xyphenyl]- 1 , 1 -dioxo- 1 ,2,5-thiadiazolidin-3-one;
3-[3-Hydroxy-4-(l,l,4-trioxo-l,2,5-thiadiazolidin-2-yl)-benzyl]-benzoic acid methyl ester;
5-(4-Biphenyl-3-ylmethyl-2-hydroxyphenyl)- 1 , 1 -dioxo- 1 ,2,5-thiadiazolidin-3-one;
5-[4-(3-Fluoro-4-methylbenzyl)-2-hydroxyphenyl]- 1,1 -dioxo- l,2,5-thiadiazolidin-3-one; 5-[2-Hydroxy-4-(4-methylbenzyl)phenyl]- 1 , 1 -dioxo- 1 ,2,5-thiadiazolidin-3-one;
5-[2-Hydroxy-4-(4-hydroxybenzyl)phenyl]- 1,1 -dioxo- l,2,5-thiadiazolidin-3-one;
5-[4-(3-Fluorobenzyl)-2 -hydro xyphenyl]- 1 , 1 -dioxo- 1 ,2,5-thiadiazolidin-3-one;
5-[4-(4-terM3utylbenzyl)-2-hydroxyphenyl]- 1,1 -dioxo- l,2,5-thiadiazolidin-3-one;
5-[4-{2-Benzenesulfonylmethylbenzyl)-2-hydroxyphenyl]- 1 , 1 -dioxo- 1 ,2,5- thiadiazolidin-3-one;
5-[2-Hydroxy-4-(3-methylbenzyl)phenyl]- 1,1 -dioxo- l,2,5-thiadiazolidin-3-one;
{2-[3-Hydroxy-4-(l,l,4-trioxo-l,2,5-thiadiazolidin-2-yl)-benzyl]-phenyl}-carbamic acid tert-buty\ ester;
7V-{2-[3-Hydroxy-4-(l,l,4-trioxo-l,2,5-thiadiazolidin-2-yl)-benzyl]-phenyl}-C-phenyl- methanesulfonamide;
7V-{2-[3-Hydroxy-4-(l,l,4-trioxo-l,2,5-thiadiazolidin-2-yl)-benzyl]-phenyl}- benzenesulfonamide;
Ethanesulfonic acid {2-[3-hydroxy-4-( 1 , 1 ,4-trioxo- 1 ,2,5-thiadiazolidin-2-yl)-benzyl]- phenyl} -amide; Propane- 1 -sulfonic acid {2-[3-hydroxy-4-(l,l,4-trioxo-l,2,5-thiadiazolidin-2-yl)-benzyl]- phenyl} -amide;
Butane- 1 -sulfonic acid {2-[3-hydroxy-4-(l,l,4-trioxo-l,2,5-thiadiazolidin-2-yl)-benzyl]- phenyl} -amide;
C-Cyclohexyl-N-{2-[3-hydroxy-4-(l,l,4-trioxo-l,2,5-thiadiazolidin-2-yl)-benzyl]- phenyl}-methanesulfonamide; N-{2-[3-Hydroxy-4-(l,l,4-trioxo-l,2,5-thiadiazolidin-2-yl)-benzyl]-phenyl}- methanesulfonamide;
N-{2-[3-Hydroxy-4-(l,l,4-trioxo-l,2,5-thiadiazolidin-2-yl)-benzyl]-phenyl}-4- isopropylbenzenesulfonamide; N-{2-[3-Hydroxy-4-(l,l,4-trioxo-l,2,5-thiadiazolidin-2-yl)-benzyl]-phenyl}- aminosulfonamide;
N-{3-[3-Hydroxy-4-(l,l,4-trioxo-l,2,5-thiadiazolidin-2-yl)-benzyl]-naphthalen-2-yl}- methanesulfonamide;
N-{2-[3-Hydroxy-4-( 1 , 1 ,4-trioxo- 1 ,2,5-thiadazolidin-2-yl)-benzyl]-phenyl}-acetamide; 4-fert-Butyl-N-{2-[3-hydroxy-4-(l,l,4-trioxo-l,2,5-thiadiazolidin-2-yl)-benzyl]-phenyl}- benzamide;
N-{2-[3-Hydroxy-4-( 1 , 1 ,4-trioxo- 1 ,2,5-thiadiazolidin-2-yl)-benzyl]-phenyl}-benzamide;
5-[4-(4-Ethylpyridin-2-ylmethyl)-2-hydroxyphenyl]-l ,l -dioxo- l,2,5-thiadiazolidin-3- one; 5-[4-(6-Methoxypyridin-2-ylmethyl)-2-hydroxyphenyl]-l,l-dioxo-l,2,5-thiadiazolidin-3- one;
5-(2-Hydroxy-4-pyridin-2-ylmethylphenyl)- 1 , 1 -dioxo- 1 ,2,5-thiadiazolidin-3-one;
5-[2-Hydroxy-4-(2-methanesulfonylbenzyl)-phenyl]- 1,1 -dioxo- l,2,5-thiadiazolidin-3- one; N-{2-[3-Hydroxy-4-(l,l,4-trioxo-l,2,5-thiadiazolidin-2-yl)-benzyl]-phenyl}-N- methylmethanesulfbnamide;
5-[2-Hydroxy-4-(2-methanesulfonylmethylbenzyl)-phenyl]- 1 , 1 -dioxo- 1,2,5- thiadiazolidin-3-one;
5-{4-(3-Methansulfonylphenyl)methyl-2-hydroxyphenyl}-l,l-dioxo-l,2,5-thiadiazolidin- 3-one;
C-{2-[3-Hydroxy-4-(l,l,4-trioxo-l,2,5-thiadiazolidin-2-yl)-benzyl]-phenyl}-N,N- dimethylmethanesulfonamide;
Methanesulfonic acid 2-[3-hydroxy-4-(l,l,4-trioxo-l,2,5-thiadiazoldin-2-yl)-benzyl]- phenyl ester; Methanesulfonic acid 3-[3-hydroxy-4-(l,l,4-trioxo-l,2,5-thiadiazolidin-2-yl)-benzyl]- naphthalen-2-yl ester; Methanesulfonic acid 2-[3-hydroxy-4-( 1 , 1 ,4-trioxo- 1 ,2,5-thiadiazolidin-2-yl)-benzyl]- naphthalen-1-yl ester;
Methanesulfonic acid 2-[3-hydroxy-4-(l,l,4-trioxo-l,2,5-thiadiazolidin-2-yl)-benzyl]-4- methylphenyl ester; Methanesulfonic acid l-[3-hydroxy-4-(l,l,4-trioxo-l,2,5-thiadiazolidin-2-yl)-benzyl]- naphthalen-2-yl ester;
Methanesulfonic acid 2-[3-hydroxy-4-(l,l,4-trioxo-l,2,5-thiadiazolidin-2-yl)-benzyl]-4- methoxyphenyl ester;
Methanesulfonic acid 2-[3-hydroxy-4-( 1 , 1 ,4-trioxo- 1 ,2,5-thiadiazolidin-2-yl)-benzyl]-6- methylphenyl ester;
Ethanesulfonic acid 2-[3-hydroxy-4-(l,l,4-trioxo-l,2,5-thiadiazolidin-2-yl)-benzyl]-4- methylphenyl ester;
Propane- 1 -sulfonic acid 2-[3-hydroxy-4-(l,l,4-trioxo-l,2,5-thiadiazolidin-2-yl)-benzyl]-
4-methylphenyl ester; Methanesulfonic acid 4-chloro-2-[3-hydroxy-4-(l,l,4-trioxo-l,2,5-thiadiazolidin-2-yl)- benzyl]-phenyl ester;
Methanesulfonic acid 2-[3-hydroxy-4-( 1 , 1 ,4-trioxo- 1 ,2,5-thiadiazolidin-2-yl)-benzyl]-5- methylphenyl ester;
Methanesulfonic acid 4-chloro-2-[3-hydroxy-4-(l,l,4-trioxo-l,2,5-thiadiazolidin-2-yl)- benzyl]-6-methylphenyl ester;
Ethanesulfonic acid 2-[3-hydroxy-4-( 1 , 1 ,4-trioxo- 1 ,2,5-thiadiazolidin-2-yl)-benzyl]- phenyl ester;
Propane- 1 -sulfonic acid 2-[3-hydroxy-4-( 1 , 1 ,4-trioxo- 1 ,2,5-thiadiazolidin-2-yl)-benzyl]- phenyl ester; 5-[4-(2-Fluoro-4-methylbenzyl)-2-hydroxyphenyl]-l,l-dioxo-l,2,5-thiadiazolidin-3-one;
3-[3-Hydroxy-4-(l,l,4-trioxo-l,2,5-thiadiazolidin-2-yl)-benzyl]-jV-methylbenzamide potassium salt;
3-[3-Hydroxy-4-(l,l,4-trioxo-l,2,5-thiadiazolidin-2-yl)-benzyl]-benzoic acid dipotassium salt; 2-[3-Hydroxy-4-(l,l,4-trioxo-l,2,5-thiadiazolidin-2-yl)-benzyl]-benzoic acid;
5-[4-(2,5-Difluorobenzyl)-2-hydroxyphenyl]-l,l-dioxo-l,2,5-thiadiazolidin-3-one; 5-[4-(3-Ethylbenzyl)-2-hydroxyphenyl]-l,l-dioxo-l,2,5-thiadiazolidin-3-one;
5-(2-Hydroxy-4-phenoxyphenyl)-l,l-dioxo-l,2,5-thiadiazolidin-3-one potassium salt;
2-Hydroxy-6-[3-hydroxy-4-(l,l,4-trioxo-l,2,5-thiadiazolidin-2-yl)-benzyl]-benzonitrile;
2-[3-Hydroxy-4-(l,l,4-trioxo-l,2,5-thiadiazolidin-2-yl)-benzyl]-4- trifluoromethylbenzonitrile;
2-[3-Hydroxy-4-(l,l,4-trioxo-l,2,5-thiadiazolidin-2-yl)-benzyl]-4-methylbenzonitrile;
2-[3-Hydroxy-4-( 1 , 1 ,4-trioxo-l ,2,5-thiadiazolidin-2-yl)-benzyl]-6-methyl-benzonitrile;
2-[3-Hydroxy-4-( 1 , 1 ,4-trioxo- 1 ,2,5-thiadiazolidin-2-yl)-benzyl]-4- trifluoromethylbenzonitrile; 5-(2-Hydroxy-4-phenylsulfanylphenyl)- 1 , 1 -dioxo- 1 ,2,5-thiadiazolidin-3 -one;
2-[3-Hydroxy-4-(l,l,4-trioxo-l,2,5-thiadiazolidin-2-yl)-phenylsulfanyl]-4- trifluoromethylbenzonitrile;
2-[3-Hydroxy-4-(l,l,4-trioxo-l,2,5-thiadiazolidin-2-yl)-phenylsulfanyl]-6- trifluoromethylbenzonitrile; Methanesulfonic acid 2-[3-diethylcarbamoyloxy-4-(l,l,4-trioxo-l,2,5-thiadiazolidin-2- yl)-benzyl]-phenyl ester;
Methanesulfonic acid 2-[3-isopropoxycarbonyloxy-4-( 1 , 1 ,4-trioxo- 1 ,2,5-thiadiazolidin-2- yl)-benzyl]-phenyl ester;
N-{4-Chloro-2-[3-hydroxy-4-(l,l,4-trioxo-l,2,5-thiadiazolidin-2-yl)-benzyl]-phenyl}- methanesulfonamide;
7V-{2-[3-Hydroxy-4-(l,l,4-trioxo-l,2,5-thiadiazolidin-2-yl)-benzyl]-4-methylphenyl}- methanesulfonamide;
7V-{4-Fluoro-2-[3-hydroxy-4-(l,l,4-trioxo-l,2,5-thiadiazolidin-2-yl)-benzyl]-phenyl}- methanesulfonamide; N-{4-Fluoro-2-[3-hydroxy-4-(l,l,4-trioxo-l,2,5-thiadiazolidin-2-yl)-benzyl]-phenyl}- benzenesulfonamide;
Ethanesulfonic acid {4-fluoro-2-[3-hydroxy-4-(l,l,4-trioxo-l,2,5-thiadiazolidin-2-yl)- benzyl] -phenyl } -amide;
Propane-2-sulfonic acid {4-fluoro-2-[3-hydroxy-4-(l,l,4-trioxo-l,2,5-thiadiazolidin-2- yl)-benzyl]-phenyl}-amide; Propane- 1 -sulfonic acid {2-[3-hydroxy-4-(l,l,4-trioxo-l,2,5-thiadiazolidin-2-yl)-benzyl]-
4-methylphenyl } -amide;
Λr-{4-Fluoro-2-[3-hydroxy-4-(l,l,4-trioxo-l,2,5-thiadiazolidin-2-yl)-benzyl]-phenyl}-C- pheny 1 -methanesu 1 fonamide ; Ethanesulfonic acid {4-chloro-2-[3-hydroxy-4-(l,l,4-trioxo-l,2,5-thiadiazolidin-2-yl)- benzyl]-phenyl} -amide;
Propane-2-sulfonic acid {4-chloro-2-[3-hydroxy-4-(l , 1 ,4-trioxo- 1 ,2,5-thiadiazolidin-2- yl)-benzyl]-phenyl}-amide;
Propane- 1 -sulfonic acid {4-chloro-2-[3-hydroxy-4-(l,l,4-trioxo-l,2,5-thiadiazolidin-2- yl)-benzyl]-phenyl}-amide;
Ethanesulfonic acid {4-chloro-2-[3-hydroxy-4-(l,l,4-trioxo-l,2,5-thiadiazolidin-2-yl)- benzyl]-6-methylphenyl}-amide;
N- { 2-[3 -Hydroxy-4-( 1 , 1 ,4-trioxo- 1 ,2,5 -thiadiazo lidin-2-y l)-benzyl] -6-methylphenyl } - methanesul fonamide; N-{2-[3-Hydroxy-4-(l,l,4-trioxo-l,2,5-thiadiazolidin-2-yl)-benzyl]-4,6- dimethylphenyl}-methanesulfonamide;
Ethanesulfonic acid {2-[3-hydroxy-4-(l,l,4-trioxo-l,2,5-thiadiazolidin-2-yl)-benzyl]-6- methylphenyl} -amide;
Propane- 1 -sulfonic acid {2-[3-hydroxy-4-(l,l,4-trioxo-l,2,5-thiadiazolidin-2-yl)-benzyl]- 6-methylphenyl} -amide;
Ethanesulfonic acid {2-[3-hydroxy-4-(l,l,4-trioxo-l,2,5-thiadiazolidin-2-yl)-benzyl]-4,6- dimethylphenyl} -amide;
N-{4-Chloro-2-[3-hydroxy-4-(l,l,4-trioxo-l,2,5-thiadiazolidin-2-yl)-benzyl]-6- methylphenyl}-methanesulfonamide; N-{4-Chloro-2-[3-hydroxy-4-(l,l,4-trioxo-l,2,5-thiadiazolidin-2-yl)-benzyl]-6- methylphenyl}-methanesulfonamide;
Λr-{2-[3-Hydroxy-4-(l,l,4-trioxo-l,2,5-thiadiazolidin-2-yl)-benzyl]-5-methylphenyl}- methanesulfonamide;
N-{2-[3-Hydroxy-4-(l,l,4-trioxo-l,2,5-thiadiazolidin-2-yl)-benzyl]-6-methoxyphenyl}- methanesulfonamide; N-{5-Chloro-2-[3-hydroxy-4-( 1 , 1 ,4-trioxo- 1 ,2,5-thiadiazolidin-2-yl)-benzyl]-phenyl }- methanesulfonamide;
Ethanesulfonic acid {2-[3-hydroxy-4-(l,l,4-trioxo-l,2,5-thiadiazolidin-2-yl)-benzyl]-4- methylphenyl} -amide; Methanesulfonic acid 4-ethyl-2-[3-hydroxy-4-( 1,1, 4-trioxo-l, 2, 5-thiadiazolidin-2-yl)- benzyl]-phenyl ester;
Methanesulfonic acid 4-tert-butyl-2-[3-hydroxy-4-( 1,1, 4-trioxo-l, 2,5-thiadiazolidin-2- yl)-benzyl]-phenyl ester;
Diethylcarbamic acid 2-[3-hydroxy-4-( 1,1, 4-trioxo-l, 2,5-thiadiazolidin-2-yl)-benzyl]-4- methylphenyl ester;
Ethanesulfonic acid {4-ethyl-2-[3-hydroxy-4-( 1 , 1 ,4-trioxo- 1 ,2,5-thiadiazolidin-2-yl)- benzyl]-phenyl} -amide;
Propane- 1 -sulfonic acid {4-ethyl-2-[3-hydroxy-4-( 1 , 1 ,4-trioxo- 1 ,2,5-thiadiazolidin-2-yl)- benzyl]-phenyl}-amide; N- {4-Ethyl-2-[3-hydroxy-4-( 1 , 1 ,4-trioxo- 1 ,2,5-thiadiazolidin-2-yl)-benzyl]-phenyl } - methanesulfonamide;
N-{4-Benzyl-2-[3-hydroxy-4-(l,l,4-trioxo-l,2,5-thiadiazolidin-2-yl)- benzylphenyl}methanesulfonamide;
N-{3-[3-Hydroxy-4-(l,l,4-trioxo-l,2,5-thiadiazolidin-2-yl)-benzyl]-biphenyl-4-yl}- methanesulfonamide;
N-{2-[3-Hydroxy-4-(l,l, 4-trioxo-l, 2,5-thiadiazolidin-2-yl)-benzyl]-4-methoxyphenyl}- methanesulfonamide;
Ethanesulfonic acid {2-[3-hydroxy-4-( 1,1, 4-trioxo-l, 2,5-thiadiazolidin-2-yl)-benzyl]-4- methoxypheny 1 } -amide; Propane- 1 -sulfonic acid {2-[3-hydroxy-4-( 1,1, 4-trioxo-l, 2,5-thiadiazolidin-2 -yl)-benzyl]-
4-methoxyphenyl} -amide;
Methanesulfonic acid 5-[3-hydroxy-4-( 1,1, 4-trioxo-l, 2,5-thiadiazolidin-2-yl)-benzyl]-7- methylindan-4-yl ester;
Methanesulfonic acid 6-[3-hydroxy-4-( 1 , 1 ,4-trioxo- 1 ,2,5-thiadiazolidin-2-yl)-benzyl]- indan-5-yl ester; N-{2-[4-(l,l-dioxido-4-oxo-l,2,5-thiadiazolidin-2-yl)-3-hydroxybenzyl]-l,4- dimethylphenyl}sulfamide;
JV-{2-[4-(l,l-dioxido-4-oxo-l,2,5-thiadiazolidin-2-yl)-3-hydroxybenzyl]-l-methyl-4- chlorophenyl}sulfamide; JV-{2-[4-(l,l-dioxido-4-oxo-l,2,5-thiadiazolidin-2-yl)-3-hydroxybenzyl]-4- ethylphenyl}sulfamide;
Methanesulfonic acid 2-[3-hydroxy-4-(l,l,4-trioxo-l ,2,5-thiadiazolidin-2-yl)-benzyl]-6- isopropylphenyl ester;
Methanesulfonic acid 2-[3-hydroxy-4-(l,l,4-trioxo-l,2,5-thiadiazolidin-2-yl)-benzyl]-5- methylphenyl ester;
Methanesulfonic acid 2-chloro-6-[3 -hydroxy-4-( 1 , 1 ,4-trioxo- 1 ,2,5-thiadiazolidin-2-y I)- benzyl]-phenyl ester;
Methanesulfonic acid 5-chloro-2-[3-hydroxy-4-(l,l,4-trioxo-l,2,5-thiadiazolidin-2-yl)- benzyl]-phenyl ester; Methanesulfonic acid 2-[3-hydroxy-4-(l,l,4-trioxo-l,2,5-thiadiazolidin-2-yl)-benzyl]-5- methoxyphenyl ester;
Methanesulfonic acid 2-[3-hydroxy-4-(l,l,4-trioxo-l,2,5-thiadiazolidin-2-yl)-benzyl]-6- methoxyphenyl ester;
N-{2-Chloro-6-[3-hydroxy-4-(l,l,4-trioxo-l,2,5-thiadiazolidin-2-yl)-benzyl]-phenyl}- methanesulfonamide;
Methanesulfonic acid 2-[3-hydroxy-4-(l,l,4-trioxo-l,2,5-thiadiazolidin-2-yl)-benzyl]-
4,6-dimethylphenyl ester;
Benzoic acid 5-benzyl-2-(l,l,4-trioxo-l,2,5-thiadiazolidin-2-yl)-phenyl ester;
Benzoic acid 5-(2-methanesulfonyloxybenzyl)-2-(l,l,4-trioxo-l,2,5-thiadiazolidin-2-yl)- phenyl ester;
Benzoic acid 5-(2-methanesulfonyloxy-5-methylbenzyl)-2-(l,l,4-trioxo-l,2,5- thiadiazolidin-2-yl)-phenyl ester;
Benzoic acid 5-(2-methanesulfonylamino-5-methylbenzyl)-2-(l,l,4-trioxo-l,2,5- thiadiazolidin-2-yl)-phenyl ester; Benzoic acid 5-(2-methanesulfonylaminobenzyl)-2-(l,l,4-trioxo-l,2,5-thiadiazolidin-2- yl)-phenyl ester; Benzoic acid 5-[2-(benzoylmethanesulfonylamino)-5-methylbenzyl]-2-(l,l,4-trioxo- l,2,5-thiadiazolidin-2-yl)-phenyl ester;
Benzoic acid 5-[2-(benzoylmethanesulfonylamino)-benzyl]-2-(l,l,4-trioxo-l,2,5- thiadiazolidin-2-yl)-phenyl ester; 2-Amino-3-methylbutyric acid 5-(2-methanesulfonyloxy-benzyl)-2-(l,l,4-trioxo-l,2,5- thiadiazolidin-2-yl)-phenyl ester;
Benzoic acid 5-(5-chloro-2-methanesulfonylamino-3-methylbenzyl)-2-(l,l,4-trioxo- l,2,5-thiadiazolidin-2-yl)-phenyl ester;
Benzoic acid 5-(2-methanesulfonylamino-3,5-dimethylbenzyl)-2-(l,l,4-trioxo-l,2,5- thiadiazolidin-2-yl)-phenyl ester;
2-Amino-3-methylbutyric acid 5-(2-methanesulfonyloxy-5-methylbenzyl-2-(l,l,4-trioxo- l,2,5-thiadiazolidin-2-yl)-phenyl ester;
Benzoic acid S^-methanesulfonyloxy-S^-dimethylbenzyO^^lJ^-trioxo-l^^1 thiadiazolidin-2-yl)-phenyl ester; Methanesulfonic acid 2-[3-methoxycarbonyloxy-4-(l,l,4-trioxo-l,2,5-thiadiazolidin-2τ yl)-benzyl]-4-methylphenyl ester;
2-Amino-3-methylbutyric acid 5-(2-methanesulfonylamino-benzyl)-2-(l,l,4-trioxo-l,2,5- thiadiazolidin-2-yl)-phenyl ester;
2-( 1 , l-dioxido-4-oxo- 1 ,2,5-thiadiazolidin-2-yl)-5-{2- [(methoxycarbonyl)(methylsulfonyl)-amino]-3,5-dimethylbenzyl}phenyl methyl carbonate;
Carbonic acid 5-(2-methanesulfonylamino-3,5-dimethylbenzyl)-2-(l,l,4-trioxo-l,2,5- thiadiazolidin-2-yl)-phenyl ester methyl ester;
Benzoic acid 5-(2-methanesulfonylamino-4-methylbenzyl)-2-(l,l,4-trioxo-l,2,5- thiadiazolidin-2-yl)-phenyl ester;
Benzoic acid 5-(2-methanesulfonyloxy-4-methylbenzyl)-2-(l,l,4-trioxo-l,2,5- thiadiazolidin-2-yl)-phenyl ester;
Benzoic acid 5-[2-(benzoylmethanesulfonylamino)-4-methylbenzyl]-2-(l,l,4-trioxo-
1 ,2,5-thiadiazolidin-2-yl)-phenyl ester; Benzoic acid 5-(2-methanesulfonyloxy-3-methylbenzyl)-2-(l,l,4-trioxo-l,2,5- thiadiazolidin-2-yl)-phenyl ester; Benzoic acid 5-(5-chloro-2-methanesulfonyloxy-3-methylbenzyl)-2-( 1 , 1 ,4-trioxo- 1 ,2,5- thiadiazolidin-2-yl)-phenyl ester;
Benzoic acid 5-[2-(benzoylmethanesulfonylamino)-3-methylbenzyl]-2-(l,l,4-trioxo- 1 ,2,5-thiadiazolidin-2-yl)-phenyl ester; Benzoic acid 5-(2-methanesulfonylamino-3-methylbenzyl)-2-( 1,1, 4-trioxo- 1,2,5- thiadiazolidin-2-yl)-phenyl ester;
2-Methylbenzoic acid 5-(2-methanesulfonyloxy-5-methylbenzyl)-2-(l , 1 ,4-trioxo- 1 ,2,5- thiadiazolidin-2-yl)-phenyl ester; and
5-(4-Benzyl-2-hydroxy-6-methylphenyl)-l,l-dioxo-l,2,5-thiadiazolidin-3-one; or a pharmaceutically acceptable salt thereof.
Category 5 PTP Inhibitors
The methods o the invention can be practiced with the compounds of the formula
Figure imgf000098_0001
wherein Q is: i) -X, or ii) -Y-(CH2)n-(CR8R9)p-(CH2)m-Z-X in which
Y is oxygen or S(O)q in which q is zero or an integer of 1 or 2; or Y is -C≡C- or -C=C-; or
Y is cyclopropyl or
Y is absent; n and m are, independently from each other, zero or an integer from 1 to 8; R8 and R9 are, independently from each other, hydrogen, hydroxyl, alkoxy, alkanoyl, alkanoylamino, alkoxycarbonyl, aralkyl, heteroaryl, heterocyclyl, carbamoyl, aryl, or alkyl; or
R8 and R9 combined are alkylene which together with the carbon atom to which they are attached form a 3- to 7-membered ring; p is zero or an integer selected from 1 or 2 Z is absent; Z is -C(O)-O-; or Z is -C(O)-; or Z is -C(O)-NRα-alkylene- or -C(O)-NRα-alkylene-O-, wherein Ra is H or lower alkyl; or
Z is -CO-NRα-(CH2)n.-(CR8 R9 )p-(CH2)m. - or -C(O)-NRα-(CH2)n -(CR8.R9 )p- (CH2)m- -O-, wherein p' is zero or an integer of 1, n' and m' are, independently from each other, zero or an integer from 1 to 8, R8- and R9- are, independently from each other, hydrogen or lower alkyl, Ra is H or lower alkyl; or
Z is -NRα'-C(O)-, or -NRα'-C(O)-O-, wherein Ra' is H or lower alkyl, or Ra' and R9 combined are alkylene which together with the carbon atom to which they are attached form a 3- to 7-membered ring; or Z is -C(O)-NH-NH-C(O)-O-; or Z is -S(O)2-, or -S(O)-; or
Z is -NRp-S(O)2- , wherein Rβ is H, lower alkyl, or Rβ and R9 combined are alkylene which together with the carbon atom to which they are attached form a 3- to 7-membered ring; or Z is -NH-S(O)2-NH-C(O)-O-; or Z is -NRy-C(O)-NRy'-; wherein Ry' is H, alkyl, aryl, heterocyclyl or lower alkoxy and Rγ is H, lower alkyl, or Rγand R9 combined are alkylene which together with the carbon atom to which they are attached form a 3- to 7-membered ring; or Rγ' and X combined are alkylene which together with the carbon atom to which they are attached form a 3- to 7-membered ring or Z is -NRx-C(O)-NH-S(O)2-, wherein Rτ is H or lower alkyl,
X is hydrogen, hydroxy, NH2, halogen, alkoxy, alkylthio, alkyl, -S(O)-OH, alkyl, cycloalkyl, cycloalkoxy, acyl, acyloxy, carbamoyl, optionally substituted amino, cyano, trifluoromethyl, free or esterified carboxy, heterocyclyl, heterocyclooxy, heteroaryl, heteroaralkyl, aryl, aralkyl, aralkoxy, aryloxy, aralkylthio, arylthio; Ri is hydrogen, -C(O)R4, -C(O)NR5R6 or -C(O)OR7 in which R4 and R5 are, independently from each other, hydrogen, cycloalkyl, aryl, heterocyclyl, aralkyl, heteroaralkyl or alkyl optionally substituted with one to four substituents selected from the group consisting of halogen, cycloalkyl, cycloalkoxy, alkoxy, alkyloxyalkoxy, amino, alkylamino, dialkylamino, aryl, aryloxy and heterocyclyl; R^ and R7 are, independently from each other, cycloalkyl, aryl, heterocyclyl, aralkyl, heteroaralkyl or alkyl optionally substituted with one to four substituents selected from the group consisting of halogen, cycloalkyl, cycloalkoxy, alkoxy, alkyloxyalkoxy, amino, alkylamino, dialkylamino, aryl, aryloxy and heterocyclyl;
R2 and R3 are, independently from each other, hydrogen, halogen, (Q^alkyl or (Ci-3)alkoxy; or a pharmaceutically acceptable salt thereof, and wherein n + m + p is > 1 or is 0, when X is aryl, and Y and Z are absent, n + m + p is not 0 when X is -O-aryl, and Y and Z are absent, or n + m + p is not 0 when X is -S-aryl, and Y and Z are absent, or n + m + p is not 0 when X is ~CH2-aryl, and Y and Z are absent, or n + m + p is not 0 when X is aryl, Z is absent and Y is -O- or Y is -S-, or wherein Q cannot be -CH2-aryl, -S-aryl or -O-aryl.
Prefrably, the orientation of the Z fonction is with the X group on the right side of the listed function -Z->X e.g. Z is -NRα'-C(O)- means Z is -NRα'-C(O)-X.
Preferred are the compounds of formula (I), designated as the ALPHA group, wherein Q is: -Y-(CH2)n-(CR8R9)p-(CH2)m-Z-X in which
Y is oxygen or S(O)q in which q is zero or an integer of 1 or 2; or Y is -C≡C- or -C=C-; or
Y is cyclopropyl or
Y is absent; n and m are, independently from each other, zero or an integer from 1 to 8; R8 and R9 are, independently from each other, hydrogen, hydroxyl, alkoxy, alkanoyl, alkanoylamino, alkoxycarbonyl, aralkyl, heteroaryl, heterocyclyl, carbamoyl, aryl, or alkyl; or R8 and R9 combined are alkylene which together with the carbon atom to which they are attached form a 3- to 7-membered ring; p is zero or an integer selected from 1 or 2
Z is absent; Z is -C(O)-O-; or
Z is -C(O)-; or
Z is -C(O)-NRα-alkylene- or -C(O)-NRα-alkylene-O-, wherein Rαis H or lower alkyl; or
Z is -CO-NRα-(CH2)n >-(CR8 >R9 >V-(CH2)m > -, Or -C(O)-NRa-(CH2V-(CRrR9Op - (CH2)m' -O-, wherein p' is zero or an integer of 1, n' and m' are, independently from each other, zero or an integer from 1 to 8, R8' and R9' are, independently from each other, hydrogen or lower alkyl, Ra is H or lower alkyl; or
Z is -NRα'-C(O)-, or -NRa' -C(O)-O-, wherein Ra' is H or lower alkyl, or Ra' and R9 combined are alkylene which together with the carbon atom to which they are attached form a 3- to 7-membered ring; or
Z is -C(O)-NH-NH-C(O)-O-; or
Z is -S(O)2-, or -S(O)-; or
Z is -NRβ-S(O)2- , wherein Rβ is H, lower alkyl, or Rβ and R9 combined are alkylene which together with the carbon atom to which they are attached form a 3- to 7-membered ring; or
Z is -NH-S(O)2-NH-C(O)-O-; or
Z is -NRγ-C(O)-NRγ'-; wherein Rγ' is H, alkyl, aryl, heterocyclyl, or lower alkoxy and
Rγ is H, lower alkyl, or Ryand R9 combined are alkylene which together with the carbon atom to which they are attached form a 3- to 7-membered ring; or Rγ) and X combined are alkylene which together with the carbon atom to which they are attached form a 3- to
7-membered ring or
Z is -NRT-C(O)-NH-S(O)2-, wherein Rτ is H or lower alkyl,
X is hydrogen, hydroxy, NH2, halogen, alkoxy, alkylthio, alkyl, -S(O)-OH, alkyl, cycloalkyl, cycloalkoxy, acyl, acyloxy, carbamoyl, optionally substituted amino, cyano, trifluoromethyl, free or esterified carboxy, heterocyclyl, heterocyclooxy, heteroaryl, heteroaralkyl, aryl, aralkyl, aralkoxy, aryloxy, aralkylthio, arylthio; Ri is hydrogen, -C(O)R4, -C(O)NR5R6 or -C(O)OR7 in which
R4 and R5 are, independently from each other, hydrogen, cycloalkyl, aryl, heterocyclyl, aralkyl, heteroaralkyl or alkyl optionally substituted with one to four substituents selected from the group consisting of halogen, cycloalkyl, cycloalkoxy, alkoxy, alkyloxyalkoxy, amino, alkylamino, dialkylamino, aryl, aryloxy and heterocyclyl;
R6 and R7 are, independently from each other, cycloalkyl, aryl, heterocyclyl, aralkyl, heteroaralkyl or alkyl optionally substituted with one to four substituents selected from the group consisting of halogen, cycloalkyl, cycloalkoxy, alkoxy, alkyloxyalkoxy, amino, alkylamino, dialkylamino, aryl, aryloxy and heterocyclyl; R2 and R3 are, independently from each other, hydrogen, halogen, (Ci-3)alkyl or (Ci.3)alkoxy; or a pharmaceutically acceptable salt thereof, and wherein n + m + p is > 1 or is 0, when X is aryl, and Y and Z are absent, n + m + p is not 0 when X is -O-aryl, and Y and Z are absent, or n + m + p is not 0 when X is -S-aryl, and Y and Z are absent, or n + m + p is not 0 when X is -CH2-aryl, and Y and Z are absent, or n + m + p is not 0 when X is aryl, Z is absent and Y is -O- or Y is -S-, or wherein Q cannot be -CH2-aryl, -S-aryl or -O-aryl.
Prefrably, the orientation of the Z fonction is with the X group on the right side of the listed function -Z^X e.g. Z is -NRα'-C(O)- means Z is -NRα'-C(0)-X.
Preferred are the compounds in the ALPHA group wherein;
Y is oxygen; or Y is -C≡C- or -C=C-; or
Y is cyclopropyl or
Y is absent; and
X is, hydrogen, hydroxy, NH2, halogen, alkoxy, alkylthio, alkyl, -S(O)-OH, alkyl, cycloalkyl, cyano, trifluoromethyl, free or esterified carboxy, heterocyclyl, heteroaryl, heteroaralkyl, aryl, aralkyl, aryloxy;
Preferred are the compounds in the ALPHA group wherein R2 and R3 are hydrogen; or a pharmaceutically acceptable salt thereof.
Preferred are the compounds in the ALPHA group wherein
Ri is hydrogen; or a pharmaceutically acceptable salt thereof.
Further preferred are the compounds in the ALPHA group wherein n is zero or an integer from 1 to 4; m is zero or an integer from 1 to 4; p is zero or 1 ; or a pharmaceutically acceptable salt thereof.
Especially preferred are the compounds in the ALPHA group, wherein m + n + p is between 0 and 7 or preferably between 0 and 5, or a pharmaceutically acceptable salt thereof.
Preferred are the compounds of formula (I), designated as the A group, wherein Q is -Y-(CH2)n-(CR8R9)p-(CH2)m-Z-X, in which
Y is oxygen or S(O)q in which q is zero or an integer of 1 or 2; or
Y is -C≡C- or -C=C-; or
Y is cyclopropyl; or
Y is absent; n and m are, independently from each other, zero or an integer from 1 to 8;
R8 and R9 are, independently from each other, hydrogen, hydroxyl, alkoxy, alkanoyl, alkanoylamino, alkoxycarbonyl, aralkyl, heteroaryl, heterocyclyl, carbamoyl, aryl, or alkyl; p is zero or an integer selected from 1 or 2 Z is absent;
Z is -CO-O-; or
Z is -CO-; or
X is hydrogen, hydroxy, NH2, halogen, alkoxy, alkylthio, -SO-OH, alkyl, cycloalkyl, cycloalkoxy, acyl, acyloxy, carbamoyl, optionally substituted amino, cyano, trifluoromethyl, free or esterified carboxy, heterocyclyl, heterocyclooxy, heteroaryl, heteroaralkyl, aryl, aralkyl, aralkoxy, aryloxy, aralkylthio, arylthio; or a pharmaceutically acceptable salt thereof.
Preferred are the compounds in the A group wherein
Y is oxygen; or Y is cyclopropyl; or
Y is absent; or a pharmaceutically acceptable salt thereof.
Preferred are the compounds in the A group wherein R8 and R9 are, independently from each other, hydrogen, alkoxy, alkanoyl, alkoxycarbonyl, aralkyl, aryl, or alkyl; or a pharmaceutically acceptable salt thereof.
Preferred are the compounds in the A group wherein X is hydrogen, hydroxy, alkyl, heterocyclyl, heteroaryl, aryl; or a pharmaceutically acceptable salt thereof.
Preferred are the compounds in the A group wherein
R2 and R3 are hydrogen; or a pharmaceutically acceptable salt thereof. Preferred are the compounds in the A group wherein
Ri is hydrogen; or a pharmaceutically acceptable salt thereof.
Further preferred are the compounds in the A group wherein n is zero or an integer from 1 to 3; m is zero or an integer from 1 to 3; p is zero or 1 ; or a pharmaceutically acceptable salt thereof.
Especially preferred are the compounds in the A group, wherein m + n + p is between 0 and 4, or a pharmaceutically acceptable salt thereof.
Other preferred compounds are the compounds in the A group, wherein m + n + p is between 1 and 3, and n is 1, or a pharmaceutically acceptable salt thereof.
Other preferred compounds are the compounds in the A group, wherein X is phenyl.
Preferred are the compounds of formula (I), designated as B, wherein; Q is -Y-(CH2)n-(CRgR9)p-(CH2)m-Z-X, in which
Y is oxygen or S(O)q in which q is zero or an integer of 1 or 2; or
Y is -C≡C- or -C=C-; or Y is cyclopropyl; or
Y is absent; n and m are, independently from each other, zero or an integer from 1 to 8;
Rg and R9 are, independently from each other, hydrogen, hydroxyl, alkoxy, alkanoyl, alkanoylamino, alkoxycarbonyl, aralkyl, heteroaryl, heterocyclyl, carbamoyl, aryl, or alkyl; or
Rg and R9 combined are alkylene which together with the carbon atom to which they are attached form a 3- to 7-membered ring; p is zero or an integer selected from 1 or 2
Z is absent; X is hydrogen, hydroxy, NH2, halogen, alkoxy, alkylthio, -SO-OH, alkyl, cycloalkyl, cycloalkoxy, acyl, acyloxy, carbamoyl, optionally substituted amino, cyano, trifluoromethyl, free or esterified carboxy, heterocyclyl, heterocyclooxy, heteroaryl, heteroaralkyl, aryl, aralkyl, aralkoxy, aryloxy, aralkylthio, arylthio; or a pharmaceutically acceptable salt thereof.
Preferred are the compounds in the B group wherein Rg and R9 are, independently from each other, hydrogen, alkoxy, alkanoyl, alkoxycarbonyl, aralkyl, or alkyl; or a pharmaceutically acceptable salt thereof.
Preferred are the compounds in the B group wherein
X is hydrogen, NH2, hydroxy, alkylthio, -SO-OH, alkyl, cycloalkyl, cyano, trifluoromethyl, free or esterified carboxy, heterocyclyl, heteroaryl, aryl; or a pharmaceutically acceptable salt thereof.
Preferred are the compounds in the B group wherein R2 and R3 are hydrogen; or a pharmaceutically acceptable salt thereof.
Preferred are the compounds in the B group wherein Ri is hydrogen; or a pharmaceutically acceptable salt thereof.
Further preferred are the compounds in the B group wherein n is zero or an integer from 1 to 3; m is zero or an integer from 1 to 3; p is zero or 1 ; or a pharmaceutically acceptable salt thereof.
Especially preferred are the compounds in the B group, wherein m + n + p is between 0 and 6 or preferably 0 and 4, or a pharmaceutically acceptable salt thereof.
Other preferred compounds are the compounds in the B group, wherein m + n is between 0 and 6 or preferably 0 and 4, and p is 0, or a pharmaceutically acceptable salt thereof. Other preferred compounds are the compounds in the B group, wherein X is selected from phenyl or heteroaryl, preferably unsusbtituted or substituted by at least one substituent e.g. one or two, which is preferably a substituent selected from carboxy, carbamoyl, and lower alkyl, or a pharmaceutically acceptable salt thereof.
Other preferred compounds are the compounds in the B group, wherein m + n is 1 , 2 or 3, preferably 1 or 2, m + m + p is preferably 2 or 3, p is 1 or 0, and
X is cycloalkyl, heterocyclyl, heteroaryl, or aryl, preferably unsusbtituted or substituted by at least one substituent e.g. one or two, which is preferably a substituent selected from sulfonamido, carboxy, carbamoyl, and lower alkyl, or a pharmaceutically acceptable salt thereof.
Other preferred compounds are the compounds in the B group, wherein m + n is 1, 2 or 3, preferably 1 or 2, m + n + p is 2, 3 or 4, preferably 2 or 3, p is 1 or 0, and
X is aryl, preferably unsusbtituted or substituted by at least one substituent e.g. one or two, which is preferably a substituent selected from sulfonamido, carboxy, carbamoyl, and lower alkyl, or a pharmaceutically acceptable salt thereof.
Other preferred compounds are the compounds in the B group, wherein m + n is 1, 2 or 3, preferably 1 or 2, p is 1 or 0, and
X is "amide" type heterocyclyl, cycloalkyl substituted by at least one substituent e.g. one or two, which is preferably sulfonamide, or aryl substituted by at least one substituent e.g. one or two, which is preferably sulfonamido or a pharmaceutically acceptable salt thereof.
Preferred are the compounds of formula (I), designated as the C , wherein Q is -Y-(CH2)n-(CR8R9)p-(CH2)m-Z-X, in which Y is oxygen or S(O)q in which q is zero or an integer of 1 or 2; or
Y is -C≡C- or -C=C-; or
Y is absent; n and m are, independently from each other, zero or an integer from 1 to 8;
R8 and R9 are, independently from each other, hydrogen, hydroxyl, alkoxy, alkanoyl, alkanoylamino, alkoxycarbonyl, aralkyl, heteroaryl, heterocyclyl, carbamoyl, aryl, or alkyl; or
R8 and R9 combined are alkylene which together with the carbon atom to which they are attached form a 3- to 7-membered ring; p is zero or an integer selected from 1 or 2 Z is -CO-NRα-alkylene- or -CO-NRα-alkylene-O-, wherein Rq is H or lower alkyl; or
Z is -CO-NRα-(CH2)n'-(CR8'R9')p'-(CH2)m' - or
-CO-NRα-(CH2V-(CR8 >R90p>-(CH2)m' -CK wherein p' is zero or an integer of 1, n' and m' are independently from each other, zero or an integer from 1 to 8, R8- and R9- are, independently from each other, hydrogen or lower alkyl, Ra is H or lower alkyl; or
Z is -NRα'-CO-, or -NRα'-CO-O- wherein Ra' is, H or lower alkyl, or Ra' and R9 combined are alkylene which together with the carbon atom to which they are attached form a 3- to 7-membered ring; or
Z is -CO-NH-NH-CO-O-; or X is hydrogen, hydroxy, NH2, halogen, alkoxy, alkylthio, -SO-OH, alkyl, cycloalkyl, cycloalkoxy, acyl, acyloxy, carbamoyl, optionally substituted amino, cyano, trifluoromethyl, free or esterifϊed carboxy, heterocyclyl, heterocyclooxy, heteroaryl, heteroaralkyl, aryl, aralkyl, aralkoxy, aryloxy, aralkylthio, arylthio; or a pharmaceutically acceptable salt thereof.
Preferred are the compounds in the C group wherein Y is absent; or a pharmaceutically acceptable salt thereof.
Preferred are the compounds in the C group wherein R8 and R9 are, independently from each other, hydrogen, alkanoylamino, aralkyl, aryl, or alkyl; or a pharmaceutically acceptable salt thereof.
Preferred are the compounds in the C group wherein X is hydrogen, alkyl, cycloalkyl, free or esterified carboxy, aryl, aralkyl, aryloxy; or a pharmaceutically acceptable salt thereof.
Preferred are the compounds in the C group wherein R2 and R3 are hydrogen; or a pharmaceutically acceptable salt thereof.
Preferred are the compounds in the C group wherein
Ri is hydrogen; or a pharmaceutically acceptable salt thereof.
Further preferred are the compounds in the C group wherein n is zero or an integer from 1 to 3; m is zero or an integer from 1 to 3; p is zero or 1 ; or a pharmaceutically acceptable salt thereof.
Especially preferred are the compounds in the C group, wherein m + n + p is between 0 and 6 or preferably between 0 and 4, or a pharmaceutically acceptable salt thereof.
Other preferred compounds are the compounds in the C group, wherein m + n + p is between 1 and 3 (i.e. 1, 2 or 3) m + n is between 1 and 3 (i.e. 1, 2 or 3) and p is 0 m + n + p is between 1 and 3 (i.e. 1, 2 or 3) and p is 1 m is 0, n is between 1 and 2 (i.e. 1, or 2) and p is 1 or a pharmaceutically acceptable salt thereof.
Especially preferred are the compounds in the C group, wherein n' and m' are independently from each other, zero or an integer from 1 to 6, and p' is zero or an integer of 1, or a pharmaceutically acceptable salt thereof.
Especially preferred are the compounds in the C group, wherein p' + n' + m' is comprised between zero and 5, or between 3 and 5 i.e. 3, 4 or 5, or a pharmaceutically acceptable salt thereof.
Especially preferred are the compounds in the C group, wherein n' and m' are independently from each other, zero or an integer from 1 to 6, preferably from 1 to 4, or a pharmaceutically acceptable salt thereof.
Other preferred compounds are the compounds in the C group, wherein n' + m' is between 0 and 5, or between 3 and 5, preferably 4, and p' is 0, or a pharmaceutically acceptable salt thereof.
Especially preferred are the compounds in the C group, wherein
X is phenyl, preferably unsusbtituted or substituted preferably by at least one, e.g. one or two, of the substituents selected preferably from alkoxycarbonyl, carboxy, alkoxy, cyano, lower alkyl, (lower alkyl)-NHC(O)-, (lower alkyl)2-NC(O> and hydroxy.
Preferred are the compounds of formula (I), designated as the D group, wherein Q is -Y-(CH2)n-(CR8R9)p-(CH2)m-Z-X, in which Y is absent; n and m are, independently from each other, zero; p is zero; Z is absent; X is hydrogen, hydroxy, NH2, halogen, alkoxy, alkylthio, -SO-OH, alkyl, cycloalkyl, cycloalkoxy, acyl, acyloxy, carbamoyl, optionally substituted amino, cyano, trifluoromethyl, free or esterified carboxy, heterocyclyl, heterocyclooxy, heteroaryl, heteroaralkyl, aryl, aralkyl, aralkoxy, aryloxy, aralkylthio, arylthio; or a pharmaceutically acceptable salt thereof.
Preferred are the compounds in the D group wherein
X is halogen, cyano, trifluoromethyl, heterocyclyl, heteroaryl, aryl, or a pharmaceutically acceptable salt thereof.
Preferred are the compounds in the D group wherein R2 and R3 are hydrogen; or a pharmaceutically acceptable salt thereof.
Preferred are the compounds in the D group wherein Ri is hydrogen; or a pharmaceutically acceptable salt thereof.
Further preferred are the compounds in the D group wherein X is aryl or heteroaryl, or a pharmaceutically acceptable salt thereof.
Especially preferred are the compounds in the D group, wherein
X is aryl substituted by an "amide" type heterocyclyl, or a pharmaceutically acceptable salt thereof.
Preferred are the compounds of formula (I), designated as the E group, wherein Q is -Y-(CH2)n-(CR8R9)p-(CH2)m-Z-X, in which Y is oxygen or S(O)q in which q is zero or an integer of 1 or 2; or
Y is -C≡C- or -C=C-; or
Y is absent; n and m are, independently from each other, zero or an integer from 1 to 8; Rg and R9 are, independently from each other, hydrogen, hydroxyl, alkoxy, alkanoyl, alkanoylamino, alkoxycarbonyl, aralkyl, heteroaryl, heterocyclyl, carbamoyl, aryl, or alkyl; or
R8 and R9 combined are alkylene which together with the carbon atom to which they are attached form a 3- to 7-membered ring; p is zero or an integer selected from 1 or 2
Z is -SO2-, or -SO-; or
Z is -NRβ-SO2- , wherein Rβ is H, lower alkyl, or Rβ and R9 combined are alkylene which together with the carbon atom to which they are attached form a 3- to 7-membered ring preferably 5-, 6- or 7- membered ring; or Z is -NH-SO2-NH-CO-O-; or
X is hydrogen, hydroxy, NH2, halogen, alkoxy, alkylthio, -SO-OH, alkyl, cycloalkyl, cycloalkoxy, acyl, acyloxy, carbamoyl, optionally substituted amino, cyano, trifluoromethyl, free or esterified carboxy, heterocyclyl, heterocyclooxy, heteroaryl, heteroaralkyl, aryl, aralkyl, aralkoxy, aryloxy, aralkylthio, arylthio; or a pharmaceutically acceptable salt thereof.
Preferred are the compounds in the E group wherein
Y is absent; or a pharmaceutically acceptable salt thereof.
Preferred are the compounds in the E group wherein
R8 and R9 are, independently from each other, hydrogen, aralkyl, heteroaryl, heterocyclyl, heterocyclyl, carbamoyl; or
Rg and R9 combined are alkylene which together with the carbon atom to which they are attached form a 3- to 7-membered ring; or a pharmaceutically acceptable salt thereof.
I l l Preferred are the compounds in the E group wherein
X is hydrogen, alkyl, cycloalkyl, heteroaryl, aryl, aralkyl; or a pharmaceutically acceptable salt thereof.
Preferred are the compounds in the E group wherein R2 and R3 are hydrogen; or a pharmaceutically acceptable salt thereof.
Preferred are the compounds in the E group wherein R] is hydrogen; or a pharmaceutically acceptable salt thereof.
Further preferred are the compounds in the E group wherein n is zero or an integer from 1 to 4; m is zero or an integer from 1 to 4; p is zero or 1 ; or a pharmaceutically acceptable salt thereof.
Especially preferred are the compounds in the E group, wherein m + n + p is between 0 and 7 or preferably between 0 and 5, or a pharmaceutically acceptable salt thereof.
Other preferred compounds are the compounds in the E group, wherein i) m + n + p is 2 or 3, or ii) m +n is 2 or 3, and p is 0 , or iii) n is 1 or 2, m is 0 or 1, and p is 1 when Rβ and R9 combined are alkylene which together with the carbon atom to which they are attached form a 5-, 6- or 7- membered ring or a pharmaceutically acceptable salt thereof.
Other preferred compounds are the compounds in the E group, wherein m + n is 1 or 2, m is 0 or 1, and p is 1, or n is 1 or 2, m is 0 or 1, and p is 1 when R8 is hydrogen and R9 is selected from aralkyl, heteroaryl, heterocyclyl, heterocyclyl, or carbamoyl; or a pharmaceutically acceptable salt thereof.
Other preferred compounds are the compounds in the E group, wherein
X is selected from phenyl, biphenyl, benzyl, lower alkyl, methyl substituted by on or two pheny, ethyl substituted by on or two pheny, or methyl substituted by cycloalkyl
Preferred are the compounds of formula (I), designated as the F group, wherein Q is -Y-(CH2)n-(CR8R9)p-(CH2)m-Z-X, in which
Y is oxygen or S(O)q in which q is zero or an integer of 1 or 2; or
Y is -C≡C- or -C=C-; or
Y is absent; n and m are, independently from each other, zero or an integer from 1 to 8;
R8 and R9 are, independently from each other, hydrogen, hydroxyl, alkoxy, alkanoyl, alkanoylamino, alkoxycarbonyl, aralkyl, heteroaryl, heterocyclyl, carbamoyl, aryl, or alkyl; or
R8 and R9 combined are alkylene which together with the carbon atom to which they are attached form a 3- to 7-membered ring; p is zero or an integer selected from 1 or 2
Z is -NRγ-CO-NRγ1-; wherein Ry1 is H, alkyl, aryl, heterocyclyl, or lower alkoxy and Rγ is H, lower alkyl, or Rγand R9 combined are alkylene which together with the carbon atom to which they are attached form a 3- to 7-membered ring; or Rγ' and X combined are alkylene which together with the carbon atom to which they are attached form a 3- to
7-membered ring; or
Z is -NRT-CO-NH-SO2-, wherein Rτ is H or lower alkyl,
X is hydrogen, hydroxy, NH2, halogen, alkoxy, alkylthio, -SO-OH, alkyl, cycloalkyl, cycloalkoxy, acyl, acyloxy, carbamoyl, optionally substituted amino, cyano, trifluoromethyl, free or esterifϊed carboxy, heterocyclyl, heterocyclooxy, heteroaryl, heteroaralkyl, aryl, aralkyl, aralkoxy, aryloxy, aralkylthio, arylthio; or a pharmaceutically acceptable salt thereof.
Preferred are the compounds in the F group wherein Y is absent; or a pharmaceutically acceptable salt thereof.
Preferred are the compounds in the F group wherein R8 and R9 are, independently from each other, hydrogen; or a pharmaceutically acceptable salt thereof.
Preferred are the compounds in the F group wherein
X is hydrogen, alkyl, cycloalkyl, heterocyclyl, aryl, aralkyl; or a pharmaceutically acceptable salt thereof.
Preferred are the compounds in the F group wherein R2 and R3 are hydrogen; or a pharmaceutically acceptable salt thereof.
Preferred are the compounds in the F group wherein Rγ' is H or lower alkyl, or a pharmaceutically acceptable salt thereof.
Preferred are the compounds in the F group wherein
Ri is hydrogen; or a pharmaceutically acceptable salt thereof.
Especially preferred are the compounds in the F group, wherein m + n + p is between 0 and 7 or preferably between 0 and 5 or between 2 and 3, or a pharmaceutically acceptable salt thereof.
Further preferred are the compounds in the F group wherein n is zero or an integer from 1 to 4; m is zero or an integer from 1 to 4; p is zero or 1 ; or a pharmaceutically acceptable salt thereof.
Especially preferred are the compounds in the F group, wherein m + n + p is 2 or 3, and
X is lower alkyl, phenyl, benzyl, or cyclohexyl, or a pharmaceutically acceptable salt thereof.
Compound according to any of the aboved described groups wherein; the term alkyl preferably refers to a lower alkyl, aryl is preferably a phenyl, and/or when R8 and R9 are present, at least one of R8 or R9 is hydrogen.
Particular embodiments of the compounds are: the below specific exemplified compounds,
3-{2-[3-Hydroxy-4-(l,l,4-trioxo-l,2,5-thiadiazolidin-2-yl)-phenyl]-ethyl}-benzamide 3-{2-[3-Hydroxy-4-(l,l,4-trioxo-l,2,5-thiadiazolidin-2-yl)-phenyl]-ethyl}-N-methyl benzamide 3-{2-[3-Hydroxy-4-(l,l,4-trioxo-l,2,5-thiadiazolidin-2-yl)-phenyl]-ethyl}-N,N- dimethylbenzamide
4-{2-[3-Hydroxy-4-(l,l,4-trioxo-l,2,5-thiadiazolidin-2-yl)-phenyl]-ethyl}-N,N- dimethylbenzamide
4-{2-[3-Hydroxy-4-(l,l,4-trioxo-l,2,5-thiadiazolidin-2-yl)-phenyl]-ethyl}-benzamide 4-{2-[3-Hydroxy-4-(l,l,4-trioxo-l,2,5-thiadiazolidin-2-yl)-phenyl]-ethyl}-N- methylbenzamide
3-{2-[3-Hydroxy-4-(l,l,4-trioxo-l,2,5-thiadiazolidin-2-yl)-phenyl]-ethyl}-benzoic acid 4-{2-[3-Hydroxy-4-(l,l,4-trioxo-l,2,5-thiadiazolidin-2-yl)-phenyl]-ethyl}-benzoic acid 4-{2-[3-Hydroxy-4-(l,l,4-trioxo-l,2,5-thiadiazolidin-2-yl)-phenyl]-ethyl}-benzonitrile 2-{2-[3-Hydroxy-4-(l,l,4-trioxo-l,2,5-thiadiazolidin-2-yl)-phenyl]-ethyl}-benzonitrile 5 -(2-Hydroxy-4-phenethylphenyl)- 1 , 1 -dioxo- 1 ,2,5-thiadiazolidin-3-one 5-{2-Hydroxy-4-[2-(3-methoxyphenyl)-ethyl]-phenyl}-l,l-dioxo-l,2,5-thiadiazolidin-3- one
5-{4-[2-(3-Fluorophenyl)-ethyl]-2-hydroxyphenyl}-l,l-dioxo-l,2,5-thiadiazolidin-3-one
5-{4-[2-(2-Fluorophenyl)-ethyl]-2-hydroxyphenyl}-l,l-dioxo-l,2,5-thiadiazolidin-3-one 5-[2-Hydroxy-4-(2-pentafluorophenylethyl)-phenyl]-l,l-dioxo-l,2,5-thiadiazolidin-3-one
5-[2-Hydroxy-4-(2-p-tolylethyl)-phenyl]-l,l-dioxo-l,2,5-thiadiazolidin-3-one
5-{2-Hydroxy-4-[2-(4-octylphenyl)-ethyl]-phenyl}-l,l-dioxo-l,2,5-thiadiazolidin-3-one
5-[4-(2-Biphenyl-4-yl-ethyl)-2-hydroxyphenyl]-l,l-dioxo-l,2,5-thiadiazolidin-3-one
5-{4-[2-(4-tert-Butylphenyl)-ethyl]-2-hydroxyphenyl}-l,l-dioxo-l,2,5-thiadiazolidin-3- one
5-{4-[2-(2,5-Dimethylphenyl)-ethyl]-2-hydroxyphenyl}-l,l-dioxo-l,2,5-thiadiazolidin-3- one
5-{4-[2-(2,4-Dimethylphenyl)-ethyl]-2-hydroxyphenyl}-l,l-dioxo-l,2,5-thiadiazolidin-3- one 5-{2-Hydroxy-4-[2-(4-trifluoromethylphenyl)-ethyl]-phenyl}-l , 1 -dioxo- 1 ,2,5- thiadiazolidin-3-onβ
Acetic acid 4-{2-[3-hydroxy-4-(l,l,4-trioxo-l,2,5-thiadiazolidin-2-yl)-phenyl]-ethyl}- phenyl ester
5-{2-Hydroxy-4-[2-(4-phenoxyphenyl)-ethyl]-phenyl}- 1,1 -dioxo- l,2,5-thiadiazolidin-3- one
5-[2-Hydroxy-4-(2-pyridin-4-ylethyl)-phenyl]- 1,1 -dioxo- l,2,5-thiadiazolidin-3-one
5-[2-Hydroxy -4-(2-pyridin-3-yl-ethyl)-phenyl]- 1,1 -dioxo- l,2,5-thiadiazolidin-3-one
5-[2-Hydroxy-4-(2-naphthalenethyl)-phenyl]- 1,1 -dioxo- l,2,5-thiadiazolidin-3-one
5-[2-Hydroxy-4-(2-quinolin-3-yl-ethyl)-phenyl]-l,l-dioxo-l,2,5-thiadiazolidin-3-one 5-{4-[2-(4,6-Diamino-[l,3,5]triazin-2-yl)-ethyl]-2-hydroxy-phenyl}-l,l-dioxo-l,2,5- thiadiazolidin-3-one
5-[2-Hydroxy-4-(2-phenylpropyl)-phenyl]-l,l-dioxo-l,2,5-thiadiazolidin-3-one
5-{4-[2-(2-Aminophenyl)-propyl]-2-hydroxyphenyl}- 1,1 -dioxo- l,2,5-thiadiazolidin-3- one 3-[3-Hydroxy-4-(l,l,4-trioxo-l,2,5-thiadiazolidin-2-yl)-phenyl]-2-phenylpropionic acid ethyl ester 5-[2-Hydroxy-4-(l-methyl-2-phenylethyl)-phenyl]-l,l-dioxo-l,2,5-thiadiazolidin-3-one
5 - { 2-Hydroxy-4-[2-(6-methoxypyridin-2-yl)-ethyl] -phenyl } - 1 , 1 -dioxo- 1,2,5- thiadiazolidin-3-one
5-[2-Hydroxy-4-((E)-2-pyridin-3-yl-vinyl)-phenyl]-l,l-dioxo-l,2,5-thiadiazolidin-3-one 5-[2-Hydroxy-4-(l-methoxy-2-phenylethyl)-phenyl]-l,l-dioxo-l,2,5-thiadiazolidin-3-one
5-[2-Hydroxy-4-(3-oxo-2-phenylbutyl)-phenyl]-l,l-dioxo-l,2,5-thiadiazolidin-3-one
5-{2-Hydroxy-4-[2-(2H-pyrazol-3-yl)-ethyl]-phenyl} -1,1 -dioxo- l,2,5-thiadiazolidin-3- one
5- {2-Hydroxy-4-[2-( 1 H-pyrazol-4-yl)-ethyl]-phenyl } - 1 , 1 -dioxo- 1 ,2,5-thiadiazolidin-3- one
5 - { 2-Hydroxy-4-[2-( 1 -methyl- 1 H-pyrazol-4-yl)-ethyl] -phenyl } - 1 , 1 -dioxo- 1,2,5- th iadiazolidin-3 -one
5-[2-Hydroxy-4-(2-thiazol-5-yl-ethyl)-phenyl]-l,l-dioxo-l,2,5-thiadiazolidin-3-one
5 - { 4-[2-(2,4-Dimethyl-thiazol-5 -yl)-ethyl] -2-hydroxyphenyl } - 1 , 1 -dioxo- 1 ,2,5 - th iadiazolidin-3 -one
5-[2-Hydroxy-4-(2-[ 1 ,2,4]triazol-yl-ethyl)-phenyl]- 1 , 1 -dioxo- 1 ,2,5-thiadiazolidin-3-one
5-[2-Hydroxy-4-(2-imidazol-l-yl-ethyl)-phenyl]-l,l -dioxo- l,2,5-thiadiazolidin-3-one
5-{2-Hydroxy-4-[2-(2-methyl-thiazol-5-yl)-ethyl]-phenyl}-l,l-dioxo-l,2,5- th iadiazolidin-3 -one 5 - { 2-Hydroxy-4-[2-(2-propyl-thiazol-5 -yl)-ethyl]-phenyl } - 1 , 1 -dioxo- 1,2,5- th iadiazolidin-3 -one
5-(2-Hydroxy-4-{2-[4-methyl-2-(4-trifluoromethyl-phenyl)-thiazol-5-yl]-ethyl}-phenyl)-
1 , 1 -dioxo- 1 ,2,5-thiadiazolidin-3-one
5-{2-Hydroxy-4-[2-(2-methyl-4-trifluoromethyl-thiazol-5-yl)-ethyl]-phenyl}-l,l-dioxo- l,2,5-thiadiazolidin-3-one
5-{4-[2-(lH-Benzoimidazol-2-yl)-ethyl]-2-hydroxyphenyl}-l,l-dioxo-l,2,5- th iadiazolidin-3 -one
5-[2-Hydroxy-4-(3-phenylpropyl)-phenyl]- 1,1 -dioxo- l,2,5-thiadiazolidin-3-one
5 - {4-[3 -(3,4-Dimethoxyphenyl)-propyl] -2-hydroxyphenyl } - 1 , 1 -dioxo- 1,2,5- thiadiazolidin-3-one
5-[2-Hydroxy-4-(2-methyl-3-phenylpropyl)-phenyl]-l,l-dioxo-l,2,5-thiadiazolidin-3-one 5-[2-Hydroxy-4-(3-hydroxy-3-phenylpropyl)-phenyl]-l,l-dioxo-l,2,5-thiadiazolidin-3- one
5-(2-Hydroxy-4-phenethyloxyphenyl)-l,l-dioxo-l,2,5-thiadiazolidin-3-one
5-[2-Hydroxy-4-(4-phenylbutyl)-phenyl]-l,l-dioxo-l,2,5-thiadiazolidin-3-one {3-[3-Hydroxy-4-(l,l,4-trioxo-l,2,5-thiadiazolidin-2-yl)-phenyl]-propyl}-carbamic acid tert-butyl ester
5-[4-(3-Aminopropyl)-2-hydroxyphenyl]-l,l-dioxo-l,2,5-thiadiazolidin-3-one
{2-[3-Hydroxy-4-(l,l,4-trioxo-l,2,5-thiadiazolidin-2-yl)-phenyl]-ethyl}-carbamic acid tert-butyl ester {(S)-l-Benzyl-2-[3-hydroxy-4-(l,l,4-trioxo-l,2,5-thiadiazolidin-2-yl)-phenyl]-ethyl}- carbamic acid tert-butyl ester
{3-[3-Hydroxy-4-(l,l,4-trioxo-l,2,5-thiadiazolidin-2-yl)-phenyl]-l,l-dimethylpropyl}- carbamic acid tert-butyl ester
2-{2-[3-Hydroxy-4-(l,l,4-trioxo-l,2,5-t hiadiazolidin-2-yl)-phenyl]-ethyl}-piperidine-l- carboxylic acid tert-butyl ester
2-{2-[3-Hydroxy-4-(l,l,4-trioxo-l,2,5-thiadiazolidin-2-yl)-phenyl]-ethyl}-azepane-l- carboxylic acid tert-butyl ester
3-[3-Hydroxy-4-(l,l,4-trioxo-l,2,5-thiadiazolidin-2-yl)-benzyl]-piperidine-l -carboxylic acid tert-butyl ester 5-(2-Hydroxy-4-piperidin-3-ylmethylphenyl)-l,l-dioxo-l,2,5-thiadiazolidin-3-one
{(lR*,2S*)-2-[3-Hydroxy-4-(l,l,4-trioxo-l,2,5-thiadiazolidin-2-yl)-benzyl]- cyclohexyl}-carbamic acid tert-butyl ester
N-{2-[3-Hydroxy-4-(l,l,4-trioxo-l,2,5-thiadiazolidin-2-yl)-phenyl]-ethyl}-benzamide
4-Fluoro-N-{2-[3-hydroxy-4-(l,l,4-trioxo-l,2,5-thiadiazolidin-2-yl)-phenyl]-ethyl}- benzamide
N-{2-[3-Hydroxy-4-(l,l,4-trioxo-l,2,5-thiadiazolidin-2-yl)-phenyl]-ethyl}-acetamide
N-{2-[3-Hydroxy-4-(l,l,4-trioxo-l,2,5-thiadiazolidin-2-yl)-phenyl]-ethyl}-propionamide
N-{2-[3-Hydroxy-4-(l,l,4-trioxo-l,2,5-thiadiazolidin-2-yl)-phenyl]-ethyl}-isobutyramide
N-{2-[3-Hydroxy-4-(l,l,4-trioxo-l,2,5-thiadiazolidin-2-yl)-phenyl]-ethyl}-2,2-dimethyl- propionamide Adamantane- 1 -carboxylic acid {2-[3-hydroxy-4-( 1 , 1 ,4-trioxo- 1 ,2,5-thiadiazolidin-2-yl)- pheny 1] -ethyl } -amide
N-{3-[3-Hydroxy-4-(l,l,4-trioxo-l,2,5-thiadiazolidin-2-yl)-phenyl]-propyl}-acetamide
4-Fluoro-N-{3-[3-hydroxy-4-(l,l,4-trioxo-l,2,5-thiadiazolidin-2-yl)-phenyl]-propyl}- benzamide
-{3-[3-Hydroxy-4-(l,l,4-trioxo-l,2,5-thiadiazolidin-2-yl)-phenyl]-propyl}-propionamide
N-{3-[3-Hydroxy-4-(l,l,4-trioxo-l,2,5-thiadiazolidin-2-yl)-phenyl]-propyl}- isobutyramide
N-{3-[3-Hydroxy-4-(l,l,4-trioxo-l,2,5-thiadiazolidin-2-yl)-phenyl]-propyl}-2,2- dimethyl-prop ionamide
Adamantane- 1 -carboxylic acid {3-[3-hydroxy-4-(l,l,4-trioxo-l,2,5-thiadiazolidin-2-yl)- pheny 1] -propyl } -amide
5-[2-Hydroxy-4-((S)-5-oxopyrrolidin-2-ylmethyl)-phenyl]-l,l-dioxo-l,2,5- thiadiazolidin-3-one 6-[3-Hydroxy-4-(l,l,4-trioxo-l,2,5-thiadiazolidin-2-yl)-benzyl]-lH-pyridin-2-one
6-[3-Hydroxy-4-(l,l,4-trioxo-l,2,5-thiadiazolidin-2-yl)-benzyl]-piperidin-2-orie
7-[3-Hydroxy-4-(l,l,4-trioxo-l,2,5-thiadiazolidin-2-yl)-benzyl]-azepan-2-one
(R)-3-[3-Hydroxy-4-(l,l,4-trioxo-l,2,5-thiadiazolidin-2-yl)-benzyl]-3,4-dihydro-2H- isoquinolin-1-one (S)-3-[3-Hydroxy-4-(l,l,4-trioxo-l,2,5-thiadiazolidin-2-yl)-benzyl]-2,3-dihydro- benzo[c]azepin- 1 -one
(R)-3-[3-Hydroxy-4-(l,l,4-trioxo-l,2,5-thiadiazolidin-2-yl)-benzyl]-2,3,4,5- tetrahydrobenzo[c]azepin-l-one l-[3-Hydroxy-4-(l,l,4-trioxo-l,2,5-thiadiazolidin-2-yl)-benzyl]-l,2,4,5- tetrahydrobenzo[c]azepin-3-one l-[3-Hydroxy-4-(l,l,4-trioxo-l,2,5-thiadiazolidin-2-yl)-benzyl]-l,3,4,5- tetrahydrobenzo[d]azepin-2-one
7-[3-Hydroxy-4-(l,l,4-trioxo-l,2,5-thiadiazolidin-2-yl)-benzyl]-6,7-dihydro- dibenzo[c,e]azepin-5-one (S)-7-[3-Hydroxy-4-(l,l,4-trioxo-l,2,5-thiadiazolidin-2-yl)-benzyl]-6,7-dihydro- dibenzo[c,e]azepin-5-one 3-[3-Hydroxy-4-( 1 , 1 ,4-trioxo- 1 ,2,5-thiadiazolidin-2-yl)-benzyl]-3,4-dihydro-2H- naphtho[ 1 ,8-cd]azepin- 1 -one
5-{4-[2-(l-Acetylpiperidin-2-yl)-ethyl]-2-hydroxyphenyl}-l,l-dioxo-l,2,5- thiadiazolidin-3-one N-{(lR*,2S*)-2-[3-Hydroxy-4-(l,l,4-trioxo-l,2,5-thiadiazolidin-2-yl)-benzyl]- cyclohexyl } -acetamide
N-{(S)-l-Benzyl-2-[3-hydroxy-4-(l,l,4-trioxo-l,2,5-thiadiazolidin-2-yl)-phenyl]-ethyl}-
2,2,2-trifluoroacetamide
N-{4-[3-Hydroxy-4-(l,l,4-trioxo-l,2,5-thiadiazolidin-2-yl)-phenyl]-butyl}-phthalamic acid
2-{4-[3-Hydroxy-4-(l,l,4-trioxo-l,2,5-thiadiazolidin-2-yl)-phenyl]-butyl}-isoindole-l,3- dione
3-[3-Hydroxy-4-( 1 , 1 ,4-trioxo- 1 ,2,5-thiadiazolidin-2-yl)-phenyl]-N-isopropyl-N- methylpropionamide 5-{4-[3-(3,4-Dihydro-lH-isoquinolin-2-yl)-3-oxopropyl]-2-hydroxyphenyl}-l,l-dioxo- l,2,5-thiadiazolidin-3-one
N'-{3-[3-Hydroxy-4-(l,l,4-trioxo-l,2,5-thiadiazolidin-2-yl)-phenyl]-propionyl}- hydrazinecarboxylic acid tert-butyl ester
N-Butyl-3-[3-hydroxy-4-(l,l,4-trioxo-l,2,5-thiadiazolidin-2-yl)-phenyl]-propionamide 3-[3-Hydroxy-4-( 1 , 1 ,4-trioxo- 1 ,2,5-thiadiazolidin-2-yl)-phenyl]-N-pentylpropionamide
N-Hexyl-3-[3-hydroxy-4-(l,l,4-trioxo-l,2,5-thiadiazolidin-2-yl)-phenyl]-propionamide
3-[3-Hydroxy-4-(l, 1 ,4-trioxo- 1 ,2,5-thiadiazolidin-2-yl)-phenyl]-N-(4-phenylbutyl)- propionamide
3-[3-Hydroxy-4-( 1 , 1 ,4-trioxo- 1 ,2,5-thiadiazolidin-2-yl)-phenyl]-N-(5-phenylpentyl)- propionamide
N-(2-Hydroxyphenyl)-3-[3-hydroxy-4-(l,l,4-trioxo-l,2,5-thiadiazolidin-2-yl)-phenyl]- propionamide
3-[3-Hydroxy-4-(l,l,4-trioxo-l,2,5-thiadiazolidin-2-yl)-phenyl]-N-phenylpropionamide
3-[3-Hydroxy-4-( 1 , 1 ,4-trioxo- 1 ,2,5-thiadiazolidin-2-yl)-phenyl]-N-o-tolyl-propionamide 3-[3-Hydroxy-4-( 1 , 1 ,4-trioxo- 1 ,2,5-thiadiazolidin-2-yl)-phenyl]-N-isopropyl- propionamide 2-{3-[3-Hydroxy-4-(l,l,4-trioxo-l,2,5-thiadiazolidin-2-yl)-phenyl]-propionylamino}-2- methylpropionic acid
2-Hydroxy-6-(4-{3-[3-hydroxy-4-(l,l,4-trioxo-l,2,5-thiadiazolidin-2-yl)-phenyl]- propionylamino}-butoxy)-benzoic acid methyl ester 2-(4-{3-[3-Hydroxy-4-(l,l ,4-trioxo-l ,2,5-thiadiazolidin-2-yl)-phenyl]-propionylamino}- butoxy)-benzoic acid methyl ester
2-(4-{3-[3-Hydroxy-4-(l,l,4-trioxo-l,2,5-thiadiazolidin-2-yl)-phenyl]-propionylamino}- butoxy)-benzoic acid
3-[3-Hydroxy-4-( 1 , 1 ,4-trioxo- 1 ,2,5-thiadiazolidin-2-yl)-phenyl]-N-(4-phenoxybutyl)- propionamide
3-[3-Hydroxy-4-(l,l ,4-trioxo-l,2,5-thiadiazolidin-2-yl)-phenyl]-N-[4-(2- trifluoromethylphenoxy)-butyl]-propionamide
3-[3-Hydroxy-4-(l,l ,4-trioxo-l,2,5-thiadiazolidin-2-yl)-phenyl]-N-[4-(2- methanesulfonylphenoxy)-butyl]-propionamide 3-[3-Hydroxy-4-(l,l,4-trioxo-l,2,5-thiadiazolidin-2-yl)-phenyl]-N-[4-(3- methoxyphenoxy)-butyl]-propionamide
N-[4-(2,3-Dimethoxyphenoxy)-butyl]-3-[3-hydroxy-4-(l,l,4-trioxo-l,2,5-thiadiazolidin-
2-yl)-phenyl]-propionamide
N-[4-(3-Hydroxyphenoxy)-butyl]-3-[3-hydroxy-4-( 1 , 1 ,4-trioxo- 1 ,2,5-thiadiazolidin-2- yl)-phenyl]-propionamide
N-[4-(2-Hydroxyphenoxy)-butyl]-3-[3-hydroxy-4-(l, 1 ,4-trioxo- 1,2, 5-thiadiazolidin-2- yl)-phenyl]-propionamide
N-[4-(3-Hydroxy-2-methoxyphenoxy)-butyl]-3-[3-hydroxy-4-( 1 , 1 ,4-trioxo- 1 ,2,5- thiadiazolidin-2-yl)-phenyl]-propionamide N-[4-(3-Hydroxy-2-methylphenoxy)-butyl]-3-[3-hydroxy-4-( 1 , 1 ,4-trioxo- 1 ,2,5- thiadiazolidin-2-yl)-phenyl]-propionamide
N-[4-(2-Acetyl-3-methoxyphenoxy)-butyl]-3-[3-hydroxy-4-(l, 1 ,4-trioxo- 1 ,2,5- thiadiazolidin-2-yl)-phenyl]-propionamide
2-Hydroxy-6-(4-{3-[3-hydroxy-4-( 1 , 1 ,4-trioxo- 1 ,2,5-thiadiazolidin-2-yl)-phenyl]- propionylamino}-butoxy)-N,N-dimethylbenzamide2-(4-{3-[3-Hydroxy-4-( 1 , 1 ,4-trioxo- l,2,5-thiadiazolidin-2-yl)-phenyl]-propionylamino}-butoxy)-6,N,N-trimethylbenzamide 2-Fluoro-6-(4-{3-[3-hydroxy-4-(l,l,4-trioxo-l,2,5-thiadiazolidin-2-yl)-phenyl]- propionylamino}-butoxy)-N,N-dimethylbenzamide
2-Hydroxy-6-(4-{3-[3-hydroxy-4-(l,l,4-trioxo-l,2,5-thiadiazolidin-2-yl)-phenyl]- propionylamino}-butoxy)-benzoic acid N-[4-(2-Acetyl-3-hydroxyphenoxy)-butyl]-3-[3-hydroxy-4-( 1,1, 4-trioxo- 1,2,5- thiadiazolidin-2-yl)-phenyl]-propionamide
N-[4-(2-Cyano-3-hydroxyphenoxy)-butyl]-3-[3-hydroxy-4-( 1,1, 4-trioxo- 1,2,5- thiadiazolidin-2-yl)-phenyl]-propionamide
N-[4-(3-Hydroxy-2-methanesulfinylphenoxy)-butyl]-3-[3-hydroxy-4-(l ,1 ,4-trioxo-l ,2,5- thiadiazolidin-2-yl)-phenyl]-propionamide
N-[4-(3-Hydroxy-2-methanesulfonylphenoxy)-butyl]-3-[3-hydroxy-4-(l ,1 ,4-trioxo-l ,2,5- thiadiazolidin-2-yl)-phenyl]-propionamide
2-(4-{2-Acetylamino-3-[3-hydroxy-4-(l,l,4-trioxo-l,2,5-thiadiazolidin-2-yl)-phenyl]- propionylamino}-butoxy)-6-hydroxybenzoic acid methyl ester 2-(4-{(S)-2-Acetylamino-3-[3-hydroxy-4-(l,l,4-trioxo-l,2,5-thiadiazolidin-2-yl)- phenyl]-propionylamino}-butoxy)-6-hydroxybenzoic acid methyl ester
3-[3-Hydroxy-4-(l ,1 ,4-trioxo-l ,2,5-thiadiazolidin-2-yl)-phenyl]-propionic acid methyl ester
3-[3-Hydroxy-4-(l, 1, 4-trioxo- l,2,5-thiadiazolidin-2-yl)-phenyl]-2-methylpropionic acid methyl ester
3-[3-Hydroxy-4-(l,l,4-trioxo-l,2,5-thiadiazolidin-2-yl)-phenyl]-2-methylpropionic acid tert-butyl ester
( 1 R* ,2R*)-2-[3 -Hydroxy-4-( 1 , 1 ,4-trioxo- 1 ,2,5 -thiadiazol idin-2-y l)-pheny 1] - cyclopropanecarboxylic acid ethyl ester (lR*,2S*)-2-[3-Hydroxy-4-( 1,1, 4-trioxo- l,2,5-thiadiazolidin-2-yl)-phenyl]- cyclopropanecarboxylic acid ethyl ester
N-[3-Hydroxy-4-(l,l,4-trioxo-l,2,5-thiadiazolidin-2-yl)-benzyl]-N- methylbenzenesulfonamide
N-[3-Hydroxy-4-(l ,1 ,4-trioxo-l ,2,5-thiadiazolidin-2-yl)-benzyl]-N- methylmethanesulfonamide C-Cyclohexyl-N-{2-[3-hydroxy-4-(l,l,4-trioxo-l,2,5-thiadiazolidin-2-yl)-phenyl]-ethyl}- methanesulfonamide
N-{2-[3-Hydroxy-4-(l,l,4-trioxo-l,2,5-thiadiazolidin-2-yl)-phenyl]-ethyl}- methansulfonamide Ethanesulfonic acid {2-[3-hydroxy-4-(l,l,4-trioxo-l,2,5-thiadiazolidin-2-yl)-phenyl]- ethyl} -amide
Butane- 1 -sulfonic acid {2-[3-hydroxy-4-(l,l,4-trioxo-l,2,5-thiadiazolidin-2-yl)-phenyl]- ethyl} -amide
Propane-2-sulfonic acid {2-[3-hydroxy-4-(l,l,4-trioxo-l,2,5-thiadiazolidin-2-yl)-phenyl]- ethyl} -amide
Octane- 1 -sulfonic acid {2-[3-hydroxy-4-(l,l,4-trioxo-l,2,5-thiadiazolidin-2-yl)-phenyl]- ethyl} -amide
N-{2-[3-Hydroxy-4-(l,l,4-trioxo-l,2,5-thiadiazolidin-2-yl)-phenyl]-ethyl}- benzenesulfonamide N-{2-[3-Hydroxy-4-(l,l,4-trioxo-l,2,5-thiadiazolidin-2-yl)-phenyl]-ethyl}-C-phenyl- methansulfonamide
4-Fluoro-N-{2-[3-hydroxy-4-(l,l,4-trioxo-l,2,5-thiadiazolidin-2-yl)-phenyl]-ethyl}- benzenesulfonamide
3,4-Dichloro-N-{2-[3-hydroxy-4-(l,l,4-trioxo-l,2,5-thiadiazolidin-2-yl)-phenyl]-ethyl}- benzenesulfonamide
3-(4-{2-[3-Hydroxy-4-(l,l,4-trioxo-l,2,5-thiadiazolidin-2-yl)-phenyl]-ethylsulfamoyl}- phenyl)-propionic acid
2-Hydroxy-5-{2-[3-hydroxy-4-(l,l,4-trioxo-l,2,5-thiadiazolidin-2-yl)-phenyl]- ethylsulfamoyl}-benzoic acid Naphthalene- 1 -sulfonic acid {2-[3-hydroxy-4-(l,l,4-trioxo-l,2,5-thiadiazolidin-2-yl)- phenyl] -ethyl } -amide
2-Naphthalen-l-yl-ethanesulfonic acid {2-[3-hydroxy-4-(l,l,4-trioxo-l,2,5- thiadiazolidin-2-yl)-phenyl]-ethyl}-amide
N-{3-[3-Hydroxy-4-(l,l,4-trioxo-l,2,5-thiadiazolidin-2-yl)-phenyl]-propyl}- methansulfonamide N-{3-[3-Hydroxy-4-(l , 1 ,4-trioxo- 1 ,2,5-thiadiazolidin-2-yl)-phenyl]-propyl}- benzenesulfonamide
N-fS-tS-Hydroxy^-C^l^-trioxo-l^^-thiadiazolidin^-yO-pheny^-propylJ-C- phenylmethanesulfonamide C-(4-Fluorophenyl)-N-{3-[3-hydroxy-4-(l , 1 ,4-trioxo-l ,2,5-thiadiazolidin-2-yl)-phenyl]- propyl } -methanesulfonamide
N- { 3 -[3-Hydroxy-4-( 1 , 1.,4-trioxo- 1 ,2 ,5 -thiadiazolidin-2-y l)-pheny 1] -propyl } -4- isopropylbenzenesulfonamide
N-{3-[3-Hydroxy-4-(l,l,4)-trioxo-l ,2,5-thiadiazolidin-2-yl)-phenyl]-propyl}-4- trifluoromethylbenzenesulfonamide
N-{3-[3-Hydroxy-4-(l , 1 ,4-trioxo-l ,2, 5-thiadiazolidin-2-yl)-phenyl]-propyl}-4- trifluoromethoxybenzenesulfonamide
C-(3-Aminophenyl)-N-{3-[3-hydroxy-4-(l,l ,4-trioxo-l,2,5-thiadiazolidin-2-yl)-phenyl]- propyl}-methanesulfonamide N-{3-[3-Hydroxy-4-(l,l,4-trioxo-l,2,5-thiadiazolidin-2-yl)-phenyl]-propyl}-2,4,6- triisopropylbenzenesulfonamide
2-Hydroxy-5-{3-[3-hydroxy-4-(l,l ,4-trioxo-l ,2,5-thiadiazolidin-2-yl)-phenyl]- propylsulfamoyl} -benzoic acid
3-Amino-N-{3-[3-hydroxy-4-(l , 1 ,4-trioxo-l ,2,5-thiadiazolidin-2-yl)-phenyl]-propyl}- benzenesulfonamide
4-Amino-N-{3-[3-hydroxy-4-(l , 1 ,4-trioxo-l ,2, 5-thiadiazolidin-2-yl)-phenyl]-propyl}- benzenesulfonamide
N-{3-[3-Hydroxy-4-(l,l,4-trioxo-l,2,5-thiadiazolidin-2-yl)-phenyl]-propyl}-3,5- dimethylbenzenesulfonamide N-{3-[3-Hydroxy-4-(l,l,4-trioxo-l,2,5-thiadiazolidin-2-yl)-phenyl]-propyl}-2,5- dimethylbenzenesulfonamide
N-{3-[3-Hydroxy-4-(l ,l,4-trioxo-l,2,5-thiadiazolidin-2-yl)-phenyl]-propyl}-2,4,6- trimethylbenzenesulfonamide
4-tert-Butyl-N-{3-[3-hydroxy-4-(l , 1 ,4-trioxo- 1 ,2,5-thiadiazolidin-2-yl)-phenyl]-propyl}- benzenesulfonamide 4-( 1 , 1 -Dimethylpropyl)-N-{3-[3-hydroxy-4-( 1 , 1 ,4-trioxo- 1 ,2,5-thiadiazolidin-2-yl)- phenyl] -propyl }-benzenesulfonamide
N-{3-[3-Hydroxy-4-(l,l,4-trioxo-l,2,5-thiadiazolidin-2-yl)-phenyl]-propyl}-3,4- dimethoxybenzenesulfonamide N-{3-[3-Hydroxy-4-(l,l,4-trioxo-l,2,5-thiadiazolidin-2-yl)-phenyl]-propyl}-2,5-bis-
(2,2,2-trifluoroethoxy)-benzenesulfonamide
Biphenyl-4-sulfonic acid {3-[3-hydroxy-4-(l,l,4-trioxo-l,2,5-thiadiazolidin-2-yl)- phenyl] -propyl } -amide
N-{3-[3-Hydroxy-4-(l,l,4-trioxo-l,2,5-thiadiazolidin-2-yl-phenyl]-propyl}-2- phenoxybenzenesulfonamide
N-{3-[3-Hydroxy-4-(l,l,4-trioxo-l,2,5-thiadiazolidin-2-yl)-phenyl]-propyl}-3- phenoxybenzenesulfonamide
N-{3-[3-Hydroxy-4-(l,l,4-trioxo-l,2,5-thiadiazolidin-2-yl)-phenyl]-propyl}-2,5-bis-
(2,2,2-trifluoroethoxy)-benzenesulfonamide 2,2-Diphenylethanesulfonic acid {3-[3-hydroxy-4-(l,l,4-trioxo-l,2,5-thiadiazolidin-2- yl)-phenyl]-propyl} -amide
C-(2-Aminophenyl)-N{3-[3-hydroxy-4-(l,l,4-trioxo-l,2,5-thiadiazolidin-2-yl)-phenyl]- proρyl}-methanesulfonamide
Naphthalene- 1 -sulfonic acid {3-[3-hydroxy-4-( 1 , 1 ,4-trioxo- 1 ,2,5-thiadiazolidin-2-yl)- phenyl]-propyl}-amide
C-Cyclohexyl-N-IS-^-hydroxy^^lJ^-trioxo-l^^-thiadiazolidin^-yO-phenyl]- propyl}-methanesulfonamide
2-Naphthalen-l-yl-ethanesulfonic acid {3-[3-hydroxy-4-( 1,1, 4-trioxo- 1,2,5- thiadiazolidin-2-yl)-phenyl]-propyl} -amide 2-Phenyl-2-(2-trifluoromethylphenyl)-ethanesulfonic acid {3-[3-hydroxy-4-(l,l,4-trioxo- l,2,5-thiadiazolidin-2-yl)-phenyl]-propyl} -amide
2-Oxo-2H-chomene-6-sulfonic acid {3-[3-hydroxy-4-(l , 1 ,4-trioxo- 1 ,2,5-thiadiazolidin-2- yl)-phenyl]-propyl} -amide
N-{3-[3-Hydroxy-4-(l,l,4-trioxo-l,2,5-thiadiazolidin-2-yl)-phenylpropyl}-N- isopropylbenzenesulfonamide N-(l-{2-[3-Hydroxy-4-(l,l,4-trioxo-l,2,5-thiadiazolidin-2-yl)-phenyl]-ethyl}- cyclopropyl)-benzenesulfonamide
N-{(S)-l-Benzyl-2-[3-hydroxy-4-(l,l,4-trioxo-l,2,5-thiadiazolidin-2-yl)-phenyl]-ethyl}- methanesulfonamide Ethanesulfonic acid {(S)-l-benzyl-2-[3-hydroxy-4-(l,l,4-trioxo-l,2,5-thiadiazolidin-2- y l)-phenyl] -ethyl } -amide
N-ICSVl-Benzyl^-fS-hydroxy^-ClJ^-trioxo-l^^-thiadiazolidin^-yO-phenylj-ethyl}-
C-phenyl-methanesulfonamide
N-ICR^l-Benzyl^-P-hydroxy^-ClJ^-trioxo-l^^-thiadiazolidin^-yO-phenylJ-ethyl}- C-phenylmethanesulfonamide
N-{4-[3-Hydroxy-4-(l,l,4-trioxo-l,2,5-thiadiazolidin-2-yl)-phenyl]-butyl}- methanesulfonamide
N-{5-[3-Hydroxy-4-(l,l,4-trioxo-l,2,5-thiadiazolidin-2-yl)-phenyl]-pentyl}- methanesulfonamide 5-[2-Hydroxy-4-( 1 -methanesulfonylpiperidin-3-ylmethyl)-phenyl]- 1 , 1 -dioxo- 1,2,5- thiadiazolidin-3-one
5-{2-Hydroxy-4-[2-(l-methanesulfonylpiperidin-2-yl)-ethyl]-phenyl}-l,l-dioxo-l,2,5- thiadiazolidin-3-one
5-{4-[2-(l-Benzenesulfonylpiperidin-2-yl)-ethyl]-2-hydroxyphenyl}-l,l-dioxo-l,2,5- thiadiazolidin-3-one
5-{4-[2-((S)-l-Benzenesulfonylpiperidin-2-yl)-ethyl]-2-hydroxyphenyl}- 1,1 -dioxo- 1,2,5- thiadiazolidin-3-one
5-{4-[2-((R)-l-Benzenesulfonylpiperidin-2-yl)-ethyl]-2-hydroxyphenyl}- 1,1 -dioxo- 1,2,5- thiadiazolidin-3-one 5 - { 4-[2-( 1 -Benzenesulfony lpyrrolidin-2-y l)-ethy 1] -2-hydroxypheny 1 } - 1 , 1 -dioxo- 1,2,5- thiadiazolidin-3-one
5- {4-[2-( 1 -Benzenesulfonyl- 1 H-pyrrol-2-yl)-ethyl]-2-hydroxyphenyl} - 1 , 1 -dioxo- 1 ,2,5- thiadiazolidin-3-one
5-{4-[2-(l-Benzenesulfonylpyrrolidin-3-yl)-ethyl]-2-hydroxyphenyl}- 1,1 -dioxo- 1,2,5- thiadiazolidin-3-one 5- {4-[2-( 1 -Benzenesulfonylazepan-2-yl)-ethyl]-2-hydroxyphenyl}- 1 , 1 -dioxo- 1,2,5- thiadiazolidin-3 -one
5-{2-Hydroxy-4-[2-((R)-2-methanesulfonyl-l,2,3,4-tetrahydroisoquinolin-3-yl)-ethyl]- phenyl } - 1 , 1 -dioxo- 1 ,2,5 -thiadiazolidin-3 -one 5-{4-[2-((R)-2-Benzenesulfonyl-l,2,3,4-tetrahydroisoquinolin-3-yl)-ethyl]-2- hydroxyphenyl}-l,l-dioxo-l,2,5-thiadiazolidin-3-one
5-(2-Hydroxy-4-{2-[2-(4-trifluoromethylbenzenesulfonyl)-l,2,3,4-tetrahydroisoquinolin-
3-yl]-ethyl}-phenyl)-l,l-dioxo-l,2,5-thiadiazolidin-3-one
5-{2-Hydroxy-4-[2-(2-phenylmethanesulfonyl-l,2,3,4-tetrahydroisoquinolin-3-yl)-ethyl]- phenyl}- 1,1 -dioxo- 1, 2, 5-thiadiazolidin-3-one
5-{4-[2-( 1,1 -Dioxo- l,2-thiazinan-3-yl)-ethyl]-2-hydroxyphenyl}- 1,1 -dioxo- 1,2,5- thiadiazolidin-3-one
N-{(lR*,2S*)-2-[3-Hydroxy-4-(l,l,4-trioxo-l,2,5-thiadiazolidin-2-yl)-benzyl]- cyclohexyl}-methanesulfonamide N-{(lR,2S)-2-[3-Hydroxy-4-(l,l,4-trioxo-l,2,5-thiadiazolidin-2-yl)-benzyl]- cyclohexyl}-methanesulfonamide
N-{(lS,2R)-2-[3-Hydroxy-4-(l,l,4-trioxo-l,2,5-thiadiazolidin-2-yl)-benzyl]- cyclohexyl}-methanesulfonamide
Ethanesulfonic acid {( 1 R*,2S*)-2-[3-hydroxy-4-( 1 , 1 ,4-trioxo- 1 ,2,5-thiadiazolidin-2-yl)- benzyl]-cyclohexyl}-amide N-{(lR*,2S*)-2-[3-Hydroxy-4-(l,l,4-trioxo-l,2,5- thiadiazolidin-2-yl)-benzyl]-cyclohexyl}-benzenesulfonamide
(S)-2-Benzenesulfonylamino-3-[3-hydroxy-4-(l,l,4-trioxo-l,2,5-thiadiazolidin-2-yl)- phenyl]-N-pentylpropionamide
(S)-2-Benzenesulfonylamino-3-[3-hydroxy-4-(l,l,4-trioxo-l,2,5-thiadiazolidin-2-yl)- phenyl]-N-(4-phenylbutyl)-propionamide
N-{(S)-l-(lH-Benzoimidazol-2-yl)-2-[3-hydroxy-4-(l,l,4-trioxo-l,2,5-thiadiazolidin-2- yl)-phenyl]-ethyl}-benzenesulfonamide tert-Buty\ [({2-[4-(l,l-dioxido-4-oxo-l,2,5-thiadiazolidin-2-yl)-3- hydroxyphenyl]ethyl}amino)sulfonyl]carbamate l-Cyclohexyl-3-{2-[3-hydroxy-4-(l,l,4-trioxo-l,2,5-thiadiazolidin-2-yl)-phenyl]-ethyl}- urea l-{2-[3-Hydroxy-4-(l,l,4-trioxo-l,2,5-thiadiazolidin-2-yl)-phenyl]-ethyl}-3-phenyl-urea l-Ethyl-3-{2-[3-hydroxy-4-(l,l,4-trioxo-l,2,5-thiadiazolidin-2-yl)-phenyl]-ethyl}-urea l-Adamantan-l-yl-3-{2-[3-hydroxy-4-(l,l,4-trioxo-l,2,5-thiadiazolidin-2-yl)-phenyl]- ethyl}-urea Benzenesulfonyl-N- {2-[3-hydroxy-4-( 1 , 1 ,4-trioxo- 1 ,2,5-thiadiazolidin-2-yl)-phenyl]- ethyl}-urea
1 -(2,4-Dimethoxybenzyl)-3-{2-[3-hydroxy-4-( 1 , 1 ,4-trioxo- 1 ,2,5-thiadiazolidin-2-yl)- phenyl] -ethyl } -urea
1 -(2-Hydroxyethyl)-3-{2-[3-hydroxy-4-( 1 , 1 ,4-trioxo- 1 ,2,5-thiadiazolidin-2-yl)-phenyl]- ethyl} -urea
3-{2-[3-Hydroxy-4-(l , 1 ,4-trioxo-l ,2,5-thiadiazolidin-2-yl)-phenyl]-ethyl}- 1 , 1 -bis-(2- methoxyethyl)-urea
Moφholine-4-carboxylic acid {2-[3-hydroxy-4-( 1 , 1 ,4-trioxo- 1 ,2,5-thiadiazolidin-2-yl)- pheny 1] -ethyl } -amide 4-(3-{2-[3-Hydroxy-4-(l ,l,4-trioxo-l,2,5-thiadiazolidin-2-yl)-phenyl]-ethyl}-ureido)- piperidine-1-carboxylic acid tert-butyl ester l-{2-[3-Hydroxy-4-(l , 1 ,4-trioxo-l ,2,5-thiadiazolidin-2-yl)-phenyl]-ethyl}-3-piperidin-4- yl-urea
1 -{3-[3-Hydroxy-4-(l, 1 ,4-trioxo-l ,2, 5-thiadiazolidin-2-yl)-phenyl]-propyl}-3-phenyl- urea l-Cyclohexyl-S-IS-tS-hydroxy^-ClJ^-trioxo-l^^-thiadiazolidin^-yO-phenyl]- propyl}-urea
■l-Adamantan-l-yl-3-{3-[3-hydroxy-4-(l,l,4-trioxo-l,2,5-thiaidiazolidin-2-yl)-phenyl]- propyl}-urea 3-{3-[3-Hydroxy-4-(l,l,4-trioxo-l,2,5-thiadiazolidin-2-yl)-phenyl]-propyl}-lH- quinazoline-2,4-dione
S-tS-Hydroxy^-C^l^-trioxo-l^^-thiadiazolidin^-yO-benzyπ-piperidine-l-carboxylic acid ethylamide
5-(2-Hydroxy-4-methanesulfonylmethylphenyl)- 1 , 1 -dioxo- 1 ,2,5-thiadiazolidin-3-one 5-(4-Ethanesulfonylmethyl-2-hydroxy-phenyl)- 1 , 1 -dioxo- 1 ,2,5-thiadiazolidin-3-one 5-[2-Hydroxy-4-(propane-2-sulfonylmethyl)-phenyl]-l,l-dioxo-l,2,5-thiadiazolidin-3- one
5-(4-Benzenesulfonylmethyl-2-hydroxyphenyl)- 1 , 1 -dioxo- 1 ,2,5-thiadiazolidin-3-one 5-(2-Hydroxy-4-methanesulfinylmethylphenyl)-l,l-dioxo-l,2,5-thiadiazolidin-3-one 5-(4-Ethanesulfinylmethyl-2-hydroxyphenyl)- 1,1 -dioxo- l,2,5-thiadiazolidin-3-one
5-[2-Hydroxy-4-(propane-2-sulfinylmethyl)-phenyl]- 1,1 -dioxo- l,2,5-thiadiazolidin-3-one 5-(2-Hydroxy-4-methy lsulfanylmethylphenyl)- 1 , 1 -dioxo- 1 ,2,5-thiadiazolidin-3-one 5-(4-Ethylsulfanylmethyl-2-hydroxyphenyl)- 1,1 -dioxo- l,2,5-thiadiazolidin-3-one 5-(2-Hydroxy-4-isopropylsulfany lmethylphenyl)- 1 , 1 -dioxo- 1 ,2,5-thiadiazolidin-3-one 5-[4-(2-Benzenesulfonylethyl)-2-hydroxyphenyl]- 1,1 -dioxo- l,2,5-thiadiazolidin-3-one 5-[4-(4-Benzenesulfonylbutyl)-2-hydroxyphenyl]- 1 , 1 -dioxo- 1 ,2,5-thiadiazolidin-3-one 5- {4-[3-( 1 , 1 -Dioxotetrahydrothiophen-2-yl)-prop- 1 -ynyl]-2-hydroxyphenyl } - 1 , 1 -dioxo- l,2,5-thiadiazolidin-3-one 5-{4-[3-( 1,1 -Dioxotetrahydrothiophen-2-yl)-propyl]-2-hydroxyphenyl}- 1,1 -dioxo- 1,2,5- thiadiazolidin-3-one
5-[2-Hydroxy-4-(3-oxopentyl)-phenyl]- 1,1 -dioxo- l,2,5-thiadiazolidin-3-one 5-[2-Hydroxy-4-(2-methyl-3-oxopentyl)-phenyl]-l,l-dioxo-l,2,5-thiadiazolidin-3-one 5-[2-Hydroxy-4-(2-methyl-3-oxo-3-phenylpropyl)-phenyl]- 1,1 -dioxo- 1,2,5- thiadiazolidin-3 -one 5-[4-(2-Benzoylbutyl)-2-hydroxyphenyl]- 1,1 -dioxo- l,2,5-thiadiazolidin-3-one 5-[4-(2-Benzoylpentyl)-2-hydroxyphenyl]- 1,1 -dioxo- l,2,5-thiadiazolidin-3-one 5-[2-Hydroxy-4-(3 -oxo-2,3-diphenylpropyl)-phenyl]- 1 , 1 -dioxo- 1 ,2,5-thiadiazolidin-3- one 5-[4-(2-Benzyl-3-oxo-3-phenylpropyl)-2-hydroxyphenyl]- 1,1 -dioxo- 1,2,5-thiadiazolidin- 3-one
5-[4-(2,2-Dimethyl-3-oxo-3-phenylpropyl)-2-hydroxyphenyl]- 1,1 -dioxo- 1,2,5- thiadiazolidin-3-one
5-[2-Hydroxy-4-( 1 -oxo-indan-2-ylmethyl)-phenyl]- 1 , 1 -dioxo- 1 ,2,5-thiadiazolidin-3-one
5-[2-Hydroxy-4-(6-oxo-6,7,8,9-tetrahydro-5H-benzocyclohepten-5-ylmethyl)-phenyl]- 1,1 -dioxo- 1 ,2,5-thiadiazolidin-3-one 5-[2-Hydroxy-4-(2-methoxy-3-oxo-3-phenylpropyl)-phenyl]- 1 , 1 -dioxo- 1 ,2,5- thiadiazolidin-3-one
5-[2-Hydroxy-4-(3-hydroxy-2-methyl-3-phenylpropyl)-phenyl]-l,l-dioxo-l,2,5- thiadiazolidin-3-one 5-{2-Hydroxy-4-[2-(hydroxylphenylmethyl)-butyl]-phenyl}-l,l-dioxo-l,2,5- thiadiazolidin-3-one
5-{2-Hydroxy-4-[2-(hydroxyphenylmethyl)-pentyl]-phenyl}-l,l-dioxo-l,2,5- thiadiazolidin-3-one
5-[4-(2-Benzyl-3-hydroxy-3-phenylpropyl)-2-hydroxyphenyl]- 1,1 -dioxo- 1,2,5- thiadiazolidin-3-one
5-[2-Hydroxy-4-(3-hydroxy-2,2-dimethyl-3-phenylpropyl)-phenyl]-l,l-dioxo-l,2,5- thiadiazolidin-3-one
5-[2-Hydroxy-4-( 1 -hydroxyindan-2-ylmethyl)-phenyl]- 1 , 1 -dioxo- 1 ,2,5-thiadiazolidin-3- one 5-[2-Hydroxy-4-(3-hydroxy-2-methoxy-3-phenyl-propyl)-phenyl]- 1,1 -dioxo- 1,2,5- thiadiazolidin-3-one
5-(2-Hydroxy-4-vinylphenyl)-l,l-dioxo-l,2,5-thiadiazolidin-3-one
5-[2-Hydroxy-4-( 1 -hydroxyethyl)-phenyl]- 1 , 1 -dioxo- 1 ,2,5-thiadiazolidin-3-one
5-[2-Hydroxy-4-(2-hydroxyhexyl)-phenyl]- 1 , 1 -dioxo- 1 ,2,5-thiadiazolidin-3-one 5-[2-Hydroxy-4-(3-hydroxybutyl)-phenyl]- 1,1 -dioxo- l,2,5-thiadiazolidin-3-one
5-{2-Hydroxy-4-[2-(l-hydroxycyclohexyl)-ethyl]-phenyl} -1,1 -dioxo- 1,2,5- thiadiazolidin-3-one
5-[2-Hydroxy-4-(4,4,4-trifluoro-3-hydroxy-3-phenylbutyl)-phenyl]- 1,1 -dioxo- 1,2,5- thiadiazolidin-3-one 5-(3-Hydroxybiphenyl-4-yl)-l,l-dioxo-l,2,5-thiadiazolidin-3-one
5-(3,3'-Dihydroxybiphenyl-4-yl)-l,l-dioxo-l,2,5-thiadiazolidin-3-one
[3'-Hydroxy-4'-(l,l,4-trioxo-l,2,5-thiadiazolidin-2-yl)-biphenyl-4-yl]-acetic acid
5,5'-(3,3'-Dihydroxybiphenyl-4-yl)-l,l,l ',l '-tetraoxo-l,l ',2,2',5,5'-dithiadiazolidin-
3,3 '-one 5-(4-Furan-3-yl-2-hydroxyphenyl)-l,l-dioxo-l,2,5-thiadiazolidin-3-one
5-(2-Hydroxy-4-thiophen-3-yl-phenyl)-l,l-dioxo-l,2,5-thiadiazolidin-3-one 5-(4-Benzoftιran-3-yl-2-hydroxyphenyl)- 1 , 1 -dioxo- 1 ,2,5-thiadiazolidin-3-one 5-[2-Hydroxy-4-(6-methoxybenzofiiran-3-yl)-phenyl]- 1 , 1 -dioxo- 1 ,2,5-thiadiazolidin-3- one
5-(2-Hydroxy-4-thiazol-5-yl-phenyl)-l,l-dioxo-l,2,5-thiadiazolidin-3-one 5-(2-Hydroxy-4-thiazol-2-yl-phenyl)- 1 , 1 -dioxo- 1 ,2,5-thiadiazolidin-3-one
5-[2-Hydroxy-4-(lH-pyrrol-3-yl)-phenyl]- 1,1 -dioxo- l,2,5-thiadiazolidin-3-one 5-[2-Hydroxy-4-( 1 H-pyrazol-3-yl)-phenyl]- 1 , 1 -dioxo- 1 ,2,5-thiadiazolidin-3-one 5-[2-Hydroxy-4-( 1 H-pyrazol-4-yl)-phenyl]- 1 , 1 -dioxo- 1 ,2,5-thiadiazolidin-3-one 5-[2-Hydroxy-4-( 1 -propyl- lH-pyrazol-4-yl)-phenyl]- 1 , 1 -dioxo- 1 ,2,5-thiadiazolidin-3-one 5-[2-Hydroxy-4-(l-isobutyl-lH-pyrazol-4-yl)-phenyl]-l,l-dioxo-l,2,5-thiadiazolidin-3- one
5-{2-Hydroxy-4-[ 1 -(3-methylbutyl)- 1 H-pyrazol-4-yl] -phenyl}- 1 , 1 -dioxo- 1 ,2,5- thiadiazolidin-3-one 5-[2-Hydroxy-4-(tetrahydroftιran-3-yl)-phenyl]- 1,1 -dioxo- l,2,5-thiadiazolidin-3-one 5-[4-(2,3-Dihydrobenzofuran-3-yl)-2-hydroxyphenyl]- 1,1 -dioxo- l,2,5-thiadiazolidin-3- one
5-(2-Hydroxy-4-thiazol-2-ylmethylphenyl)- 1,1 -dioxo- l,2,5-thiadiazolidin-3-one 5-[2-Hydroxy-4-(2H-pyrazol-3-ylmethyl)-phenyl]- 1 , 1 -dioxo- 1 ,2,5-thiadiazolidin-3-one 5-(2-Hydroxy-4-pyrazol- 1 -ylmethyl-phenyl)- 1 , 1 -dioxo- 1 ,2,5-thiadiazolidin-3-one 5-[2-Hydroxy-4-(3-trifluoromethylpyrazole-l-ylmethyl)-phenyl]- 1,1 -dioxo- 1,2,5- thiadiazolidin-3-one
5-[3-Hydroxy-4-(l,l,4-trioxo-l,2,5-thiadiazolidin-2-yl)-phenyl]-pentanoic acid 4-[3-Hydroxy-4-( 1 , 1 ,4-trioxo- 1 ,2,5-thiadiazolidin-2-yl)-phenyl]-butane- 1 -sulfinic acid 4-[3-Hydroxy-4-(l,l,4-trioxo-l,2,5-thiadiazolidin-2-yl)-phenyl]-butyronitrile 4-[3-Hydroxy-4-( 1 , 1 ,4-trioxo- 1 ,2,5-thiadiazolidin-2-yl)-phenyl]-2-methyl-butyronitrile 4-[3-Hydroxy-4-( 1 , 1 ,4-trioxo- 1 ,2,5-thiadiazolidin-2-yl)-phenyl]-3,3- dimethylbutyronitrile
[3-Hydroxy-4-( 1 , 1 ,4-trioxo- 1 ,2,5-thiadiazolidin-2-yl)-phenoxy]-acetic acid 2- trimethylsilanylethyl ester [3-Hydroxy-4-( 1 , 1 ,4-trioxo- 1 ,2,5-thiadiazolidin-2-yl)-phenoxy]-acetic acid 3-[3-Hydroxy-4-(l,l,4-trioxo-l,2,5-thiadiazolidin-2-yl)-phenoxy]-l,3,4,5-tetrahydro- benzo[b]azepin-2-one
5-(4-Ethyl-2-hydroxyphenyl)-l,l-dioxo-l,2,5-thiadiazolidin-3-one 5 -(4-Hexyl -2-hydroxyphenyl)- 1 , 1 -dioxo- 1 ,2,5 -thiadiazol idin-3 -one 5-(2-Hydroxy-4-isobutylphenyl)- 1 , 1 -dioxo- 1 ,2,5-thiadiazolidin-3 -one
5-[4-(3,3-Dimethylbutyl)-2-hydroxyphenyl]- 1,1 -dioxo- l,2,5-thiadiazolidin-3-one 5-[2-Hydroxy-4-(3,3,3-trifluoropropyl)-phenyl]- 1,1 -dioxo- l,2,5-thiadiazolidin-3-one 5-(4-Cyclopentylmethyl-2-hydroxyphenyl)- 1 , 1 -dioxo- 1 ,2,5-thiadiazolidin-3-one 5-(4-Cyclohexylmethyl-2-hydroxyphenyl)- 1,1 -dioxo- l,2,5-thiadiazolidin-3-one 5-{2-Hydroxy-4-[l-(2,4,6-trimethylphenyl)-ethyl]-phenyl}-l,l-dioxo-l,2,5- thiadiazolidin-3-one
5-[4-(2-Aminobenzyl)-2-hydroxyphenyl]- 1,1 -dioxo- l,2,5-thiadiazolidin-3-one 5-[2-Hydroxy-4-(2-hydroxybenzyl)-phenyl]- 1 , 1 -dioxo- 1 ,2,5-thiadiazolidin-3 -one 5-[2-Hydroxy-4-(2-hydroxy-5-methylbenzyl)-phenyl]- 1,1 -dioxo- 1, 2,5-thiadiazolidin-3- one
5-[4-(2-Aminomethylbenzyl)-2-hydroxyphenyl]-l,l -dioxo- l,2,5-thiadiazolidin-3-one 5-[2-Hydroxy-4-(2-methoxymethylbenzyl)-phenyl]- 1,1 -dioxo- 1,2,5 -thiadiazol idin-3 -one {2-[3 -Hydroxy-4-( 1 , 1 ,4-trioxo- 1 ,2,5-thiadiazolidin-2-yl)-benzyl]-phenyl} -acetonitrile {2-[3 -Hydroxy-4-( 1 , 1 ,4-trioxo- 1 ,2,5-thiadiazolidin-2-yl)-benzyl]-phenyl } -acetic acid methyl ester
{2-[3-Hydroxy-4-(l,l,4-trioxo-l,2,5-thiadiazolidin-2-yl)-benzyl]-phenyl} -acetic acid N-Ethyl-2-{2-[3-hydroxy-4-(l,l,4-trioxo-l,2,5-thiadiazolidin-2-yl)-benzyl]-phenyl}- acetamide 5-(2-Hydroxy-4-{2-[2-(4-methylpiperidin-l-yl)-2-oxo-ethyl]-benzyl}-phenyl)-l,l-dioxo- l,2,5-thiadiazolidin-3-one
5-{2-Hydroxy-4-[2-(2-hydroxyethyl)-benzyl]-phenyl}- 1,1 -dioxo- l,2,5-thiadiazolidin-3- one
5-[2-Hydroxy-4-(pyridine-2-carbonyl)-phenyl]- 1,1 -dioxo- l,2,5-thiadiazolidin-3-one
5 -(4-Benzenesulfonyl-2-hydroxyphenyl)- 1 , 1 -dioxo- 1 ,2,5 -thiadiazol idin-3 -one 5 -(2-Hydroxy-4-trifluoromethylphenyl)- 1 , 1 -dioxo- 1 ,2,5 -thiadiazol idin-3-one 5-(2-Hydroxy-4-methoxyphenyl)-l,l-dioxo-l,2,5-thiadiazolidin-3-one 3-Hydroxy-4-( 1 , 1 ,4-trioxo- 1 ,2,5-thiadiazolidin-2-yl)-benzonitrile, and 5-(4-Chloro-2-hydroxyphenyl)- 1 , 1 -dioxo- 1 ,2,5-thiadiazolidin-3-one or a pharmaceutically acceptable salt thereof.

Claims

ClaimsWe Claim
1. A method of treating a musculoskeletal disease, the method comprising identifying an individual exhibiting the musculoskeletal disease or at risk for developing the musculoskeletal disease; and administering to the individual a therapeutically effective amount of a PTP inhibitor sufficient to alleviate the musculoskeletal disease.
2. Use of a PTP inhibitor in the manufacture of a medicament for the treatment or prevention of a musculoskeletal disease.
3. The method or use of any preceeding claim, wherein the musculoskeletal disease is muscle atrophy.
4. The method or use of claim 3, wherein the muscle atrophy is a result of treatment with a glucocorticoid.
5. The method or use of claim 4, wherein the glucocorticoid is Cortisol, dexamethasone, betamethasone, prednisone, methylprednisolone, or prednisolone.
6. The method or use of claim 3, wherein the muscle atrophy is a result of denervation due to nerve trauma.
7. The method or use of claim 3, wherein the muscle atrophy is a result of degenerative, metabolic, or inflammatory neuropathy.
8. The method or use of claim 7, wherein the neuropathy is caused by Guillian-Barre syndrome, peripheral neuropathy, or exposure to environmental toxins or drugs.
9. The method or use of claim 3, wherein the muscle atrophy is a result of an adult motor neuron disease, infantile spinal muscular atrophy, juvenile spinal muscular atrophy, autoimmune motor neuropathy with multifocal conductor block, paralysis due to stroke or spinal cord injury, skeletal immobilization due to trauma, prolonged bed rest, voluntary inactivity, involuntary inactivity, metabolic stress or nutritional insufficiency, cancer, AIDS, fasting, rhabdomyolysis, a thyroid gland disorder, diabetes, benign congenital hypotonia, central core disease, nemalene myopathy, myotubular (centronuclear) myopathy, burn injury, chronic obstructive pulmonary disease, liver disease, sepsis, renal failure, congestive heart failure, or ageing.
10. The method or use of claims 1 or 2, wherein the musculoskeletal disease is a muscular dystrophy syndrome.
11. The method or use of claim 10, wherein the muscular dystrophy is Duchenne, Becker, myotonic, fascioscapulohumeral, Emery-Deifuss, oculopharyngeal, scapulohumeral, limb girdle, a congenital muscular dystrophy, or hereditary distal myopathy.
12. The method or use of claims 1 or 2, wherein the musculoskeletal disease is osteoporosis, a bone fracture, short stature, or dwarfism.
13. The method or use of any preceeding claim, wherein the PTP inhibitor is a compound of the formula
Figure imgf000136_0001
wherein Q combined together with the carbon atoms to which it is attached form an aromatic, or a partially or fully saturated nonaromatic 5- to 8-membered carbocyclic or heterocyclic ring;
Ri is hydrogen, -C(O)R6, -C(O)NR7R8 or -C(O)OR9 in which R6 and R7 are, independently from each other, hydrogen, cycloalkyl, aryl, heterocyclyl, aralkyl, heteroaralkyl or alkyl optionally substituted with one to four substituents selected from the group consisting of halogen, cycloalkyl, cycloalkoxy, alkoxy, alkyloxyalkoxy, amino, alkylamino, dialkylamino, aryl, aryloxy and heterocyclyl; R8 and R9 are, independently from each other, cycloalkyl, aryl, heterocyclyl, aralkyl, heteroaralkyl or alkyl optionally substituted with one to four substituents selected from the group consisting of halogen, cycloalkyl, cycloalkoxy, alkoxy, alkyloxyalkoxy, amino, alkylamino, dialkylamino, aryl, aryloxy and heterocyclyl; R2, R3, R4 and R5 are, independently from each other, hydrogen, hydroxy, halogen, cyaho, nitro, alkoxy, alkylthio, alkylthiono, sulfonyl, free or esterified carboxy, carbamoyl, sulfamoyl, optionally substituted amino, cycloalkyl, aryl, heterocyclyl, alkenyl, alkynyl or (Ci_8)alkyl optionally substituted with one to four substituents selected from the group consisting of halogen, hydroxy, cycloalkyl, cycloalkoxy, acyl, acyloxy, alkoxy, alkyloxyalkoxy, amino, alkylamino, dialkylamino, acylamino, carbamoyl, thiol, alkylthio, alkylthiono, sulfonyl, sulfonamido, sulfamoyl, nitro, cyano, free or esterified carboxy, aryl, aryloxy, arylthio, alkenyl, alkynyl, aralkoxy, heteroaralkoxy, heterocyclyl and heterocyclyloxy; or
R2 and R3 combined are alkylene which together with the ring atoms to which they are attached form a 3- to 7-membered fused ring; or
R2 and R3 combined are alkylene which together with the carbon atom to which they are attached form a 3- to 7-membered spirocyclic ring; or a pharmaceutically acceptable salt thereof.
14. The method or use of any of claims 1 to 12, wherein the PTP inhibitor is a compound of the formula
Figure imgf000138_0001
wherein Ri is hydrogen, -C(O)R2, -C(O)NR3R4 or -C(O)OR5 in which
R2 and R3 are, independently from each other, hydrogen, cycloalkyl, aryl, heterocyclyl, aralkyl, heteroaralkyl or alkyl optionally substituted with one to four substituents selected from the group consisting of halogen, cycloalkyl, cycloalkoxy, alkoxy, alkyloxyalkoxy, amino, alkylamino, dialkylamino, aryl, aryloxy and heterocyclyl;
R4 and R5 are, independently from each other, cycloalkyl, aryl, heterocyclyl, aralkyl, heteroaralkyl or alkyl optionally substituted with one to four substituents selected from the group consisting of halogen, cycloalkyl, cycloalkoxy, alkoxy, alkyloxyalkoxy, amino, alkylamino, dialkylamino, aryl, aryloxy and heterocyclyl;
U, W and V are, independently from each other, hydrogen, hydroxy, halogen, cyano, nitro, alkoxy, alkylthio, alkylthiono, sulfonyl, free or esterified carboxy, carbamoyl, sulfamoyl, optionally substituted amino, cycloalkyl, aryl, aryloxy, arylthio, heterocyclyl, heterocycloyloxy, alkenyl, alkynyl or (Ci^alkyl optionally substituted with one to four substituents selected from the group consisting of halogen, hydroxy, cycloalkyl, cycloalkoxy, acyl, acyloxy, alkoxy, alkyloxyalkoxy, amino, alkylamino, dialkylamino, acylamino, carbamoyl, thiol, alkylthio, alkylthiono, sulfonyl, sulfonamido, sulfamoyl, nitro, cyano, free or esterified carboxy, aryl, aryloxy, arylthio, alkenyl, alkynyl, aralkoxy, heteroaralkoxy, heterocyclyl and heterocyclyloxy; or U and W combined together with the carbon atoms to which they are attached form an optionally substituted aromatic, or a partially or fully saturated nonaromatic 5- to 8-membered carbocyclic or heterocyclic ring; or
W and V combined together with the carbon atoms to which they are attached form an optionally substituted aromatic, or partially or fully saturated nonaromatic 5- to
8-membered carbocyclic or heterocyclic ring; or a pharmaceutically acceptable salt thereof.
15. The method or use of any of claims 1 to 12, wherein the PTP inhibitor is a compound of the formula
Figure imgf000139_0001
wherein
Ri is hydrogen, -C(O)R5, -C(O)NR6R7 or -C(O)OR8 in which
R5 and R6 are, independently from each other, hydrogen, cycloalkyl, aryl, heterocyclyl, aralkyl, heteroaralkyl or alkyl optionally substituted with one to four substituents selected from the group consisting of halogen, cycloalkyl, cycloalkoxy, alkoxy, alkyloxyalkoxy, amino, alkylamino, dialkylamino, aryl, aryloxy and heterocyclyl;
R7 and R8 are, independently from each other, cycloalkyl, aryl, heterocyclyl, aralkyl, heteroaralkyl or alkyl optionally substituted with one to four substituents selected from the group consisting of halogen, cycloalkyl, cycloalkoxy, alkoxy, alkyloxyalkoxy, amino, alkylamino, dialkylamino, aryl, aryloxy and heterocyclyl;
R2, R3 and R4 are, independently from each other, hydrogen, hydroxy, halogen, cyano, nitro, alkoxy, alkylthio, alkylthiono, sulfonyl, free or esterified carboxy, carbamoyl, sulfamoyl, optionally substituted amino, cycloalkyl, aryl, heterocyclyl, alkenyl, alkynyl or (Ci-8)alkyl optionally substituted with one to four substituents selected from the group consisting of halogen, hydroxy, cycloalkyl, cycloalkoxy, acyl, acyloxy, alkoxy, alkyloxyalkoxy, amino, alkylamino, dialkylamino, acylamino, carbamoyl, thiol, alkylthio, alkylthiono, sulfonyl, sulfonamido, sulfamoyl, nitro, cyano, free or esterified carboxy, aryl, aryloxy, arylthio, alkenyl, alkynyl, aralkoxy, heteroaralkoxy, heterocyclyl and heterocyclyloxy; or
R2 and R3 combined are alkylene which together with the ring atoms to which they are attached form a 5- to 7-membered fused ring provided R2 and R3 are attached to carbon atoms adjacent to each other; or
R2 and R3 combined together with the carbon atom to which they are attached form a fused 5- to 6-membered aromatic or heteroaromatic ring provided R2 and R3 are attached to carbon atoms adjacent to each other;
X is hydrogen, fluoro, cyano, or free or esterified carboxy; or
X is -NR9C(O)R10, -NR9C(O)ORi1, -NR9S(O)2R12, -(CH2)H1S(O)2R13, -OS(O)2R14 or -OnC(O)NR15R16 in which R9 is hydrogen, lower alkyl, acyl, alkoxycarbonyl or sulfonyl;
R1O, R11, R12, R13 and R14 are, independently from each other, cycloalkyl, aryl, heterocyclyl, aralkyl, heteroaralkyl or (C1-8)alkyl optionally substituted with one to four substituents selected from the group consisting of halogen, hydroxy, cycloalkyl, cycloalkoxy, acyl, acyloxy, alkoxy, alkyloxyalkoxy, amino, alkylamino, dialkylamino, acylamino, carbamoyl, thiol, alkylthio, alkylthiono, sulfonyl, sulfonamido, sulfamoyl, nitro, cyano, free or esterified carboxy, aryl, aryloxy, arylthio, alkenyl, alkynyl, aralkoxy, heteroaralkoxy, heterocyclyl and heterocyclyloxy; or
R1O, R12 and R13 are, independently from each other, -NR17R1S in which R17 and R18 are, independently from each other, hydrogen, alkyl, cycloalkyl, aralkyl, aryl or heterocyclyl; or R17 and R18 combined are alkylene which together with the nitrogen atom to which they are attached form a 4- to 7-membered ring; R15 and R16 are, independently from each other, hydrogen, alkyl, cycloalkyl, aralkyl, aryl or heterocyclyl; or Ri5 and Ri6 combined are alkylene which together with the nitrogen atom to which they are attached form a 4- to 7-membered ring; m and n are, independently from each other, zero or an integer of 1 ; or
C-X is replaced by nitrogen;
Y is CH2, O or S; or a pharmaceutically acceptable salt thereof.
16. The method or use of any of claims 1 to 12, wherein the PTP inhibitor is a compound of the formula
Figure imgf000141_0001
wherein
Q is alkoxy, alkylthio, alkylthiono, sulfonyl, cycloalkyl, aryl, aryloxy, heterocyclyl, alkenyl, alkynyl or (Ci.g)alkyl optionally substituted with one to four substituents selected from the group consisting of halogen, hydroxy, cycloalkyl, cycloalkoxy, acyl, acyloxy, alkoxy, alkyloxyalkoxy, optionally substituted amino, carbamoyl, thiol, alkylthio, alkylthiono, sulfonyl, sulfamoyl, nitro, cyano, free or esterified carboxy, aryl, aryloxy, arylthio, alkenyl, alkynyl, aralkoxy, heteroaralkoxy, heterocyclyl and heterocyclyloxy;
Ri is hydrogen, -C(O)R4, -C(O)NR5R6 or -C(O)OR7 in which R4 and R5 are, independently from each other, hydrogen, cycloalkyl, aryl, heterocyclyl, aralkyl, heteroaralkyl or alkyl optionally substituted with one to four substituents selected from the group consisting of halogen, cycloalkyl, cycloalkoxy, alkoxy, alkyloxyalkoxy, amino, alkylamino, dialkylamino, aryl, aryloxy and heterocyclyl; R6 and R7 are, independently from each other, cycloalkyl, aryl, heterocyclyl, aralkyl, heteroaralkyl or alkyl optionally substituted with one to four substituents selected from the group consisting of halogen, cycloalkyl, cycloalkoxy, alkoxy, alkyloxyalkoxy, amino, alkylamino, dialkylamino, aryl, aryloxy and heterocyclyl;
R2 and R3 are, independently from each other, hydrogen, halogen, (Ci-3)alkyl or (C1-3)alkoxy; or a pharmaceutically acceptable salt thereof.
17. The method or use of any of claims 1 to 12, wherein the PTP inhibitor is a compound of the formula
Figure imgf000142_0001
wherein Q is: i) -X, or ii) -Y-(CH2)n-(CR8R9)p-(CH2)m-Z-X in which; Y is oxygen or S(O)q in which q is zero or an integer of 1 or 2; or
Y is -C≡C- or -C=C-; or
Y is cyclopropyl or
Y is absent; n and m are, independently from each other, zero or an integer from 1 to 8; R8 and R9 are, independently from each other, hydrogen, hydroxyl, alkoxy, alkanoyl, alkanoylamino, alkoxycarbonyl, aralkyl, heteroaryl, carbamoyl, aryl, or alkyl; or
R8 and R9 combined are alkylene which together with the carbon atom to which they are attached form a 3- to 7-membered ring; p is zero or an integer selected from 1 or 2
Z is absent; Z is -C(O)-O-; or
Z is -C(O)-; or
Z is -C(O)-NRα-alkylene- or -C(O)-NRα-alkylene-O-, wherein Rq is H or lower alkyl; or Z is -CO-NRα-(CH2)n'-(CRg.R9'V-(CH2)m. - or -C(O)-NRa-(CH2V-(CR8 R9Op-
(CH2)m> -O-, wherein p' is zero or an integer of 1, n' and m' are, independently from each other, zero or an integer from 1 to 8, Rg' and R9' are, independently from each other, hydrogen or lower alkyl, RD is H or lower alkyl; or Z is -NRα'-C(O)-, or -NRα'-C(O)-O-, wherein Ra' is H or lower alkyl, or Ra' and R9 combined are alkylene which together with the carbon atom to which they are attached form a 3- to 7-membered ring; or
Z is -C(O)-NH-NH-C(O)-O-; or
Z is -S(O)2-, or -S(O)-; or Z is -NRβ-S(O)2- , wherein Rβ is H, lower alkyl, or Rβ and R9 combined are alkylene which together with the carbon atom to which they are attached form a 3- to 7-membered ring; or
Z is -NH-S(O)2-NH-C(O)-O-; or
Z is -NRy-C(O)-NRy'-; wherein Rγ' is H, alkyl, aryl, heterocyclyl, or lower. alkoxy and Rγ is H, lower alkyl, or Ryand R9 combined are alkylene which together with the carbon atom to which they are attached form a 3- to 7- membered ring; or Ry' and X combined are alkylene which together with the carbon atom to which they are attached form a 3- to 7-membered ring or
Z is -NRT-C(O)-NH-S(O)2-, wherein Rτ is H or lower alkyl, X is hydrogen, hydroxy, NH2, halogen, alkoxy, alkylthio, alkyl, -S(O)-OH, alkyl, cycloalkyl, cycloalkoxy, acyl, acyloxy, carbamoyl, optionally substituted amino, cyano, trifluoromethyl, free or esterifϊed carboxy, heterocyclyl, heterocyclooxy, heteroaryl, heteroaralkyl, aryl, aralkyl, aralkoxy, aryloxy, aralkylthio, arylthio; s hydrogen, -C(O)R4, -C(O)NR5R6 or -C(O)OR7 in which R4 and R5 are, independently from each other, hydrogen, cycloalkyl, aryl, heterocyclyl, aralkyl, heteroaralkyl or alkyl optionally substituted with one to four substituents selected from the group consisting of halogen, cycloalkyl, cycloalkoxy, alkoxy, alkyloxyalkoxy, amino, alkylamino, dialkylamino, aryl, aryloxy and heterocyclyl;
Rό and R7 are, independently from each other, cycloalkyl, aryl, heterocyclyl, aralkyl, heteroaralkyl or alkyl optionally substituted with one to four substituents selected from the group consisting of halogen, cycloalkyl, cycloalkoxy, alkoxy, alkyloxyalkoxy, amino, alkylamino, dialkylamino, aryl, aryloxy and heterocyclyl;
R2 and R3 are, independently from each other, hydrogen, halogen, (Ci.3)alkyl or (Ci-3)alkoxy; or a pharmaceutically acceptable salt thereof, and wherein n + m + p is > 1 or is 0, when X is aryl, and Y and Z are absent, n + m + p is not 0 when X is -O-aryl, and Y and Z are absent, or n + m + p is not 0 when X is -S-aryl, and Y and Z are absent, or n + m + p is not 0 when X is -CH2-aryl, and Y and Z are absent, or n + m + p is not 0 when X is aryl, Z is absent and Y is -O- or Y is -S-, or wherein Q cannot be -CH2-aryl, -S-aryl or -O-aryl.
18. The method of any preceeding claim, further comprising administering an IGFl molecule to the individual.
19. The use of IGFl and a PTP inhibitor in the manufacture of a medicament for the treatment of a musculoskeletal disease.
20. A method of increasing muscle or bone mass in an individual, the method comprising identifying an individual in which increasing muscle or bone mass is desirable; and administering to the individual an amount of a PTP inhibitor sufficient to increase the muscle or bone mass in the individual.
21. Use of a PTP inhibitor in the manufacture of a medicament for increasing muscle or bone mass in an individual.
PCT/US2007/086058 2006-12-01 2007-11-30 Inhibitors of protein tyrosine phosphatase for the treatment of muscle atrophy and related disorders WO2008067527A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US87215706P 2006-12-01 2006-12-01
US60/872,157 2006-12-01

Publications (1)

Publication Number Publication Date
WO2008067527A1 true WO2008067527A1 (en) 2008-06-05

Family

ID=39111299

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2007/086058 WO2008067527A1 (en) 2006-12-01 2007-11-30 Inhibitors of protein tyrosine phosphatase for the treatment of muscle atrophy and related disorders

Country Status (1)

Country Link
WO (1) WO2008067527A1 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009068689A2 (en) * 2007-11-30 2009-06-04 Novartis Ag Combination of protein tyrosine phosphatase inhibitors and human growth hormone for the treatment of muscle atrophy and related disorders

Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5965558A (en) * 1995-06-19 1999-10-12 Ontogen Corporation Modulators of proteins with phosphotyrosine recognition units
US6605753B1 (en) * 1998-07-24 2003-08-12 Merck & Co., Inc. Protein tyrosine phosphate-1B (PTP-1B) deficient mice and uses thereof
WO2003082841A1 (en) * 2002-04-03 2003-10-09 Novartis Ag 5-substituted 1,1-dioxo-`1,2,5!thiazolidine-3-one derivatives as ptpase 1b inhibitors
WO2004041799A1 (en) * 2002-11-07 2004-05-21 Astrazeneca Ab 5- (substituted phenyl) -thiadiazolidine-3-ones and their use as ptp1b
WO2004050646A1 (en) * 2002-11-29 2004-06-17 Astrazeneca Ab 1, 2, 5-thiadiazolidin-3-one 1, 1 dioxide derivatives as inhibitors of protein tyrosine phosphatase ptp1b
US20050154011A1 (en) * 2003-02-20 2005-07-14 The Procter & Gamble Company Tetrahydroisoquinolnyl sulfamic acids
WO2007067615A2 (en) * 2005-12-08 2007-06-14 Novartis Ag Thiadiazole derivatives as antidiabetic agents
WO2007067613A1 (en) * 2005-12-08 2007-06-14 Novartis Ag 1,2,5-thiazolidine derivatives useful for treating conditions mediated by protein tyrosine phosphatases (ptpase)
WO2007067614A1 (en) * 2005-12-08 2007-06-14 Novartis Ag l, l, 3-TRI0X0-l, 2, 5-THIADIAZ0LIDINES AND THEIR USE AS PTP-ASES INHIBITORS

Patent Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5965558A (en) * 1995-06-19 1999-10-12 Ontogen Corporation Modulators of proteins with phosphotyrosine recognition units
US6605753B1 (en) * 1998-07-24 2003-08-12 Merck & Co., Inc. Protein tyrosine phosphate-1B (PTP-1B) deficient mice and uses thereof
WO2003082841A1 (en) * 2002-04-03 2003-10-09 Novartis Ag 5-substituted 1,1-dioxo-`1,2,5!thiazolidine-3-one derivatives as ptpase 1b inhibitors
WO2004041799A1 (en) * 2002-11-07 2004-05-21 Astrazeneca Ab 5- (substituted phenyl) -thiadiazolidine-3-ones and their use as ptp1b
WO2004050646A1 (en) * 2002-11-29 2004-06-17 Astrazeneca Ab 1, 2, 5-thiadiazolidin-3-one 1, 1 dioxide derivatives as inhibitors of protein tyrosine phosphatase ptp1b
US20050154011A1 (en) * 2003-02-20 2005-07-14 The Procter & Gamble Company Tetrahydroisoquinolnyl sulfamic acids
WO2007067615A2 (en) * 2005-12-08 2007-06-14 Novartis Ag Thiadiazole derivatives as antidiabetic agents
WO2007067613A1 (en) * 2005-12-08 2007-06-14 Novartis Ag 1,2,5-thiazolidine derivatives useful for treating conditions mediated by protein tyrosine phosphatases (ptpase)
WO2007067614A1 (en) * 2005-12-08 2007-06-14 Novartis Ag l, l, 3-TRI0X0-l, 2, 5-THIADIAZ0LIDINES AND THEIR USE AS PTP-ASES INHIBITORS

Non-Patent Citations (9)

* Cited by examiner, † Cited by third party
Title
AMERICAN JOURNAL OF PHYSIOLOGY, vol. 286, no. 1 Part 1, January 2004 (2004-01-01), pages C138 - C144, ISSN: 0002-9513 *
BLACK E ET AL: "Structure-based design of protein tyrosine phosphatase-1B inhibitors", BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, OXFORD, GB, vol. 15, no. 10, 16 May 2005 (2005-05-16), pages 2503 - 2507, XP004877713, ISSN: 0960-894X *
DATABASE BIOSIS [online] BIOSCIENCES INFORMATION SERVICE, PHILADELPHIA, PA, US; January 2004 (2004-01-01), DALLA LIBERA LUCIANO ET AL: "Beneficial effects of GH/IGF-1 on skeletal muscle atrophy and function in experimental heart failure.", XP002471806, Database accession no. PREV200400152647 *
DATABASE MEDLINE [online] US NATIONAL LIBRARY OF MEDICINE (NLM), BETHESDA, MD, US; December 2001 (2001-12-01), CHAKRAVARTHY M V ET AL: "The molecular responses of skeletal muscle satellite cells to continuous expression of IGF-1: implications for the rescue of induced muscular atrophy in aged rats.", XP002471807, Database accession no. NLM11915927 *
FIASCHI T ET AL: "Low molecular weight protein-tyrosine phosphatase is involved in growth inhibition during cell differentiation", JOURNAL OF BIOLOGICAL CHEMISTRY, AMERICAN SOCIETY OF BIOLOCHEMICAL BIOLOGISTS, BIRMINGHAM,, US, vol. 276, no. 52, 28 December 2001 (2001-12-28), pages 49156 - 49163, XP002968935, ISSN: 0021-9258 *
HULLEY P A ET AL: "Glucocorticoid-induced osteoporosis in the rat is prevented by the tyrosine phosphatase inhibitor, sodium orthovanadate", BONE (NEW YORK), vol. 31, no. 1, July 2002 (2002-07-01), pages 220 - 229, XP002471804, ISSN: 8756-3282 *
INTERNATIONAL JOURNAL OF SPORT NUTRITION AND EXERCISE METABOLISM DEC 2001, vol. 11 Suppl, December 2001 (2001-12-01), pages S44 - S48, ISSN: 1526-484X *
KONTARIDIS MARIA I ET AL: "Role of SHP-2 in fibroblast growth factor receptor-mediated suppression of myogenesis in C2C12 myoblasts", MOLECULAR AND CELLULAR BIOLOGY, vol. 22, no. 11, June 2002 (2002-06-01), pages 3875 - 3891, XP002471805, ISSN: 0270-7306 *
SUGANO MASAHIRO ET AL: "A protein tyrosine phosphatase inhibitor accelerates angiogenesis in a rat model of hindlimb ischemia", JOURNAL OF CARDIOVASCULAR PHARMACOLOGY, vol. 44, no. 4, October 2004 (2004-10-01), pages 460 - 465, XP009096857, ISSN: 0160-2446 *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009068689A2 (en) * 2007-11-30 2009-06-04 Novartis Ag Combination of protein tyrosine phosphatase inhibitors and human growth hormone for the treatment of muscle atrophy and related disorders
WO2009068689A3 (en) * 2007-11-30 2009-08-06 Novartis Ag Combination of protein tyrosine phosphatase inhibitors and human growth hormone for the treatment of muscle atrophy and related disorders

Similar Documents

Publication Publication Date Title
US20100305036A1 (en) Combination of protein tyrosine phosphatase inhibitors and human growth hormone for the treatment of muscle atrophy and related disorders
EP1986633B1 (en) Treatment of duchenne muscular dystrophy
US8084448B2 (en) Organic compounds
US4826860A (en) Substituted 2-aminobenzothiazoles and derivatives useful as cerebrovascular agents
US5908830A (en) Combination therapy for the treatment of diabetes and obesity
JP5639743B2 (en) Tuberous sclerosis treatment
JP5283511B2 (en) Thiadiazole derivatives for the treatment of neurodegenerative diseases
EP0343643A2 (en) Arylmethylenyl derivatives of thiazolidnones, imidazolidinones and oxazolidinones useful as antiallergy agents and antiinflamatory agents
US8119666B2 (en) 1,2,5-thiazolidine derivatives useful for treating conditions mediated by protein tyrosine phosphatases (PTPase)
EP2101783A2 (en) Method of preventing or treating myocardial ischemia
BRPI0709750A2 (en) combinations of therapeutic agents for cancer treatment
CA2586761A1 (en) Methods of treating diabetes mellitus
RU2008127254A (en) THIADIAZOLE DERIVATIVES AS ANTI-DIABETIC AGENTS
US20110071164A1 (en) Erg channel openers for the treatment of cardiac arrhythmias
JP2009534415A (en) Pharmacological control of the action of AMPA receptor modulators on neurotrophin expression
EP2089026A2 (en) Inhibitors of protein tyrosine phosphatase for the promotion of physiological cardiac hypertrophy
CN101801375A (en) Insulin sensitisers and methods of treatment
WO2008067527A1 (en) Inhibitors of protein tyrosine phosphatase for the treatment of muscle atrophy and related disorders
EP0869785B1 (en) 4-hydroxycoumarin-3-carboxamides for the treatment of non-insulin dependent diabetes mellitus
US20100056460A1 (en) Combination of organic compounds
WO2005023238A1 (en) Erg channel openers for the treatment of hyperexcitability-related neuronal diseases

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 07854866

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 07854866

Country of ref document: EP

Kind code of ref document: A1